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professionals and scientists who partner with 
 these  women to improve outcomes through 
the identifi cation of better treatment 
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Preface and Acknowl edgments
I fi rst met Dana Dreibelbis at the 2014 Annual Meeting of the American 
Society of Clinical Oncology. Rutgers University Press offered me the 
opportunity to edit a short clinical book as part of a new publishing initia-
tive. I immediately knew that I wanted to put together a book that summa-
rizes the seminal clinical  trials that have  shaped the practice of gynecologic 
oncology.
Clinical  trials have been instrumental in creating our current clinical 
practice paradigms. A clinician taking care of a  woman with gynecologic 
cancer needs to understand this history in order to deliver evidence- based 
care. In some cases, clinical  trials fi ndings result in clear establishment of 
standard of care therapy. In other cases, optimal treatment regimens are 
not yet defi ned, but clinical  trials provide data to inform the clinician 
regarding treatment options and ongoing controversies.
The clinical  trials history of any fi eld is vast, making it diffi cult and 
time- consuming for any individual to collect and synthesize. Currently, 
a textbook focused on clinical  trials in gynecologic oncology does not 
exist. Clinical  trials are discussed in general textbooks but often within 
lengthy chapters that cover many other topics.  There is no standardized 
formatting and the reader must wade through the text in order to fi nd rel-
evant information.
The concept for this textbook is to provide a concise, user- friendly ref-
erence that focuses solely on clinical  trials in gynecologic oncology. The 
text is formatted in a standardized fashion so the reader can rapidly fi nd 
relevant information. The seminal phase III  trials that have  shaped the 
fi eld are outlined in a standard format to include the details on the ratio-
nale for the trial, the patient population studied, treatment details of the 
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experimental arms, assessments, endpoints, statistical considerations, 
results, conclusions and further commentary. Standardized  tables high-
light the salient and relevant results by summarizing patient characteristics, 
treatment delivery, effi cacy and toxicities from each seminal phase III trial. 
The full reference and PMID number are provided for each study so that 
the reader can easily fi nd the original text and reference for further reading. 
A list of the abbreviations used in the text is provided at the end of the book 
for the reader’s con ve nience.
This text focuses on the seminal phase III clinical  trials that have been 
conducted in patients with epithelial ovarian cancer and represents the 
fi rst in a series of books. Similar textbooks outlining clinical  trials in other 
gynecologic malignancies such as uterine and cervical cancer are forth-
coming. I am so appreciative to Dana Dreibelbis and the rest of the staff at 
RUP for giving this series of textbooks the opportunity to exist.
The care of  women with gynecologic malignancies is  shaped through 
the rich history of clinical  trials.  There is no one- size- fi ts- all approach 
when it comes to making treatment decisions. Rather,  there are a varied 
number of treatment options for vari ous clinical scenarios and clinicians 
often need to make treatment recommendations based on nuances such 
as individual patient and tumor characteristics as well as treatment side 
effect profi les. I hope you  will fi nd this book to be a useful reference to 
easily fi nd information regarding the effi cacy as well as toxicity profi les 
of vari ous treatment regimens.





Approximately 30% of epithelial ovarian cancers are diagnosed at an early 
stage and can be completely resected at the time of surgery. GOG 7601 
defi ned low- risk tumors that include stage IA and IB, grade 1 cancer, where 
adjuvant chemotherapy can be safely omitted. High- risk early- stage ovarian 
cancers include stage I, grade 3; stage IC; clear cell; and stage II cancers. In 
this high- risk subgroup, the GICOG and GOG 95  trials demonstrated a 
lower risk of recurrence with the administration of platinum- based adjuvant 
chemotherapy. The ACTION and ICON1  trials demonstrated improved 
overall survival with platinum chemotherapy (mostly carboplatin) com-
pared to observation but suggested that the benefi t does not apply to patients 
who had complete surgical staging. GOG 157 showed no difference in sur-
vival between 3 and 6 cycles of carboplatin and paclitaxel, but an explor-
atory analy sis suggested a benefi t for 6 cycles with serous histologies.
GOG 7601 (Young, NEJM 1990)
REFERENCE
• Young RC, et al. Adjuvant therapy in stage I and stage II epithelial ovar-
ian cancer. Results of two prospective randomized  trials. N Engl J 
Med. 1990;322(15):1021-1027. PMID: 2181310. (Young et al. 1990)
TRIAL SPONSORS
• Ovarian Cancer Study Group (Mayo Clinic, MD Anderson Hospital 
and Tumor Institute, National Cancer Institute, Ros well Park Memorial 
Institute)
• Gynecologic Oncology Group (GOG)
CHAPTER 1
Early  Stage Epithelial 
Ovarian Cancer
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• Survival rates vary among patients with early- stage epithelial ovarian 
cancer. The 5- year survival ranges from 50% to 70% for patients with 
stage I ovarian cancer. The 5- year survival ranges from 38% to 60% for 
patients with stage II ovarian cancer.
• Pathologic  factors such as cell type and grade only partially account 
for the variable survivals.
• Earlier studies have demonstrated the importance of thorough surgi-
cal staging in order to balance prognostic  factors among treatment 
groups.
• GOG 7601/7602 studies  were performed to evaluate the impact of 
adjuvant therapy following surgical resection and comprehensive 
staging on outcomes of patients with early- stage epithelial cancer. 
 Because the entire abdomen is at risk for metastatic disease,  these 
 trials included only  those patients with a standardized and compre-
hensive surgical exploration in order to determine the true benefi t of 
adjuvant therapy.
• GOG 7601 evaluated patients with lower- risk disease classifi ed as stage 
IA and IB and grade 1 or grade 2 epithelial ovarian cancer.
• GOG 7602 evaluated patients with higher- risk disease classifi ed as 
stage I, grade 3 or any stage II epithelial ovarian cancer.
PATIENT POPULATION
• N = 92.
• Enrollment started in 1976 by the Ovarian Cancer Study Group and in 
1978 by the Gynecologic Oncology Group. Enrollment ended in Octo-
ber 1984.
Inclusion Criteria
• Patients with stage IA and IB and grade 1 or grade 2 epithelial ovarian 
cancer  after complete surgical staging  were enrolled.
• Staging was performed through a vertical incision and included total 
abdominal hysterectomy, bilateral salpingo- oophorectomy, and partial 
infracolic omentectomy. The tumor capsule was evaluated for rupture, 
excrescences, and adhesions requiring sharp dissection. Ascitic fl uid was 
examined for malignant cells. In the absence of ascites, separate 250- mL 
saline washings  were obtained from the pelvis and both abdominal gut-
ters. Suspicious lesions  were biopsied. Random biopsies of the pelvic 
peritoneum, cul- de- sac peritoneum, right and left abdominal gutter peri-





toneum, and the undersurface of the right diaphragm  were obtained. Pel-
vic and para- aortic lymph nodes  were palpated and sampled.
• Adequate bone marrow, renal, and liver function.
TREATMENT DETAILS
Arm 1
• No further treatment.
Arm 2
• Melphalan 0.2 mg/kg orally daily for 5 days, repeated  every 4 to 6 
weeks for 12 cycles or 18 months, whichever came fi rst.
ASSESSMENTS
• Before 1983, noninvasive staging procedures such as chest radiogra-
phy, intravenous pyelography, and lymphangiography  were utilized.
• When clinically indicated, pelvic ultrasonography, barium enema, pelvic 
and abdominal computed tomography (CT) scanning, and proctosig-
moidoscopy  were performed.
• Patients  free of recurrent disease 18 months  after study entry under-
went routine surgical reexploration.
• Symptomatic patients underwent earlier exploration  unless  there was 
documented recurrent disease on noninvasive study.
• At reexploration, all patients underwent peritoneal washings as well as 
biopsies of the right and left paracolic gutters, cul- de- sac, lateral pelvic 
wall, small bowel mesentery, and omentum.
• Biopsies  were also performed of adhesions and known sites of prior 








• Target sample size of 110 patients. Accrual was terminated  after 8 years 
of enrollment at 74% of the goal  because the observed rate of relapse 
was so low that it ruled out the possibility of eventually detecting a 
moderate difference between the 2 groups.
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• Method of Kaplan and Meier was used to calculate life- table proper-
ties of survival and disease- free survival (Kaplan and Meier 1958).
• Log- rank test was used to compare survival distributions (Mantel 1966).
• Cox proportional hazards regression was used to compare survival  after 
adjusting for baseline characteristics and to investigate the prognostic 
signifi cance of baseline variables.
Table 1.1  Results of GOG 7601
Treatment arm
No further treatment
N = 38 evaluable
Melphalan
N = 43 evaluable Statistics
Patient characteristics
Median age 50 years 40 years
Residual tumor 0% 0%
Stage Iai 94.7% 93.0%




Clear cell 2.6% 11.6%
Other 23.7% 20.9%
Grade 1 36.8% 44.2%
Grade 2 13.2% 16.3%
Reclassifi ed as LMP 39.5% 27.9%
Effi cacy
Recurrences N = 4 N = 1
Deaths:
 Ovarian cancer, primary N = 3 N = 1
 Ovarian cancer, secondary N = 1 N = 0
 Complication N = 0 N = 1 
(aplastic anemia)
 Other N = 0 N = 0
5- year disease- free survival 91% 98% P = NS
5- year overall survival 94% 98% P = NS
Toxicity
Myelosuppression Not applicable 79%
Aplastic anemia N = 1, 
occurred 6 years 
 after  treatment
NS, not signifi cant.





• Methods described by Simon  were used to calculate confi dence limits 
(Simon 1986).
CONCLUSION OF TRIAL
• Patients with a diagnosis of stage Iai or Ibi disease  after comprehensive 
surgical staging have an excellent 5- year survival rate of >90%. Adju-
vant therapy with oral melphalan did not improve outcomes. In light 
of the toxicity and risk of second cancers, the identifi cation of a group 
of patients in whom adjuvant therapy can be withheld represents a sig-
nifi cant fi nding.
COMMENTS
• Clear cell tumors had poorer outcomes. When considering patients who 
had central pathology review, 38% (3 of 8) of patients with clear cell 
tumors relapsed compared to 3% (2 of 63) of patients with other histo-
logic tumor types.
• Ovarian tumors of borderline malignancy have a more indolent course 
than invasive tumors (Scully 1977; Bjorkholm et al. 1982). The 5- year 
survival was unchanged when patients with borderline tumors  were 
excluded from the analy sis (exact survival numbers are not provided 
in the manuscript).
GOG 7602 (Young, NEJM 1990)
REFERENCE
• Young RC, et al. Adjuvant therapy in stage I and stage II epithelial ovarian 
cancer. Results of two prospective randomized  trials. N Engl J Med. 
1990;322(15):1021-1027. PMID: 2181310. (Young et al. 1990)
TRIAL SPONSOR
• Ovarian Cancer Study Group (Mayo Clinic, MD Anderson Hospital 
and Tumor Institute, National Cancer Institute, Ros well Park Memorial 
Institute)
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• GOG 7601/7602  were performed to evaluate the impact of adjuvant 
therapy following surgical resection and comprehensive staging on out-
comes of patients with early- stage epithelial cancer.
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• GOG 7601 evaluated patients with lower- risk disease: stage IA and IB 
and grade 1 or grade 2 epithelial ovarian cancer.
• GOG 7602 evaluated patients with higher- risk disease: stage I grade 3 or 
any stage II epithelial ovarian cancer.
PATIENT POPULATION
• N = 145.
• Enrollment started in 1976 by the Ovarian Cancer Study Group and 
in 1978 by the Gynecologic Oncology Group. Enrollment ended in 
November 1986.
Inclusion Criteria
• Stage I, grade 3 or stage II epithelial ovarian cancer.
• Staging was performed through a vertical incision and included total 
abdominal hysterectomy, bilateral salpingo- oophorectomy, and partial 
infracolic omentectomy. The tumor capsule was evaluated for rupture, 
excrescences, and adhesions requiring sharp dissection. Ascitic fl uid 
was examined for malignant cells. In the absence of ascites, separate 
250- mL saline washings  were obtained from the pelvis and both 
abdominal gutters. Suspicious lesions  were biopsied. Random biopsies 
of the pelvic peritoneum, cul- de- sac peritoneum, right and left abdom-
inal gutter peritoneum, and the undersurface of the right diaphragm 
 were obtained. Pelvic and para- aortic lymph nodes  were palpated and 
sampled.
• Adequate bone marrow, renal, and liver function.
TREATMENT DETAILS
Arm 1
• Melphalan 0.2 mg/kg orally daily for 5 days, repeated  every 4 to 6 weeks 
for 12 cycles or 18 months, whichever came fi rst.
Arm 2
• Intraperitoneal 32P at a dose of 15 mCi of chromic phosphate (dose was 
7.5 mCi before 1979).
ASSESSMENTS
• Noninvasive staging procedures: chest radiography, intravenous pyelog-
raphy, and lymphangiography (before 1983).
• When clinically indicated: pelvic ultrasonography, barium enema, pelvic 
and abdominal CT scanning, and proctosigmoidoscopy.





• Patients  free of recurrent disease 18 months  after study entry underwent 
routine surgical reexploration.
• Symptomatic patients underwent earlier exploration  unless  there was 
documented recurrent disease on noninvasive study.
• At reexploration, all patients underwent peritoneal washings as well as 
biopsies of the right and left paracolic gutters, cul- de- sac, lateral pelvic 
wall, small bowel mesentery, and omentum. Biopsies  were also performed 
of adhesions and known sites of prior disease. Results have been pre-








• Group A: stage Iai or Ibi disease with poorly differentiated histologic 
grades and  those with stage Ibii or Ibii disease.
• Group B: stage IIa or IIb disease.
• Group C: stage Ic or IIc disease or any patient with detectable disease.
Sample Size
• The target sample size of 142 was achieved.
Statistical Tests
• Method of Kaplan and Meier was used to calculate life- table properties 
of survival and disease- free survival (Kaplan and Meier 1958).
• Log- rank test was used to compare survival distributions (Mantel 
1966).
• Cox proportional hazards regression was used to compare survival  after 
adjusting for baseline characteristics and to investigate the prognostic 
signifi cance of baseline variables.
• Methods described by Simon  were used to calculate confi dence limits 
(Simon 1986).
CONCLUSION OF TRIAL
• In a higher- risk group of patients with early- stage epithelial ovarian 
cancer, the 5- year survival was approximately 80% and did not differ 





 Table 1.2  Results of GOG 7602
Treatment arm
Melphalan
N = 68 evaluable
32P
N = 73 evaluable Statistics
Patient characteristics
Median age 51 years 52 years
Residual tumor 2.9% 5.5%
Stage Iai 4.4% 1.4%
Stage Iaii 16.2% 23.3%
Stage Ibii 7.4% 0%
Stage Ic 11.8% 9.6%
Stage IIa 0% 6.9%
Stage IIb 44.1% 46.6%




Clear cell 19.1% 13.7%
Other 26.4% 20.5%
Grade 1 25.0% 28.8%
Grade 2 26.8% 27.4%
Grade 3 14.7% 15.1%
Reclassifi ed as LMP 14.7% 19.2%
Effi cacy
Recurrences N = 13 N = 14
Deaths
Ovarian cancer, primary N = 10 N = 12
Ovarian cancer, secondary N = 0 N = 2
Complication N = 2 N = 0
Other N = 3 N = 2




Death, pre- leukemia N = 2
Abdominal pain, mild- moderate 21%
Abdominal pain, severe 6%
Surgery, bowel obstruction 6%
LMP, low malignant potential.





between adjuvant oral melphalan and intraperitoneal 32P. Given the 20% 
recurrence rate, adjuvant therapy should be administered to this group 
of patients, and 32P is preferred over melphalan  because of its limited 
toxicity and no known risk of leukemia.
COMMENTS
• Clear cell tumors had poorer outcomes. When considering patients who 
had central pathology review, 35% (9 of 26) of patients with clear cell 
tumors relapsed compared to 15% (16 of 107) of patients with other his-
tologic tumor types.
• Melphalan use was associated with risk of myeloproliferative disorders 
and acute leukemia.  These complications are uncommon but a known 
catastrophic risk (Reimer et al. 1977; Greene et al. 1982).
• The 5- year survival of 80% in this trial is substantially better than the 
previously reported 5- year survival rates of 40% to 60% in other  trials. 
While the comprehensive surgical staging mandated in this trail may 
have identifi ed a group with better prognosis, it is impossible to know 
what impact this had on survival within this trial.
• The majority of recurrences  were distant (32%) or abdominal (39%), 
confi rming prior observations that the entire abdominal cavity is at risk 
of recurrence.
• 32P was considered the preferred adjuvant treatment arm from this trial. 
Given the evidence of effi cacy of platinum- containing regimens in 
advanced ovarian cancer (Decker et al. 1982; Levin and Hryniuk 1987; 
Neijt et al. 1987), the GOG has designed a replacement trial comparing 
intraperitoneal 32P with 3 cycles of cyclophosphamide and cisplatin 
(GOG 95).
• Patients with borderline tumors  were evenly distributed between treat-
ment arms, and the comparisons of therapeutic effi cacy  were not affected 
by the exclusion of  these patients in the analy sis.
GICOG  Trials (Bolis, Ann Oncol 1995)
REFERENCE
• Bolis G, et al. Adjuvant treatment for early epithelial ovarian cancer: 
results of two randomised clinical  trials comparing cisplatin to no 
further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo 
Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol. 
1995;6(9):887-893. PMID: 8624291. (Bolis et al. 1995)
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• Gruppo Interregionale Collaborativo in Oncologico Ginecologia 
(GICOG), Italy
RATIONALE FOR TRIAL
• Postoperative therapy for early stage ovarian cancer is controversial.
• Approximately 30% of patients die of disease despite appropriate 
surgery.
•  There is a small subset of patients with early- stage ovarian cancer who 
require no further treatment  after surgery (stage IA, grade 1), but  there 
is a lack of consensus about  whether other early- stage patients benefi t 
from postoperative adjuvant therapy (NIH consensus conference . . . 
1995).
• Three dif fer ent adjuvant treatment approaches have been used— 
including abdominopelvic radiotherapy, intraperitoneal radioactive 
chromic phosphate (32P), and chemotherapy— but most  trials have lacked 
adequate sample size and power to detect signifi cant differences among 
the treatment groups (Smith et al. 1975; Dembo et al. 1979; Hreshchyshyn 
et al. 1980; Gronroos et al. 1984; Klaassen et al. 1988; Young et al. 1990; 
Vergote et al. 1992; Redman et al. 1993).
• This report is of 2 multicenter randomized  trials from Italy to deter-
mine the effi cacy of cisplatin in adjuvant treatment of early- stage ovar-
ian cancer.
PATIENT POPULATION
• N = 271 enrolled in 2 randomized  trials.
• Enrollment from March 1983 to October 1990.
• Enrollment per FIGO 1976 staging criteria.
Inclusion Criteria
• Trial 1: stage IA and stage IB, grade 2 or 3 early ovarian cancer.
• Trial 2: stage Iaii, Ibii, Ic early ovarian cancer.
• No prior therapy except surgery.
• Age <75 years.
• No previous or simultaneous cancers.
• Adequate bone marrow, liver, and renal function.
• No concomitant diseases precluding the use of trial treatments.
• Randomization within 42 days of initial surgery.
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• Vertical incision to completely visualize abdominal cavity.
• Abdominal hysterectomy, bilateral salpingo- oophorectomy, and infra-
colic omentectomy.
• Pelvic and para- aortic lymph node addressed by palpation and biopsied 
(selective when suspicious).
• Random biopsies of liver, diaphragm, pelvic, and abdominal peritoneal 
surfaces.
• Cytologic examination of pelvic and abdominal  free fl uid or washings.
Trial 1
• Arm 1: no further therapy.
• Arm 2: cisplatin 50 mg/m2  every 28 days for 6 cycles.
Trial 2
• Arm 1: 32P.
• Arm 2: cisplatin 50 mg/m2  every 28 days for 6 cycles.
• Note that from February 1988 to January 1989,  there was a shortage of 
32P, and all patients enrolled during this time frame received cisplatin. 
 Because randomization was not pos si ble, the principal analy sis was 
removed from all patients enrolled during this period.
Cisplatin Administration (Trials 1 and 2)
• Antiemetic prophylaxis with metoclopramide and/or dexamethasone 
and/or benzodiazepines.
• Hydration with normal saline 500 mL over 1 hour prior to cisplatin 
and 2 L of normal saline (with 40 mEq potassium chloride) over 6 hours 
 after cisplatin infusion.
• Postponed for up to 2 weeks if serum creatinine >2 mg/100 mL or 
 24- hour creatinine clearance was below 50 mL/min. Discontinued if 
values persisted beyond 4 weeks.
32P Administration (Trial 2)
• 7 to 109 mCi-260-370 MBq.
• Injected into the abdomen in 2 L normal saline.
ASSESSMENTS
• Presurgical staging procedures.
• Chest radiography, intravenous pyelography, and lymphangiography.
• If indicated: pelvic ultrasonography, pelvic and abdominal CT scan, 
barium enema, and proctosigmoidoscopy.
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• Toxicity recorded according to World Health Organ ization recommen-
dations (Miller et al. 1981).
• Followed  every 3 months for 2 years and  every 6 to 12 months there-
after.
• CT scans, chest x- rays, and ultrasounds assessments  were done when 
clinically indicted.
• CA125 had been used on a routine basis since 1987 but was not used 
as proof or recurrence in the absence of other positive fi ndings.
ENDPOINTS
• Overall survival.
• Relapse- free survival.
STATISTICAL CONSIDERATIONS
• Kaplan- Meier curves used to describe survival curves (Kaplan and 
Meier 1958).
• Cumulative incidence was calculated to describe the pattern of dif fer-
ent relapses (Gelman et al. 1990).
• Log- rank test and Cox proportional hazards regression model  were 
used to test the signifi cance of chemotherapy effect (Cox 1972; Peto and 
Peto 1972).
• Cox analy sis with backward se lection procedure was used to select 
among baseline covariates, including age, grade, histotype, and surgi-
cal vs clinical nodal assessment.
• A global test of heterogeneity comparing a model with covariates plus 
the  factor of interest to one with only covariates was used to test the 
prognostic role of categorical variables with more than 2 levels (Cox 
1972).
• Cutoff date for analy sis was December 1993: median follow-up time was 
76 months, and maximum observation time was 121 months.
CONCLUSION OF TRIAL
• This is the fi rst trial to demonstrate a reduced relapse rate with use of 
adjuvant cisplatin chemotherapy in patients with early- stage ovarian 
cancer. The impact of cisplatin use on survival remains unclear.
COMMENTS
• Cisplatin was dosed at 50 mg/m2 in both  trials, and this is not consid-
ered a suboptimal dose.
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N = 41 Statistics
Patient characteristics
Age <45 21.4% 21.9%
Age 45-55 30.9% 30.7%
Age >55 57.6% 46.3%




Clear cell 23.8% 9.8%
Other 4.8% 2.4%
Grades 1-2 76.2% 58.5%
Grade 3 23.8% 41.5%
Lymph nodes
Clinical assessment 57.1% 65.8%
Surgical assessment 42.9% 34.1%
Treatment delivery
No dose modifi cation NA 92%
Effi cacy
Recurrences 35% 17%
Pelvis only 14% 6%
Nodes only 3% 3%
Abdominal 18% 8%
5- year DFS 65% 83% HR 0.48 (0.20-1.14)
Deaths 18% 12%
Ovarian cancer 18% 7%
Other  causes 0% 5%
5- year OS 82% 88% HR 1.15 (0.44-2.98)
Toxicity
Nausea/vomiting Not reported >66%
DFS, disease- free survival; HR, hazard ratio; NA, not applicable; OS, overall survival.
• At time of recurrence, patients initially treated with adjuvant cispla-
tin had a greater risk of  dying compared to the patients initially treated 
with 32P or observation. This suggests that  these patients might have 
a more virulent disease or re sis tance to chemotherapy. Two  trials are 
evaluating the question of immediate platinum therapy vs delaying 
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N = 82 Statistics
Patient characteristics
Age <45 24.0% 22.1%
Age 45-55 44.0% 37.7%
Age >55 32.0% 40.3%




Clear cell 20.0% 20.8%
Other 6.7% 2.6%
Grades 1-2 72.0% 71.4%
Grade 3 28.0% 28.6%
Lymph nodes
Clinical assessment 45.3% 55.8%
Surgical assessment 54.7% 44.2%
Treatment delivery
No dose modifi cation Not reported 92%
Could not be implanted 15 of 75 eligible N/A
Effi cacy
Recurrences 34% 15%
Pelvis only 16% 7%
Nodes only 3% 0%
Abdominal 15% 8%
5- year DFS 65% 85% HR 0.42 (0.22-0.80)
Deaths 21% 19%
Ovarian cancer 21% 16%
Other  causes 0% 3%
5- year OS 79% 81% 0.72 (0.37-1.43)
Toxicity
Nausea/vomiting Not reported >66%
DFS, disease- free survival; HR, hazard ratio; OS, overall survival.
platinum therapy to the time of relapse (Trimbos 1991; Ghersi et al. 
1992).
• Lymphadenectomy did not appear to play an impor tant prognostic role 
in  these  trials.




GICOG  Trials 15
•  These 2  trials demonstrate the cisplatin is active, even when used at low 
doses. The authors conclude that in non- high- risk patients, treatment 
should only be administered at the time of relapse (stage IA, grade 1). 
 Whether or not adjuvant chemotherapy should be administered for stage 
IC disease is still unclear.
GOG 95 (Young, JCO 2003)
REFERENCE
• Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early 
ovarian cancer: a randomized phase III trial of intraperitoneal 32P or 
intravenous cyclophosphamide and cisplatin— a gynecologic oncology 
group study. J Clin Oncol. 2003;21(23):4350-4305. PMID: 14645424. 
(Young et al. 2003)
TRIAL SPONSORS
• Gynecologic Oncology Group (GOG)
• North Central Cancer Treatment Group (NCCTG)
• Southwest Oncology Group (SWOG)
RATIONALE FOR TRIAL
• Among patients with early- stage ovarian cancer, approximately 20% 
with stage I and 50% with stage II  will die of recurrent disease.
•  Trials conducted by the GOG and  others defi ned a subset of patients 
(stage IA and IB, grade 1) who have >90% chance for long- term sur-
vival without additional treatment beyond surgery (Dembo et al. 1979; 
Klaassen et al. 1988; Young et al. 1990; Vergote et al. 2001).
• For higher- risk patients with early disease, platinum or platinum/32P 
combinations have demonstrated modest benefi t, but no trial has been 
defi nitive (Vergote et al. 1992; Bolis et al. 1995).
• The GOG began a randomized trial in 1986 to compare 32P with cyclo-
phosphamide and cisplatin in patients with early- stage ovarian cancer 
and a high risk for recurrence. This manuscript summarizes the mature 
results of the trial with a median follow-up of 10 years.
PATIENT POPULATION
• N = 251 enrolled.
• Accrual between 1986 and 1994.
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• Early- stage ovarian cancer  after defi nitive surgery and no macroscopic 
residual disease.
• Stage IA or IB (grade 3), stage IC or II (any grade), or any stage I or II 
with clear cell histology.
• Adequate bone marrow, renal, and hepatic function.
• Surgical staging was generally done through a vertical midline inci-
sion and included a total abdominal hysterectomy, bilateral salpingo- 
oophorectomy, partial infracolic omentectomy, and resection of all 
gross disease. The tumor capsule was examined for rupture, excres-
cences, or any adhesions requiring sharp dissection. Peritoneal fl uid 
volume was estimated and aspirated, or separate washings from the 
pelvis, paracolic gutter, and infradiaphragmatic areas  were sent. All 
peritoneal surfaces (including the undersurfaces of both diaphragms, 
serosa, and mesentery)  were to be visually inspected and palpated for 
evidence of implants. If  there was no vis i ble metastatic disease, biop-
sies of the cul- de- sac, vesico- uterine peritoneum, bilateral pelvic side 
walls, paracolic gutters, undersurface of the diaphragm, and sampling 
of the pelvic and para- aortic lymph nodes  were performed.
Exclusion Criteria
• Borderline or low malignant potential tumors  were excluded.
TREATMENT DETAILS
Arm 1: intraperitoneal 32P
• Single dose of 15 mCi intraperitoneal 32P.
• Before administration of 32P, 99m technetium or radio- opaque contrast 
material was used to evaluate the adequacy of intraperitoneal distribu-
tion.  Those with inadequate distribution  were not treated.
Arm 2: Cyclophosphamide and Cisplatin
• Cyclophosphamide 1 g/m2.
• Cisplatin 100 mg/m2.
• Three cycles  every 21 days.
ASSESSMENTS
• Not specifi ed in manuscript.
ENDPOINTS
• Not specifi ed in manuscript.







• Planned sample size was 200 patients  until at least 28 deaths  were 
reported in the 32P arm.
• Assuming a proportional hazards model, the planned sample size would 
provide greater than 80% chance of detecting a true treatment effect, 
improving the 5- year survival rate from 80% to 90% with a type I error 
of 0.05 for a 1- tail log- rank test.
Statistical Tests
• Kaplan- Meier used to estimate cumulative survival function (Kaplan 
and Meier 1958).
• Proportional hazards model used to estimate the crude and adjusted 
hazards ratios (Cox 1972).
• Cumulative or marginal incidence of recurrence used to estimate the 
probability of recurrence in the presence of competing risks (Gaynor 
et al. 1993). This is the preferred method when  there are competing 
risks. Methods that treat noncancer deaths as censored survival times 
tend to overestimate the probability of recurrence.
CONCLUSION OF TRIAL
• In early- stage epithelial ovarian cancer at high risk for recurrence,  there 
was no difference in survival between adjuvant 32P or cyclophospha-
mide (C) and cisplatin (P), (CP). However,  there was lower cumulative 
recurrence with CP, making this the preferred adjuvant therapy for this 
patient population.
COMMENTS
• Ten- year probability of recurrence varied by stage.
• 27% risk for stage I.
• 44% risk for stage II.
• Ten- year survival rate for all patients on this trial was 68%.
• Other prognostic indicators:
• Presence of ascites was associated with a higher risk of recurrence 
 after adjusting for stage and grade.
• Clear cell histology had a relapse rate similar to grade 1 tumors in 
this trial.
• While both therapies  were well tolerated,  there  were diffi culties with 
32P administration.
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• 7% had inadequate distribution.
• 3% had small bowel perforation.
• Although  there is no difference in survival between treatment arms, 
the lower recurrence with chemotherapy and the diffi culties with 32P 
administration make chemotherapy the preferred treatment regimen. 
 These data are consistent with  those of 2 prior prospective  trials.






N = 119 Statistics
Patient characteristics
Age <49 30.9% 24.3%
Age 50-69 52.7% 60.5%
Age >70 16.4% 15.1%
Stage IA 8.2% 13.4%
Stage IB 0.9% 2.5%
Stage IC 61.8% 52.9%
Stage IIA 3.6% 8.4%
Stage IIB 2.7% 6.7%




Clear cell 23.6% 21.0%
Other 16.3% 16.7%
Grade 1 25.5% 25.2%
Grade 2 23.6% 27.7%
Grade 3 27.3% 26.1%
Clear cell 23.6% 21.0%
Treatment delivery
Did not receive treatment N = 10 N = 1
Effi cacy
10- year recurrence rate 35% 28% 29% lower with CP (NS)







CP, cyclophosphamide + cisplatin; NS, not signifi cant.





• The Norwegian Radium Hospital trial compared 32P to cisplatin in 
347 patients with completely resected stage I to III ovarian cancer. 
 There was no difference in 5- year disease- free survival. Late bowel 
complications occurred more frequently with 32P (9% vs 2%) (Ver-
gote et al. 1992).
• An Italian multicenter trial compared 32P to cisplatin in patients with 
stage IAii, IBii, and IC ovarian cancer. The 5- year disease- free sur-
vival rate was better with cisplatin (85% vs 65%, P = .008).  There was 
no difference in overall survival (Bolis et al. 1995).
• Putting this trial in the context of the ACTION and ICON1  trials 
(Colombo et al. 2003; Trimbos et al. 2003a; Trimbos et al. 2003b), data 
support the use of platinum- based chemotherapy for high- risk stage I 
and II ovarian cancer.  Whether surgical staging  will allow for exclu-
sion of adjuvant chemotherapy requires further study.
• While this trial advocates for the use of cisplatin and cyclophospha-
mide, better adjuvant therapy is required. In this trial, only 65% of stage 
I and 52% of stage II patients are expected to be alive and  free of recur-
rent ovarian cancer.
ICON1/ACTION Combined Analy sis (Trimbos, 
JNCI 2003)
REFERENCE
• Trimbos JB, et al. International Collaborative Ovarian Neoplasm trial 
1 and Adjuvant ChemoTherapy in Ovarian Neoplasm trial: two paral-
lel randomized phase III  trials of adjuvant chemotherapy in patients 
with early- stage ovarian carcinoma. J Natl Cancer Inst. 2003a;95(2):105-
112. PMID: 12529343. (Trimbos et al. 2003a)
TRIAL SPONSORS
• Eu ro pean Organ ization of Research and Treatment in Cancer (EORTC)
• Adjuvant ChemoTherapy in Ovarian Neoplasm Trial (ACTION)
• International Collaborative Ovarian Neoplasm (ICON1)
RATIONALE FOR TRIAL
• The question of adjuvant therapy to improve survival in  women with 
early- stage ovarian cancer has not been reliably answered to date.
• Patients with well or moderately differentiated early- stage ovarian can-
cer (stages I- IIA) may be treated with surgery alone.
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• However,  because the 5- year survival rate has been reported to be as 
low as 50% based on stage and grade of the tumor, vari ous  trials have 
investigated the use of adjuvant chemotherapy to improve survival 
outcomes.
• Whole abdominal radiation with intraperitoneal radioactive chromic 
phosphate (Richardson et al. 1985).
• GOG trial of observation vs melphalan (Young et al. 1990) included 
only 46 patients. No difference was found in the 2 arms.
• Italian trial of observation vs cisplatin included only 83 patients (Bolis 
et al. 1995). Cisplatin improved disease- free survival (hazard ratio 
[HR], 0.35; 95% confi dence interval [CI], 0.14-0.89) but did not impact 
overall survival (HR, 1.15; 95% CI, 0.44-2.98).
• Scandinavian study of observation vs carboplatin included only 162 
patients (Trope et al. 2000). No difference was found in the 2 arms.
• This was a preplanned combined analy sis of 2 parallel, randomized 
controlled  trials that compared platinum- based adjuvant chemotherapy 
with observation  after surgery for early- stage ovarian cancer.
• ICON1: International Collaborative Ovarian Neoplasm 1.
• ACTION: Adjuvant ChemoTherapy in Ovarian Neoplasm.
PATIENT POPULATION
• N = 925; 477 in ICON1 and 448 in ACTION.
• Enrollment between November 1990 and January 2000.
Eligibility for ACTION
• High- risk early- stage ovarian cancer, defi ned as FIGO stage IA and IB 
with grade 2 or 3 tumor; all grades of FIGO stages IC to IIA; all clear cell 
carcinomas.
• Strict guidelines given for comprehensive surgical staging.
Eligibility for ICON1
• All patients with histologically confi rmed epithelial ovarian cancer 
 were eligible if the clinician was uncertain  whether or not the patient 
would benefi t from immediate adjuvant chemotherapy. Patients of all 
stages  were potentially eligible, but the majority who  were enrolled had 
stage I or II disease.
• Guidelines for surgical staging: total hysterectomy, bilateral salpingo- 
oophorectomy, and omentectomy (total supracolonic omentectomy if 
grossly involved or removal of the distal 2 cm if grossly normal).
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• Patients received chemotherapy at the time of confi rmed recurrence.
Arm 2: Chemotherapy
• ACTION: At least 4 cycles of platinum- based regimen.
• Single- agent carboplatin.
• Single- agent cisplatin.
• Combination carboplatin.
• Combination cisplatin.
• ICON1: 6 courses of platinum- based adjuvant chemotherapy.
• CAP: cyclophosphamide (C) + doxorubicin/Adriamycin (A) + cis-
platin (P).
• Single- agent carboplatin.
• Other regimens that included platinum at a predefi ned minimum 
dose.
ASSESSMENTS
• Confi rmation of recurrence.
• ACTION: cytologic or histologic confi rmation.
• ICON1: clinical, radiologic, or histologic diagnosis.
ENDPOINTS
• Overall survival for both studies (primary endpoint).
• Recurrence- free survival for both studies.
STATISTICAL CONSIDERATIONS
• Analyzed by intention- to- treat basis.
• All statistical tests  were 2- sided.
• Stratifi ed log- rank test (by trial) used to compare survival between 
treatment arms.
• Log- rank statistics used to calculate hazard ratios.
• Kaplan- Meier curves to compare survival curves.
• Exploratory subgroup analyses  were performed to determine  whether 
the effect of chemotherapy was dif fer ent based on age, tumor stage, 
histologic cell type, and cell differentiation.
• χ2 test for interaction or trend was used to compare differences in rela-
tive effect size.










N = 465 Statistics
Patient characteristics
Age <55 51% 50%
Age 55-65 32% 27%
Age >65 17% 23%
Stage I <1% 2%
Stage IA 38% 36%
Stage IB 9% 10%
Stage IC 45% 45%
Stage II 6% 7%
Stage III 1% <1%




Clear cell 13% 15%
Other 6% 7%
Missing N = 14 N = 20
Grade 1 23% 22%
Grade 2 46% 47%
Grade 3 32% 32%
Unknown grade N = 16 N = 19
Treatment delivery




Single- agent cisplatin 3%
CAP 2%
Missing N = 40
Effi cacy
5- year OS 74% 82% HR 0.67 (0.50-0.90)
5- year RFS 65% 76% HR 0.64 (0.50-0.82)
Toxicity Not reported Not reported
CAP, cyclophosphamide + Adriamycin/doxorubicin + cisplatin; HR, hazard ratio; OS, overall 
survival; RFS, recurrence- free survival.
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• Systematic review of lit er a ture to identify all similarly performed  trials 
in early- stage ovarian cancer comparing platinum- based chemotherapy 
to observation.
• Pooled hazard ratio calculated to represent the overall risk of an event 
on immediate chemotherapy vs an event during observation.
• χ2 test for heterogeneity was used to test for statistical heterogeneity 
in all  trials.
CONCLUSION OF TRIAL
• The combined analy sis of the ICON1 and ACTION  trials demonstrates 
that platinum- based adjuvant chemotherapy improves overall survival 
and recurrence- free survival at 5 years in patients with early- stage ovar-
ian cancer.
COMMENTS
•  There was no evidence that the effect of adjuvant chemotherapy was 
any dif fer ent for any subgroups analyzed.
• Subgroup analy sis for staging completeness could not be done  because 
information about surgical staging was not collected in ICON1.
• Defi nitive conclusions are limited by small numbers within the subsets.
• Kaplan- Meier survival curves demonstrate an early and sustained 
separation of the curves for both overall survival (OS) and recurrence- 
free survival (RFS).
• The results of both individual  trials are similar to one another, with both 
demonstrating a benefi t from adjuvant chemotherapy administration 
(Colombo et al. 2003; Trimbos et al. 2003b).
• Overall survival.
• ACTION: HR, 0.69 (0.44-1.08).
• ICON1: HR, 0.66 (0.45-0.97).
• Recurrence- free survival.
• ACTION: HR, 0.63 (0.44-0.92).
• ICON1: HR, 0.65 (0.46-0.91).
• Systematic review of the lit er a ture identifi ed 8 randomized  trials com-
paring adjuvant chemotherapy to observation in early- stage ovarian 
cancer.
• Four  trials used melphalan or other non- platinum- based chemother-
apy and  were of limited relevance to clinical practice at the time 
(Hreshchyshyn et al. 1980; Krafft et al. 1980; Sigurdsson et al. 1982; 
Young et al. 1990).
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• Four  trials, including ACTION and ICON1,  were analyzed to provide 
a pooled estimate of the impact of platinum- based adjuvant che-
motherapy (Bolis et al. 1995; Trope et al. 2000; Colombo et al. 2003; 
Trimbos et al. 2003b).
• Pooled HR for OS: 0.72 (0.55-0.94; P = .17).
• Pooled HR for RFS: 0.66 (0.53-0.83; P < .001).
• No evidence for heterogeneity between the  trials.
• Only one- sixth of the patients in this trial  were optimally staged.
• While some might use this trial to justify the administration of platinum- 
based chemotherapy to the majority of patients with early- stage ovarian 
cancer, some might argue that evidence to support the use of adjuvant 
chemotherapy in optimally staged patients is lacking.
• Approximately 20% to 25% of patients with incompletely staged early 
ovarian cancer  will have occult stage III disease (Piver et al. 1978; 
Piver 1982; Young et al. 1983; Helewa et al. 1986). This might explain 
the benefi cial effect seen with adjuvant chemotherapy in the ICON1/
ACTION  trials.
• This trial suggests that single- agent carboplatin may be the treatment 
of choice for early- stage ovarian cancer.
• Strengths of the combined analy sis include the large number of patients 
included as well as the consistent results across the 2  trials.
ACTION (Trimbos, JNCI 2003; Trimbos, 
JNCI 2010)
REFERENCES
• Trimbos JB, et al. Impact of adjuvant chemotherapy and surgical stag-
ing in early- stage ovarian carcinoma: Eu ro pean Organisation for Research 
and Treatment of Cancer- Adjuvant ChemoTherapy in Ovarian Neoplasm 
trial. J Natl Cancer Inst. 2003b;95(2):113-125. PMID: 12529344. (Trim-
bos et al. 2003b)
• Trimbos B, et al. Surgical staging and treatment of early ovarian 
cancer: long- term analy sis from a randomized trial. J Natl Cancer Inst. 
2010;102(13):982-987. PMID: 20445161. (Trimbos et al. 2010)
TRIAL SPONSORS
• Eu ro pean Organ ization for Research and Treatment of Cancer (EORTC)
• Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION)






• Approximately 10% to 50% of patients with early- stage ovarian can-
cer treated with surgery have a recurrence. This high recurrence rate 
has led to vari ous attempts to use adjuvant treatment.
• A GOG trial randomized patients with stage IA or IB and grade 1 or 2 
ovarian cancer to observation or oral melphalan following surgery.  There 
was no survival difference, and although the number of patients in the 
trial was too small to draw defi nitive conclusions, the authors advocated 
for withholding chemotherapy for patients with comprehensively staged, 
low- grade, early- stage ovarian cancer (Young et al. 1990).
• An Italian study randomized patients with early stage- ovarian cancer 
to observation or cisplatin chemotherapy  after surgery. Chemotherapy 
led to a decrease in recurrence- free survival (HR, 0.35; 95% CI, 0.14-
0.89) but no difference in overall survival (HR, 1.15; 95% CI, 0.44-2.98). 
Salvage therapy was more effective in patients in the observation 
arm. The authors advocated for deferring chemotherapy  until the time 
of recurrence (Bolis et al. 1995).
• A Scandinavian study randomized 162 patients with early- stage ovarian 
cancer to observation or carboplatin following surgery.  There was no 
difference in disease- specifi c survival (HR, 0.94; 95% CI, 0.37-2.36) or 
overall survival (HR, 0.98; 95% CI, 0.52-1.83) (Trope et al. 2000).
• All prior randomized  trials of adjuvant chemotherapy in early- stage 
ovarian cancer have lacked statistical power to demonstrate an impact 
on survival. Prior  trials have not accounted for the adequacy of surgi-
cal staging. Approximately 24% of non– optimally staged patients with 
early- stage ovarian cancer have occult stage III disease (Young et al. 
1983; Helewa et al. 1986; Soper et al. 1992; Schueler et al. 1998).
• The ACTION trial was a phase III trial conducted to test the effi cacy 
of adjuvant chemotherapy on survival in patients with early- stage ovar-
ian cancer with an emphasis on the extent of surgical staging.
PATIENT POPULATION
• N = 448.
• Enrollment between November 1990 and January 2000 from 40 cen-
ters in 9 Eu ro pean countries.
Inclusion Criteria
• Epithelial ovarian cancer.
• FIGO stages IA- IB, grades 2-3
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• All stages IC and IIA.
• All stages I to IIA with clear cell histology.
• Surgical treatment.
• Total abdominal hysterectomy, bilateral salpingo- oophorectomy, sur-
gical staging.
• Conservative surgery consisting of unilateral salpingo- oophorectomy 
and surgical staging permitted for stage IA cancers (Zanetta et al. 
1997; Morice et al. 2001).
• Surgical staging had to consist of at least careful inspection and pal-
pation of peritoneal surfaces, biopsies of suspicious lesions.
• Staging categories.
• Optimal: inspection and palpation of all peritoneal surfaces, biopsies 
of any suspicious lesions, peritoneal washings, infracolic omentec-
tomy, peritoneal washings, blind biopsies (from the pouch of Douglas, 
bladder, pelvic sidewalls, paracolic gutters, right hemidiaphragm), iliac 
and periaortic lymph node sampling.
• Modifi ed: anything between optimal and minimal staging.
• Minimal: inspection and palpation of all peritoneal surfaces and the 
retroperitoneal area, biopsies of any suspicious lesions for metasta-
ses, peritoneal washings, and infracolic omentectomy.
• Inadequate: less than minimal staging but at least careful inspection 
and palpation of all peritoneal surfaces and the retroperitoneal area, 
biopsies of any suspicious lesions for metastases.
Exclusion Criteria
• Prior or concomitant second malignancy.
• WHO per for mance status greater than 3.
• Prior treatment with chemotherapy or radiation therapy.
• Expected inadequacy of follow-up.
• Interval of more than 6 weeks between surgery and randomization.
TREATMENT DETAILS
Arm 1: Observation
•  After surgery, no treatment  until recurrence.
Arm 2: Chemotherapy
• At least 4 courses of a platinum- based regimen following surgery, but 
6 courses  were recommended.
• Allowed regimens.
• Single- agent platinum of cisplatin 75 mg/m2.





• Single- agent platinum of carboplatin 350 mg/m2.
• Combination platinum- based regimens.
• Dose modifi cations for drug toxicity.
• Each center had to defi ne its adjuvant chemotherapy regimen and stay 
with that regimen for the duration of the trial.
Treatment  After Recurrence
• Confi rmed cytologically or histologically.
• Had to be the same chemotherapy regimen utilized by the center in the 
adjuvant treatment arm.
ASSESSMENTS
• No details in manuscript.
ENDPOINTS
• Overall survival (primary endpoint).
• Recurrence- free survival.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Institution.
• FIGO stage.
• Grade of tumor differentiation.
Sample Size
• Sample size was set arbitrarily to at least 1000 patients to account for 
the long life expectancy of patients with early- stage ovarian cancer 
and the small expected improvement in survival with chemotherapy.
• Interim analyses  were performed at fi xed intervals.
• Consideration was given to stopping the trial if the P value for the com-
parison of survival between treatment arms fell below .01.
• The committee closed the study in 2000 before the target accrual was 
achieved  because patient accrual took longer than expected.
Statistical Tests
• Kaplan- Meier method for time- to- event analy sis.
• Log- rank test to compare survival.
• Cox proportional hazards regression model to analyze prognostic 
 factors.










N = 224 Statistics
Patient characteristics
Median age (range) 55 (22-77) 54 (18-84)
Stage IA 33% 35%
Stage IB 8% 8%
Stage IC 51% 50%





Clear cell 12% 17%
Other/unknown 7% 6%
Grade 1 12% 12%
Grade 2 51% 50%
Grade 3 35% 35%
Unknown grade 2% 3%
Optimal staging 34% 34%
Modifi ed staging 30% 31%
Minimal staging 27% 24%
Inadequate staging 9% 11%
Missing information 1% 0%
Treatment delivery
Cisplatin + cyclophosphamide N/A 47%
Single- agent carboplatin N/A 33%
Protocol violations 13 received 
chemo
14 had no 
chemo
Effi cacy (2003)
No recurrence 73% 82%
Recurrence
Locoregional recurrence 9% 6%
Extrapelvic recurrence 13% 9%
Combined recurrence 5% 3%
5- year overall survival 78% 85% HR 0.69 (0.44-1.08)
Optimally staged No difference
Non- optimally staged HR 1.75 (1.04-2.95)
5- year recurrence- free survival 68% 76% HR 0.63 (0.43-0.92)
Optimally staged HR 1.14 (0.54-2.39)
Non- optimally staged HR 1.78 (1.15-2.77)





• χ2 test for interaction to compare difference in relative size of treatment 
effects between subgroups of staging per for mance.
• In the 2010 publication of long- term follow up, the median follow-up 
was 10.1 years (with a cutoff date of May 23, 2008). The analy sis was 
repeated using cancer- specifi c survival to reduce the bias of deaths from 
 causes other than ovarian cancer (this risk increases with the duration 
of follow-up).
• Cancer- specifi c survival was mea sured from date of randomization to 
date of death from ovarian cancer. Data  were censored at time of last 
known date alive for patients who had died of  causes other than ovar-
ian cancer.
• Recurrence- free survival was mea sured from date of randomization 
to date of fi rst documented date of recurrence or death from any 
cause.
CONCLUSION OF TRIAL
• With 5.5 years of follow- up: In patients with early stage ovarian can-
cer, adjuvant chemotherapy improved recurrence- free survival. The 
benefi t was limited to patients with nonoptimal staging (ie, patients with 
more risk of undiagnosed residual disease). In this cohort of patients, 
of whom two- thirds had under gone nonoptimal surgical staging,  there 
was no difference in overall survival observed.





N = 224 Statistics
Effi cacy (2010, long- term 
follow- up)
Recurrences 38.8% 27.2%
10- year cancer- specifi c survival 76% 82% HR 0.73 (0.48-1.13)
Optimally staged 89% 85% HR 1.58 (0.61-4.08)
Non- optimally staged 69% 80% HR 0.58 (0.35-0.95)
10- year recurrence- free survival 62% 70% HR 0.64 (0.46-0.89)
Optimally staged 72% 78% HR 0.73 (0.38-1.42)
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• With 10.1 years of follow- up: Long- term analyses supported the 
original conclusions of the trial but now show that optimal surgical 
staging is associated with improved overall survival. The benefi t to 
adjuvant chemotherapy was limited to patients with nonoptimal sur-
gical staging.
COMMENTS
• Prognostic  factors for recurrence- free and overall survival included
• Staging adequacy
• Tumor grade
• This study did not fi nd stage to be a prognostic  factor. Stage IC disease 
was not associated with a higher risk of recurrence or death compared 
to moderately or poorly differentiated stage IA and IB disease. This 
might be impor tant to consider when defi ning high- risk early- stage 
ovarian cancer.
• Of the 448 patients, 151 had optimal staging.
• Among patients in the observation arm, nonoptimal staging was 
associated with worse overall survival (HR, 2.31; 95% CI, 1.08-4.96) 
and recurrence- free survival (HR, 1.82; 95% CI, 1.02-3.24) compared 
to patients undergoing optimal staging.
• Among patients receiving adjuvant chemotherapy,  there was no dif-
ference in overall or recurrence- free survival.
•  Because this study demonstrated that the poorer prognosis of non– 
optimally staged patients could be corrected by administration of adju-
vant chemotherapy, chemotherapy may have its impact on treating 
small- volume occult implants and metastases.
•  There was a difference in salvage rates in patients treated for recurrent 
disease.
• In non– optimally staged patients, the salvage rates  after observation 
and chemotherapy  were similar (70% and 64%).
• In optimally staged patients, salvage chemotherapy was more suc-
cessful  after observation than  after adjuvant chemotherapy (75% 
and 46%).
• If this  were a reproducible fi nding in other studies,  these data would 
provide support to postponing chemotherapy  until time of recurrence, 
as long as optimal surgical staging had been performed.
• Adjuvant chemotherapy is effective in patients with occult residual dis-
ease (due to nonoptimal surgical staging).





• Interpretation of results from this study should include consideration 
for the smaller sample sizes when performing subgroup analyses.
• In long- term analy sis, optimal surgical staging was associated with bet-
ter survival ( Table 1.8).
• While the trial makes conclusions about surgical staging procedures 
and survival, the trial was not originally designed to look at this 
question.
• In long- term analy sis limited to the grade 3 tumors, administration of 
chemotherapy  after optimal staging does not improve outcomes 
( Table 1.9). This may be due to the tendency for  these tumors to metas-
tasize earlier (Young et al. 1983).
• Design of this study permits no clear- cut guidelines for the treatment 
of all early- stage ovarian cancers. However, the authors conclude that 
 these data support the recommendation that all patients with nonopti-
mal staging be offered restaging or adjuvant chemotherapy if restaging 
is not feasible. They further conclude that this trial provides convincing 
 Table 1.8  ACTION Trial: Effi cacy at Long- Term Follow- Up
Effi cacy (2010, long- term follow-up) Optimal Nonoptimal Statistics
10- year cancer- specifi c survival
Observation 89% 69% HR 3.28 (1.47-7.33)
Chemotherapy 85% 80% HR 1.27 (0.62-2.58)
10- year recurrence- free survival
Observation 72% 56% HR 1.91 (1.17-3.11)
Chemotherapy 78% 65% HR 1.64 (0.91-2.93)
HR, hazard ratio.
 Table 1.9  ACTION Trial: Effi cacy at Long- Term Follow- Up, Limited to Grade 3 Tumors
Effi cacy (2010, long- term follow-up) Observation Chemotherapy Statistics
Limited to grade 3 tumors
10- year cancer- specifi c survival
Optimally staged 85% 69% HR 2.58 (0.66-9.99)
Non- optimally staged 56% 77% HR 0.40 (0.19-0.81)
10- year recurrence- free survival
Optimally staged 64% 49% HR 1.25 (0.53-2.95)
Non- optimally staged 52% 55% HR 0.58 (0.33-1.02)
HR, hazard ratio.
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evidence to withhold chemotherapy for optimally staged patients, 
including  those with grade 3 tumors, and cite evidence that 20% of 
long- term survivors of ovarian cancer  will develop secondary malig-
nancies as a result of treatment with platinum- based chemotherapy 
(Travis et al. 1996).
ICON1 (Colombo, JNCI 2003)
REFERENCE
• Colombo N, et al. International Collaborative Ovarian Neoplasm trial 
1: a randomized trial of adjuvant chemotherapy in  women with early- 
stage ovarian cancer. J Natl Cancer Inst. 2003;95(2):125-132. PMID: 
12529345. (Colombo et al. 2003)
TRIAL SPONSORS
• Three parallel  trials.
• Istituto Mario Negri in Milan, Italy.
• Swiss Group for Clinical Cancer Research (SAAK) in Bern, 
Switzerland.
• Clinical  Trials Unit of the Medical Research Council (MRC CTU), 
Cancer Division, London, United Kingdom.
RATIONALE FOR TRIAL
• Early- stage ovarian cancer represents approximately 30% of ovarian 
cancers. While early- stage ovarian cancer has a better prognosis than 
stage III and IV disease, 50%  will recur (Bjorkholm et al. 1982; Dent 
et al. 2000).
• Low- risk early- stage ovarian cancer is cured with surgery alone, but 
 there is no clear consensus on what represents low- risk disease.
• No randomized trial has demonstrated a survival advantage of adjuvant 
therapy in early- stage ovarian cancer  after surgery, including  those using 
intraperitoneal radiation therapy, systemic chemotherapy, or abdom-
inal and pelvic radiation therapy (Hreshchyshyn et al. 1980; Krafft 
et al. 1980; Sigurdsson et al. 1982; Sevelda et al. 1987; Klaassen et al. 
1988; Young et al. 1990; Vergote et al. 1992; Chiara et al. 1994; Bolis 
et al. 1995; Fyles et al. 1998; Trope et al. 2000).
• This trial was designed to answer  whether immediate adjuvant chemo-
therapy  after surgery would improve outcomes in patients with early- 
stage epithelial ovarian cancer.






• N = 477 enrolled.
• Enrollment between August 1991 and January 2000 from 84 centers 
in 5 countries (United Kingdom, Ireland, Brazil, Switzerland, and Italy).
• Anticipating the need for a large number of patients to demonstrate 
improved outcomes (with low rates of recurrence and death in early- stage 
ovarian cancer), the eligibility criteria  were kept as  simple as pos si ble.
• A patient was eligible if the clinician was unsure  whether the patient 
required immediate chemotherapy and the patient had histologically 
confi rmed epithelial ovarian cancer.
• Patient fi t to receive chemotherapy.
• No prior malignant disease (except nonmelanoma skin cancer) and 
no prior radiation therapy or chemotherapy.
TREATMENT DETAILS
Surgery
• All vis i ble tumor had to be removed.
• Thorough surgical staging with total abdominal hysterectomy, bilateral 
salpingo- oophorectomy, and omentectomy, where appropriate,  were 
recommended as the minimum procedures.
Arm 1: Observation
Arm 2: Chemotherapy
• Recommended: 6 cycles of single- agent carboplatin or CAP (cyclophos-
phamide + doxorubicin + cisplatin), although other platinum- containing 
regimens (combination carboplatin or single- agent cisplatin)  were allowed.
• Recommended dose of carboplatin.
• Single- agent: area  under the curve (AUC) 5 mg/mL.
• Combination: AUC 4 mg/mL.
• AUC method of Calvert (Calvert et al. 1989) where GFR is mea sured 
glomerular fi ltration rate.
• Recommended dose of cisplatin.
• Single agent: 70 mg/m2.
• Recommended dose of CAP.
• Cyclophosphamide 500 mg/m2.
• Doxorubicin 50 mg/m2.
• Cisplatin 50 mg/m2.
• Type of planned chemotherapy regimen had to be registered prior to 
randomization.
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• Collected 6 and 12 months  after randomization and yearly thereafter.
• Information collected on patients’ vital and disease status and treat-
ment for recurrence.
ENDPOINTS
• Overall survival, defi ned as time from randomization to time of death 
from any cause (primary endpoint).
• Recurrence- free survival, defi ned as time to clinically defi ned recur-
rence or death from any cause.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Center.
• FIGO stage.
• Degree of tumor differentiation.
Sample Size
• Sample size calculation was complicated by the fact that survival was 
likely to vary with tumor stage and the diffi culty in estimating the pro-
portions of patients with each stage.
• Trial originally planned to include 2000 patients to have 90% power to 
detect and absolute increase in 5- year survival of 7% (from 60% to 67%) 
at 2- sided α of 0.05.
• Single in de pen dent data monitoring committee would monitor com-
bined data from both ICON1 and ACTION  trials (Trimbos et al. 
2003a). Trial would not be stopped  unless the results  were extremely 
positive— that is, P < .001.
• During the trial, the data- monitoring committee noted that survival 
was better than anticipated and that accrual was slow. The sample size 
across both  trials was reduced to 900 patients. In a combined analy sis, 
this would provide 90% power to detect an improvement in 3- year 
survival of 6% (from 85% to 91%) at a 2- sided α of 0.05.
Statistical Tests
• Kaplan- Meier curves for OS and RFS.
• Mantel- Cox version of log- rank test to compare survival curves.
• Stratifi ed log- rank test to allow for differences across the 2 random-
izing centers.










N = 241 Statistics
Patient characteristics
Median age 55 56
No residual 99% 99%
≤2 cm residual <1% 1%
Stage I 2% 4%
Stage IA 41% 37%
Stage IB 11% 11%
Stage IC 39% 41%
Stage II 6% 6%




Clear cell 16% 14%
Other 5% 10%
Grade 1 32% 31%
Grade 2 40% 42%
Grade 3 28% 27%
Treatment delivery
Single- agent carboplatin 87%
Combination cisplatin 11%
Combination carboplatin 2%
Single- agent cisplatin <1%
Unspecifi ed chemotherapy <1%
No chemotherapy N = 12 (6%)
Chemotherapy N = 6
6 cycles per protocol 49%
6 cycles with modifi cations 31%
<6 cycles of chemo 15%
Effi cacy
5- year overall survival 70% 79% HR 0.66 (0.45-0.97)
5- year recurrence- free survival 62% 73% HR 0.65 (0.46-0.91)
Toxicity Not reported Not reported
HR, hazard ratio.
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• In  women with early- stage ovarian cancer, administration of adjuvant 
chemotherapy improved 5- year overall survival (70% vs 79%) and 
5- year recurrence- free survival (62% vs 73%).
COMMENTS
• ICON1 and ICON2  were initiated at the same time with  simple eligi-
bility criteria so that all patients with epithelial ovarian cancer could be 
considered for entry into one of  these  trials: ICON1 for early- stage dis-
ease and ICON2 for advanced stage disease.
• The clinician was asked  whether the patient required immediate 
chemotherapy.
• If the clinician was uncertain, then they  were asked to consider enroll-
ment to ICON1 with randomization to observation vs immediate 
chemotherapy.
• If the clinical was certain, then they  were asked to consider enrollment 
to ICON2 with randomization to CAP (cyclophosphamide + doxorubi-
cin + cisplatin) vs single- agent carboplatin (International Collaborative 
Ovarian Neoplasm 1998).
• ICON1 is the largest trial performed to date in early- stage ovarian can-
cer and provides evidence that adjuvant platinum- based chemotherapy 
delays recurrence and improves survival in a broad spectrum of patients 
with early- stage epithelial ovarian cancer.
• While the inclusion criteria for ICON1  were broad with no restrictions 
on stage or grade, 90% of patients had stage I to IC disease and likely 
representative of patients seen in clinical practice.
• When ICON1 was launched,  there was limited lit er a ture to support the 
use of adjuvant chemotherapy in  these patients.
• Three small, randomized  trials compared observation to immediate 
treatment following surgery for early- stage ovarian cancer (Hresh-
chyshyn et al. 1980; Krafft et al. 1980; Young et al. 1990).
• Two small, randomized  trials  were inconclusive when comparing 
delayed to immediate platinum- based chemotherapy in patients with 
early- stage ovarian cancer (Bolis et al. 1995; Trope et al. 2000).
• A meta- analy sis of  these  trials supports the use of platinum- based che-
motherapy in early- stage ovarian cancer (O’Brien and Fleming 1979).
• Limitations to ICON1





• This was an open study that is subject to ascertainment bias. However, 
the primary endpoint of overall survival is less likely to have been 
affected by bias. Ascertainment of recurrence was by radiographic 
criteria, and all patients  were followed on the same radiographic 
assessment timeline, regardless of treatment arm. This also minimizes 
the likelihood of ascertainment bias.
•  There was a small amount of crossover among the groups. However, 
the authors predict that the crossover would diminish the possibility 
of observing an effect and that the benefi t of adjuvant chemotherapy 
was, if anything, underestimated in this trial.
• Given that the majority of patients in this trial received single- agent 
carboplatin, this should be considered the treatment of choice for patients 
with early- stage epithelial ovarian cancer.
GOG 157 (Bell, Gynecol Oncol 2006)
REFERENCE
• Bell J, et al. Randomized phase III trial of three versus six cycles of 
adjuvant carboplatin and paclitaxel in early stage epithelial ovarian 
carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 
2006;102(3):432-439. PMID: 16860852. (Bell et al. 2006)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• Approximately 30% of ovarian cancers pres ent at early stage and can 
be completely resected at the time of initial surgery.
• The question about need for adjuvant therapy for early- stage epithelial 
ovarian cancer has been the subject of numerous clinical  trials in the 
prior 20 years.
• Patients with stage IA or IB disease and favorable histology have excel-
lent survival of greater than 90% at 6 years  after surgical staging only. 
Adjuvant chemotherapy is considered unnecessary for  these patients 
if a thorough surgical staging has been performed (Young et al. 1990).
• A subgroup of patients with early- stage ovarian cancer have signifi cant 
5- year recurrence rates of approximately 25% to 45% and require adju-
vant chemotherapy.  These patients include
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• The optimal adjuvant chemotherapy regimen for  these high- risk, early- 
stage epithelial ovarian cancer patients remains unknown. However, the 
following series of  trials led the GOG to select platinum- based chemo-
therapy as standard treatment for  these patients.
• An earlier GOG trial demonstrated similar survival rates of approxi-
mately 80% at 6 years with  either intraperitoneal 32P or oral melphalan 
(Young et al. 1990).
• A subsequent GOG study compared intraperitoneal 32P with 3 cycles 
of cisplatin plus cyclophosphamide. The recurrence rate was 31% 
lower on the cisplatin regimen, but this was not a statistically signifi -
cant fi nding (Young et al. 2003).
• A multicenter Italian trial compared intraperitoneal 32P to cisplatin 
in stage IC ovarian cancer and found cisplatin to signifi cantly reduce 
the relapse rate by 61% (Bolis et al. 1995).
• Carboplatin and paclitaxel is the standard adjuvant chemotherapy reg-
imen for advanced stage ovarian cancer (Alberts et al. 1992; McGuire 
et al. 1996). This led to the se lection of  these drugs for this trial.
• The optimal duration of chemotherapy is unknown.
• In advanced ovarian cancer, 3  trials comparing 5 to 6 cycles with 
8 to 12 cycles of cisplatin- based chemotherapy demonstrated no ben-
efi t beyond 6 cycles (Bertelsen et al. 1999).
• In early- stage ovarian cancer, the GOG has historically used 3 cycles 
of chemotherapy as standard treatment.
• This study was designed to compare recurrence rates with 3 vs 6 cycles 
of carboplatin and paclitaxel chemotherapy in patients with surgically 
resected early- stage ovarian cancer.
PATIENT POPULATION
• N = 457 enrolled, 427 eligible.
• Enrollment between March 1995 and May 1998.
Inclusion Criteria
• Early- stage epithelial ovarian cancer.
• Stages: IA grade 3 or clear cell, stage IB grade 3 or clear cell, stage 
IC, and stage II.





• Staging operation with completely resected tumor.
• Required procedures included total hysterectomy, bilateral salpingo- 
oophorectomy, resection of all gross disease, aspiration of  free perito-
neal fl uid, peritoneal washings for cytology, infracolic omentectomy, 
selective bilateral pelvic and para- aortic node dissections, peritoneal 
biopsies from 4 pelvic locations and bilateral paracolic areas, and 
right diaphragm cytology or biopsy.
• Surgical reports, pathology reports, and representative pathology mate-
rials  were reviewed centrally to confi rm eligibility.
• No prior treatment except surgery.
• Adequate bone marrow, renal, and hepatic function.
• GOG per for mance status less than 3 (listed as less than 4 in the manu-
script, but this is likely an error).
• Entered in the trial within 6 weeks following staging laparotomy.
Exclusion Criteria
• Borderline or low malignant potential tumors  were ineligible.
TREATMENT DETAILS
• Randomized to 3 or 6 cycles of chemotherapy.
• Chemotherapy details.
• Paclitaxel 175 mg/m2 by 3- hour infusion.
• Carboplatin AUC 7.5 by 30- minute infusion.
• Treatment was administered  every 21 days.
• Standard paclitaxel premedications included dexamethasone, diphen-
hydramine, and cimetidine.
• Treatment modifi cations designed to maximize dose intensity.
• Minimum blood counts for treatment.
• ANC (absolute neutrophil count) 1500 cells/mm3.
• Platelets of 100,000 cells/mm3.
• Treatment modifi cations  were instituted sequentially.
• Course delay.
• Dose reduction (only if delay more than 2 weeks).
• Filgrastim (only if recurrent delays or neutropenic complications  after 
dose reduction).
ASSESSMENTS
• Toxicity assessed by standard GOG toxicity criteria.
• Weekly blood counts.
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• Physical exam prior to each treatment, then  every 3 months for 2 years, 
 every 6 months for 3 years, then  every year.
ENDPOINTS
• Primary endpoint was recurrence rate. Recurrence was defi ned as any 
clinical or radiographic evidence of new tumor.
• Time at risk of recurrence. Assessed from the date of registration to 




• Sample size of 330 patients.
• Calculated to provide an 85% chance of identifying a 50% reduced 
risk of recurrence with a 1- tailed α of 0.05. This is comparable to 
increasing the expected percentage of patients who are recurrence 
 free at 4 years from 80.6% to 89.8%.
• Interim analy sis was to be conducted when at least 35 recurrences 
 were noted in order to rule out an extreme difference in the recur-
rence rate between the groups.
• Data  were considered to be mature for results release when at least 
21% of the eligible patients had experienced a recurrence.
• To account for a pos si ble loss of statistical power if patients random-
ized to 6 cycles did not receive all 6 cycles, the statistical design 
allowed for an increase in the minimum required number of events 
necessary for study maturity by increasing  either the targeted accrual 
or the postaccrual follow-up period (Lachlin and Foulkes 1986).
Statistical Tests
• Proportional hazards model was used to compare recurrence rates, 
adjusted for FIGO stage and histologic grade.
• The cumulative incidence of cancer recurrence was estimated using a 
procedure that treats non- cancer- related death as a competing risk (Pepe 
and Mori 1993).
CONCLUSION OF TRIAL
• Six cycles of adjuvant chemotherapy does not signifi cantly reduce the 
cancer recurrence rates compared to 3 cycles of chemotherapy in patients 
with high- risk, early- stage ovarian cancer. The additional cycles of 
chemotherapy signifi cantly increased toxicity.





 Table 1.11  Results of GOG 157
Treatment arm
CP × 3 cycles
N = 213
CP × 6 cycles
N = 214 Statistics
Patient characteristics
Age <50 32.4% 33.6%
Age 50-70 53.5% 49.5%
Age >70 14.1% 16.8%
Stage I 66.2% 71.0%




Clear cell 32.9% 28.0%
Other 15.0% 14.9%
Grade 1 12.7% 15.9%
Grade 2 23.5% 22.9%
Grade 3 31.0% 33.2%
Treatment delivery





Patient refused 0.5% 1.4%
Other 0.0% 0.9%
Effi cacy
5- year recurrence rate 25.4% 20.1% HR 0.76 (0.51-1.13)
Complete staging 23% 20% HR 0.79
Incomplete staging Not reported Not reported HR 0.66
5- year survival rate 81% 83% HR 1.02 (0.66-1.57)
Toxicity
Grade 3/4 neurotoxicity 2% 11% P < .01
Grade 4 granulocytopenia 52% 66% P < .01
Grade 2-4 anemia 32% 48% P < .01
CP, carboplatin + paclitaxel; HR, hazard ratio.
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•  After adjusting for FIGO stage and tumor grade, the recurrence risk 
was 24% lower in patients receiving 6 cycles of chemotherapy (HR, 
0.76; 95% CI, 0.51-1.13).
• A large number of patients had incomplete or inadequately documented 
staging procedures (58 in the 3- cycle arm and 68 in the 6- cycle arm).
• The 5- year cumulative recurrence risk was 22% for patients with com-
plete staging and 26% for patients without (not statistically signifi cant).
• The estimated benefi t of 6 cycles was slightly less for patients who had 
complete staging (HR, 0.79) compared to  those with incomplete or 
incompletely documented staging (HR, 0.66). However,  there is not sig-
nifi cant evidence of heterogeneity in the treatment effect.
• Cumulative incidence of recurrence within 5 years for dif fer ent sub-
groups, irrespective of treatment regimen:
• Stage I, complete staging: 18%.
• Stage II, complete staging: 31%.
• Stage I, incomplete staging: 20%.
• Stage II, incomplete staging: 40%.
• One patient developed myelodysplastic syndrome 3.5 years  after study 
entry. Due to a prior report of a dose- response relationship between 
platinum- based chemotherapy and secondary leukemia (Travis et al. 
1999), limiting therapy to the fewest effective number of cycles should 
be considered.
• Patients with early epithelial ovarian cancer appear to have a similar 
risk of recurrence, regardless of the type of adjuvant therapy received. 
Across dif fer ent  trials, the 5- year disease- free rate is
• GOG 157 (this trial): 75% to 80%.
•  After 12 cycles of melphalan or intraperitoneal 32P (Young et al. 1990): 
78% to 80%.
•  After 3 cycles of cisplatin and cyclophosphamide (Young et al. 
2003): 79%.
•  After 6 cycles of cisplatin (Vergote et al. 1992): 79%.
•  After 32P (Vergote et al. 1992): 82%.
•  After any platinum- based chemotherapy (Trimbos et al. 2003a): 76%.
• Approximately 15% to 30% of patients with early epithelial ovarian 
cancer have re sis tance to chemotherapy. This poses the question as to 
 whether withholding postoperative chemotherapy  until recurrence 
would result in acceptable overall survival while sparing the majority 
of patients who do not need chemotherapy from unnecessary toxicity.





• This question was studied in the ACTION trial in which patients  were 
randomized to  either 4 or more cycles of adjuvant chemotherapy or 
observation (Trimbos et al. 2003b).
• ACTION showed a signifi cant improvement in 5- year recurrence- free 
survival in patients receiving chemotherapy (76% vs 68%; P = .02) 
but no difference in overall survival (85% vs 78%; P = .10).
• Patients who had suboptimal surgical staging and randomized to obser-
vation had signifi cantly worse recurrence- free survival (78% vs 65%; 
P = .009) and overall survival (84% vs 75%; P = .03).
• In patients who had optimal surgical staging,  there was no difference 
in recurrence- free survival (83% vs 80%) or overall survival (87% vs 
89%). However, this represents only 34% of the overall patient popula-
tion in the trial, and the numbers may be too small to draw defi nitive 
conclusions.
• Retrospective studies suggest that withholding adjuvant treatment for 
patients with unstaged low- risk early ovarian cancers results in a higher 
rate of cancer recurrence compared to patients who have surgically doc-
umented stage I disease (Le et al. 2002).
• The ACTION trial suggest that high- risk stage I patients who have 
under gone complete surgical staging may have the option to delay che-
motherapy  until cancer recurrence without signifi cantly compromising 
survival (Trimbos et al. 2003).
• GOG 157 suggests that  after complete surgical staging, patients with 
high- risk, early- stage ovarian cancer could be treated with 3 cycles of 
adjuvant carboplatin and paclitaxel chemotherapy, and 3 additional 
cycles would provide only a marginal reduction in the risk of recurrence 
while increasing toxicity.
• The risk of recurrent cancer in this patient population appears to be 
relatively unchanged over the years, and  future studies should investi-
gate combination chemotherapy, biological modifi ers, and molecular 
targets.
GOG 157 Exploratory Analy sis (Chan, Gynecol 
Oncol 2010)
REFERENCE
• Chan JK, et al. The potential benefi t of 6 vs. 3 cycles of chemotherapy in 
subsets of  women with early- stage high- risk epithelial ovarian cancer: 
an exploratory analy sis of a Gynecologic Oncology Group study. Gyne-
col Oncol. 2010;116(3):301-306. PMID: 19945740. (Chan et al. 2010)
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• This was an exploratory analy sis of GOG 157 to determine  whether 
any subgroups  were more likely to benefi t from 6 vs 3 cycles of adju-
vant chemotherapy.
CONCLUSIONS
• This exploratory analy sis suggests that patients with early- stage, high- 
risk ovarian cancer and serous histology benefi t from 6 compared to 
3 cycles of adjuvant paclitaxel and carboplatin chemotherapy. The 
additional chemotherapy reduced the risk of recurrence but did not 
infl uence overall survival.
COMMENTS
• Early- stage epithelial ovarian cancer represents a heterogeneous group 
of tumors.
• The results of this study are consistent with prior studies that demon-
strate higher response rates to chemotherapy of serous compared to 
clear cell cancers.
• Pectasides (Pectasides et al. 2006): 81% vs 54% response rates for 
serous vs clear cell.
• Sugiyama (Sugiyama et al. 2000): 72.5% vs 11.1% response rates for 
serous vs clear cell.
• This exploratory study was not planned during the design of the origi-
nal trial, and the trial was not adequately powered for subset analyses. 
This leaves open the possibility that  these results are generated by 
chance. A test of homogeneity showed that  there is no statistically sig-
nifi cant evidence that the treatment effect varies across histologies.
• It is pos si ble that more cycles of chemotherapy delayed recurrence 
rather than prevented relapse and improved survival.





 Table 1.12  Results of GOG 157 Exploratory Analy sis
Treatment Arm
CP × 3 cycles
N = 213
CP × 6 cycles
N = 214 Statistics
Effi cacy
5- year RFS
Age ≤ 55 HR 0.73 (0.38, 1.39)
Age >55 HR 0.69 (0.42, 1.15)
Per for mance status 0 HR 0.98 (0.58, 1.63)
Per for mance status 
1-2
HR 0.49 (0.27, 0.90)
Stage IA or IB HR 0.74 (0.25, 2.21)
Stage IC HR 0.75 (0.41, 1.36)
Stage II HR 0.76 (0.42, 1.39)
Serous 60.4% 82.7% HR 0.33 (0.14, 0.77)
Non- serous 78.6% 78.7% HR 0.94 (0.60, 1.49)
Endometrioid HR 1.07 (0.47, 2.44)
Clear cell HR 0.90 (0.43, 1.91)
Mucinous HR 1.68 (0.30, 9.29)
Other HR 0.74 (0.28, 1.93)
Grade 1 HR 0.36 (0.09, 1.45)
Grade 2 HR 0.67 (0.30, 1.49)
Grade 3 HR 0.78 (0.42, 1.45)
No ascites HR 0.83 (0.52, 1.33)
Ascites HR 0.56 (0.27, 1.15)
No tumor rupture HR 0.60 (0.37, 0.99)
Tumor rupture HR 1.03 (0.53, 1.97)
Cytology negative HR 0.67 (0.42, 1.08)
Cytology positive HR 0.85 (0.42, 1.70)
5- year OS
Serous 73.2% 85.6% P = 0.19
 Non- serous 84.1% 83.0%
CP, carboplatin + paclitaxel; HR, hazard ratio; OS, overall survival; RFS, recurrence- free 
survival.





The standard of care adjuvant chemotherapy regimen for advanced 
ovarian cancer evolved from cyclophosphamide + doxorubicin/Adria-
mycin + cisplatin (CAP) (GOG 47) to cyclophosphamide + cisplatin (CP) 
(GOG 52) to paclitaxel + cisplatin (TP) (GOG 111, OV-10) to paclitaxel + car-
boplatin (TC) (Danish Netherlands Trial, GOG 158, AGO/OVAR-3). How-
ever, outcomes may be similar with single- agent platinum therapies (GOG 
132, ICON2) or with the exclusion of paclitaxel (ICON3). Outcomes are 
improved but toxicities are increased with intraperitoneal cisplatin admin-
istration (GOG 104, GOG 114, GOG 172). Outcomes appear to be improved 
with dose density (JGOG 3016) but are not improved with dose intensity 
(GOG 97) or weekly administration (MITO-7). Addition of a third drug 
to the paclitaxel and carboplatin backbone does not improve overall sur-
vival (GOG 182/ICON5, AGO- OVAR9, OV16, ICON7, GOG218), but the 
substitution of a dif fer ent drug for paclitaxel does not compromise out-
comes (SCOTROC, MITO-2).
GOG 47 (Omura, Cancer 1986)
REFERENCE
• Omura GA, et al. A randomized trial of cyclophosphamide and doxo-
rubicin with or without cisplatin in advanced ovarian carcinoma. Cancer. 
1986;57(9):1725-1730. PMID: 3513943. (Omura et al. 1986)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
CHAPTER 2
Advanced Stage Epithelial 
Ovarian Cancer
Adjuvant Chemotherapy






• The combination of doxorubicin and cyclophosphamide resulted in a 
better response rate than melphalan in patients with bulky disease (32% 
vs 20%). However, overall survival was not improved (Omura et al. 1983).
• Cisplatin was found to be a highly active agent in ovarian cancer.
• This trial was performed to determine  whether the addition of cispla-
tin to doxorubicin and cyclophosphamide would improve results.
PATIENT POPULATION
• N = 516, of which 440  were evaluable.
• Enrolled between June 1979 and March 1982.
• Stage IV or suboptimal stage III (defi ned as residual lesions greater than 
3 cm) primary ovarian cancer or recurrent ovarian cancer equivalent 
to suboptimal stage III or stage IV.
TREATMENT DETAILS
Arm 1: CA (Cyclophosphamide + doxorubicin).
• Cyclophosphamide 500 mg/m2.
• Adriamycin (doxorubicin) 50 mg/m2.
• Administered  every 3 weeks × 8 courses over 6 months.
Arm 2: CAP (Cyclophosphamide + doxorubicin + Cisplatin).
• Cyclophosphamide 500 mg/m2.
• Adriamycin (doxorubicin) 50 mg/m2.
• Cisplatin 50 mg/m2.
• Administered  every 3 weeks × 8 courses over 6 months.
Additional Treatment Details
• Complete responders underwent second- look laparotomy.
• If no evidence of disease or all disease resected, patients received cyclo-
phosphamide alone  every 3 weeks, escalating from 500 mg/m2 to 1100 mg/
m2  until relapse or a total of 12 months  after second- look surgery.
• If residual cancer  after second- look surgery, patients went off treatment 
and  were followed for survival.
Dose Reductions
• Grade 3 granulocyte or platelet toxicity with recovery by next cycle: dose 
reduced to 75% for doxorubicin and cyclophosphamide (not reduced 
for cisplatin).
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• Grade 4 granulocyte or platelet toxicity with recovery to next cycle: 
dose reduced to 50% for doxorubicin and cyclophosphamide and cis-
platin reduced to 25%.
• Dose could be escalated by 25% increments for each subsequent course 
 until the full dose was reached if  there was no further toxicity.
Doxorubicin
• Stopped if congestive heart failure or any other life- threatening cardiac 
toxicities.
• Total cumulative dose not to exceed 400 mg/m2.
Cisplatin
• Held if blood urea nitrogen (BUN) >30 mg/dL or creatinine >2 mg/dL.
• Restarted only  after BUN <25 mg/dLand creatinine <1.5 mg/dL.
ASSESSMENTS
Evaluation of Response
• Complete response (CR): disappearance of all gross disease for at least 
1 month.
• Partial response (PR): 50% or greater reduction in product of each lesion 
size in 2 perpendicular dia meters for at least 1 month.
ENDPOINTS
• Response rate (primary endpoint).
STATISTICAL CONSIDERATIONS
• Sample size projections  were based on complete response rate of 35% 
for CA and an increase of 15% for CAP.
CONCLUSION OF TRIAL
• The addition of cisplatin to cyclophosphamide and doxorubicin (CAP) 
improves response rate, response duration, survival in patients with mea-
sur able disease, and progression- free interval in all patients (mea sur able 
and nonmea sur able) compared to CA alone. The addition of cisplatin is a 
signifi cant step forward in the management of ovarian cancer.
• The value of maintenance therapy with cyclophosphamide is unclear. 
The benefi t on continued treatment needs to be balanced against the 
risk of leukemogenesis from prolonged treatment with an alkylating 
agent.









N = 215 evaluable
CA + cisplatin 
(CAP)
N = 225 evaluable Statistics
Patient characteristics
Median age (range) 56 (25-70) 57 (23-70)
Grade 3 38% 40%
Stage III 65% 66%




Unspecifi ed 19% 15%
Mucinous 3% 5%
Clear cell 4% 3%
Other 7% 11%
Treatment delivery No details No details
Effi cacy
CR 25% 51% P < .0001
PR 22% 24%
Stable disease 43% 19%
Progressive disease 9% 5%
Response duration 8.8 months 14.6 months P = .02
Progression- free interval 7.7 months 13.1 months P < .0001
Survival (mea sur able disease) 15.7 months 19.7 months P < .03
Survival (nonmea sur able disease) 18.7 months 18.9 months NS
Toxicity
G3/4 WBC 80/189 (42%) 116/195 (59%)
G3/4 platelet 2/189 (1%) 17/195 (9%)
G3/4 GI 14/194 (7%) 31/198 (16%)
CR, complete response; GI, gastrointestinal; NS, not signifi cant; PR, partial response; WBC, white 
blood cells.
• No survival advantage was seen for CAP in nonmea sur able cases. 
 These cases ranged from minimally bulky to massive but clinically 
nonmea sur able disease. Most  women treated with CA ended up 
receiving cisplatin as secondary therapy, and this may have infl uenced 
the mea sure ment of postprotocol survival. However, this would be 
relevant to both mea sur able and nonmea sur able cases and does not 
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necessarily account for the lack of survival difference with nonmea-
sur able cases.
COMMENTS
• Cisplatin was commercially available when this trial was conducted, 
so crossover to cisplatin use  after completion of the trial may have 
blunted survival differences.
GOG 52 (Omura, JCO 1989)
REFERENCE
• Omura GA, et al. Randomized trial of cyclophosphamide plus cispla-
tin with or without doxorubicin in ovarian carcinoma: a Gynecologic 
Oncology Group Study. J Clin Oncol. 1989;7(4):457-465. PMID: 2926470. 
(Omura et al. 1989)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• GOG 47 demonstrated cyclophosphamide, doxorubicin, and cisplatin 
(CAP) to be superior to cyclophosphamide and doxorubicin (CA). CAP 
improved complete response rate, response duration, and progression- 
free interval. CAP improved survival only in patients with mea sur able 
disease (Omura et al. 1986).
• Prior studies suggest that doxorubicin does not confer a treatment 
advantage.
• This study was designed to compare CP (omitting doxorubicin) with 
CAP in patients with optimal cytoreduction.
PATIENT POPULATION
• N = 349 evaluable patients.
• Enrolled from April 1981 to July 1985.
• Small- volume stage III ovarian cancer (<1 cm, therefore no clinically 
mea sur able lesions to follow).
• Ineligible: prior cancer, prior irradiation or chemotherapy, major organ 
dysfunction, history of congestive heart failure, complete disability, 
borderline cancers.






Arm 1: CP (cyclophosphamide + Cisplatin).
• Cyclophosphamide 1000 mg/m2.
• Cisplatin 50 mg/m2.
• Administered  every 3 weeks for 8 cycles.
Arm 2: CAP (Cyclophosphamide + Adriamycin + Cisplatin)
• Cyclophosphamide 500 mg/m2.
• Adriamycin (doxorubicin) 50 mg/m2.
• Cisplatin 50 mg/m2.
• Administered  every 3 weeks for 8 cycles.
• Dosing schedules  were chosen to anticipation of comparable hemato-
logic toxicities.
Second- Look Laparotomy
• Patients without progression underwent second- look laparotomy at 6 
months.
• Negative second look— followed without additional treatment.
• Positive second look— went off treatment part of study.
Dose Reductions
• Grade 3 granulocyte or platelet toxicity with recovery by next cycle: 
cyclophosphamide and doxorubicin doses  were reduced to 75%; cis-
platin was not decreased.
• Grade 4 granulocyte or platelet toxicity with recovery by next cycle: 
cyclophosphamide and doxorubicin doses  were reduced to 50%; cis-
platin was reduced to 75%.
• Doses could be escalated by 25% for each subsequent course  until 100% 
if no further severe myelosuppression was noted.
Doxorubicin
• Stopped if congestive heart failure or any other life- threatening cardiac 
condition.
• Total cumulative dose was not to exceed 400 mg/m2.
Cisplatin
• Held if BUN >30 mg/dL or creatinine >2 mg/dL.
• Restarted only  after BUN and creatinine returned to acceptable levels.
ASSESSMENTS
• Radiographs and scans  every 3 months.
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• Progression- free interval (PFI) (primary endpoint).




• Study designed assuming a median PFI of 2 years for CP with a 1- tail 
test at the .05 level. Statistical power is 97% and 76% for a 15% and 10% 
increase in the 2- year PFI rate.





CP + doxorubicin 
(CAP)
N = 173 Statistics
Patient characteristics
Median age 56 (19-80) 53 (23-80)
Residual disease 72% 71%
Grade 3 33% 36%




Clear cell 6% 11%
Other 23% 18%
Treatment delivery
Cyclophosphamide 24% decrease in dose 21% decrease in dose
Cisplatin 7% decrease in dose 10% decrease in dose
Doxorubicin 22% decrease in dose
Average cycle time 25.8 days 26.1 days
Effi cacy
Progression- free interval 22.7 months 24.6 months NS
Overall survival 31.2 months 38.9 months NS
Negative second look 30.2% 32.8% NS
Toxicity
G3/4 leukocyte 55% 57% NS
G3/4 thrombocytopenia 1% 2%
G3 nausea/vomiting 3.6% 9.3%
NS, not signifi cant.






• Mantel- Haenszel χ2 test to compare frequency of negative second- look 
laparotomy.
• Cox proportional hazards model, likelihood ratio test to compare 
survival.
CONCLUSION OF TRIAL
• Doxorubicin does not improve outcomes in optimal stage III ovarian 
cancer.
COMMENTS
• Second- look surgery does not infl uence survival outcomes as better 
options for “salvage” therapy are needed.
• Residual disease status had a large impact on progression- free inter-
val. However, once a negative second look was documented, residual 
disease status no longer had an impact.
• Low grade and younger age  were also favorable  factors for outcome.
• Timing of chemotherapy initiation did not have an impact on survival.
• Clear cell carcinoma had the worst progression- free interval and survival.
• Cyclophosphamide dose was lower in CAP (500) vs CP (1000).
GOG 97 (McGuire, JCO 1995)
REFERENCE
• McGuire WP, et al. Assessment of dose- intensive therapy in subopti-
mally debulked ovarian cancer: a Gynecologic Oncology Group study. J 
Clin Oncol. 1995;13(7):1589-1599. PMID: 7602348. (McGuire et al. 1995)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• The current standard therapy at the time of this trial was the 2- drug 
regimen of cyclophosphamide and cisplatin.
• The 2- drug regimen had been shown to be as effi cacious as and less 
toxic than a 4- drug regimen (Neijt et al. 1991).
• This trial was designed to evaluate chemotherapy dose intensity on ovar-
ian cancer survival and response in patients with bulky residual disease.
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• N = 458 eligible.
• Enrolled between January 1987 and April 1990.
Inclusion Criteria
• Stage III epithelial ovarian cancer with >1 cm residual disease  after sur-
gical cytoreduction or stage IV disease.
• Patients  were allowed to have clinically mea sur able or nonmea sur able 
(assessable) disease.
• GOG per for mance status of 0, 1, or 2.
• Adequate bone marrow (white blood cells [WBC] >3 × 109/L, plate-
lets >100 × 109/L), renal (serum creatinine <2 mg/dL) and hepatic func-
tion (serum bilirubin and aspartate aminotransferase [AST] <2 times 
the upper limit of institutional norm)
• Study entry within 6 weeks of the surgical procedure.
Exclusion Criteria
• Borderline tumors, prior therapy, any other malignant disease other 
than nonmelanoma skin cancer.
TREATMENT DETAILS
Arm 1: Standard Therapy
• Cyclophosphamide 500 mg/m2 (166 mg/m2/wk).
• Cisplatin 50 mg/m2 (16.6 mg/m2/wk).
• Treatment  every 3 weeks for 8 courses.
Arm 2: Intensive Therapy
• Cyclophosphamide 1000 mg/m2 (333 mg/m2/wk).
• Cisplatin 100 mg/m2 (33.3 mg/m2/wk).
• Treatment  every 3 weeks for 4 courses.
• Patients in the intensive therapy group received the same total dose of 
chemotherapy but at 1.97 times greater dose intensity than the standard 
therapy group.
Management of Toxicities
• To maintain dose intensity, patients  were not allowed to undergo dose 
reductions.
• Hematologic toxicity was managed with treatment delays. If delay was 
greater than 3 weeks, the patient was taken off study and monitored 
for survival.





• No delay was allowed for any grade gastrointestinal toxicity, G1 or G2 
peripheral neurotoxicity, mild renal toxicity (creatinine ≤2 mg/dL or 
creatinine clearance ≥50 mL/min), or mild ototoxicity (<–10 dB reduc-
tion in high- frequency discrimination).
• Per sis tent and more severe neurologic, otic, or renal toxicity required 
removal of the patient from the study.
• If a patient developed hemorrhagic cystitis, an equitoxic dose of chlo-
rambucil was substituted for cyclophosphamide.
ASSESSMENTS
• Baseline history and physical examination, laboratory procedures, imag-
ing studies to assess disease mea sure ments.
• Functional Living Index– Cancer (FLIC) given before chemother-
apy,  after each course of treatment, and 6 weeks  after last course of 
treatment.
• Tumor mea sure ments  after each 2 courses of therapy.
• Second- look laparotomy performed  after completing therapy on patients 
without mea sur able disease or patients who achieved a complete clini-
cal response to determine the pathologic response rate. Failure to undergo 
surgery was considered a major protocol violation.
• Cancer antigen 125 (CA125) was monitored but never used as an indi-
cator of disease status.
ENDPOINTS
• Overall survival (OS).
• Progression- free survival (PFS).
• Response.
STATISTICAL CONSIDERATIONS
• Kaplan- Meier used to estimate survival (Kaplan and Meier 1958).
• Log- rank test used to assess the in de pen dence of PFS, OS, and random-
ized treatment (Mantel 1966).
• Linear proportional hazards model was used to estimate the treatment 
effects while adjusted for other pretreatment  factors (Cox 1972).
• A proportional hazards model with an interaction term was used to 
determine the homogeneity of the treatment effect for  those with and 
without mea sur able disease.










N = 223 Statistics
Patient characteristics
Median age (range) 60 (22-80) 60 (20-83)
Mea sur able disease 38% 36%
Stage III, <2 cm 5% 9%
Stage III,  ≥2 cm 63% 57%
Stage IV, <2 cm 8% 16%




Clear cell 4% 2%
Other 13% 12%
Treatment delivery
Days between courses 21-25 22-28
Median total dose
Cisplatin 391 mg/m2 394 mg/m2 NS
Cyclophosphamide 3906 mg/m2 3943 mg/m2 NS
Effi cacy
Complete response 36% 30% NS
Partial response 24% 25%
Stable disease 32% 28%
Progression 1% 11%
Death before evaluation 5% 6%
Negative SL, mea sur able 10% 10% NS
Negative SL, nonmea sur able 16% 19%
Median PFS 12.1 months 14.3 months NS
Median OS 19.5 months 21.3 months NS
Toxicity
G3/4 WBC 39% 82% <.005
G3/4 platelet <1% 22% <.005
G3/4 anemia <3% 9% <.005
G3/4 GI/vomiting 3% 16% <.005
G3/4 renal <1% 5% <.005
G3/4 febrile neutropenia 0% 2% <.005
G3/4 sepsis/infection <2% 5% <.05
Removed due to toxicity 7% 17%
Death attributed to treatment N = 1 N = 2
Progression or death before
completing therapy 23.8% 7.6%
CP, cyclophosphamide + cisplatin; GI, gastrointestinal; NS, not signifi cant; OS, overall survival; PFS, 
progression- free survival; SL, second look; WBC, white blood cells.





• The Kruskal- Wallis rank test adjusted for tied ranks was used to test 
the in de pen dence of dose intensity, total dose delivered, and severity 
of toxicity relative to the assigned treatment (Kruskal and Wallis 1952).
• The Mantel- Haenszel χ2 test was used to determine the in de pen dence 
of treatment and response and was stratifi ed by disease measurability 
(Mantel and Haenszel 1959).
CONCLUSIONS OF TRIAL
• Clinical and pathologic response rates, response duration, and survival 
 were similar between treatment arms, but adverse events (hematologic, 
gastrointestinal, febrile episodes, sepsis, and renal toxicities)  were more 
common and severe in the dose- intensive therapy group.
• This study provides no evidence to support the hypothesis that modest 
increases in dose intensity (without increasing total dose) have an 
impact on outcome.
COMMENTS
• Dose modifi cation was rigorously controlled in this trial to maintain 
dose intensity.
• Neither high- dose chemotherapy (with or without autologous bone mar-
row rescue) nor modest dose intensifi cation (as studied in this trial) 
overcame the development of chemore sis tance.
GOG 111 (McGuire, NEJM 1996)
REFERENCE
• McGuire WP, et al. Cyclophosphamide and cisplatin compared with 
paclitaxel and cisplatin in patients with stage III and stage IV ovarian 
cancer. N Engl J Med. 1996;334(1):1-6. PMID: 7494563. (McGuire 
et al. 1996)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• At the time of trial design, the standard of care for advanced epithelial 
ovarian cancer in the United States was a combination of an alkylating 
agent and cisplatin, specifi cally cyclophosphamide and cisplatin. How-
ever, long- term disease control with this regimen was less than 10% in 
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 women with incompletely resected stage III and less than 5% in  women 
with stage IV disease.
• In 1989, a phase II trial reported that paclitaxel produced a 24% response 
rate in patients with platinum- resistant ovarian cancer (McGuire et al. 
1989). Another phase II trial reported a 37% response rate in 1994 
(Thigpen et al. 1994). This made paclitaxel the most active single- agent 
drug ever evaluated by the GOG in a phase II study in ovarian cancer.
• A phase I trial of paclitaxel and cisplatin demonstrated the safety of 
the combination when paclitaxel was given fi rst as a 24- hour infusion 
(Rowinsky et al. 1991a).
• Based on the activity of paclitaxel in the salvage setting, the safety of 
the combination of paclitaxel and cisplatin, and the need for better treat-
ment alternatives than the current standard of care, the GOG conducted 
this phase III study to evaluate the effi cacy of the paclitaxel + cisplatin 
combination as standard fi rst- line therapy in patients with incompletely 
resected stage III or any stage IV ovarian cancer.
PATIENT POPULATION
• N = 386.
• Accrual began in April 1990 and completed its goal within 2 years.
Inclusion Criteria
• Stage IV or suboptimal stage III (defi ned as residual disease >1 cm) 
epithelial ovarian cancer.
• Having under gone surgical debulking; having received no prior 
chemotherapy or radiation; having a GOG per for mance status of 0 
to 2 and having adequate hematologic (WBC ≥3000/mm3, platelet 
count >100,000/mm3), renal (serum creatinine <2.0 mg/dL), and liver 
(serum bilirubin and serum AST <2 times the upper limit of normal 
for the institution) function.
• Entry within 6 weeks of the debulking procedure.
Exclusion Criteria
• Borderline tumors, taking antiarrhythmic medi cation, any prior can-
cer other than nonmelanoma skin cancer.
TREATMENT DETAILS
Arm 1: Standard Therapy Group— Cyclophosphamide + Cisplatin
• Cyclophosphamide 750 mg/m2 intravenous (IV)
• Cisplatin 75 mg/m2 IV at rate of 1 mg/min.
• Treatment  every 3 weeks for 6 courses.





Arm 2: Experimental Therapy Group— Paclitaxel and Cisplatin
• Paclitaxel 135 mg/m2 IV as a 24- hour continuous infusion.
• Cisplatin 75 mg/m2 IV at a rate of 1 mg/min.
• Treatment  every 3 weeks for 6 courses.
• Pretreatments.
• Dexamethasone 20 mg orally or IV 14 and 7 hours before infusion.
• Diphenhydramine 50 mg IV 30 minutes before infusion.
• Any histamine H2 antagonist IV 30 minutes before infusion.
Treatment Delays
• Delayed week by week  until WBC >3000/mm3 and platelet count 
>100,000/mm3.
• No delay allowed for any gastrointestinal toxicity, grade 1 or 2 periph-
eral neurotoxicity, mild renal toxicity (creatinine ≤2 mg/dL or creati-
nine clearance of ≥50 mL/min), or mild ototoxicity (reduction of ≤10 dB 
in high- frequency discrimination).
Treatment Withdrawal
• For treatment delays exceeding 3 weeks due to hematologic toxicity.
• For more severe neurologic, renal, or otic toxicity that had not resolved 
by the time of the next scheduled dose.
• For cardiac toxic effects (other than asymptomatic sinus bradycardia).
• For severe allergic reaction (bronchospasm, hypotension, diffuse urti-
caria) during the paclitaxel infusion.
Dose Modifi cations— Cyclophosphamide
• Reduction to 500 mg/m2 for grade 4 hematologic toxicity (WBC ≤ 1000/
mm3, absolute neutrophil count (ANC) ≤500/mm3, platelet count 
<25,000/mm3).
• Reescalation in subsequent dose if nadir counts not grade 4.
Dose Modifi cations— Paclitaxel
• Reduction to 110 mg/m2 for grade 4 hematologic toxicity (WBC ≤ 1000/
mm3, ANC ≤ 500/mm3, platelet count < 25,000/mm3).
• Reescalation in subsequent dose if nadir counts not grade 4.
Dose Modifi cations— Cisplatin
• Not allowed.
ASSESSMENTS
• Imaging studies before and  after  every other course of therapy.
• Adverse events graded by toxicity criteria of the GOG.
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• Reassessment laparotomy to determine pathologic response required 
for  those without mea sur able disease and  those with measureable dis-
ease and complete clinical response.
ENDPOINTS
• Progression- free survival (primary endpoint).
• Overall survival.
STATISTICAL CONSIDERATIONS
• Kaplan- Meier to estimate the cumulative proportion surviving.
• Two- tailed log- rank test to assess the in de pen dence of PFS, OS, and 
randomized treatment assessment.
• Linear proportional hazards analy sis to estimate relative risk adjusted 
for pretreatment  factors.
• Proportional hazards with an interaction term to assess the homogene-
ity of the treatment effect across prognostic groups.
• Kruskal- Wallis rank test adjusted for tiered ranks to test the in de pen-
dence of the severity of toxicity with the assigned treatment.
• Pearson’s χ2 test to test the in de pen dence of response and treatment.
CONCLUSION OF TRIAL
• Incorporation of paclitaxel into fi rst- line chemotherapy for patients with 
incompletely resected stage III and IV epithelial ovarian cancer improves 
both progression- free and overall survival. Paclitaxel and cisplatin are 
associated with an estimated 40% reduction in the risk of death com-
pared to cyclophosphamide and cisplatin.
COMMENTS
• At the start of the study, all  women receiving paclitaxel underwent car-
diac monitoring as patients receiving paclitaxel therapy had previously 
been reported to experience bradyarrhythmias with atrioventricular 
block and ventricular irritability (Rowinsky et al. 1991b). Only 7 women 
had grade 2 or higher cardiac episodes (fi rst- degree heart block, ischemic 
events without infarction), so the requirement for cardiac monitoring 
was removed  toward the end of the study.
• The benefi t of paclitaxel did not appear to be due to a poorer than antic-
ipated outcome among the patients receiving standard therapy.
• The benefi t of paclitaxel did not appear to be limited to the subpopula-
tions with mea sur able disease or stage III disease.











N = 184 Statistics
Patient characteristics
Median age (range) 60 (27-80) 59 (20-84)
Mea sur able disease 57% 54%
Stage III 64% 67%




Clear cell 2% 2%
Other 15% 12%
Grade 1 7% 4%
Grade 2 41% 45%
Grade 3 52% 51%
Treatment delivery
Interval between cycles 21-28 days 21 days
Completed 6 cycles 78% 87%
Discontinuation due to
Progression or death 11% 5%
Toxicity or declined 10% 8%
Effi cacy
Overall response rate 60% 73%
Complete response (CR) 31% 51% P = .01
Partial response (PR) 29% 22%
Pathologic CR 20% 26% NS
PFS 13 months 18 months RR 0.7, P < .001
OS 24 months 38 months RR 0.6, P < .001
Toxicity
G3/4 neutropenia 83% 92% <.05
G3/4 thrombocytopenia 3% 3%
G3/4 anemia 8% 9%
G3/4 gastrointestinal 11% 15%
Fever 11% 20% <.05
Alopecia 37% 63% <.05
G3/4 renal <2% <1%
Any neurologic 21% 28%
Allergic reaction 0% 4% <.05
Death due to treatment N = 6 N = 4
NS, not signifi cant; OS, overall survival; PFS, progression- free survival; RR, relative risk.
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• Paclitaxel was in limited use when this trial was conducted. Therefore, 
crossover occurred to a lesser degree  after the conclusion of the trial 
and  there was likely to be less blunting of the survival outcomes.
GOG 104 (Alberts, NEJM 1996)
REFERENCE
• Alberts DS, et al. Intraperitoneal cisplatin plus intravenous cyclophos-
phamide versus intravenous cisplatin plus intravenous cyclophosphamide 
for stage III ovarian cancer. N Engl J Med. 1996;335(26):1950-1955. 
PMID: 8960474. (Alberts et al. 1996)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• In an attempt to maximize the activity of cisplatin against ovarian can-
cer,  trials have investigated its delivery directly into the peritoneal 
cavity. This results in intraperitoneal cisplatin concentrations that are 
12 to 15 times greater than the concentration in plasma (Howell et al. 
1982; Goel et al. 1989).
• Survival may be improved with salvage intraperitoneal chemother-
apy in patients with small (<1 cm) residual masses  after upfront 
 chemotherapy and second- look surgery (Howell et al. 1987; Kirmani 
et al. 1991).
• This trial was conducted to compare intraperitoneal and intravenous 
cisplatin administration in the upfront adjuvant treatment of patients 
with stage III ovarian cancer and residual masses less than 2 cm in size.
PATIENT POPULATION
• N = 654 enrolled, 546 eligible.
• Enrollment between June 1986 and July 1992.
• Stage III epithelial ovarian cancer with less than 2 cm residual disease.
• Surgery that included exploratory laparotomy with at least total abdom-
inal hysterectomy, bilateral salpingo- oophorectomy, omentectomy, 
and debulking to optimal (<2 cm size) status.
• Enrollment within 4 weeks of surgery.
• Per for mance status of 0 to 2; adequate blood counts, renal function 
(serum creatinine ≤1.5 mg/dL or creatinine clearance ≥40 mL/min).






Arm 1: Intravenous Cyclophosphamide + Intravenous Cisplatin
• Cyclophosphamide 600 mg/m2 in 150 mL of diluent over 60 to 90 min-
utes IV.
• Cisplatin 100 mg/m2 in 500 to 1000 mL of normal saline at a rate of 
1 mg/min.
• IV hydration with at least 1 L of normal saline with 3 g of magnesium 
sulfate and 40 g of mannitol over a period of 1 to 2 hours.
• Treatment  every 3 weeks for 6 cycles.
Arm 2: Intravenous Cyclophosphamide + Intraperitoneal Cisplatin
• Cyclophosphamide 600 mg/m2 in 150 mL of diluent over 60 to 90 
minutes IV.
• Cisplatin 100 mg/m2 in 2 L of normal saline warmed to body tempera-
ture and instilled into the peritoneal cavity as fast as pos si ble.
• IV hydration with at least 1 L of normal saline with 3 g of magnesium 
sulfate and 40 g of mannitol over a period of 1 to 2 hours.
• Treatment  every 3 weeks for 6 cycles.
Treatment Delays
• Delay for a maximum of 2 weeks to allow for resolution of toxic effects.
Treatment Discontinuation
• Cisplatin discontinued and cyclophosphamide increased to 1000 mg/m2.
• For grade 2 or higher peripheral neuropathy.
• For serum creatinine >1.9 mg/dL.
• Treatment discontinued permanently.
• For serum creatinine >1.9 mg/dL for 8 weeks.
ASSESSMENTS
• Serum CA125 before each cycle.




• Pathologic complete response rate.
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• Initial trial design had a power of 93% to detect a difference in the haz-
ard ratio for death of 0.67 with a 2- sided P value of .05 and 215 patients 
per treatment arm.
• With a Pearson χ2 approximation and 2- sided P value of .05,  there was 85% 
power to detect a difference of pathologic response rate of 55% vs 40%.
• Accrual was extended for another year in January 1991 to achieve a large 
enough sample size to do a separate analy sis of data from patients with 
residual tumors <0.5 cm. With the plan to accrue 560 patients (390 with 
tumors <0.5 cm), the power to detect a hazard ratio of 0.67 was 88%.
Statistical Tests
• Cox regression analyses.
• Two- sided Fisher’s exact tests to compare toxicities.
CONCLUSION OF TRIAL
• Intraperitoneal cisplatin was associated with a 20% improvement in 
survival and a 24% reduction in the risk of death compared to intrave-
nous cisplatin.
• Pathologic complete response rates are greater in the subset of patients 
with ≤0.5-cm residual tumor masses, supporting the observation that 
the penetration of intraperitoneal cisplatin is limited to a depth of 0.1 
to 1 mm from the surface of the tumor (Los et al. 1989).
COMMENTS
•  There was a higher rate of pathologic complete response (pCR) among 
patients receiving intraperitoneal compared to intravenous cisplatin. 
However, among the 400 patients eligible for second- look surgery (no 
clinical evidence of disease at completion of therapy), 103 did not 
undergo surgery or they had inadequate surgery, creating bias.  Because 
of this bias, the pCR data are reported without statistical comparisons.
• Covariates associated with improved survival included (and thus 
included in the fi nal Cox model).
• No gross residual disease (P < .001).
• Younger age (P < .001).
• Non– clear cell and nonmucinous histology (P < .001).
• Enrollment  after surgery (P < .001).












N = 267 Statistics
Patient characteristics
Median age (range) 56 (21-85) 59 (24-84)
Minimal residual <0.5 cm 72% 73%
No gross residual 26% 25%




Clear cell 2% 2%
Other 20% 20%
Grade 1 13% 11%
Grade 2 30% 31%
Grade 3 57% 58%
Treatment delivery
Completed 6 cycles 58% 58%




Complete PR (second look) 36% 47%
OS 41 months 49 months HR 0.76, P = .02
OS, <0.5 cm residual 46 months 51 months HR 0.8, P = .10
Toxicity
Treatment- related death N = 0 N = 2
>G3 anemia 25% 26% NS
>G3 granulocytopenia 69% 56% .0002
>G3 leukopenia 50% 40% .04
>G3 thrombocytopenia 9% 8% NS
≥G2 abdominal pain 2% 18% <.001
≥G2 tinnitus 14% 7% .01
≥G2 hearing loss 15% 5% <.001
≥G2 neuromuscular 25% 15% .02
≥G2 pulmonary effects 0.4% 3% .002
HR, hazard ratio; OS, overall survival; PR, pathologic response.
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• Neutropenia, tinnitus, and hearing loss  were experienced more fre-
quently in the intravenous arm. Abdominal pain was experienced 
more frequently in the intraperitoneal arm, but pain usually resolved 
within 24 hours and was generally manageable with weak opioid or 
nonopioid drugs. Dyspnea occurred more frequently with intraper-
itoneal administration, likely due to compression of the base of the 
lungs.
• This trial was published shortly  after GOG 111 (McGuire et al. 1996), 
which demonstrated the superiority of paclitaxel + cisplatin over cyclo-
phosphamide + cisplatin. Ongoing studies  will plan to evaluate the 
effi cacy of intraperitoneal cisplatin with paclitaxel.
ICON2 (Lancet 1998)
REFERENCE
• ICON2: randomised trial of single- agent carboplatin against three- 
drug combination of CAP (cyclophosphamide, doxorubicin, and cispla-
tin) in  women with ovarian cancer. ICON Collaborators. International 
Collaborative Ovarian Neoplasm Study. Lancet. 1998;352(9140):1571-
1576. PMID: 9843101. (International Collaborative Ovarian Neoplasm 
Group 1998)
TRIAL SPONSORS
• International Collaborative Ovarian Neoplasm Study
• Instituto Mario Negri in Milan, Italy
• Swiss Institute for Cancer Research (SIAK) in Bern, Switzerland
• Medical Research Council’s Cancer  Trials Offi ce in Cambridge, 
United Kingdom
RATIONALE FOR TRIAL
• Five meta- analyses representing data from 45 randomized controlled 
 trials suggest that immediate platinum- based treatment is better than 
non- platinum- based treatment, combination therapy is better than single- 
agent platinum, and  there is no difference between carboplatin and 
cisplatin  either as single agents or within combination regimens (Che-
motherapy in advanced ovarian cancer . . .  1991).
• Two meta- analyses focusing on the role of doxorubicin suggest that 
the combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) 





is better than cyclophosphamide and cisplatin (CP) (Cyclophosphamide 
plus cisplatin . . .  1991; A’Hern and Gore 1995). The 3- drug regimen 
is associated with a marginal improvement in 5- year survival from 
20% to 26%.
• While many believed CAP to be the most effective drug regimen for 
advanced ovarian cancer at this time,  there was an open question as to 
 whether single- agent platinum (the most active agent in the combination) 
administered at full dose would provide equivalent or better survival 
outcomes compared to CAP.
• Carboplatin was chosen as the single- agent platinum in this study 
because it is less toxic than cisplatin at optimally tolerated doses and 
has similar effi cacy. Single- agent carboplatin was the most widely used 
regimen in the United Kingdom, and CAP was the most widely used regi-
men in Italy at this time.
PATIENT POPULATION
• N = 1526.
• Patients entered between January 1991 and July 1996.
• ICON2 was run as 3 parallel  trials through (1) the Instituto Mario Negri 
in Milan, Italy; (2) the Swiss Institute for Cancer Research (SIAK) in 
Bern, Switzerland; (3) and the Medical Research Council’s Cancer 
 Trials Offi ce in Cambridge, United Kingdom.
• Patients  were recruited from 132 centers in 9 countries.
• Histologically confi rmed invasive epithelial ovarian cancer; fi t to 
receive chemotherapy; no prior chemotherapy or radiation therapy; no 
previous malignancy (excluding nonmelanoma skin cancer); adequate 
renal function.
• No restrictions on extent of surgery, but total abdominal hysterectomy, 
bilateral salpingo- oophorectomy, and thorough staging  were recom-
mended as the minimum procedures.
• Eligibility criteria  were intentionally left wide to promote recruitment.
TREATMENT DETAILS
Arm 1: CAP (Cyclophosphamide, Adriamycin, Cisplatin)
• Cyclophosphamide 500 mg/m2.
• Adriamycin (doxorubicin) 50 mg/m2.
• Cisplatin 50 mg/m2.
• One cycle  every 3 weeks for 6 cycles.
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• Carboplatin area  under the curve (AUC) 5.
• Dose determined by AUC method of Calvert (Calvert et al. 1989). Glo-
merular fi ltration rate (GFR) was determined by radioisotope method 
or the Cockcroft formula. If GFR was determined by creatinine clear-
ance, carboplatin dose was recommended to be reduced by 10%.
• One cycle  every 3 weeks for 6 cycles.
ASSESSMENTS
• Pretreatment data  were collected at the time of randomization.
• Treatment and initial follow-up data  were collected 6 months  later.
• Further follow- data  were collected 12 months  after randomization and 
 every year thereafter.
ENDPOINTS





• Five- year survival estimated to be 20% in the carboplatin group. To 
detect an improvement in survival with CAP to 26% with 90% power 
and to 25% with 85% power at a signifi cance level of 5%, the maxi-
mum accrual target was set to 2000 patients.
Statistical Tests
• Kaplan- Meier curves, Mantel- Cox version of log- rank test.
• Stratifi ed log- rank test to allow for differences across 3 centers.
• Cox proportional hazards model to account for imbalances in pretreat-
ment characteristics.
CONCLUSION OF TRIAL
•  There was no difference in PFS or OS between CAP and single- agent 
carboplatin.
• Neither treatment was more effective in any subgroup analyses, sug-
gesting that the results of ICON2 are applicable to a broad range of 
patients.










N = 760 Statistics
Patient characteristics
Italy 64% 64%
United Kingdom 20% 20%
Switzerland 7% 7%
Other 7% 10%
Age <55 38% 35%
Age 55-65 31% 33%
Age >65 31% 33%
No residual 31% 31%
≤2 cm residual 25% 24%
>2 cm residual 45% 45%
Stage I 11% 13%
Stage II 12% 11%
Stage III 63% 62%




Clear cell 5% 5%
Other 21% 20%
Grade 1 13% 11%
Grade 2 32% 31%
Grade 3 46% 50%
Unknown grade 9% 10%
Treatment delivery
Received 6 cycles 80% 81%
Received 0 cycles N = 34 N = 14
Effi cacy
1- year PFS 63% 60% HR 0.92, P = .20
Median PFS 17 months 15.5 months favoring CAP
2- year OS 60% 60% HR 1, P = .98
Median OS 33 months 33 months
Toxicity (collected in Italy only)
Alopecia 70% 4%
G 3/4 leucopenia 36% 10%
G 3/4 Nausea, vomiting 20% 9%
G 3/4 thrombocytopenia 6% 16%
CAP, cyclophosphamide + Adriamycin/doxorubicin + cisplatin; HR, hazard ratio; PFS, progression- 
free survival; OS, overall survival.
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• CAP was more toxic than carboplatin, causing more alopecia, leucopenia, 
nausea, and vomiting. Carboplatin caused more thrombocytopenia.
• Single- agent carboplatin is a safe and effective standard treatment 
option for patients with advanced ovarian cancer.
COMMENTS
• Recruitment to ICON2 was stopped in July 1996 before the planned 
2000 patients had been enrolled due to an interest in testing paclitaxel- 
containing regimens in the context of data from GOG 111 (McGuire 
et al. 1996). ICON3 began recruitment in February 1995 comparing 
the combination of paclitaxel + carboplatin with single- agent carbo-
platin or CAP (International Collaborative Ovarian Neoplasm Group 
2002).
GOG 132 (Muggia, JCO 2000)
REFERENCE
• Muggia FM, et al. Phase III randomized study of cisplatin versus pacli-
taxel versus cisplatin and paclitaxel in patients with suboptimal stage 
III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin 
Oncol. 2000;18(1):106-115. PMID: 10623700. (Muggia et al. 2000)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• Despite the activity of cisplatin in advanced ovarian cancer, the long- 
term survival of suboptimally cytoreduced patients remains poor.
• Paclitaxel has been established as a salvage treatment of patients with 
platinum- sensitive and platinum- resistant ovarian cancer (McGuire 
et al. 1989; Thigpen et al. 1994).
•  Because the possibility existed that paclitaxel may be more active 
than cisplatin, this trial was designed to compare the activity of single- 
agent cisplatin vs single- agent paclitaxel vs combination cisplatin and 
paclitaxel.
PATIENT POPULATION
• N = 648 registered, 614 eligible.
• Accrual between March 1992 and May 1994.





• Histologically confi rmed epithelial ovarian cancer; stage III disease 
with at least 1 mass >1 cm residual or any stage IV disease; no prior 
anticancer medi cations or radiation; normal marrow (granulocytes 
>1500/μL; platelets >100,000/μL); normal renal function (serum cre-
atinine <1.5 mg/dL); normal liver function (alanine aminotransferase 
[ALT], AST <2 times normal; bilirubin <1.5 mg/dL); GOG per for mance 
score of 0, 1, or 2.
• Ineligible: borderline tumors; any other prior malignancy other than 
basal cell carcinoma or in situ of the cervix; primary peritoneal tumor 
or lack of tumor in the ovaries.
• Registration within 6 weeks of staging surgery.
TREATMENT DETAILS
• Higher single- agent doses  were selected  because studying lower doses 
might have led to less defi nitive conclusions.
Arm 1: Single- Agent Cisplatin
• Cisplatin 100 mg/m2 IV.
• Repeated  every 3 weeks for 6 courses.
• Dose adjustment of cisplatin by 50% for grade 2 or higher thrombocy-
topenia or any other grade 2 nonhematologic toxicity (with the excep-
tion of nausea and vomiting); any grade tinnitus.
• Dose held for cisplatin for any grade 3 or 4 nephropathy or neuropathy 
 until toxicity completely resolved.
Arm 2: Single- Agent Paclitaxel
• Paclitaxel 200 mg/m2 IV over 24 hours.
• Repeated  every 3 weeks for 6 courses.
• Dose adjustment of paclitaxel to 150 mg/m2 for any grade 4 neutrope-
nia or grade 3 neutropenia requiring hospitalization.
Arm 3: Combination Cisplatin + Paclitaxel (Same Regimen as GOG 111) 
(McGuire et al. 1996)
• Paclitaxel 135 mg/m2 IV over 24 hours.
• Cisplatin 75 mg/m2 IV.
• Repeated  every 3 weeks for 6 courses.
• Dose adjustment of paclitaxel to 110 mg/m2 for any grade 4 neutrope-
nia or grade 3 neutropenia requiring hospitalization.
• Dose adjustment of cisplatin by 50% for grade 2 or higher thrombo-
cytopenia or any other grade 2 nonhematologic toxicity (with the 
ex ception of nausea and vomiting); any grade tinnitus.
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• Dose held for cisplatin for any grade 3 or 4 nephropathy or neuropathy 
 until toxicity completely resolved.
Treatment Delays
• Delay  until platelet count >100,000/μL and ANC >1500/μL.
• Granulocyte colony- stimulating  factors (G- CSFs)  were permitted if 
ANC failed to recover to >1500/μL within 21 days of the last treatment 
despite 1 dose- level reduction or if neutropenia- related complications 
occurred at the reduced dose level.
ASSESSMENTS
• Baseline computed tomography (CT) scan (within 3 weeks), CA125, 







• Sample size provides 80% chance of detecting a true 29% decrease in 
the hazard ratio (40% increase in PFS) with a type I error limited to .05.
CONCLUSION OF TRIAL
• Response rates  were signifi cantly lower and progression- free survival 
was shorter with paclitaxel monotherapy compared to the cisplatin- 
containing regimens.
•  There was no difference in overall survival between the 3 treatment 
arms.
• Combination therapy had a better toxicity profi le than the high- dose 
monotherapy regimens.
COMMENTS
• Cisplatin and paclitaxel monotherapies  were discontinued more fre-
quently than the combination regimen due to toxicity or patient refusal 
(cisplatin only) or due to early progression (paclitaxel only).
• Toxicities.
• Paclitaxel associated with more severe neutropenia, fever, and 
alopecia.














Age <50 23% 23% 22%
Age 50-69 59% 59% 61%
Age ≥70 18% 18% 16%
Mea sur able disease 61% 61% 62%
Stage III 65% 72% 73%
Stage IV 35% 28% 27%
Serous 71% 74% 65%
Endometrioid 7% 7% 10%
Mucinous 2% 3% 2%
Clear cell 1% 1% 4%
Other 19% 15% 16%
Grade 1 8% 9% 6%
Grade 2 41% 39% 37%
Grade 3 51% 52% 57%
Treatment delivery
Completed 6 courses 69% 71% 81%
Discontinuation due to
Toxicity or refusal 17% 4% 7%
Early progression 7% 20% 6%
Effi cacy
CR 42% 21% 43%
PR 25% 21% 23%
No response 33% 57% 33%
Pathologic CR Not assessed 6% 24% (P < .03)
Median PFS 16.4 months 10.8 months 14.1 months
Median OS 30.2 months 25.9 months 26.3 months
Toxicity
G3/4 granulocytopenia 48% 96% 94%
G3/4 thrombocytopenia 4% 3% 3%
G3/4 anemia 11% 6% 8%
G3/4 GI toxicity 33% 10% 18%
G3/4 renal toxicity 4% 0% <1%
G3/4 neurologic toxicity 11% 1% 5%
CR, complete response; GI, gastrointestinal; OS, overall survival; PFS, progression- 
free survival; PR, partial response.
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• Cisplatin associated with more severe anemia, thrombocytopenia, 
neurotoxicity, nephrotoxicity, and gastrointestinal toxicity.
• Salvage therapy was initiated before clinical progression in all 3 treat-
ment arms.
• Among patients receiving cisplatin only, 52% received paclitaxel as 
next nonprotocol regimen.
• Among patients receiving paclitaxel only, 69% received a regimen 
containing cisplatin or carboplatin as next nonprotocol regimen.
• Among patients receiving combination cisplatin and paclitaxel, 39% 
received further cisplatin or carboplatin and 40% received a regi-
men containing neither platinum nor paclitaxel as next nonprotocol 
regimen.
• GOG initiated this trial before the results of GOG 111  were available 
(McGuire et al. 1996).
• This trial needs to be considered in the context of GOG 111 (McGuire 
et al. 1996) and OV-10 (Piccart et al. 2000), 2  trials that both demon-
strated the superiority of cisplatin + paclitaxel over cisplatin + cyclophos-
phamide. In contrast, GOG 132 demonstrates no difference between 
cisplatin + paclitaxel vs cisplatin alone (Muggia et al. 2000).
• Both paclitaxel and cisplatin  were commercially available at the time 
of GOG 132, and many patients crossed over early (before disease 
progression)  after participating in the trial. While this may be respon-
sible for blunting of a survival difference, if one exists, this trial was 
not designed to evaluate differences between concurrent and sequen-
tial treatment strategies, and one cannot conclude that  these are equiv-
alent strategies from  these data. However,  these data are provocative 
and suggest that sequential therapy may be an acceptable treatment 
strategy for  future studies.
• During GOG 111, paclitaxel was not commercially available. Dur-
ing the European- Canadian OV-10 trial, paclitaxel was available, but 
it was not generally used  until demonstrated progression. Based on 
the OV-10 study, the withholding of paclitaxel  until clinical progres-
sion is not an acceptable treatment strategy.
• The divergent results between GOG 132 and GOG 111/OV-10 might 
be explained by the higher dose of cisplatin (100 mg/m2) in the GOG 
132 regimen. This might also be explained by a pos si ble antagonis-
tic effect of cyclophosphamide when combined with cisplatin. How-
ever, when considered in the context of the available lit er a ture,  there 
is no direct evidence to suggest this to be the case.
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Danish Netherlands Trial (Neijt, JCO 2000)
REFERENCE
• Neijt JP, et al. Exploratory phase III study of paclitaxel and cisplatin 
versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin 
Oncol. 2000;18(17):3084-3092. PMID: 10963636. (Neijt et al. 2000)
TRIAL SPONSOR
• Supported by grants from Bristol- Meyers Squibb.
RATIONALE FOR TRIAL
• Cisplatin + paclitaxel was recommended as the current standard of care. 
However, paclitaxel was infused over 24 hours and administration 
required hospitalization for at least 48 hours. Administration of pacli-
taxel over 3 hours at a higher dose resulted in a dif fer ent toxicity profi le 
(Eisenhauer et al. 1994; Connelly et al. 1996).
• The substitution of carboplatin for cisplatin results in an improved tox-
icity profi le with less nephrotoxicity, ototoxicity, and neurotoxicity but 
more myelotoxicity when used as a single agent. However, carboplatin 
was found to be less effective than cisplatin in a number of solid tumors, 
and its use was not recommended in the initial treatment of ovarian 
cancer where the goal of treatment was long- term survival and cure 
(Vermorken et al. 1993; Lokich and Anderson 1998).
• This exploratory trial was conducted to evaluate the combination of 
paclitaxel (3- hour infusion) with cisplatin or carboplatin to address the 
following questions:
• How many cycles are safe and feasible when administered to 
outpatients?
• Is neurotoxicity less with carboplatin compared to cisplatin?
• Are the regimens equal in effi cacy?
• Is  there enough activity to justify the costs of a larger randomized study?
PATIENT POPULATION
• N = 213; 208 eligible.
• Accrual between March 1994 and March 1997.
• Epithelial ovarian cancer, International Federation of Gynecol ogy and 
Obstetrics (FIGO) stages IIB to IV.
• Adequate bone marrow function (WBC >3 × 109/L; platelet count 
>100 × 109/L); adequate renal function (serum creatinine >120 μmol/L; 
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creatinine clearance >60 mL/min/1.73 m2); adequate liver function (bil-
irubin level >25 μmol/L).
• Exclusion criteria: World Health Organ ization (WHO) per for mance 
status of 4; age >75 years or <18 years; complete bowel obstruction; 
symptomatic brain metastases; prior chemotherapy or radiation ther-
apy; history of ventricular arrhythmia; history of congestive heart 
failure; myo car dial infarction within 6 months of randomization; 
borderline tumors; second malignant disease; active infection; other 
serious medical conditions; prior allergic reactions to Cremophor EL.
TREATMENT DETAILS
Arm 1: Paclitaxel + Cisplatin (Administered as Inpatient)
• Paclitaxel 175 mg/m2 IV over 3 hours.
• Cisplatin 75 mg/m2 IV.
• Treatment  every 3 weeks for 6 cycles.
Arm 2: Paclitaxel + Carboplatin (Administered as Outpatient)
• Paclitaxel 175 mg/m2 IV over 3 hours.
• Carboplatin AUC 5 IV. GFR based on creatinine clearance, EDTA 
(ethylenediaminetetraacetic acid) clearance, or the Cockcroft- Gault 
formula (Cockroft and Gault 1976). Dose (mg) = 5 × (GFR + 25) (Calvert 
et al. 1989).
• Treatment  every 3 weeks for 6 cycles
Standard Premedications
• Dexamethasone 20 mg orally 12 and 6 hours prior to chemotherapy.
• Diphenhydramine 50 mg IV.
• Cimetidine 300 mg IV (or ranitidine 50 mg IV).
• Antiemetics at investigators discretion.
Dose Reductions
• According to nadirs and nadir duration (Neijt et al. 1997).
Treatment Continuations
• Six cycles of treatment  unless progressive disease or unacceptable 
toxicity.
• If assessable disease and no change in disease status  after 6 cycles, then 
2 additional courses and additional treatment at the discretion of the 
investigator.
• If partial response, treatment continuation  until progression or toxicity.
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• If complete response, then 3 additional courses  after date of documented 
response.
• If nonassessable disease, then treatment with 6 cycles  until progression or 
toxicity with subsequent treatment at the discretion of the investigator.
Surgery
• Initial cytoreductive surgery.
• If unresectable disease at time of initial surgery, then maximum cyto-
reductive surgery recommended as soon at tumor masses  were deemed 
resectable.
• Second- look laparotomy was not recommended.
ASSESSMENTS
• Baseline CA125, CT scan, labs.
• Blood counts weekly.
• CA125 with each cycle of treatment, 1 month  after completing therapy 
and  every 3 months thereafter.
• Pelvic examination  after 3 and 6 cycles.
• Scans performed at the time CA125 started to increase or when pro-
gressive disease suspected on exam. Scans repeated  after 3 courses if 
normal CA125 level at study entry or if CA125 values had not decreased 





• With a PFS estimate of 20 months for cisplatin + paclitaxel, the study 
was designed with α of .05 and power of 80% to detect a hazard ratio of 
1.67 (PFS as low as 12 months for carboplatin + paclitaxel). Assuming 
an accrual over 3 years, a total number of 196 patients  were needed with 
140 events.
• PFS and OS analyzed with Kaplan- Meier survival curves with P val-
ues calculated by the log- rank and Breslow tests for signifi cance.
Statistical Tests
• Neurotoxicity- free period assessed by Kaplan- Meier.
• Cox proportional hazards model used for effects of treatment, age, 
WHO per for mance status, residual tumor size, FIGO stage, grade, 












N = 100 Statistics
Patient characteristics
Median age 56 years 56 years
Residual disease ≤1 cm 44% 41%
Residual disease >1 cm 56% 59%
Stage II 10% 11%
Stage III 69% 70%




Clear cell 1% 6%
Other 20% 28%
Grade 1 5% 11%
Grade 2 33% 20%
Grade 3 39% 47%
Unknown grade 23% 22%
Treatment delivery
6 cycles (at least) 79% 89%
12 cycles 3% 4%
Discontinued for toxicity 17% 5%
Effi cacy
Overall response 62% 66%
Clinical complete 35% 40%
Partial 26% 25%
No change 19% 16%
Progression 11% 13%
Median PFS HR 1.07 (95% CI, 0.78-1.48)
Median OS 30 months 32 months HR 0.85 (95% CI, 0.59-1.24)
Toxicity (6 cycles)
G3/4 hemoglobin 1% 6% NS
G3/4 granulocytes 50% 70% <.01
G3/4 platelets 1% 6% <.01
G2/3 fever 8% 11% NS
G3 nausea 17% 14% <.01
G3 neurotoxicity 6% 2% NS
CI, confi dence interval; HR, hazard ratio; NS, not signifi cant; PFS, progression- free survival; OS, overall 
survival.
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histology, body weight, body surface, and baseline laboratory values 
on PFS.
CONCLUSION OF TRIAL
• The paclitaxel + carboplatin combination is safe and easy to adminis-
ter to outpatients and is less toxic than paclitaxel + cisplatin. Due to the 
small number of patients and the wide confi dence intervals around sur-




• No difference in hair loss, fever, mucositis, diarrhea, allergic reactions, 
pulmonary toxicity, cutaneous complications, cardiac events, arthral-
gia, myalgia, constipation, or renal toxicities.
• Neurotoxicity (greater than grade 1) occurred earlier with paclitaxel + 
cisplatin.
• Neurotoxicity occurred in the paclitaxel + carboplatin arm, but it was 
less frequent, was less severe, and occurred  later compared to the 
neurotoxicity occurring in the cisplatin- containing arm.
• CA125 assessments  were performed and elevations  were the fi rst sign 
of progressive disease in 70% of patients who had an elevated level at 
study entry.
•  Because this study determined treatment duration differently from 
other studies, many patients received more than 6 cycles of treatment. 
Likely due to the better tolerability of the carboplatin- containing regi-
men, more  women on this arm received prolonged treatment. It is not 
clear  whether this resulted in an impact on PFS.
• Univariate analy sis found the following  factors to predict worse PFS: 
residual disease, stage, low hemoglobin levels, high platelet counts, and 
high number of granulocytes.  These fi ndings may implicate interleukin 
6 (IL-6) and C- reactive protein in poor outcome. The prognostic impact 
of hemoglobin, platelets, and granulocytes dis appears in a multivariate 
analy sis that included tumor mass, suggesting that IL-6 cytokine release 
may be related to tumor size.
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OV-10 (Piccart, JNCI 2000)
REFERENCE
• Piccart MJ, et al. Randomized intergroup trial of cisplatin- paclitaxel 
versus cisplatin- cyclophosphamide in  women with advanced epithelial 
ovarian cancer: three- year results. J Natl Cancer Inst. 2000;92(9): 
699-708. PMID: 10793106. (Piccart et al. 2000)
TRIAL SPONSORS
• EORTC (Eu ro pean Organ ization for Research and Treatment of 
Cancer)
• NOCOVA (Nordic Gynecological Cancer Study Group)




• GOG 111 was conducted in the United States and reported better out-
come with paclitaxel- cisplatin than cyclophosphamide- cisplatin in sub-
optimally debulked stage III/IV ovarian cancer patients (abstract at 
ASCO in 1993, published in 1996) (McGuire et al. 1996).
• This was a confi rmatory trial conducted in Eu rope and Canada.
• In contrast to the administration of Taxol over 24 hours in GOG 111, 
Taxol was given as a 3- hour infusion in this trial. A prior European- 
Canadian collaborative trial found a PFS advantage for Taxol 175 mg/m2 
administration over 3 hours in a 2 × 2 factorial design evaluating 
paclitaxel dose (135 or 175 mg/m2) and infusion time (3 hours or 24 
hours) in patients with recurrent ovarian cancer (Eisenhauer et al. 
1994).
PATIENT POPULATION
• N = 680 recruited.
• Trial or ga nized in April 1994, accrual completed in August 1995.
Inclusion Criteria
• Histologically confi rmed epithelial ovarian cancer, stage IIB, IIC, III, 
or IV.
• Initial surgery within 8 weeks.
• Optimal (≤1 cm residual) or suboptimal (>1 cm residual) cytoreduction.






• WHO per for mance status of 4.
• Inadequate bone marrow function (neutrophil count <1.5 × 109/L; platelet 
count <100 × 109/L).
• Inadequate liver function (bilirubin >25 μmol/L).
• Inadequate renal function.
• Prior chemotherapy or radiotherapy.
• Complete bowel obstruction.
• Brain metastases.
• Borderline histology.
• Carcinoma of unknown origin.
• Atrial or ventricular arrhythmias.
• Congestive heart failure.
• Myo car dial infarction within 6 months.
• Second malignant disease excluding basal cell carcinoma of the skin 
or in situ carcinoma of the cervix.
• Inability to follow up.
• Active infection.
• Other serious under lying medical conditions.
TREATMENT DETAILS
Arm 1: Cyclophosphamide + Cisplatin (CP)
• Cyclophosphamide 750 mg/m2 IV rapid injection.
• Cisplatin 75 mg/m2 IV over 1 hour.
• Administered  every 3 weeks.
• Premedications with antiemetics.
• Hydration: 1- L prehydration over 3 hours + posthydration of 1 L over 3 
hours (outpatient) or 2 to 3 L over 15 hours (inpatient).
Arm 2: Taxol + Cisplatin (TP)
• Paclitaxel 175 mg/m2 IV over 3 hours. Dose was escalated to 200 mg/m2 
IV in the second cycle if no febrile neutropenia.
• Cisplatin 75 mg/m2 IV over 1 hour.
• Premedications.
• Dexamethasone 20 mg orally 12 hours and 6 hours before paclitaxel.
• Diphenhydramine 50 mg IV 30 minutes before paclitaxel.
• Ranitidine 50 mg IV 30 minutes before paclitaxel.
• Antiemetics.
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• Hydration: 1- L prehydration over 3 hours + posthydration of 1 L over 3 
hours (outpatient) or 2 to 3 L over 15 hours (inpatients).
Dose Modifi cations and Drug Substitutions
• For febrile neutropenia or prolonged myelosuppression (G4 neutrope-
nia and/or thrombocytopenia for 2 successive weekly counts):
• Paclitaxel reduced 20%.
• Cyclophosphamide reduced 20%.
• Cisplatin dose not reduced.
• G- CSF used only if toxic effects occurred despite dose reduction.
• Substitution of carboplatin for cisplatin.
• Severe renal toxicity (creatinine clearance <45 mL/min per 1.73 m2).
• Substantial hearing loss.
• WHO grade 3 or 4 neurotoxicity.
• Discontinuation of paclitaxel.
• WHO grade 3 or 4 neurotoxicity.
• Severe hypersensitivity reactions.
• Severe cardiac arrhythmias.
Other Treatment Details
• Interval cytoreduction and second- look surgeries allowed.
• Patients who had progressed  were allowed to receive any secondary 
treatment at the investigator’s discretion, including taxanes.
• Patients without disease progression  after 6 cycles could receive another 
3 cycles of optional protocol treatment.
• Cyclophosphamide + cisplatin— options for 3 additional cycles.
• Cyclophosphamide + cisplatin.




• Paclitaxel + cisplatin— options for 3 additional cycles.
• Paclitaxel + cisplatin.




• Cyclophosphamide + carboplatin.






• Clinical and radiologic assessment  after 3 cycles of therapy.
• Final response status was assigned  after 6 cycles of therapy by clinical 
and radiologic assessment or by second- look surgery.
• CA125 mea sure ments  were not used to assess response, except for nor-
malization required for complete response status.
• CT scans  were performed at baseline and  after 3 cycles, 6 cycles, and 9 
cycles.
• Once off protocol therapy, patients  were monitored with exam and 
CA125 assessment  every 3 months for 2 years and  every 6 months 
thereafter. CT scans  were not performed routinely but  were ordered in 
the setting of symptoms or CA125 elevation.
ENDPOINTS
• PFS (defi ned as date of randomization to date of progression, death, or 
start of new therapy).
• Clinical response rate.
• Overall survival (defi ned as date of randomization to date of death).
• Quality of life.
• Cost- effectiveness.
• Potential use of CA125 as a surrogate for patient outcome.
STATISTICAL CONSIDERATIONS
Sample Size
• Target accrual of 600 patients to have an 80% probability of detect-
ing an increase in the median PFS by 33% with a 2- sided signifi -
cance level of 5%. Calculations  were based on an accrual time of 18 
months.
Statistical Tests
• Kaplan- Meier curves with 2- sided unstratifi ed log- rank test.
• Cox proportional hazards regression model.
• Two- sided χ2 test or 2- sided Fisher’s exact test.
• Two- sided Kruskal- Wallis test.
CONCLUSION OF TRIAL
• This trial confi rms the conclusions of GOG 111, which demonstrated the 
superiority of paclitaxel + cisplatin over cyclophosphamide + cisplatin.












N = 342 Statistics
Patient characteristics
Median age (range) 58 (22-85) 58 (23-79)
No residual 15.7% 17.5%
Residual disease ≤1 cm 18.6% 21.1%
Residual disease >1 cm 65.4% 61.1%
Stage II 6.8% 6.4%
Stage III 72.5% 74.9%




Clear cell 5.3% 4.4%
Other 13.0% 14.3%
Grade 1 8.6% 8.2%
Grade 2 25.4% 26.9%
Grade 3 56.8% 57.6%
Unknown grade 9.2% 7.3%
Treatment delivery
Median cycles (range) 6 (0-10) 6 (0-10)
>6 cycles 26.2% 33.3%
Switch to carboplatin 8.9% 11.8%
Cisplatin dose reduction 21.4% 30.1% P < .001
Cisplatin dose delay 59.8% 36.3%
Paclitaxel dose increase 71.1%
D/C for toxicity 4.5% 6.5%
Crossover to paclitaxel 48%
Effi cacy
Pathologic CR 25% 42.5%
Microscopic residual 20.5% 23%
Overall response 44.7% 58.6% P = .01
Complete response 27.3% 40.7% P = .01
Partial response 17.4% 17.9%
Stable disease 15.5% 11.7%
Progressive disease 13.0% 4.9%
Median PFS 11.5 months 15.5 months HR 0.74, P = .0005
Median OS 25.8 months 35.6 months HR 0.73, P = .0016
Toxicity (fi rst 6 cycles)
G3/4 neutropenia 71% 64%
Febrile neutropenia 3% 2%






• Accrual completed in 1995, 4 months before GOG 111 was published 
(McGuire et al. 1996).
• A total of 680 patients  were accrued in only 15 months and marked a 
turning point in the ability to conduct intergroup  trials.
• PFS was selected as the primary endpoint as more crossover to pacli-
taxel was anticipated. Despite the 48% crossover rate, this study found 
PFS and OS differences in  favor of the paclitaxel- containing regimen 
(vs 8% crossover rate in GOG 111).
• Differences between OV-10 and GOG 111.
• OV-10 had broader inclusion criteria with inclusion of stage II patients, 
inclusion of patients with suboptimal cytoreduction, ability of patients 
to undergo secondary cytoreduction, and interval debulking surgery.
• OV-10 allowed up to 9 cycles of chemotherapy, administered pacli-
taxel over 3 hours rather than 24 hours, mandated dose escalation of 
paclitaxel, and allowed substitution of carboplatin for cisplatin in the 
setting of toxicity.
• The rate of neurotoxicity of 14% in OV-10 was higher than the 4% rate 
reported in GOG 111.
• This may be attributed to the paclitaxel dose escalation (built into 
the protocol due to the uncertainties of optimal dosing schedule) and 
the option to give 9 cycles of treatment (built into the protocol to 







N = 342 Statistics
G3/4 thrombocytopenia 5% 2%
G3/4 nausea 19% 13.3%
G3/4 vomiting 17% 10%
G3 stomatitis 0% 0.6%
G3 alopecia 20% 50%
G3 arthralgia 0.6% 3%
G3 myalgia 0% 6%
G3/4 neurosensory 0.6% 14.3%
G3 neuromotor 0.3% 3%
G3 ototoxicity 4% 2%
Severe hypersensitivity 1% 4%
CR, complete response; D/C, discontinued; HR, hazard ratio; OS, overall survival; PFS, progression- 
free survival.
(continued)
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account for the possibility that prior evidence supporting 6 cycles did 
not apply to this new regimen).
• This trial provides strong level I evidence to support paclitaxel + cis-
platin as the new standard of care, and it refutes the claim that paclitaxel 
administration should be delayed  until relapse.
GOG 114 (Markman, JCO 2001)
REFERENCE
• Markman M, et al. Phase III trial of standard- dose intravenous cispla-
tin plus paclitaxel versus moderately high- dose carboplatin followed by 
intravenous paclitaxel and intraperitoneal cisplatin in small- volume 
stage III ovarian carcinoma: an intergroup study of the Gynecologic 
Oncology Group, Southwestern Oncology Group, and Eastern Coop-
erative Oncology Group. J Clin Oncol. 2001;19(4):1001-1007. PMID: 
11181662. (Markman et al. 2001)
TRIAL SPONSORS
• Gynecologic Oncology Group (GOG)
• Southwest Oncology Group (SWOG)
• Eastern Cooperative Oncology Group (ECOG)
RATIONALE FOR TRIAL
• Current standard of care is platinum + paclitaxel, but the majority of 
patients still die of ovarian cancer.
• Studies suggest the utility of giving cisplatin by the intraperitoneal (IP) 
route (Alberts et al. 1996; Markman 1998).
• This trial also employed the concept of administering systemic che-
motherapy to chemically debulk residual tumors by giving 2 cycles of 
moderately high- intensity carboplatin (AUC 9) before administering IP 
chemotherapy (Shapiro et al. 1997).
PATIENT POPULATION
• N = 523 patients entered, 462 eligible.
• Enrollment from August 1992 to April 1995.
Inclusion Criteria
• Stage III epithelial ovarian cancer.
• Tumor debulking to optimal residual (<1 cm).





• Entry within 6 weeks of surgery.
• Adequate bone marrow (WBC ≥3000 cells/mm3; platelets ≥100,000/
mm3); adequate renal function (creatinine clearance ≥50 mL/min); 
adequate hepatic function (bilirubin ≤1.5 times normal; serum 




• Suboptimal residual disease.
• Stage IV disease.
• Prior chemotherapy or radiotherapy.
• Septicemia, severe infection acute hepatitis, or severe bleeding.
• GOG per for mance status of 3 or 4.
• Other malignancy excluding nonmelanoma skin cancer.
• Congestive heart failure, unstable angina, or myo car dial infarction 
within 6 months.
• Not expected to tolerate the hemodynamic effects of sinus bradycardia.
• Abnormal cardiac conduction.
• Taking medi cations known to affect cardiac conduction.
TREATMENT DETAILS
• Originally designed as a 3- arm trial with 1 arm receiving cispla-
tin + cyclophosphamide. When the results of GOG 111 showed inferi-
ority of this regimen to paclitaxel + cisplatin (McGuire et al. 1996), this 
arm was discontinued and the 66 patients enrolled to this arm  were not 
analyzed.
Arm 1: Paclitaxel IV + Cisplatin IV
• Paclitaxel 135 mg/m2 IV over 24 hours.
• Cisplatin 75 mg/m2 IV on day 2.
• Administered  every 21 days for 6 cycles.
Arm 2: High- Dose Carboplatin Followed by Paclitaxel IV + 
Cisplatin IP
• Carboplatin AUC 9 IV for 2 courses  every 28 days. Dose calculated 
by Calvert formula (Calvert et al. 1989) with glomerular fi ltration rate 
being considered equivalent to the creatinine clearance, which was cal-
culated by the Jelliffe method (Jelliffe 1973).
• Paclitaxel 135 mg/m2 IV over 24 hours on day 1.
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• Cisplatin 100 mg/m2 IP on day 2. Administered in 2 L of normal saline 
through an implantable peritoneal dialysis catheter (ie, Tenckhoff 
catheter).
• Paclitaxel and cisplatin administered  every 21 days for 6 cycles.
Premedications
• Standard prophylaxis to prevent paclitaxel hypersensitivity (dexa-
methasone, diphenhydramine,  either cimetidine or ranitidine).
• Antiemetics and hydration programs  were left to the discretion of the 
investigator.
Treatment Modifi cations
• To maintain dose intensity, dose reductions  were not allowed.
• Treatments  were delayed  until WBC ≥3000 cells/mm3 and platelets 
≥100,000/mm3.
• Grade 3 or 4 peripheral neuropathy resulted in treatment interruption 
 until resolution to a maximum of grade 1.
ASSESSMENTS
• Second- look surgery performed within 8 weeks for all patients with-
out evidence of progressive disease.
• Frequency of CT scans not stated in manuscript.
ENDPOINTS
• PFS (defi ned as date from entry onto the protocol to the date of 
appearance of disease as determined clinically or radiographically— 
not surgically).
• OS (defi ned as date from entry onto the protocol to the date of death).
STATISTICAL CONSIDERATIONS
Sample Size
• Accrual goal of 440 patients and follow-up  until 150 deaths had occurred 
to provide 80% power to detect a 33% decrease in the hazard ratio at 
the .05 level (1- sided).
Statistical Tests
• Kaplan- Meier survival analyses, log- rank test.
• Cox model.
• Pearson’s χ2 test signifi cance level of .20.
• Mann- Whitney U test.





 Table 2.10  Results of GOG 114
Treatment arm




 IV paclitaxel + 
IP cisplatin
N = 235 Statistics
Patient characteristics
Age <51 37% 33%
Age 51-70 51% 58%
Age >70 12% 9%
No residual 36% 35%
Residual disease ≤1 cm 64% 65%





Grade 1 14% 11%
Grade 2 40% 39%
Grade 3 46% 50%
Treatment delivery
Received 6 courses 86% 71%
Refusal of second look 15.0% 22.6%
Effi cacy
Median PFS 22.2 months 27.9 months HR 0.78, P = .01
Median OS 52.2 months 63.2 months HR 0.81, P = .05
Toxicity
G3/4 WBC 62% 77% Signifi cant
G3/4 platelets 3% 49% Signifi cant
G3/4 hematologic 88% 92%
G3/4 gastrointestinal 17% 37% Signifi cant
G3/4 cardiovascular 3% 4%
G3/4 neurologic 9% 12%
G3/4 infection 2% 5%
G3/4 metabolic 1% 10% Signifi cant
Deaths N = 2 N = 2
HR, hazard ratio; IP, intraperitoneal; IV, intravenous; OS, overall survival; PFS, 
progression- free survival; WBC, white blood cells.
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•  Because the improvement in survival was of borderline signifi cance and 
at the expense of greater toxicity, the experimental arm in this trial is 
not recommended for use.
• This study confi rms the relative safety as well as the survival advan-
tage of administering IP cisplatin compared to IV cisplatin (as seen in 
GOG 104) (Alberts et al. 1996).
• Given the superior outcomes with paclitaxel plus cisplatin over cyclo-
phosphamide and cisplatin (as seen in GOG 111 and OV-10) (McGuire 
et al. 1996; Piccart et al. 2000), it is impor tant to study the impact of IP 
cisplatin when combined with paclitaxel (design of GOG 172) (Arm-
strong et al. 2006).
COMMENTS
• This study was designed recognizing that the results would not give a 
clear answer regarding the separate effects of high- dose IV carbopla-
tin or IP cisplatin.  Because the increases in survival with the experi-
mental arm  were marginal and at the expense of greater toxicity, the 
question of  future directions from this study are raised.
• Due to the imbalance and higher than expected refusals of second- look 
procedures, the endpoint of pathologic response was thought to be likely 
biased and was not reported.
ICON3 (Lancet 2002)
REFERENCE
• International Collaborative Ovarian Neoplasm Group. Paclitaxel plus 
carboplatin versus standard chemotherapy with  either single- agent car-
boplatin or cyclophosphamide, doxorubicin, and cisplatin in  women 
with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;360 
(9332):505-515. PMID: 12241653. (International Collaborative Ovarian 
Neoplasm Group 2002)
TRIAL SPONSORS
• Istituto Mario Negri in Milan, Italy
• Swiss Group for Cancer Research (SAKK) in Bern, Switzerland
• Nordic Society for Gynecologic Oncology (NSGO) in Odense, Denmark





• Medical Research Council (MRC) Cancer  Trials Offi ce in Cambridge, 
United Kingdom
RATIONALE FOR TRIAL
• The ICON2 trial compared single- agent carboplatin with the 3- drug 
regimen of cyclophosphamide, Adriamycin, and cisplatin (CAP) and 
found no difference in progression- free or overall survival between the 
treatment arms (International Collaborative Ovarian Neoplasm Group 
1998).
• Based on GOG 111, OV-10, and GOG 132, many have suggested that 
paclitaxel and cisplatin should be the standard of care for advanced 
ovarian cancer (McGuire et al. 1996; Muggia et al. 2000; Piccart et al. 
2000).
•  Because of the equivalence of cisplatin and carboplatin and the con-
cern over neurotoxicity when cisplatin and paclitaxel are administered 
together,  others have suggested that carboplatin and paclitaxel should 
be given as routine treatment (GOG 158, AGO/OVAR-3, Neijt  trials) 
(Neijt et al. 2000; du Bois et al. 2003; Ozols et al. 2003).
• ICON3 aims to compare paclitaxel + carboplatin against a non- taxane- 
containing platinum- based regimen. At the time of trial initiation, the 
results from ICON2  were not yet mature and a fi rm recommendation for 
the regimens in the control arm (carboplatin vs CAP) could not be made.
PATIENT POPULATION
• N = 2074 enrolled.
• Enrollment from February 1995 to October 1998 from 130 centers in 
8 countries.
• Invasive epithelial ovarian cancer; fi t to receive chemotherapy; no other 
malignant disease; no prior chemotherapy or radiotherapy.
• Minimum recommended surgical procedure was total abdominal hys-
terectomy, bilateral salpingo- oophorectomy, and thorough staging.
TREATMENT DETAILS
• The treating physician could choose the control regimen (carboplatin 
or CAP), but this had to be specifi ed before randomization.
Control Group— Carboplatin
• Dose determined by the AUC method of Calvert (Calvert et al. 1989) 
of 5 (GFR + 25) mg.
510-66190_ch01_3P.indd   91 11/8/16   7:49 PM





• Cyclophosphamide 500 mg/m2 IV.
• Doxorubicin 50 mg/m2 IV.
• Cisplatin 50 mg/m2 IV.
Experimental Group— Paclitaxel + Carboplatin
• Paclitaxel 175 mg/m2 IV over 3 hours.
• Carboplatin (same dosing as control arm).
ASSESSMENTS
• Data  were collected pretreatment and  after each cycle of treatment. 
During follow-up, data  were collected  every 3 months for the fi rst 
2 years,  every 6 months for the next 3 years, and  every year thereafter.
ENDPOINTS
• OS (time from randomization to death from any cause).
• PFS (time from randomization to fi rst appearance of progressive dis-
ease or death from any cause) and toxicity.
STATISTICAL CONSIDERATIONS
Sample Size
• Power analy sis based on expectation of 2- year survival of 50% in the 
control groups. An accrual target of 1000 patients in the control groups 
was selected to detect a 10% difference in 2- year survival from 50% to 
60% with 85% power and 5% signifi cance level, translating into a 
hazard ratio of 0.74.
• One year into the trial, the trial sample size was increased to a new tar-
get of 2000 patients to detect more a subtle difference of 7% difference 
from 50% to 57% 2- year survival with 85% power and 5% signifi cance 
level, corresponding to a hazard ratio of 0.81.
Statistical Tests
• Kaplan- Meier survival curves for OS and PFS  were compared using 
the Mantel- Cox version of the log- rank test. The stratifi ed log- rank test 
was used to account for the 2 control groups, the differences across the 
4 participating centers, and the difference in randomization ratios (1:1 
at 2 centers and 2:1 at 2 centers).
• χ2 test for interaction or χ2 test for trend used to test of differences in 
the relative size of effect in dif fer ent subgroup.



















































































































































































































































































































































































































































































































































































































































• The combination of paclitaxel + carboplatin is not superior to single- 
agent carboplatin or CAP.
• Paclitaxel + carboplatin is more toxic and  causes more fever, alopecia, 
and sensory neuropathy than carboplatin alone.
• ICON3 suggests that single- agent carboplatin, CAP, and paclitaxel + 
carboplatin are all safe and have similar effi cacy as fi rst- line treatments 
for ovarian cancer.
COMMENTS
• In the context of other phase III  trials, ICON3 seems to contradict the 
fi ndings of GOG 111 (McGuire et al. 1996) and OV-10 (Piccart et al. 
2000) but are in line with GOG 132 (Muggia et al. 2000). One expla-
nation is that the control arm of cisplatin + cyclophosphamide (as given 
in GOG 111 and OV-10) is inferior to the control arm of single- agent 
platinum (as given in GOG 132 and ICON3).
• About one- third of patients in the ICON3 control arms went on to 
receive a taxane  later. This raises the question of the optimum time to 
use paclitaxel in the treatment of advanced ovarian cancer and  whether 
this would be at the time of progression  after single- agent platinum.
GOG 158 (Ozols, JCO 2003)
REFERENCE
• Ozols RF, et al. Phase III trial of carboplatin and paclitaxel compared 
with cisplatin and paclitaxel in patients with optimally resected stage 
III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 
2003;21(17):3194-200. PMID: 12860964. (Ozols et al. 2003)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• The GOG 111 and OV-10 studies both demonstrated superiority of cis-
platin + paclitaxel over the control treatment of cisplatin + cyclophospha-
mide (McGuire et al. 1996; Piccart et al. 2000).
• Carboplatin is an analogue of cisplatin with less hematologic toxicity 
and comparable effi cacy.
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• A 1993 International Ovarian Cancer Consensus Conference recom-
mended that carboplatin should not be routinely used in the upfront 
treatment of patients with small- volume stage III ovarian cancer (Ver-
morken et al. 1993).
• A GOG pi lot study found the combination of carboplatin and paclitaxel 
to be active with an overall response rate of 75% and a complete response 
rate of 67% (Bookman et al. 1996).
• GOG 158 was designed as a noninferiority study to compare the effi -
cacy and toxicity of carboplatin + paclitaxel vs the standard regimen of 
cisplatin + paclitaxel.
PATIENT POPULATION
• N = 840, 792 eligible.
• Stage III epithelial ovarian cancer with <1 cm residual disease.
• No prior chemotherapy; GOG per for mance status of 0 to 2; WBC 
≥3000/μL; platelets ≥100,000/μL; serum creatinine ≤2.0 mg/dL; serum 
bilirubin and AST levels of no more than 2 times the institutional upper 
limit of normal.
TREATMENT DETAILS
Control Arm: Paclitaxel + Cisplatin
• Paclitaxel 135 mg/m2 IV over 24 hours.
• Cisplatin 75 mg/m2 IV at a rate of 1 mg/min.
• Treatment  every 3 weeks for 6 cycles.
Experimental Arm: Paclitaxel + Carboplatin
• Paclitaxel 175 mg/m2 IV over 3 hours.
• Carboplatin AUC 7.5 mg/mL/min. Dose based on the Calvert formula 
of AUC × (GFR + 25). Creatinine clearance was calculated using the 
Jelliffe formula (Jelliffe 1973).
Premedications Before Paclitaxel
• Dexamethasone 20 mg orally 12 and 6 hours before treatment.
• Diphenhydramine 50 mg IV 30 minutes before treatment.
• Cimetidine 300 mg IV 30 minutes before treatment.
Treatment Modifi cations
• If ANC ≤1000/μL and/or platelets <100,000/μL, then cycle delay, dose 
reduction, and addition of G- CSF in this sequence.
• No dose modifi cation for uncomplicated nadirs.





• If delay of 2 weeks or less, no dose modifi cation and no G- CSF.
• If delay of 2 to 3 weeks, dose modifi cation.
• If recurrent delays of more than 2 weeks or febrile neutropenia, G- CSF 
added at dose of 5 μg/kg/d for 14 days starting 24 hours  after the 
completion of chemotherapy.
• No cycle delay for gastrointestinal toxicity, grade 1 to 2 peripheral neu-
ropathy, or mild renal toxicity (serum creatinine ≤2 mg/dL or creati-
nine clearance ≥50 mL/min).
• Discontinuation of protocol therapy for more severe renal or neurolo-
gic toxicity that had not resolved before the next scheduled dose of 
therapy.
ASSESSMENTS
•  Because eligibility included tumors <1 cm only, imaging proce-
dures  were not required  until  after the completion of 6 cycles of 
chemotherapy.
• The decision of  whether to undergo second- look laparotomy was made 
at the time of random assignment.
ENDPOINTS




• A sample size of 720 patients was set with an estimated 3 years of fol-
low-up to observe 382 recurrences before testing the noninferiority 
hypothesis. This was a 1- sided test with the probability of a type I and 
type II error both set at 0.1 for a hazard ratio of 1.3 (favoring cisplatin 
plus paclitaxel).  These characteristics  were chosen to detect a moderate- 
size loss of effi cacy with the use of carboplatin plus paclitaxel.
Statistical Tests
• Cumulative proportions of survival  were based on Kaplan- Meier 
procedures.
• Relative risk estimates of treatment effects  were calculated with the 
Cox model adjusting for prognostic  factors.
• The Kruskal- Wallis rank test adjusted for ties was used to test the in de-
pen dence of severity of toxicity (grade 0 to 4) to the assigned treatment.












N = 392 Statistics
Patient characteristics
Age 21-50 33% 29%
Age 51-70 56% 58%
Age 71-90 11% 13%
No residual 36% 35%
Residual disease ≤1 cm 64% 65%




Clear cell 3% 5%
Other 14% 9%
Grade 1 11% 9%
Grade 2 35% 36%
Grade 3 54% 55%
Optional second look 50% 49%
Treatment delivery
Received 6 cycles 85% 87%
Effi cacy
Median PFS 19.4 months 20.7 months RR 0.88 (0.75-1.03)
Median OS 48.7 months 57.4 months RR 0.84 (0.70-1.02)
pCR 46% 53%
Toxicity
G3/4 leukopenia 63% 59% P < .05
G3/4 thrombocytopenia 5% 39% P < .05
G3/4 granulocytopenia 93% 89%
G3/4 gastrointestinal 23% 10% P < .05
G/34 neurologic 8% 7%
G3/4 metabolic 8% 3% P < .05
G3/4 genitourinary 3% 1% P < .05
G1/2 pain 15% 26% P < .05
pCR, pathologic complete response; OS, overall survival; PFS, progression- free survival; 
RR, relative risk.






• The combination of paclitaxel plus carboplatin is not inferior to the 
combination of paclitaxel plus cisplatin in patients with small- volume 
stage III epithelial ovarian cancer.
COMMENTS
• This trial was designed as a noninferiority trial, not to determine the 
superiority of carboplatin over cisplatin.
• The 16% reduced risk of death with carboplatin is suggestive of a pos-
si ble increase in effi cacy over cisplatin.
• The carboplatin dose (AUC 7.5) may have resulted in more platinum 
exposure than the cisplatin dose (75 mg/m2).
• In  trials combining carboplatin with cyclophosphamide,  there was no 
benefi t to increasing doses of carboplatin (Jakobsen et al. 1997; Gore 
et al. 1998). The pharmacodynamic interaction between carboplatin 
and paclitaxel may  favor higher doses of carboplatin.
• Other prospective randomized  trials comparing paclitaxel + carbopla-
tin vs paclitaxel + cisplatin:
• Danish Netherlands Trial (Neijt et al. 2000) had an insuffi cient num-
ber of patients to determine statistical equivalency.
• Arbeitsgemeinschaft Gynakologische trial from Germany (du Bois 
et al. 2003) showed no difference in PFS or OS between treatments. 
Paclitaxel was administered as 185 mg/m2 over 3 hours (vs 135 mg/
m2 over 24 hours in GOG 158) and carboplatin was dosed at AUC 6 
(vs AUC 7.5 in GOG 158).
• Both the Netherlands and German  trials included patients with stage 
II to IV disease.
• GOG 158 fails to support the concern that a 3- hour infusion of pacli-
taxel is less effi cacious than a 24- hour infusion.
• Dif fer ent toxicity profi les.
• Cisplatin was responsible for more gastrointestinal and metabolic 
toxicity.
•  There was no difference in neurotoxicity between arms. This is in 
contrast to the results of the 2 Eu ro pean  trials that both showed less 
neurotoxicity with carboplatin. This may be  because cisplatin was 
combined with a 3- hour infusion of paclitaxel in the control arms.
• Median survival  after recurrence was 23 months without difference 
between treatment groups.
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• While this trial demonstrates carboplatin + paclitaxel to be the treatment 
of choice for patients with small- volume stage III ovarian cancer, it also 
highlights the need for more effective therapies. More than 70% of 
patients experienced recurrence with the majority occurring in the fi rst 
2 years following therapy.
• GOG 182 was designed subsequently to test the addition of a third drug 
to the carboplatin and paclitaxel base.
AGO/OVAR-3 (du Bois, JNCI 2003)
REFERENCE
• du Bois A, et al. A randomized clinical trial of cisplatin/paclitaxel versus 
carboplatin/paclitaxel as fi rst- line treatment of ovarian cancer. J Natl 
Cancer Inst. 2003;95(17):1320-9. PMID: 12953086. (du Bois et al. 2003)
TRIAL SPONSOR
• Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Can-
cer Study Group
RATIONALE FOR TRIAL
• In the 1980s, 2  trials demonstrated improved survival when cisplatin 
was added to doxorubicin and cyclophosphamide (Neijt et al. 1984; 
Omura et al. 1986). Subsequent studies showed no difference between 
2- drug and 3- drug regimens (Bertelsen et al. 1987; Omura et al. 1989), 
resulting in the combination of cisplatin and cyclophosphamide being 
considered the standard of care for about a de cade.
• In the 1990s, paclitaxel replaced cyclophosphamide in the fi rst- line 
treatment of advanced ovarian cancer (McGuire et al. 1996; Piccart 
et al. 2000). Paclitaxel plus cisplatin was considered the new standard 
of care, but this was challenged by the results of the ICON3 trial (Inter-
national Collaborative Ovarian Neoplasm Group 2002).
• Despite  these advances, more than 50% of patients with advanced ovar-
ian cancer die within 5 years of original diagnosis. This makes toler-
ability of treatment and quality- of- life impor tant considerations in 
ongoing research. Carboplatin is better tolerated than cisplatin when 
combined with cyclophosphamide with no loss in effi cacy (Alberts et al. 
1992; Swenerton et al. 1992).
• Several phase I/II studies tested the feasibility of combining carbopla-
tin with paclitaxel (du Bois et al. 1997). The maximum tolerated dose 





of paclitaxel ranged from 175 to 275 mg/m2 and the maximum toler-
ated dose of carboplatin ranged from 300 to 550 mg/m2 or AUC 5 to 
AUC 7.5.
• This trial and GOG 158  were both designed as noninferiority studies 
to test the effi cacy and toxicity of carboplatin vs cisplatin when com-
bined with paclitaxel.
PATIENT POPULATION
• N = 883 screened, 798 eligible.
• Enrollment between November 1995 and November 1997.
Inclusion Criteria
• Histologically confi rmed FIGO stage IIB to IV epithelial ovarian 
cancer.
• Radical debulking surgery within 6 weeks or random assignment.
• Adequate hematologic, renal, and hepatic function: ANC >1.5 × 109 
cells/L, platelet count >100 × 109 cells/L, serum creatinine and bilirubin 
<1.25 times upper normal limit.
Exclusion Criteria
• Low malignant potential tumors.
• ECOG per for mance status >2 or Karnofsky index <60%.
• Estimated GFR <60 mL/min.
• Other malignancies.




• Congestive heart failure.
TREATMENT DETAILS
Arm 1: Paclitaxel Plus Cisplatin (PT)
• Paclitaxel 185 mg/m2 IV over 3 hours (dose capped at 400 mg).
• Cisplatin 75 mg/m2 IV over 30 minutes (dose capped at 165 mg).
Arm 2: Paclitaxel Plus Carboplatin (TC)
• Paclitaxel 185 mg/m2 IV over 3 hours (dose capped at 400 mg).
• Carboplatin AUC 6 IV over 30 to 60 minutes (dose capped at 880 mg). 
Calculated by the method of Calvert (Calvert et al. 1989) of AUC × 
(GRF +25). GFR estimated by the Jelliffe formula (Jelliffe 1973).
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• This dose was the maximum tolerated dose (MTD) in a preceding phase 
I/II trial (du Bois et al. 1997).
Dose Reductions Allowed for Toxicity
• Level 1.
• Carboplatin AUC 5.
• Cisplatin 60 mg/m2.
• Paclitaxel 160 mg/m2.
• Level 2.
• Carboplatin AUC 4.
• Cisplatin 50 mg/m2.
• Paclitaxel 135 mg/m2.
• Treatment delayed for ANC <1.5 × 109 cells/L or platelet count <100 × 109 
cells/L.
• Prophylaxis with G- CSF was not allowed, but supportive use could be 
initiated if ANC recovery took more than 36 days.
Premedications
• Dexamethasone 20 mg single dose before paclitaxel.
• Clemastine 2 mg IV 30 minutes before paclitaxel.
• Cimetidine 300 mg IV 30 minutes before paclitaxel.
• Antiemetics: serotonin type 3 receptor antagonists and corticosteroids.
• Hydration with cisplatin: pre- and postchemotherapy hydration to avoid 
nephrotoxicity.
Treatment Discontinuation
• For disease progression during therapy.
Treatment Continuation
• Patients with partial remission and residual tumor  after 6 cycles could 
receive additional treatment cycles.
ASSESSMENTS
• Chemistries before each treatment cycle.
• Hematologic par ameters mea sured weekly.
• Quality of life mea sured by the EORTC quality- of- life questionnaire 
(QLQ)– C30, version 2.0 (Aaronson et al. 1993)  after each treatment 
cycle and 3 and 6 months  after completion of treatment.
• Tumor mea sure ment was recorded before each treatment cycle by phys-
ical examination and before each third treatment cycle by imaging 
in patients with mea sur able or evaluable disease. Imaging consisted 





of ultrasound, x- ray, computed tomography, or magnetic resonance 
imaging (MRI), and a consistent modality was used at baseline and 
follow-up.
• Second- look surgery was not recommended.
• Follow-up visits  were schedule  every 3 months for the fi rst 2 years and 
 every 6 months thereafter  until 5 years  after treatment cessation.
ENDPOINTS
• Proportion of patients without progression at 2 years (primary 
endpoint).
• Toxicity.
• Response to treatment.
• Quality of life.
• Overall survival (mea sured from time of randomization).
• Progression- free survival time (mea sured from time of randomization).
STATISTICAL CONSIDERATIONS
Stratifi cation
• Patients  were stratifi ed based on residual tumor size and FIGO stage.
• Stratum 1: patients with residual tumor ≤1 cm and FIGO stage IIB, 
IIC, or III.
• Stratum 2: residual tumor >1 cm or FIGO stage IV.
Sample Size
• This was a noninferiority trial with a sample size of 692 patients to 
exclude a difference between the proportion of patients without pro-
gression at 2 years of more than 8% between arms with 80% power 
and α of 5%. This calculation was based on the assumption of an equal 
number of patients per stratum and a dropout rate of 10%. During the 
trial, the sample size was increased to 798 patients to account for more 
patients in stratum 1.
CONCLUSION OF TRIAL
•  Because carboplatin is more tolerable than cisplatin with equal treat-
ment effi cacy, the combination of carboplatin with paclitaxel may be 
in the best interest of patients with advanced ovarian cancer.
COMMENTS
•  There was greater toxicity and worse quality of life with cisplatin com-
pared to carboplatin.












N = 397 Statistics
Patient characteristics
Median age (range) 57.7 years 56.7 years
Stratum 1 (≤1 cm, II, III) 59.3% 52.9%
Stratum 2 (>1 cm, IV) 40.7% 47.1%
Residual ≤1 cm 65.9% 59.5%
Residual >1 cm 34.1% 40.5%
Stage II 7.5% 9.3%
Stage III 76.4% 72.5%
Stage IV 16.1% 18.1%
Serous 69.9% 70.8%
Other 30.1% 29.2%
Grade 1 6.7% 9.5%
Grade 2 37.3% 38.5%
Grade 3 56.0% 52.0%
Treatment delivery
Received 6 cycles 84.0% 87.7%
Treatment delay >7 days 10.3% 14.0%
Dose reductions 10.5% 11.2%
Effi cacy
Complete response 43.3% 36.5%
Partial response 33.3% 41.9%
Stable disease 10.0% 10.8%
Progressive disease 13.3% 10.8%
No progression at 2 years 40.0% 37.5% NS
Median PFS 19.1 months 17.2 months HR 1.095 (95% CI, 0.89-1.23)
Strata 1 24.2 months 26.0 months HR 0.91 (95% CI, 0.72-1.15)
Strata 2 14.3 months 13.4 months HR 1.14 (95% CI, 0.91-1.43)
Median OS 44.1 months 43.3 months HR 1.05 (95% CI, 0.87-1.26)
Strata 1 55.4 months 59.4 months HR 0.92 (95% CI, 0.70-1.22)
Strata 2 30.7 months 31.4 months HR 1.08 (95% CI, 0.85-1.38)
Toxicity
G3/4 platelets 1% 12.9%
G3/4 anemia 3.9% 5.9%
G3/4 leukopenia 10.8% 31.9%
G3/4 neutropenia 22.0% 37.0%
Febrile neutropenia 3.6% 8.0%
G3/4 infections 22.6% 35.6%
G3 nausea 13.8% 5.4%
G3 vomiting 9.1% 2.3%
Any ototoxicity 16.9% 8.8%
Any renal toxicity 19.9% 5.4%
G3/4 sensory neuropathy 13.5% 7.2%
CI, confi dence interval; HR, hazard ratio; NS, not signifi cant; PFS, progression- free survival; OS, overall survival.





• Response rates  were higher with cisplatin than carboplatin, but this did 
not translate into improved survival.
• Patients receiving carboplatin had greater myelosuppression, but this 
rarely led to symptoms such as febrile neutropenia or nonneutropenic 
infections.
• This trial supports the fi ndings from other  trials of platinum plus 
paclitaxel chemotherapy (McGuire et al. 1996; Neijt et al. 2000; Piccart 
et al. 2000).
• Direct comparisons of toxicities are diffi cult due to the dif fer ent 
grading systems used.
• Gastrointestinal and neurologic toxicities are less with carboplatin.
• The median OS time with paclitaxel + cisplatin is higher in this 
trial than  others (44.1 months vs 38 months [McGuire et al. 1996], 
35.6 months [Piccart et al. 2000], and 30 months [Neijt et al. 2000]), 
which likely refl ects a patient population with more favorable tumor 
characteristics.
SCOTROC— Scottish Randomised Trial in 
Ovarian Cancer (Vasey, JNCI 2004)
REFERENCE
• Vasey PA, et al. Phase III randomized trial of docetaxel- carboplatin 
versus paclitaxel- carboplatin as fi rst- line chemotherapy for ovarian 
carcinoma. J Natl Cancer Inst. 2004;96(22):1682-1691. PMID: 15547181. 
(Vasey et al. 2004)
TRIAL SPONSOR
• Scottish Gynaecological Cancer  Trials Group
• Supported by grants from Aventis Phar ma ceu ti cals
RATIONALE FOR TRIAL
• Docetaxel is a semisynthetic taxane with superior activity to anthra-
cyclines and paclitaxel in metastatic breast cancer.
• Phase II  trials of docetaxel in ovarian cancer demonstrate activity com-
parable to paclitaxel.
• The combination of docetaxel and carboplatin was found to be feasible.
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• N = 1077.
• Recruited from 83 international centers between October 1988 and May 
2000.
•  Women 18 years and older.
• Histologically confi rmed epithelial ovarian cancer, stages IC to IV.
• ECOG per for mance status of 0 to 2.
• No prior chemotherapy or radiotherapy.
• Adequate bone marrow, hepatic, and renal function.
• Excluded if peripheral neuropathy more than grade 2.
• Randomization within 6 weeks of surgery.
• First treatment cycle within 2 weeks of randomization.
TREATMENT DETAILS
Arm 1: Paclitaxel + Carboplatin
• Paclitaxel 175 mg/m2 IV over 3 hours.
• Carboplatin AUC 5 IV over 1 hour.
Arm 2: Docetaxel + Carboplatin
• Docetaxel 75 mg/m2 IV over 1 hour.
• Carboplatin AUC 5 over 1 hour.
Paclitaxel Treatment Details
• Dexamethasone 20 mg 12 and 6 hours prior to chemotherapy.
• Chlorpheniramine 10 mg or diphenhydramine 50 mg 1 hour prior to 
chemotherapy.
• Ranitidine 50 mg or cimetidine 300 mg 1 hour prior to chemotherapy.
• Starting dose 175 mg/m2 over 3 hours.
• Dose reduction to 135 mg/m2 over 3 hours for complicated grade 4 
neutropenia.
• Discontinued for deterioration of liver function or neurotoxicity grade 
3 or more.
• Hypersensitivity reactions— infusion stopped, symptoms treated, pacli-
taxel reinfused within 3 hours if appropriate.
Docetaxel Treatment Details
• Dexamethasone 8 mg twice a day for 3 days starting on day prior to 
chemotherapy.
• Starting dose 75 mg/m2 over 1 hour.
• Dose reduction to 60 mg/m2 over 1 hour for complicated grade 4 
neutropenia.





• Discontinued for deterioration of liver function or neurotoxicity grade 
3 or more.
• Hypersensitivity reactions— infusion stopped, symptoms treated, 
docetaxel reinfused within 3 hours if appropriate.
Carboplatin Treatment Details
• Carboplatin dose calculated by Calvert formula with edetic acid to mea-
sure GFR.
• Starting dose AUC 5 in both treatment arms.
• Dose reduction to AUC 4 for complicated grade 4 thrombocytopenia.
Antiemetics
• Granisetron 3 mg.
• Ondansetron 8 mg.
Treatment Delays
• Allowed for up to 2 weeks for:
• ANC <1500/μL.
• Platelets <100,000 /μL.
• Mucositis grade 3 or more.
• Skin toxicity grade 2 or more.
Dose Reductions
• Complicated grade 4 neutropenia.
• G- CSF 300 mg/d added for per sis tent neutropenia despite dose reduc-
tion of paclitaxel or docetaxel.
• Prophylactic antibiotics added for all subsequent cycles.
Interval Cytoreduction
• Allowed between cycles 3 and 4.
Treatment Continuation
• If partial response or complete response with elevated CA125, 3 cycles 
of carboplatin AUC 7 allowed for up to 3 additional cycles.
ASSESSMENTS
• CT scan at baseline and  after cycles 3 and 6— classifi ed according to 
Response Evaluation Criteria in Solid Tumors (RECIST).
• CA125 at baseline and before each cycle— classifi ed according to 
method of Rustin.
• Toxicity assessed by NCI- CTC, version 2.0.
• Quality of life assessed before each cycle and at 6 months and then 
 every 4 months for up to 2 years using EORTC QLQ- C30 (version 3.0) 
and EORTC QLQ- OV28 (version 1).










N = 539 Statistics
Patient characteristics
Median age (range) 59 years (19-84) 59 years (21-85)
Stage IC- II 20% 19%
Stage III- IV 80% 81%
No residual 33% 33%
≤2 cm residual 30% 30%
>2 cm residual 37% 37%
Serous 44% 44%
Endometrioid 10% 12%
Clear cell 4% 5%
Mucinous 2% 4%
Other 38% 34%
Grade 3 54% 54%
Treatment delivery





Median PFS (95% CI) 14.8 months (13.5-16.1) 15 months (13.3-16.6) HR 0.97, 
P = NS
2- year survival 68.9% 64.2% HR 1.13, 
P = NS
Complete response 28% 28% P = NS
Toxicity
G3-4 neutropenia 84% 94% P < .001
G4 neutropenia + fever 2% 11% P < .001
G4 neutropenia >7 days 3% 14% P < .001
G3-4 thromobocytopenia 10% 9% P = NS
G3-4 anemia 8% 11% P = NS
Deaths N = 1 N = 2
G2-4 neurosensory 30% 11% P < .001
G2-4 neuromotor 7% 3% P < .001







AUC, area  under the curve; CI, confi dence interval; HR, hazard ratio; NS, not signifi cant; PFS, 
progression- free survival.





• Neurotoxicity assessment at some centers with 12 questions and 5 neu-
rologic tests to report NScore at baseline,  after cycles 3 and 6, at 6 months 
and  every 4 months for up to 2 years.
• Follow-up  every 2 months with exam and CA125. CT scans for rising 
CA125.
ENDPOINTS
• Progression- free survival (primary endpoint).
• Overall survival.
• Quality of life.
STATISTICAL CONSIDERATIONS
Sample Size
• Study designed with 80% power to detect a difference of 25% increase 
in median PFS from 17 to 21.25 months. Required 1050 patients with 
minimum follow-up of 1 year.
CONCLUSIONS OF TRIAL
• Similar effi cacy between arms and acceptable toxicities in both arms.
• Compared to paclitaxel- carboplatin, docetaxel- carboplatin resulted in 
greater myelosuppression but less neurotoxicity during therapy and 
follow-up.
• Docetaxel- carboplatin is an alternative to treatment with paclitaxel- 
carboplatin in the upfront treatment of patients with stage IC to IV 
ovarian cancer.
COMMENTS
• This trial has shorter survival times compared to other  trials. Authors 
state this may be due to dif fer ent patient populations (more residual dis-
ease) or the broad defi nition of progressive disease used in this trial.
• According to the authors, the higher rate of neurotoxicity of 30% reported 
in the paclitaxel- carboplatin arm may be due to the more comprehensive 
approach to neurotoxicity monitoring in this trial.
GOG 172 (Armstrong, NEJM 2006)
REFERENCE
• Armstrong DK, et al. Intraperitoneal cisplatin and paclitaxel in ovar-
ian cancer. N Engl J Med. 2006;354(1):34-43. PMID: 16394300. (Arm-
strong et al. 2006)
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• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• Most patients with advanced ovarian cancer attain clinical remission, 
but the majority eventually relapse and die of disease.
• The intensity of intravenous therapy is limited by myelotoxicity. How-
ever, several drugs can be administered directly into the peritoneal cav-
ity. Intraperitoneal administration of chemotherapy allows for tumor 
to receive sustained exposure to high concentrations of drug while bone 
marrow and other normal tissues are relatively spared.
• Two prior GOG  trials (GOG 104 and GOG 114) evaluated intraperito-
neal administration of cisplatin in patients with low- volume ovarian 
cancer. GOG 104 demonstrated a survival advantage with intrape-
ritoneal cisplatin, but paclitaxel was not administered in the regimen 
(Alberts et al. 1996). GOG 114 demonstrated a PFS advantage and only 
borderline OS advantage with intraperitoneal cisplatin, but the inter-
pretation of the trial was complicated by the use of 2 cycles of moder-
ately intensive carboplatin, which added to the toxicity of the treatment 
(Markman et al. 2001).
• Intraperitoneal chemotherapy had not been widely accepted and used 
based on high cost, high toxicity, and lack of familiarity with intraperi-
toneal administration and catheter- placement techniques.
PATIENT POPULATION
• N = 429 enrolled, 415 eligible.
• Enrollment between March 1998 and January 2001.
• Stage III epithelial ovarian cancer with <1 cm residual mass  after 
surgery.
• GOG per for mance status of 0 to 2.
• Normal blood counts, adequate renal and hepatic function.
• Ineligibility criteria: prior chemotherapy or radiation; second primary 
cancer; low malignant potential tumors.
TREATMENT DETAILS
Arm 1: Intravenous Therapy
• Paclitaxel 135 mg/m2 IV over 24 hours on day 1.
• Cisplatin 75 mg/m2 IV on day 2.
• Treatment given  every 3 weeks for 6 cycles.





Arm 2: Intravenous/Intraperitoneal Therapy
• Paclitaxel 135 mg/m2 IV over 24 hours on day 1.
• Cisplatin 100 mg/m2 IP on day 2.
• Paclitaxel 60 mg/m2 IP on day 8.
• Intraperitoneal chemotherapy was reconstituted in 2 L of warmed nor-
mal saline and infused as rapidly as pos si ble.
• Treatment given  every 3 weeks for 6 cycles.
Premedications
• Standard premedications to prevent paclitaxel hypersensitivity.
• Hydration and antiemetics given before cisplatin.
Treatment Delays
• If ANC <1500 cells/mm3, platelets <100,000/mm3, or serum creatinine 
>2 mg/dL, then treatment delay, dose reduction, then addition of G- CSF 
(in this sequence)
• If grade 3 or 4 peripheral neuropathy, creatinine >2 mg/mL or creati-
nine clearance <50 mL/min, then treatment was postponed.
• If treatment was delayed for more than 3 weeks, patients  were removed 
from study.
• In the intraperitoneal therapy group:
• For grade 2 abdominal pain, the dose of intraperitoneal drug was 
reduced.
• For grade 3 abdominal pain, recurrent grade 2 abdominal pain  after 
dose reduction, or intraperitoneal catheter complications, dosing was 
changed to intravenous.
• For grade 2 peripheral neuropathy, the dose of cisplatin was reduced.
• For cisplatin- related toxic effects requiring discontinuation of proto-
col therapy, carboplatin was substituted for cisplatin.
ASSESSMENTS
• At registration, patients deci ded  whether they would undergo second- 
look laparotomy.
• Physical exam, history, complete blood count (CBC), chemistries, and 
CA125  were mea sured at baseline, at the completion of therapy,  every 
3 months for 24 months, then  after 6 months thereafter.
• Quality- of- life assessment with the Functional Assessment of Cancer 
Therapy— Ovarian (FACT- O) instrument (Basen- Engquist et al. 2001) 
at registration, before cycle 4, 3 to 6 weeks  after cycle 6 and 12 months 
 after the completion of therapy.
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• PFS (mea sured from date of randomization).
• OS (mea sured from date of randomization).
• Quality of life.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Patients  were randomized with stratifi cation according to residual dis-
ease and decision of  whether to undergo second- look surgery.
Sample Size
• A sample size of 384 patients with follow-up to observe 208 recurrences 
and 208 deaths allowed testing for a hazard ratio of 1.5 (favoring intra-
peritoneal administration) for recurrence and survival using a 1- sided 
log- rank test with 90% power and an α level of .05.
Statistical Tests
• Kaplan- Meier to estimate the cumulative proportions of survival 
(Kaplan and Meier 1958).
• Cox model to estimate the relative risk and confi dence intervals for 
treatment effects on progression and death (Cox 1972).
• Adjusted estimates  were based on covariates of age and histology.
• Wilcoxon rank- sum test to test the in de pen dence of the risk of severe 
and life- threatening toxic effects from treatment.
• Quality- of- life assessments  were analyzed with linear models with an 
unstructured covariance matrix. Covariance par ameters  were estimated 
with the restricted maximum likelihood.
CONCLUSION OF TRIAL
• Intravenous/intraperitoneal chemotherapy improves survival at the 
expense of greater toxicity in patients with optimally debulked stage 
III ovarian cancer.
COMMENTS
• Intraperitoneal therapy was associated with signifi cantly worse fatigue, 
pain, and hematologic, gastrointestinal, neurologic, and metabolic 
toxicities.
• The increased toxicity with intraperitoneal therapy might be attrib-
uted to the higher dose of cisplatin. The rationale for the higher dose 










N = 205 Statistics
Patient characteristics
Age 21-50 27% 31%
Age 51-70 62% 56%
Age 71-80+ 10% 13%
No residual 36% 38%
Residual disease ≤1 cm 64% 62%
Stage III 100% 100%
Serous 81% 77%
Endometrioid 6% 8%
Clear cell 4% 5%
Other 9% 9%
Grade 1 9% 12%
Grade 2 40% 35%
Grade 3 50% 52%
Elected second look 49% 49%
Treatment delivery
Completed 6 cycles 83% 42%
Effi cacy
Pathologic CR 41% 57%
Median PFS 18.3 months 23.8 months RR 0.80, P = .05
With gross residual 15.4 months 18.3 months RR 0.81, NS
With no vis i ble residual 35.2 months 37.6 months RR 0.80, NS
Median OS 49.7 months 65.6 months RR 0.75, P = .03
With gross residual 39.1 months 52.6 months RR 0.44, NS
With no vis i ble residual 78.2 months Not yet reached RR 0.69, NS
Toxicity
Treatment- related death N = 4 N = 5
G3/4 leukopenia 64% 76% P < .001
G3/4 thrombocytopenia 4% 12% P = .002
G3/4 gastrointestinal 24% 46% P < .001
G3/4 renal 2% 7% P = .03
G3/4 cardiovascular 5% 9% P = .06
G3/4 neurologic 9% 19% P = .001
G3/4 fever 4% 9% P = .02
G3/4 infection 6% 16% P = .001
G3/4 fatigue 4% 18% P < .001
G3/4 metabolic 7% 27% P < .001
G3/4 pain 1% 11% P < .001
G3/4 hepatic <1% 3% P = .05
CR, complete response; NS, not signifi cant; PFS, progression- free survival; OS, overall 
survival; RR, relative risk.
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is that capillary uptake of cisplatin from the intraperitoneal surfaces 
is slow and incomplete. This results in prolonged but lower systemic 
exposure compared to intravenous administration (Schneider 1994).
• The increased toxicity with intraperitoneal therapy might be attrib-
uted to the use of intraperitoneal paclitaxel. Paclitaxel has very 
slow intraperitoneal clearance and remains in the peritoneal cavity 
for 1 week  after administration (Francis et al. 1995). The peritoneal 
clearance could be altered by administration  after intraperitoneal 
cisplatin.
• It is not known  whether altering the treatment regimen to reduce tox-
icity  will compromise its effi cacy.
• Quality of life was worse with intraperitoneal therapy at cycle 4 and 3 
to 6 weeks  after treatment. However,  there was no difference in qual-
ity of life between groups at 1 year  after treatment.
• Patients who had a left colonic or rectosigmoid resection  were less likely 
to receive all 6 cycles of intraperitoneal therapy.
• The single- lumen venous- access catheter attached to an implantable 
subcutaneous port is associated with minimal fi brous sheath formation 
and less risk of bowel obstruction or perforation compared to the fenes-
trated intraperitoneal catheter (Alberts et al. 2002).
• The median OS time of 65.6 months in the patients receiving intra-
peritoneal therapy is the longest survival reported in a GOG phase 
3 trial.
GOG 182/ICON5 (Bookman, JCO 2009)
REFERENCE
• Bookman MA, et al. Evaluation of new platinum- based treatment reg-
imens in advanced- stage ovarian cancer: a Phase III Trial of the Gyne-
cologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419-1425. PMID: 
19224846. (Bookman et al. 2009)
TRIAL SPONSORS
• Gynecologic Oncology Group (GOG)
• Medical Research Council in the United Kingdom (MRC- UK) repre-
senting the International Collaborative Ovarian Neoplasm (ICON) 
group
• Australia and New Zealand Gynecologic Oncology Group (ANZGOG; 
Camperdown, Australia)





• Istituto Mario Negri (Milan, Italy)
• Southwest Oncology Group
• Five other groups managed by the National Cancer Institute (NCI)
RATIONALE FOR TRIAL
• Despite response rates of greater than 80%, long- term survival of ovar-
ian cancer remains poor as a result of recurrence and drug re sis tance.
• While platinum and taxanes are the core of primary treatment, other 
drugs have demonstrated activity in the recurrent setting, including 
topotecan, gemcitabine, and pegylated liposomal doxorubicin (Gordon 
et al. 2004; ten Bokkel Huinink et al. 2004; Pfi sterer et al. 2006a).
• A multiarm, multistage study was designed to compare 4 dif fer ent treat-
ment arms against a single reference arm of carboplatin and paclitaxel.
• This collaborative trial with a target accrual of 4000 patients would 
report clinical outcomes but also provide an international database, 
including outcomes in patients with uncommon histologies and ge ne-
tic mutations associated with cancer risk.
PATIENT POPULATION
• N = 4312 enrolled.
• Patients enrolled between February 2001 and September 2004.
• Stage III or IV epithelial ovarian cancer,  either optimal (≤1 cm) or sub-
optimal residual disease.
• GOG per for mance status of 0, 1, or 2.
• Labs: ANC ≥1500/μL, platelets ≥100,000/μL, creatinine ≤1.5 times 
upper limit of normal, bilirubin ≤1.5 times upper limit of normal, AST 
and alkaline phosphatase ≤2.5 times upper limit of normal.
• Baseline sensory or motor neuropathy of grade 1 or lower by the NCI 
Common Toxicity Criteria version 2.
• Breast cancer: eligible if disease  free for at least 3 years.
• Early- stage synchronous endometrial cancer: eligible if minimal inva-
sion and no high- grade features.
• Ineligible: low malignant potential tumors, carcinosarcoma, nonepithe-
lial histology.
TREATMENT DETAILS
• Dose and schedule  were designed to maximize delivery of newer agents, 
preserve exposure to paclitaxel and carboplatin, and equilibrate the risk 
of hematologic toxicity.
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Arm 1: CP (Carboplatin Paclitaxel)
• Cycles 1 to 8.
• Carboplatin AUC 6 IV on day 1.
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1.
Arm 2: CPG (Carboplatin Paclitaxel + Gemcitabine)
• Cycles 1 to 4.
• Carboplatin AUC 5 IV on day 1.
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1.
• Gemcitabine 800 mg/m2 IV over 30 minutes on day 1 and day 8.
• Cycles 5 to 8.
• Carboplatin AUC 5 IV on day 1.
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1.
Arm 3: CPD (Carboplatin Paclitaxel + Pegylated Liposomal 
Doxorubicin)
• Cycles 1 to 8.
• Carboplatin AUC 5 IV on day 1.
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1.
• Cycles 1, 3, 5, and 7.
• Pegylated liposomal doxorubicin (PLD) 30 mg/m2 IV on day 1 
(dosing of PLD  every 3 weeks was associated with unacceptable 
risk of mucosal, skin, and/or hematologic toxicity due to prolonged 
clearance, and tolerability is improved with use in alternating 
cycles).
Arm 4: CT → CP (Carboplatin Topotecan → Carboplatin Paclitaxel)
• Cycles 1 to 4.
• Topotecan 1.25 mg/m2/d IV on days 1, 2, and 3.
• Carboplatin AUC 5 IV on day 3 (delay to day 3 based on evidence of 
sequence- specifi c hematologic toxicity in phase I  trials).
• Cycles 5 to 8.
• Carboplatin AUC 6 IV on day 1.
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1.
Arm 5: CG → CP (Carboplatin Gemcitabine → Carboplatin 
Paclitaxel)
• Cycles 1 to 4.
• Gemcitabine 1000 mg/m2 IV on day 1 and day 8.
• Carboplatin AUC 6 IV on day 8 (delay to day 8 based on evidence of 
sequence- dependent hematologic toxicity in patients with lung 
cancer).





• Cycles 5 to 8.
• Carboplatin AUC 6 IV on day 1.
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1.
Supportive Mea sures
• Prophylactic hematopoietic growth  factors  were not required but could 
be added  after cycle delay and/or dose reduction for recurrent toxicity.
Surgery
• Interval cytoreduction allowed between the fourth and fi fth cycles for 
patients with suboptimal residual disease if the intent was declared at 
registration.
• Reassessment second- look surgery was not allowed as this approach 
provides no clinical benefi t and surgical assessment of small- volume 
disease could interfere with determination of PFS (Greer et al. 2005).
ASSESSMENTS
• Not stated in manuscript.
• International criteria  were  adopted to permit use of CA125 to identify 







• Cumulative dose delivery.
STATISTICAL CONSIDERATIONS
Sample Size
• In patients receiving the control CP regimen, the estimated median PFS 
and OS  were 15 months and 36 months, respectively.
• An event- triggered interim analy sis was scheduled to occur  after 240 
PFS events in the control CP arm to eliminate regimens that demon-
strated insuffi cient activity. A regimen was continued if the relative PFS 
event rate was at least 7% lower than the reference arm by pairwise 
PFS comparisons using a stratifi ed log- rank test (Peto and Peto 1972).
• The sample size provided 90% power to declare a regimen superior if 
it reduced the risk of death by 25% compared to the reference arm with 
α limited to 0.125 (0.05/4; 2- tail test) for each pairwise comparison 
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(Schoenfeld 1981). This effect size was comparable to an increase in 
the 3- year surviving proportion from 50% to 59.3%.
CONCLUSION OF TRIAL
• The addition of a third cytotoxic agent to paclitaxel and carboplatin pro-
vided a benefi t in PFS or OS  after optimal or suboptimal cytoreduc-
tion for ovarian cancer.













Median age 57.5 years 59.1 years 59.5 years 58.5 years 59.3 years
Microscopic About 25% About 25% About 25% About 25% About 25%
≤1 cm residual About 45% About 45% About 45% About 45% About 45%
>1 cm residual About 30% About 30% About 30% About 30% About 30%
Stage III 83.8% 86.7% 86.2% 86.4% 83.7%
Stage IV 16.2% 13.3% 13.8% 13.7% 16.3%
Serous About 80% About 80% About 80% About 80% About 80%
Endometrioid About 10% About 10% About 10% About 10% About 10%
Mucinous About 1% About 1% About 1% About 1% About 1%
Clear cell About 1% About 1% About 1% About 1% About 1%
Other About 5% About 5% About 5% About 5% About 5%
Treatment delivery
Overall, 79%
  completed 8 cycles
Effi cacy
Median PFS, 16 mo HR 1.00 (ref) HR 1.028, NS HR 0.984, NS HR 1.066, NS HR 1.037, NS
Median OS, 44.1 mo HR 1.00 (ref) HR 1.006, NS HR 0.952, NS HR 1.051, NS HR 1.114, NS
Toxicity
≥G4 ANC About 60% About 75% About 70% About 58% About 58%
≥G3 PLT About 25% About 60% About 40% About 29% About 58%
≥G3 Hgb About 15% About 20% About 17% About 18% About 21%
≥G3 fever About 10% About 16% About 16% About 10% About 10%
≥G2 hepatic About 5% About 11% About 5% About 5% About 9%
≥G2 neuropathy About 25% About 27% About 25% About 15% About 16%
≥G2 pulmonary About 11% About 13% About 12% About 11% About 16%
≥G3 GI About 10% About 15% About 14% About 13% About 10%
ANC, absolute neutrophil count; CG, carboplatin + gemcitabine; CP, carboplatin + paclitaxel; CPD, carbopla-
tin + paclitaxel + pegylated liposomal doxorubicin; CPG, carboplatin + paclitaxel + gemcitabine; CT, carboplatin + topo-
tecan; GI, gastrointestinal; Hgb, hemoglobin; HR, hazard ratio; NS, not signifi cant; PFS, progression- free survival; 
OS, overall survival; PLT, platelets.






• At the time of the interim analy sis, none of the experimental regimens 
reduced the PFS event rate by at least 7% compared to the control arm, 
so the study was closed in September 2004 to further accrual.
• Extent of cytoreductive surgery was an impor tant prognostic  factor for 
OS (second only to stage).
• Suboptimal (>1 cm): PFS 13 months, OS 33 months.
• Gross optimal (≤1 cm): PFS 16 months, OS 40 months.
• Microscopic residual: PFS 29 months, OS 68 months.
• This trial accrued approximately 1200 patients per year, representing 
about 6.25% of all  women with newly diagnosed ovarian cancer in the 
United States during this period.
JGOG 3016 (Katsumata, Lancet 2009; Katsumata, 
Lancet Oncol 2013)
REFERENCES
• Katsumata N, et al. Dose- dense paclitaxel once a week in combination 
with carboplatin  every 3 weeks for advanced ovarian cancer: a phase 
3, open- label, randomised controlled trial. Lancet. 2009;374(9698):1331-
1338. PMID: 19767092. (Katsumata et al. 2009)
• Katsumata N, et al. Long- term results of dose- dense paclitaxel and 
carboplatin versus conventional paclitaxel and carboplatin for treatment 
of advanced epithelial ovarian, fallopian tube, or primary peritoneal 
cancer (JGOG 3016): a randomised, controlled, open- label trial. Lancet 
Oncol. 2013;14(10):1020-6. PMID: 23948349. (Katsumata et al. 2013)
TRIAL SPONSOR
• Japa nese Gynecologic Oncology Group (JGOG)
RATIONALE FOR TRIAL
• Standard fi rst- line chemotherapy for advanced ovarian cancer consists 
of paclitaxel and carboplatin given  every 3 weeks. The 3rd International 
Gynecologic Cancer Consensus Conference in 2004 recommended 
paclitaxel 175 mg/m2 over 3 hours plus carboplatin AUC 5 to 7.5 mg/
mL per minute over 30 to 60 minutes  every 3 weeks for 6 cycles as 
fi rst- line chemotherapy (du Bois et al. 2005b).
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• The addition of another drug to paclitaxel and carboplatin given  either 
concurrently or sequentially has not improved outcomes (du Bois et al. 
2006b; Bookman et al. 2009; Hoskins et al. 2010).
• Dose- dense weekly administration of paclitaxel may be a strategy to 
improve survival as the duration of exposure, even at low concentra-
tions, can result in adequate cytotoxicity (Lopes et al. 1993; Jordan et al. 
1996). Phase 2  trials combining dose- dense paclitaxel with carbopla-
tin have demonstrated feasibility and effi cacy (Rose et al. 2005; Sehouli 
et al. 2008).
• This trial was conducted to compare standard paclitaxel and carbopla-
tin dosing against a regimen containing dose- dense weekly paclitaxel 
with carboplatin.
PATIENT POPULATION
• N = 637 enrolled, 631 eligible.
• Recruited from 85 centers in Japan from April 2003 to December 
2005.
• Stage II to IV epithelial ovarian cancer, fallopian tube cancer, perito-
neal cancer.
• Patient with a cytological diagnosis only had to meet the following 
criteria:
• Cytological diagnosis of adenocarcinoma.
• An abdominal mass of at least 2 cm in dia meter on abdominal images.
• A CA125/carcinoembryonic antigen (CEA) ratio >25 (Yedema et al. 
1992) or no evidence of gastrointestinal cancer if CA125/CEA 
ratio ≤25.
• ECOG per for mance status of 0 to 3.
• Adequate organ function: ANC >1500 cells per μL; platelet count 
>100,000 cells per μL; serum bilirubin <25.7 μmol/L; serum AST 
<100 IU/L; serum creatinine <132.6 μmol/L.
• Exclusions: prior chemotherapy; low malignant potential tumor; syn-
chronous or metachronous malignant disease within 5 years other than 
carcinoma in situ.
TREATMENT DETAILS
Arm 1: Conventional Paclitaxel + Carboplatin
• Paclitaxel 180 mg/m2 IV over 3 hours on day 1.
• Carboplatin AUC 6 mg/mL per minute IV over 1 hour on day 1; dose 
calculated with formula of Calvert (Calvert et al. 1989) using creati-





nine clearance calculated by method of Jelliffe (Jelliffe 1973), not glo-
merular fi ltration rate.
• Standard premedications prior to paclitaxel to prevent hypersensitivity.
• Treatment  every 3 weeks for 6 cycles.
• Hematologic par ameters to treat— day 1: ANC >1000 cells/μL, plate-
lets >75,000 cells/μL.
• Treatment was delayed for a maximum of 3 weeks.
Arm 2: Dose- Dense Paclitaxel + Carboplatin
• Paclitaxel 80 mg/m2 IV over 1 hour on days 1, 8, and 15.
• Carboplatin AUC 6 mg/mL per minute IV over 1 hour on day 1; dose 
calculated with formula of Calvert (Calvert et al. 1989) using creati-
nine clearance calculated by method of Jelliffe (Jelliffe 1973), not glo-
merular fi ltration rate.
• Standard premedications prior to paclitaxel to prevent hypersensitivity.
• Treatment  every 3 weeks for 6 cycles.
• Hematologic par ameters to treat— day 1: ANC >1000 cells/μL, plate-
lets >75,000 cells/μL.
• Hematologic par ameters to treat— days 8 and 15: ANC >500 cells/μL, 
platelets >50,000 cells/μL.
• Treatment was delayed for a maximum of 3 weeks.
Dose Modifi cations
• Carboplatin reduced for hematologic toxicity, including febrile neu-
tropenia, ANC <500 cells/μL persisting for ≥7 days, platelets <10,000 
cells/μL, platelets 10,000 to 50,000 cells/μL with bleeding tenden-
cies, or treatment delayed for more than 1 week for hematologic 
toxicity.
• Level 1 reduction to AUC 5 mg/mL per minute.
• Level 2 reduction to AUC 4 mg/mL per minute.
• Paclitaxel reduced for nonhematologic toxicity, including grade 2 or 
higher peripheral neuropathy.
• Conventional dose level 1 reduction to 135 mg/m2.
• Conventional dose level 2 reduction to 110 mg/m2.
• Dose- dense dose level 1 reduction to 70 mg/m2.
• Dose- dense dose level 2 reduction to 60 mg/m2.
Supportive Mea sures
• Patients did not receive G- CSF  unless they had treatment delays or neu-
tropenic complications.
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• Patients with partial or complete responses received an additional 3 
cycles of chemotherapy.
Surgery
• Interval debulking surgery  after 2 to 4 cycles of chemotherapy was 
allowed.
• Secondary debulking surgery or second- look surgery  after 6 cycles of 
chemotherapy was allowed.
ASSESSMENTS
• Radiological studies at baseline and  after 2, 4, and 6 cycles of chemo-
therapy.  After discontinuation of protocol therapy, patients had follow-
up  every 3 months for the fi rst 2 years and  every 6 months thereafter 
with exam and CA125. CT scans  were performed for symptoms or ele-
vated CA125 levels.
• CA125 criteria for disease progression (Oken et al. 1982).
• Patients with raised CA125 before treatment with return to normal 
 after treatment needed to show reelevation of CA125 to 2 times the 
upper limit of normal.
• Patients with raised CA125 before treatment that did not return 
to normal need to show evidence of CA125 ≥2 times the nadir 
level.
• Patients with CA125 in the normal range before treatment needed to 
show evidence of CA125 ≥2 times the upper limit of normal with at 
least 2 values recorded at least 1 week apart.
• In patients with mea sur able disease, clinical and radiographic mea sure-
ments had priority over CA125 levels and progression during treat-
ment could not be based on CA125 mea sure ments alone.
• Assessment of response had to be confi rmed on 2 occasions at least 4 
weeks apart.
ENDPOINTS











• Hypothesis was that the dose- dense regimen would prolong PFS by 
37.5% (from 16 months with conventional therapy to 22 months with 
dose- dense therapy). In April 2003, a sample size of 380 patients was 
planned to detect this difference with 80% power, 2- sided log- rank test, 
and α of .05.
• In January 2005, the sample size was increased to 600 to detect a 
smaller prolongation of PFS of 31.3% (from 16 to 21 months) with 80% 
power, 2- sided log- rank test, α of 0.05, accrual of 3 years, and a follow-
up of 1.5 years.
Statistical Tests
• Cumulative survival curve and median PFS time  were estimated by the 
Kaplan- Meier method.
• Two- sided χ2 tests or 2- sided Fisher’s exact tests  were used to compare 
proportions of adverse events between groups.
• Fisher’s exact test was used to compare responses.
CONCLUSIONS OF TRIAL
• Dose- dense paclitaxel with carboplatin improves survival compared to 
the conventional 3- week regimen with a 29% lower risk of disease pro-
gression and a 25% lower risk of death.
• With long- term follow-up, dose- dense treatment improves survival 
compared to conventional treatment and may be considered a new stan-
dard of care for fi rst- line treatment of ovarian cancer.
COMMENTS FROM 2009 PUBLICATION
• With a Cox proportional hazards model, PFS was longer in the dose- 
dense treatment group across all subgroups except for in patients with 
clear- cell or mucinous tumors.
• The concept of dose density is based on the hypothesis that shorter 
intervals between chemotherapy exposures would be more effective 
than dose escalation in reducing tumor burden (Norton 2001).
• Dose- dense administration was associated with more hematologic tox-
icity and more dose delays and modifi cations.
• Despite improving PFS and OS, the response rate did not differ. A lower 
dose of paclitaxel has antiangiogenic activity (Klauber et al. 1997), and 












N = 312 Statistics
Patient characteristics
Median age (range) 57 (25-84) 57 (25-87)
Residual disease ≤1 cm 45% 46%
Residual disease >1 cm 55% 54%
Cytology only 11% 11%
Primary debulking 89% 89%
Interval debulking 9% 11%
Second- look surgery 18% 12%
Stage II 17% 20%
Stage III 67% 65%




Clear cell 12% 10%
Other 16% 15%
Grade 1 13% 13%
Grade 2 22% 19%
Grade 3 23% 25%
Unknown grade 43% 42%
Treatment delivery
Completed 6+ cycles 73% 62%
Treatment delays 67% 76% P = .02
Dose reductions 35% 48% P = .001
Effi cacy
In 2009 publication
Median PFS 17.2 months 28.0 months HR 0.71, P = .0015
OS at 3 years 65.1% 72.1% HR 0.75, P = .03
Overall response 53% 56% P = NS
In 2013 publication
Median PFS 17.5 months 28.2 months HR 0.76, P = .0037
Median OS 62.2 months 100.5 months HR 0.79, P = .039
OS at 5 years 51.1% 58.7%
PFS, residual >1 cm 12.1 months 17.6 months HR 0.71, P = .0029
PFS, residual ≤1 cm 60.9 months Median not reached HR 0.74, P = .08
OS, residual >1 cm 33.5 months 51.2 months HR 0.75, P = .0027
OS, residual ≤1 cm Median not reached Median not reached HR 0.76, P = .23
PFS, serous/other 17.5 months 28.7 months HR 0.70, P = .0007





antiangiogenic agents might promote tumor dormancy by maintaining 
tumor size and prevention outgrowth (Folkman 1971).
• Frequency of neurotoxicity was similar between the groups. This may 
be due to the fact that patients receiving dose- dense therapy discontin-
ued treatment more frequently.
COMMENTS FROM 2013 PUBLICATION
• The median OS in patients with optimally resected disease (<1 cm resid-
ual) who received conventional treatment (62.2 months) was better than 
in other  trials conducted in Eu rope and the United States, demonstrating 
that Asian patients with ovarian cancer have better survival than non- 
Asian patients. This may be due to biological differences, environmen-
tal  factors, socioeconomic differences, and/or response to treatment.
• In the subgroup analyses, the greatest benefi t of the dose- dense regimen 
was in patients with optimally cytoreduced (<1 cm) non– clear cell and 
nonmucinous histologies (ie, serous or other). Other treatment strategies 
are needed for clear cell and mucinous tumors.
• Carboplatin was dosed with the formulas of Calvert and Jelliffe with-
out adjustment of serum creatinine concentrations. Glomerular fi ltra-
tion rate was estimated using the enzymatic peroxidase- antiperoxidase 
method, which can result in excessive dosing and more myelosuppres-
sion. Other methods to calculate the GFR have been proposed (Ando 
et al. 2000; Levey et al. 2006; Matsuo et al. 2009), but no consensus 







N = 312 Statistics
PFS, clear cell/mucinous 16.7 months 18.7 months HR 1.06, P = .84
OS, serous/other 61.2 months 100.5 months HR 0.76, P = .0252
OS, clear cell/mucinous 62.2 months Median not reached HR 0.92, P = .776
Toxicity
Higher with dose- dense
G3/4 anemia 44% 69% P = .0001
No difference
G3/4 neutropenia 88% 92% P = NS
G3/4 thrombocytopenia 38% 44% P = NS
G3/4 motor neuropathy 4% 5% P = NS
G3/4 sensory neuropathy 6% 7% P = NS
 G3/4 hypersensitivity 1.6% 1.9% P = NS
HR, hazard ratio; NS, not signifi cant; PFS, progression- free survival; OS, overall survival.
(continued)
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exists. Based on an analy sis demonstrating no association between 
relative dose intensity of carboplatin and PFS or OS, pos si ble exces-
sive doses of carboplatin are not thought to have contributed to the 
survival differences seen in this trial.
• Dose- dense regimens are also being evaluated in MITO-7, ICON8, and 
GOG 262. The best dosing schedule has yet to be established.
MITO-2 (Pignata, Oncology 2009; Pignata, 
JCO 2011)
REFERENCES
• Pignata S, et al. Carboplatin and pegylated liposomal doxorubicin for 
advanced ovarian cancer: preliminary activity results of the MITO-2 
phase III trial. Oncology. 2009;76(1):49-54. PMID: 19039248. (Pignata 
et al. 2009)
• Pignata S, et al. Carboplatin plus paclitaxel versus carboplatin plus 
pegylated liposomal doxorubicin as fi rst- line treatment for patients with 
ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 
2011;29(27):3628-3635. PMID: 21844495. (Pignata et al. 2011)
TRIAL SPONSOR
• Multicentre Italian  Trials in Ovarian Cancer (MITO)
• Integrated Therapeutics Group (ITG)—no role in trial design and data 
interpretation
• Schering- Plough Italy provided experimental drug—no role in trial 
design and data interpretation
• Nonprofi t Italian Association for Cancer Research
RATIONALE FOR TRIAL
•  After treatment for ovarian cancer, the risk of recurrence and death 
remains high.
• Standard treatment affects quality of life due to toxicities that include 
alopecia, neurotoxicity, and fatigue.
• Anthracyclines  were used in fi rst- line treatment of ovarian cancer 
before the introduction of taxanes and a meta- analy sis demonstrated 
the addition of doxorubicin improved survival (Cyclophosphamide plus 
cisplatin . . .  1991; Fanning et al. 1992; A’Hern and Gore 1995; Mug-
gia et al. 1997; West and Zweig 1997). However, safety concerns with 





anthracyclines include dose- limiting acute toxicity of myelosuppression 
and gastrointestinal toxicities and chronic cumulative cardiotoxicity 
and alopecia.
• PLD is doxorubicin encapsulated in liposomes coated with methoxy-
polyethylene glycol, which prolongs the circulation of the drug and its 
concentration in the tumor. This formulation results in a dif fer ent phar-
macokinetic and toxicity profi le (Theodoulou and Hudis 2004). Com-
pared to anthracyclines, PLD has less myelotoxicity, alopecia, nausea, 
vomiting, and cardiomyopathy but has more skin and mucosal toxic-
ity, including palmar- plantar erythrodysesthesia (PPE) and stomatitis 
(Muggia et al. 1997; O’Brien et al. 2004).
• In second- line treatment for platinum- sensitive ovarian cancer, a ran-
domized trial demonstrated PLD treatment to have better survival than 
topotecan treatment as well as a favorable toxicity profi le (Gordon et al. 
2004).
• A phase II study by the Group d’Investigateurs Nationaux pour l’Etude 
des Cancers Ovariens treated patients with platinum- sensitive relapsed 
ovarian cancer with carboplatin AUC 5 and PLD 30 mg/m2  every 
4 weeks and demonstrated a 63% response rate, median PFS of 9.4 
months, and median OS of 32 months. Toxicities included severe neu-
tropenia (about 50%), fever (3%), PPE (32%), and neuropathy (28%) but 
was well tolerated overall (Ferrero et al. 2007).
• Several phase I and II studies combine PLD and carboplatin in relapsed 
ovarian cancer (Goncalves et al. 2003; du Bois et al. 2006a; du Bois 
et al. 2007; Ferrero et al. 2007; Alberts et al. 2008a).
• This trial was designed to evaluate  whether carboplatin/PLD has 
superior PFS to carboplatin/paclitaxel in fi rst- line treatment of advanced 
ovarian cancer. To provide the same dose intensity of carboplatin 
in both arms, the carboplatin/PLD was dosed on an  every 3- week 
schedule.
PATIENT POPULATION
• N = 820 enrolled.
• Enrolled between January 2003 and November 2007.
• Cytologic or histologic diagnosis of epithelial ovarian cancer, stages 
IC to IV.
• Age less than 75 years.
• ECOG per for mance status of 0, 1, or 2.
• Life expectancy ≥3 months.
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• Adequate bone marrow, kidney, and liver function.
• Exclusions: prior chemotherapy; clinically relevant heart disease; other 
concomitant diseases representing contraindications to treatment drugs; 
prior or concomitant other malignancy except nonmelanoma skin can-
cer or carcinoma in situ of the uterine cervix.
TREATMENT DETAILS
Arm 1: Standard Arm: Paclitaxel + Carboplatin
• Paclitaxel 175 mg/m2 IV on day 1  every 3 weeks. Paclitaxel was diluted 
in 250 mL of normal saline and infused over 3 hours.
• Carboplatin AUC 5 IV on day 1  every 3 weeks. Doses  were calculated 
according to the Calvert formula with creatinine clearance estimated 
by the Cockcroft formula. Carboplatin was diluted in 250 mL of 5% 
dextrose in  water (D5W) and infused over 30 minutes.
• Treatment for 3 cycles with assessment and a further 3 cycles if stable 
or responding disease.
Arm 2: Experimental Arm: Carboplatin + PLD
• Carboplatin AUC 5 IV on day 1  every 3 weeks.
• PLD 30 mg/m2 IV on day 1  every 3 weeks. PLD was diluted in 250 mL 
of D5W and infused over 60 minutes  after carboplatin infusion.
• Treatment for 3 cycles with assessment and a further 3 cycles if stable 
or responding disease.
Conditions for Retreatment
• Leukocytes >3000/μL, neutrophils >1500/μL, platelets ≥100,000/μL, 
absence of grade 2 or more organ toxicity (excluding alopecia).
Dose Modifi cations
• Twenty  percent dose reduction for all drugs if ANC <500/μL or plate-
lets <50,000/μL for more than 7 days.
• Twenty  percent reduction of carboplatin and paclitaxel for neuropathy.
• Carboplatin reduced to AUC 4 for creatinine clearance <60 mL.
• For grade 2 or more skin toxicity, PLD was delayed for up to 2 weeks 
or  until toxicity resolved to grade 1 or less; other wise, PLD was inter-
rupted; 25% subsequent dose reduction if grade 3 or 4 skin toxicity 
cleared within 2 weeks.
Treatment Discontinuation
• For treatment delays of ≥2 weeks.






• CT or MRI of the abdomen and pelvis at baseline and  after 3 and 6 
cycles of chemotherapy.
• Quality of life was assessed with the EORTC QLQ- C30 (Aaronson 
et al. 1993).
• Toxicity graded according to the National Institute Common Toxicity 
Criteria (version 2.0).
• RECIST version 1.0 used for evaluation of response (Therasse et al. 
2000).
• Progression defi ned as 20% increase in the sum of the largest dia-
meters of known lesions; appearance of new lesions; increase in 
CA125 level of more than 25%; death from any cause.
ENDPOINTS




• Quality of life.
STATISTICAL CONSIDERATIONS
Sample Size
• In total, 820 patients and 632 progression events  were needed for 80% 
power of detecting a 0.80 hazard ratio of progression with a 2- tailed 
α of 0.05. This represented an improvement in PFS from 18 to 22.5 
months. No interim analyses  were planned.
• At the time of analy sis, only 556 events had occurred due to a relatively 
good prognosis population (>50% optimal debulking, one- third with no 
residual disease, high proportion of early- stage patients). This number of 
events allowed for detection of a hazard ratio (HR) of 0.79 with 80% power.
Stratifi cation  Factors
• Stratifi cation variables included center, residual disease (absent, ≤1 cm, 
>1 cm, no primary surgery), stage (IC, II, III, IV), and ECOG per for-
mance status (0, 1, 2).
Statistical Tests
• Inverted Kaplan- Meier method (Schemper and Smith 1996) to calcu-
late median follow-up and Kaplan- Meier product- limit method to 










N = 410 Statistics
Patient characteristics
Median age (range) 57 (21-77) 57 (25-77)
No residual 36.1% 36.6%
Residual disease ≤1 cm 17.1% 19.3%
Residual disease >1 cm 28.3% 27.1%
No surgery 18.5% 17.1%
Stage IC 9.0% 9.0%
Stage II 9.8% 9.5%
Stage III 59.8% 60.5%




Clear cell 3.7% 2.9%
Other 18.1% 16.1%
Grade Not reported Not reported
Treatment delivery
No treatment 1.0% (N = 4) 1.5% (N = 6)
Received 6 cycles 86.5% 81.1%






Median PFS 16.8 months 19.0 months HR 0.95, P = NS
Median OS 53.2 months 61.6 months HR 0.89, P = NS
ORR 59% 57% P = NS
Toxicity
Deaths N = 4 N = 2
Worse with PC
Alopecia 63% 14% P < .001
Any diarrhea 13% 6% P < .001
≥ G3 neuropathy 3% <1% P = .003
Worse with C- PLD
≥ G3 thrombocytopenia 2% 16% P < .001
≥ G3 anemia 4% 10% P < .001
Skin toxicities 6% 21% P < .001
Stomatitis <10% 19% P < .001





estimate PFS and OS curves (Kaplan and Meier 1958). Curves com-
pared with the log- rank test (Mantel 1966).
• Cox proportional hazards model used to assess treatment effect adjusted 
by baseline prognostic variables.
• χ2 used to compared the difference in overall response rates.
• Exact linear rank test used to compare patters of toxicity, considering 
all grades.
• χ2 and Fisher’s exact tests used to compare rates of severe toxicity.
• Quality- of- life analyses  were performed according to the EORTC man-
ual (Fayers 2001).
CONCLUSION OF TRIAL
• Carboplatin and PLD does not improve survival compared to carbo-
platin and paclitaxel but can be considered as an alternative front- line 
therapy for ovarian cancer due to its dif fer ent toxicity profi le. This 
might be a par tic u lar consideration for patients at high risk of neuro-
toxicity or  those wishing to avoid alopecia.
COMMENTS
• Residual disease and stage  were in de pen dent predictors of PFS.  There 
was no heterogeneity of treatment effect.
•  There  were no reported differences in quality of life except for more 
loss of appetite with the experimental arm and more diarrhea in the 
standard arm.
• Toxicity profi les  were dramatically dif fer ent. Carboplatin/PLD 
was associated with less hair loss and less neurotoxicity but with 
more skin toxicity and stomatitis. Carboplatin and PLD also caused 





N = 410 Statistics
No difference
≥ G3 leukopenia 19% 15% NS
≥ G3 neutropenia 50% 43% NS
Febrile neutropenia 2% <2% NS
Infections <4% <3% NS
 Bleeding <1% <1% NS
C- PLD, carboplatin + pegylated liposomal doxorubicin; HR, hazard ratio; NS, not signifi cant; PFS, 
progression- free survival; ORR, overall response rate; OS, overall survival; PC, paclitaxel + carboplatin.
(continued)
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worse hematologic toxicity but within acceptable limits for clinical 
practice.
•  These authors previously demonstrated that residual neurotoxicity 
occurs frequently  after carboplatin and paclitaxel treatment and 14% 
have per sis tent symptoms even  after 1 year (Pignata et al. 2006). Resid-
ual neurotoxicity may affect  later treatment choices.
• The MITO-2 study adds to the data regarding the role of anthracyclines 
in ovarian cancer treatment with prior data suggesting the addition 
of doxorubicin to improve survival outcomes (A’Hern and Gore 
1995).
• The fi nal MITO-2 analy sis was done with fewer events than planned 
(556 instead of 632 events) due to the favorable prognostic  factors 
of enrolled patients. A much longer follow-up time would have been 
required, and this may have resulted in dilution of PFS differences.
AGO- OVAR9 (du Bois, JCO 2010)
REFERENCE
• du Bois A, et al. Phase III trial of carboplatin plus paclitaxel with or 
without gemcitabine in fi rst- line treatment of epithelial ovarian cancer. 
J Clin Oncol. 2010;28(27):4162-4169. PMID: 20733132. (du Bois et al. 
2010)
TRIAL SPONSORS
• Gynecologic Cancer Intergroup
• Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe 
Ovarialkarzinom (AGO- OVAR)
• Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens 
(GINECO)
• Nordic Society of Gynecologic Oncology (NSGO)
RATIONALE FOR TRIAL
• A pos si ble method for improving survival in advanced ovarian cancer 
is to add a non- cross- resistant drug to platinum and paclitaxel.
• Gemcitabine was thought be a good candidate based on:
• It has single- agent activity in relapsed ovarian cancer comparable to 
standard liposomal doxorubicin in randomized  trials (Mutch et al. 
2007; Ferrandina et al. 2008).





• It can be combined with platinum in platinum- sensitive ovarian can-
cer (du Bois et al. 2001; Brewer et al. 2006).
• The combination has been shown to have higher effi cacy than car-
boplatin alone in this population (Pfi sterer et al. 2006a).
• It can be added as a third drug to platinum and taxane, which would 
allow assessment of a triplet regimen without compromising therapy 
by withholding a standard drug (Gupta et al. 2005; Hensley et al. 
2006; Friedlander et al. 2007).
• This trial was designed to compare paclitaxel/carboplatin/gemcitabine 
(du Bois et al. 2005a) to paclitaxel/carboplatin in advanced ovarian 
cancer.
PATIENT POPULATION
• N = 1784 screened, 1742 eligible.
• Between 2002 and 2004, 1742 patients  were enrolled (175 in stratum 
1, 891 in stratum 2, and 676 in stratum 3).
• FIGO stages I to IV ovarian cancer with upfront debulking surgery 
within 6 weeks before random assignment.
• Adequate hematologic, renal, and hepatic function defi ned as ANC 
≥1500 cells/μL, platelets ≥100,000 cells/μL, and serum creatinine and 
bilirubin ≤1.25 times upper normal limit.
• Exclusions: low malignant potential tumors; ECOG per for mance status 
>2; an estimated glomerular fi ltration rate of <50 mL/min; other malig-
nancies; pervious chemotherapy, immunotherapy, or radiotherapy; severe 
neuropathy; cardiac arrhythmias; or congestive heart failure.
TREATMENT DETAILS
Arm 1: Paclitaxel, Carboplatin (TC)
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1  every 3 weeks.
• Carboplatin AUC 5 IV over 30 to 60 minutes on day 1  every 3 weeks.
Arm 2: Paclitaxel, Carboplatin, Gemcitabine (TCG)
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1  every 3 weeks.
• Carboplatin AUC 5 IV over 30 to 60 minutes on day 1  every 3 weeks.
• Gemcitabine 800 mg/m2 IV over 30 to 60 minutes on days 1 and 8  every 
3 weeks.
Dosing Details and Supportive Mea sures
• Paclitaxel maximum dose of 385 mg. Dose reduction to 150 mg/m2 
(level 1) or 135 mg/m2 (level 2).
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• Carboplatin— dose calculated according to formula of Calvert (Calvert 
et al. 1989). GFR estimated using Jelliffe formula (Jelliffe 1973). Max-
imum dose of 800 mg. Dose reduction to AUC 4 (level 1/level 2).
• Gemcitabine— maximum dose of 1600 mg. Dose reduction by omis-
sion of day 8 dose (level 1).
• Dose reductions allowed for hematologic and nonhematologic toxicity.
• Treatment cycles  were delayed for ANC <1500 cells/μL or platelet count 
<100,000 cells/μL.
• Primary prophylaxis with granulocyte colony- stimulating  factor 
(G- CSF) or granulocyte macrophage colony- stimulating  factor (GM- 
CSF) was not allowed.
• Supportive G- CSF/GM- CSF could be initiated at the discretion of the 
investigator.
• All patients received antiallergic and antiemetic premedications.
• Treatment was discontinued for disease progression.
• Patients with partial remission  after 6 cycles of treatment could receive 
additional cycles.
ASSESSMENTS
• Tumor mea sure ments  were made before each cycle by exam, before 
 every third cycle by imaging (in patients with mea sur able or evaluable 
disease), and  after the last cycle. Tumor response was graded by RECIST 
(Therasse et al. 2000).
• Adverse events and toxicities  were graded according to the National 
Cancer Institute Common Toxicity Criteria (NCI- CTC). Toxicities  were 
evaluated per course and per patient to capture the worst score over all 
courses.
• Quality of life was evaluated by using global health status/quality- of- 
life score of the EORTC QLQ- C30, version 3.0 (Aaronson et al. 1993) 
and the OV-28 module specifi c for ovarian cancer, version 1.0 (Greimel 
et al. 2003). Quality of life was assessed at baseline,  after the third and 
last treatment cycles, and 3 months  after completion of treatment, and 
responses  were evaluated according to the EORTC guidelines.
• Follow-up visits  were scheduled  every 3 months in the fi rst 2 years and 
 every 6 months thereafter for a total of 5 years.
ENDPOINTS
• OS (defi ned as time from random assignment to death from any cause) 
(primary endpoint).






• Response to treatment.
• Toxicity.
• Quality of life.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Patients  were stratifi ed according to residual tumor size and FIGO 
stage.
• Stratum 1: FIGO I to IIA disease.
• Stratum 2: FIGO IIB to IIIC and residual <1 cm.
• Stratum 3: Residual tumor ≥1 cm or FIGO stage IV.
Sample Size
• To detect a clinically meaningful HR of 0.818, which corresponds 
to an increased median survival of 8 months, and to compensate 
for a 10% loss to follow-up rate, recruitment of 1716 patients was 
planned.
Statistical Tests
• Kaplan- Meier method used to analyze time- to- event data.
• Log- rank test used to compare survival distributions between groups.
• Cox proportional hazards model used to estimate hazard ratios.
• Method of Blyth- Still- Casella used to estimate response rates.
• Exact methods for stratifi ed testing including the Zelens exact test 
 were used to compare response rates.
• Wilcoxon- Mann- Whitney test was used to compare global health score 
and its difference from baseline (refl ecting summary quality- of- life 
mea sures).
CONCLUSION OF TRIAL
• The addition of gemcitabine to the paclitaxel and carboplatin back-
bone increased treatment burden, increased toxicities, and reduced 
PFS in patients with advanced epithelial ovarian cancer.
COMMENTS
• Exploratory analy sis of dif fer ent prognostic subgroups demonstrated 
no evidence of benefi t from addition of gemcitabine to treatment of any 
subgroup.










N = 860 Statistics
Patient characteristics
Median age (range) 60 (23-82) 59 (20-80)
Residual disease ≤1 cm 70.9% 69.2%
Residual disease >1 cm 29.1% 30.8%
Stage I 8.6% 8.2%
Stage II 9.4% 10.1%
Stage III 65.8% 65.3%
Stage IV 16.2% 16.3%
Serous 73.7% 75.1%
Mucinous/clear cell 4.5% 4.7%
Other 21.8% 20.2%
Grade 1 10.7% 6.9%
Grade 2 29.1% 33.7%
Grade 3 60.2% 59.4%
Treatment delivery
Received at least 6 cycles 87.2% 86.2%
Received >6 cycles 15.8% 15.8%
Treatment delay >7 days 7.5% 11.6% P < .001
At least 1 dose reduction 8.7% 15.1% P < .001
Effi cacy
Objective response rate 77.5% 86.2% P = .0303
Median PFS 19.3 months 17.8 months P < .01
Median OS 51.5 months 49.5 months P = NS
Toxicity
Worse with TCG
G3/4 hemoglobin 4.3% 17.8% P < .001
G3/4 leukocytes 28.1% 70.2% P < .001
G3/4 neutrophils 62.1% 81.5% P < .001
G3/4 platelets 4.7% 35.8% P < .001
Febrile neutropenia 2.3% 6.6% P < .001
Transfusion blood 10.0% 32.5% P < .001
Supportive care EPO 11.6% 26.7% P < .001
Supportive care G- CSF 12.8% 28.0% P < .001
 Supportive care antibiotic 14.1% 21.6% P < .001
EPO, epogen; G- CSF, granulocyte colony- stimulating  factor; NS, not signifi cant; 
PFS, progression- free survival; OS, overall survival; TC, taxol + carboplatin; TCG, 
taxol + carboplatin + gemcitabine.





• The addition of gemcitabine resulted in a disadvantage to survival in 
early ovarian cancer patients and a disadvantage to PFS in advanced 
disease, and it added to hematologic toxicity and fatigue.
• The addition of a third drug may have a detrimental effect by affect-
ing immune suppression (Zhang et al. 2003; Alberts et al. 2008).
• More than 10,000 patients have been enrolled in intergroup  trials that 
have evaluated the addition of anthracyclines, topotecan, and gemcitabine 
to standard therapy (du Bois et al. 2006b; Pfi sterer et al. 2006b; Bookman 
et al. 2009).  These  trials consistently show no added benefi t but increased 
toxicities with the addition of the third drug.
• Despite this evidence, the next generation of  trials in the GCIG net-
work is using the same design of addition of a third drug sequentially 
or concurrently to TC, but  these new  trials are using targeted therapies 
(bevacizumab, erlotonib, pazopanib, vargatef). This strategy is based 
on the assumption that the model did not fail, but the wrong drugs  were 
selected for use (Hoskins 2009).
• Promising results from phase II studies do not always translate into 
success in phase III (Zia et al. 2005). Most phase II studies choose a 
primary endpoint of response rate, but this is a surrogate endpoint that 
does not necessarily correlate with survival. Response is only mea sured 
in the subgroup of patients with bulky disease, and the addition of a 
third drug may speed the disappearance of  these masses. Survival is 
more dependent on the regrowth of chemoresistant tumor masses, 
which are not reduced by the addition of the third agent.
• The se lection of drugs for phase III evaluation might be improved by 
the use of dif fer ent endpoints that are more refl ective of chemoresis-
tant disease. This includes time to treatment failure in relation to prior 
recurrence- free survival (Harrison et al. 2007). Another approach may 
be the use of tumor kinetics seen in phase II studies to predict the sur-
vival gain achievable in phase III (Claret et al. 2009).
OV16 (Hoskins, JNCI 2010)
REFERENCE
• Hoskins P, et al. Advanced ovarian cancer: phase III randomized 
study of sequential cisplatin- topotecan and carboplatin- paclitaxel vs 
carboplatin- paclitaxel. J Natl Cancer Inst. 2010;102(20):1547-1556. 
PMID: 20937992. (Hoskins et al. 2010)
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• Gynecologic Cancer Intergroup
• NCIC Clinical  Trials Group (NCIC CTG)
• Eu ro pean Organ ization for Research and Treatment of Cancer– 
Gynecologic Cancer Group (EORTC- GCG)
• Grupo de Investigacion de Cancer de Ovario (GEICO)
RATIONALE FOR TRIAL
• A potential strategy to improve the effi cacy of treatment of advanced 
ovarian cancer is to add a third cytotoxic agent to the backbone of stan-
dard paclitaxel and carboplatin.
• Topotecan is a camptothecin analogue that has single- agent activity in 
recurrent ovarian cancer, including platinum- resistant disease (Creem-
ers et al. 1996; Kudelka et al. 1996; ten Bokkel Huinink et al. 1997; 
Bookman et al. 1998; Hoskins et al. 1998).
• To address the issue the issue of myelosuppression with paclitaxel + car-
boplatin + topotecan  triple therapy, the NCIC Clinical  Trials Groups 
(NCIC- CTG) tested a regimen that consisted of sequential doublets of 
cisplatin + topotecan followed by carboplatin + paclitaxel and found suf-
fi cient phase II activity to warrant a phase III study (Hoskins et al. 
2000).
• This trial was designed to evaluate the effi cacy of topotecan when com-
bined with standard front- line chemotherapy for advanced ovarian 
cancer.
PATIENT POPULATION
• N = 819 enrolled.
• Enrollment between August 2001 and June 2005.
• Newly diagnosed stage IIB to IV epithelial ovarian, fallopian tube, or 
primary peritoneal cancer and completed all planned primary surgery.
• Diagnosis based on:
• Histologic fi ndings, or
• Cytology if the patient had a pelvic mass with an abdominal metas-
tasis ≥2 cm in dia meter, a normal mammogram within the preced-
ing 6 weeks, and CA125 to CEA ratio ≥25. If CA125 to CEA ratio 
<25, patients  were eligible if colonoscopy/barium enema and gastros-
copy/barium meal  were negative.
• No prior chemotherapy.





• ECOG per for mance status of 0 or 1.
• Adequate hematologic reserve and liver function.
• Granulocytes ≥2000/μL.
• Platelets ≥150,000/μL.
• Creatinine less than or equal to upper normal limit.
• Exclusions: borderline ovarian tumors, prior nonsurgical therapy for 
ovarian cancer, other malignancy other than nonmelanoma skin cancer, 
in situ carcinoma of the cervix, or a solid tumor treated with curative 
intent and no evidence of disease for ≥5 years; myo car dial infarction 
within 6 months; second- or third- degree heart block  unless a pace-
maker had been implanted; contraindication to high- volume saline diure-
sis; preexisting hearing loss; neuropathy greater than grade 1.
TREATMENT DETAILS
Arm 1: Standard Treatment
• Eight cycles  every 3 weeks.
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1.
• Carboplatin AUC 5 IV over 30 minutes on day 1.
Arm 2: Experimental Treatment
• Four cycles  every 3 weeks.
• Cisplatin 50 mg/m2 IV over 60 minutes on day 1.
• Topotecan 0.75 mg/m2 IV over 30 minutes on days 1 through 5.
• Four cycles  every 3 weeks.
• Paclitaxel 175 mg/m2 IV over 3 hours on day 1.
• Carboplatin AUC 5 over 30 minutes (or per institutional standard) 
IV on day 1.
Administration Details
• Carboplatin dosed using  either the mea sured glomerular fi ltration rate 
by nuclear renogram or a calculated GFR using the Cockcroft formula.
• All drugs  were administered in solution as per the product monograph.
• Hydration and premedications  were administered per local institutional 
standards and  were not specifi ed by protocol.
Treatment Delays
•  Until granulocytes ≥1500/μL and platelets >100,000/μL.
Dose Reductions and Discontinuations
• Granulocytes ≤500/μL for >7 days; platelets <25,000/μL; febrile neu-
tropenia; grade 3 or more infection.
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• Topotecan decreased by 25% in the next cycle (no change in cispla-
tin dosing).
• Paclitaxel deceased by 25 mg/m2 and carboplatin decreased by 1 
AUC.
• Arthralgia or myalgia.
• Grade 3: paclitaxel decreased by 25 mg/m2.
• Grade 4: paclitaxel discontinued.
• Grade 4 anaphylaxis (life threatening).
• Protocol therapy discontinued.
• Neurotoxicity.
• Grade 2: paclitaxel decreased by 25 mg/m2.
• Grade 3: protocol therapy discontinued.
• Mucositis.
• Grade 2 or more: paclitaxel decrease by 25 mg/m2.
• Renal toxicity  after rehydration.
• With creatinine at 1 to 1.5 × upper limit of normal: cisplatin decreased 
by 25%.
• With creatinine >1.5 × upper limit of normal: protocol therapy 
discontinued.
Surgery
• Interval debulking was allowed  after 3 or 4 cycles of therapy for  those 
not optimally debulked at the time of study entry.
ASSESSMENTS
• On day 1 of each cycle: physical exam, CBC, serum creatinine, AST 
or ALT, serum CA125.
• On day 15 of each cycle: CBC.
• Imaging with CT scan or MRI prior to cycle 1 to obtain baseline mea-
sures except when no debulking had been done or when optimal deb-
ulking had been achieved. Further imaging  after cycle 4 (or cycle 3 if 
interval debulking had been planned) and  after cycle 8 or earlier if pro-
gression was suspected.
• Quality of life assessed using the EORTC QLQs C30 (Aaronson et al. 
1993) and OV28 (Cull et al. 2001) module at baseline and on day 1 of 
cycles 3, 5, and 7; at the end of the last cycle; and 3 and 6 months  after 
completing protocol therapy.
• QLQ C30 contains 9 multi- item scales. Five functional scales mea-
sure physical, role, cognitive, emotional, and social domains. Three 





symptom scales mea sure fatigue, pain, and nausea and vomiting. The 
fi nal scale is a global health and quality- of- life scale.
• The OV28 module assess symptoms that may be specifi c to ovarian 
cancer or its treatment, including abdominal symptoms, peripheral 
neuropathy, hormonal symptoms, attitude to disease treatment, and 
sexual functioning.
•  After treatment, follow-up  every 3 months for the fi rst 3 years, then 
 every 6 months for the next 2 years, then annually thereafter. History 
and physical exam, CA125 assessed at each visit.
• Progression was defi ned by Gynecologic Cancer Intergroup defi ni-
tion, including objective progression using RECIST criteria (Ther-
asse et al. 2000) or CA125 progression (Vergote et al. 2000).
• RECIST progression:  either a 20% increase in the sum of dia meters 
over the nadir or the appearance of new disease.
• CA125 progression: increase to more than twice the upper limit of 
normal (or of the nadir value if levels had not normalized) and con-
fi rmed at least 1 week  later. CA125 values mea sured within 4 weeks 
of surgery or other abdominal procedure such as paracentesis  were 
not considered in this evaluation.
ENDPOINTS
• PFS, defi ned as time from randomization to time of fi rst observation 
of disease progression or death from any cause (primary endpoint).
• OS.
• Adverse effects.
• Quality of life.
• Objective response (in patients with mea sur able disease by RECIST).
• CA125 normalization rates 3 months  after randomization.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Patients  were stratifi ed based on treatment center, age (≤65 or >65), 
extent of surgery (no debulking, no residual, residual <1 cm, residual 
≥1 cm).
Sample Size
• Assuming PFS of 16 months with standard therapy, this trial was 
designed to have 80% power to detect a 25% improvement in PFS from 
a median of 16 months to 20 months (HR, 0.8) using a 2- sided α of 5%. 
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At the time of fi nal analy sis, 631 progression events would be needed, 
requiring recruitment of 800 patients over 2 years and 29 months of 
follow-up.
Statistical Tests
• Stratifi ed log- rank test used to compare PFS and OS.
• Cochran- Mantel- Haenszel test used to compare CA125 normalization 
rates with adjustment for stratifi cation  factors.
• Cox proportional hazards model used to assess treatment effect  after 
adjusting for potential confounding  factors and to identify  factors pre-
dictive of PFS. Covariates included:
• Treatment.
• Stratifi cation  factors.
• Stage (II vs III/IV).
• Grade (1/2 vs 3/undifferentiated/unknown).
• Histology (serous vs other).
• Per for mance status (0 vs 1).
• The assumption of proportionality in the Cox model was assessed by 
Schoenfeld residuals.
• Fisher’s exact test was used to compare the incidence of adverse events 
between arms.
• Wilcoxon rank- sum test was used to compare changes of quality- of- 
life scores from baseline between treatment arms.
CONCLUSION OF TRIAL
• The addition of topotecan to paclitaxel and carboplatin does not improve 
outcomes and adds to the toxicity profi le in the treatment of advanced 
ovarian cancer.
COMMENTS
• More mature OS outcomes  will be reported  after continued follow-up.
• The results of this study parallel  those of the GOG 182- ICON5 study, 
which demonstrated no improvement in survival with the addition of a 
third cytotoxic agent to the paclitaxel and carboplatin backbone in the 
treatment of advanced ovarian cancer (Bookman et al. 2009).
• In GOG 182- ICON5, topotecan was dosed at 1.25 mg/m2 per day for 
3 days; topotecan was combined with carboplatin, which was given 
on day 3 rather than day 1; and the topotecan doublet was given in 
the last 4 cycles of therapy.












N = 409 Statistics
Patient characteristics
Median age (range) 57 (33-75) 57 (28-78)
No residual 22% 22%
Residual disease <1 cm 20% 25%
Residual disease ≥1 cm 36% 33%
No debulking 20% 19%
Mea sur able disease 47% 48%
Stage II 8.0% 9.0%
Stage III 64.6% 67.2%




Clear cell 5% 6%
Other 19% 21%
Grade Not reported Not reported
Treatment delivery
Completed 8 cycles 81% 78%
At least 1 cycle delay 50% 85%
Dose reductions 18% 43%
Interval debulking 17.4% 13.5%
Effi cacy
Objective response 77.2% 67.9% P = .04
Complete response 37.3% 31.1% Not reported
CA125 normalization 66.3% 57.5% P = .006
Median PFS 16.2 months 14.6 months HR 1.10 (95% CI, 
0.94-1.28)
Median OS 42.1 months 42.3 months NS
Toxicity
Death N = 2 N = 2
Worse with experimental
G4 granulocytopenia 58% 85% P < .001
Febrile neutropenia 6% 22% P < .001
G3/4 thrombocytopenia 9% 46% P < .001
Thromboembolic events 2% 7% P < .001
Nausea 77% 84% P = .01
(continued)
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• In this current trial, topotecan was dosed at 0.75 mg/m2 per day for 
5 days, topotecan was combined with cisplatin which was given on 
day 1, and the topotecan doublet was given in the fi rst 4 cycles of 
therapy.
• The hypothesis that the 5- day topotecan schedule with day 1 cisplatin 
would be synergistic was not observed to be true in this study.
• Topotecan has been tested as triplet and consolidation therapy, but no 
trial has demonstrated a survival benefi t (De Placido et al. 2004; Pfi sterer 
et al. 2006b; Bookman et al. 2009). The cells that are resistant to plati-
num and taxanes do not appear to be responsive to topotecan treatment.
• For a drug to be non- cross- resistant, it should have activity against 
refractory tumors (cancer that grows during treatment). In 4 single- 
agent studies of topotecan in the refractory setting, only 9% of patients 
responded to treatment (Creemers et al. 1996; ten Bokkel Huinink 
et al. 1997; Bookman et al. 1998; Hoskins et al. 1998).  Future  trials 
should evaluate drugs that demonstrate more effi cacy against refrac-
tory cells.
• Phase III ovarian cancer  trials that use the PFS endpoint (whose median 
is approximately 15 months for front- line  trials) for early stopping often 
complete accrual before suffi cient progression events have been seen to 
perform an interim analy sis. This trial suggests that CA125 normal-
ization rates at 3 months may be predictive of treatment effi cacy and 
would provide an earlier opportunity to perform futility analyses in 
 future phase III studies. This endpoint would require confi rmatory val-
idation as an endpoint predictive of PFS in other  trials.







N = 409 Statistics
Vomiting 41% 57% P < .001
Hospitalization 7.1% 11.3%
Erythropoietin use 13.4% 25.8%
G- CSF use 13.7% 34.7%
Worse with standard
Neurosensory 84% 74% P < .001
Allergic reactions 35% 24% P < .001
CA125, cancer antigen 125; CI, confi dence interval; G- CSF, granulocyte colony- stimulating  factor; 
HR, hazard ratio; NS, not signifi cant; PFS, progression- free survival; OS, overall survival.
(continued)





ICON7 (Perren, NEJM 2011; Oza, Lancet 
Oncol 2015)
REFERENCES
• Perren TJ, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl 
J Med. 2011;365(26):2484-96. PMID: 22204725. (Perren et al. 2011)
• Oza AM, et al. Standard chemotherapy with or without bevacizumab 
for  women with newly diagnosed ovarian cancer (ICON7): overall sur-
vival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928-
936. PMID: 26115797. (Oza et al. 2015)
TRIAL SPONSORS
• Gynecologic Cancer InterGroup (GCIG) Internal Collaboration on 
Ovarian Neoplasms (ICON7)
• Led by UK Medical Research Council Clinical  Trials Unit (MRC CTU)









• Although intraperitoneal chemotherapy administration improves sur-
vival, this is an option limited to patients with small- volume residual 
disease.
• Angiogenesis leads to tumor growth and metastasis and is an attrac-
tive target as ovarian cancers frequently express vascular endothelial 
growth  factor (VEGF).
• Bevacizumab is a monoclonal antibody that binds to VEGF- A with 
demonstrated effi cacy in colorectal, lung, renal, breast, and brain can-
cers (Hurwitz et al. 2004; Eskens and Sleijfer 2008). Phase 2  trials have 
shown effi cacy in  women with ovarian cancer (Burger et al. 2007; Can-
nistra et al. 2007; Garcia et al. 2008).
• This trial (like GOG 218) was designed to evaluate the addition of bev-
acizumab to standard chemotherapy in front- line treatment of ovarian 
cancer.
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• N = 1528 enrolled.
• From December 2006 to February 2009, patients  were enrolled from 
263 centers in the United Kingdom, Germany, France, Canada, Aus-
tralia, New Zealand, Denmark, Finland, Norway, Sweden, and Spain.
• Newly diagnosed ovarian cancer that was  either
• High- risk, stage I or IIA clear cell, or grade 3 ovarian cancer 
(enrollment limited to 10% of total study population) or
• Advanced stage IIB to IV epithelial ovarian, fallopian tube, or peri-
toneal cancer.
• ECOG per for mance status of 0, 1, or 2.
• Adequate coagulation values, bone marrow, liver, and renal function.
• No plans for further surgery before disease progression.
• Exclusions: other tumor types; previous systemic therapy; planned sur-
gery; uncontrolled hypertension.
• A high- risk subgroup was defi ned as at risk for progression and had 
similar patient characteristics to  those enrolled in GOG 218. This sub-
group included the following:
• Stage IV.
• Inoperable stage III.
• Suboptimally debulked stage III (>1 cm residual).
TREATMENT DETAILS
Arm 1: Standard Chemotherapy (PC)
• Paclitaxel 175 mg/m2 IV  every 3 weeks for 6 cycles.
• Carboplatin AUC 5 or 6 IV  every 3 weeks for 6 cycles.
Arm 2: Standard Chemotherapy + Bevacizumab (PCB)
• Paclitaxel 175 mg/m2 IV  every 3 weeks for 6 cycles.
• Carboplatin AUC 5 or 6 IV  every 3 weeks for 6 cycles.
• Bevacizumab 7.5 mg/kg IV  every 3 weeks during chemotherapy  until 
12 additional cycles or disease progression. To prevent delayed wound 
healing, bevacizumab was started with cycle 1 if chemotherapy started 
>4 weeks  after surgery and delayed  until cycle 2 if chemotherapy started 
≤4 weeks from surgery.
ASSESSMENTS
• Clinical assessments and CA125  were performed before each cycle of 
chemotherapy,  every 6 weeks in year 1,  every 3 months in years 2 and 3, 
 every 6 months in years 4 and 5, and then yearly thereafter.





•  After disease progression, assessments  were performed  every 6 months 
for 5 years, then yearly thereafter.
• CT or MRI was performed at baseline,  after cycles 3 and 6, at 9 and 12 
months  after randomization,  every 6 months in years 2 and 3, and then 
as clinically indicated  until disease progression.
• Quality of life was assessed with the EORTC QLQ- C30 and QLQ-
 OV28 questionnaires.
• Progression was defi ned by RECIST criteria (Therasse et al. 2000) and 
did not include asymptomatic progression by CA125 levels only.
• The biologic progression- free interval as calculated from date of ran-
domization to date of fi rst CA-125- based progression (Rustin et al. 
2004) or fi rst RECIST- based progression.
ENDPOINTS
• PFS (calculated from date of randomization) (primary endpoint).
• OS.
• Biologic progression- free interval.
• Response to therapy.
• Toxicity.
• Quality of life.
• Laboratory results.
• Worsened ECOG per for mance status.
• Health economics and translational research.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Patients  were stratifi ed by GCIG group, FIGO stage, and residual 
disease (stage I to III with ≤1 cm residual disease, stage I to III with 
>1 cm residual disease, stage III inoperable or stage IV), and 
planned interval between surgery and chemotherapy (≤4 weeks or 
>4 weeks).
Sample Size
• Primary analy sis was carried out with an unstratifi ed log- rank test for 
the difference in PFS between the 2 groups. The trial was designed to 
detect a 28% increase in median PFS from 18 months with standard 
chemotherapy to 23 months with the addition of bevacizumab (HR, 
0.81) with 90% power at the 5% signifi cance level. A sample size of 1520 
 women and a total of 684 events (disease progression or death)  were 
required.  After submission of the primary analy sis of PFS, regulatory 
510-66190_ch01_3P.indd   147 11/8/16   7:49 PM




authorities requested an OS analy sis with at least 365 deaths (50% of the 
required total number of deaths).
• Study was also powered to detect a difference in OS. This analy sis 
needed 715 deaths to detect an improvement in OS from 43 to 53 months 
(HR, 0.81) with 80% power at a 2- sided signifi cance level of 5%.
Statistical Tests
• Log- rank test stratifi ed by  factors used for randomization.
• Cox regression analyses adjusted for baseline covariates when propor-
tional hazards could be assumed.
• When nonproportional hazards, fl exible parametric survival models 
(Royston and Parmar 2002) to smooth survival curves  were used.
• Interaction analyses to evaluate differences in size of treatment effects 
in subgroups classifi ed by baseline characteristics, risk of progression, 
and stratifi cation  factors.
• Hazard functions to analyze the magnitude and timing of treatment 
effect.
CONCLUSIONS OF TRIAL
• Bevacizumab improved PFS by about 2 months and increased the 
response rate by about 20% in patients with ovarian cancer. Survival 
benefi ts  were greater among patients at high risk for progression with 
improved PFS of 3.6 months.
• Final overall survival results (Oza et al. 2015).
• No difference in overall survival in the trial population as a  whole.
• OS benefi t of 4 months seen in highest risk subgroup.
COMMENTS
• The benefi t of bevacizumab changed over time with maximum impact 
at 12 months. The benefi t dis appeared by 24 months. The maximum 
treatment effect coincided with the end of bevacizumab treatment and 
suggest that prolonged therapy beyond 12 months may further improve 
outcomes.
•  Because results showed evidence of nonproportional hazards, the 
restricted mean difference (the difference in areas  under the  whole 
length of the PFS curves) was a better estimate of treatment effect in 
this trial. The restricted mean difference of PFS was 20.3 months vs 
21.8 months for standard therapy vs bevacizumab, for a mean differ-
ence of 1.5 months.












N = 764 Statistics
Patient characteristics
Median age (range) 57 (18-81) 57 (24-82)
≤1 cm residual 74% 74%
>1 cm residual 26% 26%
Inoperable 2% 2%
High risk (III >1 cm/IV) 31% 30%
Stage I/IIA 10% 9%
Stage IIB/IIC 9% 9%
Stage III 69% 68%




Clear cell 8% 9%
Other 13% 12%
Grade 1 7% 5%
Grade 2 19% 23%
Grade 3 74% 71%
Treatment delivery
Received 6 cycles 91% 94%
Effi cacy
Reported in 2011
Overall response rate 48% 67% P < .001
Median PFS 17.4 months 19.8 months HR 0.87, P = .04
High- risk group 10.5 months 16.0 months HR 0.73, P = .002
Median OS Not reached Not reached HR 0.85, P = NS
High- risk group 28.8 months 36.6 months HR 0.64, P = .002
Reported in 2015
Median OS 44.6 months 45.5 months P = NS
Non- high- risk group 49.7 months 48.4 months P = NS
High- risk group 34.5 months 39.3 months HR 0.78, P = .03
Clear cell 48.0 months 47.6 months P = NS
Low stage, high grade 56.2 months 57.5 months P = NS
Low- grade serous 50.4 months 50.5 months P = NS
Updated PFS analy sis 17.5 months 19.9 months P = NS
High- risk group 10.5 months 16.0 months HR 0.73, P = .001
(continued)
510-66190_ch01_3P.indd   149 11/8/16   7:49 PM




• The addition of bevacizumab did not affect chemotherapy delivery but 
increased the range of toxic effects, including hypertension and bowel 
perforation.
• Differences between ICON7 and GOG 218: (1) patient population in 
ICON7 include patients with high- risk early- stage disease; (2) half of 
the dose of bevacizumab was used (7.5 mg/kg vs 15 mg/kg) for a shorter 
maintenance period (12 cycles vs 16 cycles).
• The bevacizumab dose used in ICON7 is one of the licensed doses for 
metastatic colorectal cancer but is half the dose for metastatic breast 
cancer.
• Final OS analy sis demonstrated an association between increasing dis-
ease severity and greater benefi t of bevacizumab.
•  Women who might not benefi t from bevacizumab in the upfront setting:
• Early- stage I/II disease, even if high grade or clear cell histology.
• Optimally debulked (<1 cm residual) stage III disease.
• Low- grade serous cancer.
• Low- stage, high- risk tumors.
• The maximum PFS benefi t coincided with the duration of bevacizumab 
treatment. The overall survival difference outlasts the duration of 
exposure and suggests a durable benefi t in the high- risk group. The 
possibility of additional benefi t with extension of treatment is being 
evaluated in the BOOST trial (NCT01426890).
• Data from ICON7 support early use of bevacizumab based on risk and 
disease burden. The role of repeated administration of bevacizumab 







N = 764 Statistics
Toxicity
Deaths N = 1 N = 4
Worse with bevacizumab
Bleeding 12% 39%
≥ G2 hypertension 2% 18%
≥ G3 thromboembolism 3% 7%
 GI perforations N = 3 N = 10
GI, gastrointestinal; HR, hazard ratio; NS, not signifi cant; PFS, progression- free survival; OS, overall 
survival.
(continued)





in the recurrent setting  after upfront use is being evaluated in the 
MITO16MANGO2b trial (NCT01802749). Benefi t to this approach in 
colorectal and breast cancer (Bennouna et al. 2013; von Minckwitz 
et al. 2014).
• Trial suggests that residual tumor burden with active angiogenesis is 
necessary for drug activity.
• Cost- effectiveness would be improved with an effective biomarker pre-
dicting response.
• May not work as well in immunologically active subtype.
• May benefi t mesenchymal subtype.
GOG 218 (Burger, NEJM 2011)
REFERENCE
• Burger RA, et al. Incorporation of bevacizumab in the primary treat-
ment of ovarian cancer. N Engl J Med. 2011;365(26):2473-2483. PMID: 
22204724. (Burger et al. 2011)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• VEGF and angiogenesis promote ovarian cancer progression and are 
inversely correlated with survival.
• Bevacizumab is a humanized anti- VEGF monoclonal antibody that 
inhibits tumor angiogenesis and has single- agent activity against epi-
thelial ovarian cancer in phase II  trials (Burger et al. 2007; Cannistra 
et al. 2007).
• This trial (like ICON7) was performed to evaluate the addition of bev-
acizumab to standard chemotherapy and as maintenance in the front- 
line treatment of ovarian cancer.
PATIENT POPULATION
• N = 1873 enrolled.
• Between October 2005 and June 2009, patients  were enrolled from 336 
institutions in the United States, Canada, South  Korea, and Japan.
• Stage III or IV epithelial ovarian, primary peritoneal, or fallopian tube 
cancer.
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• Standard abdominal surgery with maximal debulking effort within 12 
weeks of study entry.
• GOG per for mance status of 0, 1, or 2.
• No history of clinically signifi cant vascular events or intestinal 
obstruction.
• Patients with optimal resection (<1 cm residual lesions)  were originally 
excluded but then  later included  after protocol modifi cation in July 
2007.
TREATMENT DETAILS
Arm 1: Standard Chemotherapy (PC)
• Treatment  every 3 weeks for 22 cycles.
• Paclitaxel 175 mg/m2 IV on day 1 during cycles 1 to 6.
• Carboplatin AUC 6 IV on day 1 during cycles 1 to 6.
• Placebo during cycles 2 to 22.
Arm 2: Standard Chemotherapy + Initiation Bevacizumab (PCB)
• Treatment  every 3 weeks for 22 cycles.
• Paclitaxel 175 mg/m2 IV on day 1 during cycles 1 to 6.
• Carboplatin AUC 6 IV on day 1 during cycles 1 to 6.
• Bevacizumab 15 mg/kg added during cycles 2 to 6.
• Placebo during cycles 7 to 22.
Arm 3: Standard Chemotherapy + Initiation Bevacizumab + 15 
Months of Bevacizumab Maintenance (PCB + B)
• Treatment  every 3 weeks for 22 cycles.
• Paclitaxel 175 mg/m2 IV on day 1 during cycles 1 to 6.
• Carboplatin AUC 6 IV on day 1 during cycles 1 to 6.
• Bevacizumab 15 mg/kg added during cycles 2 to 22.
Treatment Discontinuation
• For disease progression, unacceptable toxic effects, completion of all 
22 cycles or withdrawal.
Supportive Care Mea sures
• Myeloid growth  factor allowed only to manage febrile neutropenia, 
grade 4 neutropenia (ANC <500/mm3) for 7 days or longer or for sub-
sequent prophylaxis
Dose Modifi cations
• For limiting peripheral neuropathy or hypersensitivity, paclitaxel was 
replaced with docetaxel 75 mg/m2.





• For weight change >10%, bevacizumab dose was modifi ed.
• Bevacizumab was delayed or discontinued based on duration and sever-
ity of:
• Hypertension: systolic blood pressure >150 mm Hg or diastolic blood 
pressure >90 mm Hg.
• Proteinuria: urine protein- to- creatinine ratio 3.5.
• Wound or bowel wall disruption (any grade, cycle 2 or  later).
• Reversible posterior leukoencephalopathy syndrome.





• Hypersensitivity of grade 3 or greater.
ASSESSMENTS
• Before cycle 1: physical exam, CA125 level, and CT or MRI of at least 
abdomen and pelvis.
• For patients without progression, imaging  after cycles 3, 6, 10, 14, 18, 
and 22.
• Serum CA125 and physical exams performed before each cycle during 
cycles 1 to 6,  every other cycle during cycles 7 to 22,  every 3 months for 
2 years,  every 6 months for years 3 to 5, and annually thereafter.
• Adverse events  were recorded with  every cycle using the National Can-
cer Institute Common Terminology Criteria for adverse events (Ver-
sion 3) and  until 30 days  after last study treatment.
• Quality of life mea sured by the Functional Assessment of Cancer 
Therapy– Ovary Trial Outcome Index (FACT- O TOI) survey (Basen- 
Engquist et al. 2001) before cycles 1, 4, 7, 13, 22, and 6 months  after 
completing study therapy.
ENDPOINTS
• Primary endpoint was initially OS, then changed to PFS in October 
2008. This occurred when patients and investigators contested main-
taining the blinding of treatment assignments  after disease progression, 
which would be necessary to maintain the integrity of the data for an 
OS endpoint.
• PFS was calculated from date of enrollment to progression by RECIST 
(Therasse et al. 2000), increase in CA125 according to GCIG criteria 
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(Rustin et al. 2001) in patients who had completed chemotherapy, global 
deterioration of health, or death from any cause. If patients  were  free 
of progression, data  were censored at the date of the last radiographic 
assessment.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Patients  were stratifi ed by GOG per for mance status, cancer stage, and 
debulking status (stage III optimal, stage III suboptimal, stage IV).
Sample Size
• A sample size of 1800 was estimated to provide 90% power to detect 
a 23% reduction in the hazard of progression with  either of the 2 
bevacizumab- containing regimens compared to the control regimen 
while limiting the overall 1- sided type I error for both comparisons 
to 2.5%.
Statistical Tests
• Relative hazard ratios  were estimated with the proportional hazards 
model (Cox 1972).
• Differences in FACT- O TOI scores  were assessed with a linear mixed 
model adjusted for baseline score and age.
• Differences in adverse events  were examined by Fisher’s exact test 
(Mehta and Petal 1983).
• Hypotheses  were tested at a 1.67% signifi cance level to account for mul-
tiple comparisons.
Other Considerations
• Treatment assignments could be revealed to investigators and patients 
in the setting of documented disease progression.
• Database was locked on February 5, 2010.
CONCLUSION OF TRIAL
• The addition of bevacizumab during and up to 10 months  after pacli-
taxel and carboplatin chemotherapy extends median PFS by 4 months 
but does not have an impact on OS in patients with advanced epithelial 
ovarian cancer.














Median age (range) 60 (25-86) 60 (24-88) 60 (22-89)
White 84.2% 83.0% 83.6%
Asian 6.6% 5.9% 6.3%
Black 4.0% 4.5% 4.3%
Hispanic 3.4% 4.5% 4.0%
Other 1.9% 2.1% 1.8%
Stage III, ≤1 cm 34.9% 32.8% 34.7%
Stage III, >1 cm 40.6% 41.0% 38.8%
Stage IV 24.5% 26.2% 26.5%
Serous 86.6% 83.0% 84.1%
Endometrioid 3.4% 2.2% 3.9%
Mucinous 1.0% 0.8% 1.3%
Clear cell 1.9% 3.7% 3.2%
Other 7.2% 10.2% 7.5%
Grade 1 5.8% 4.5% 2.9%
Grade 2 16.3% 13.8% 15.6%
Grade 3 71.2% 74.4% 73.8%
Unknown grade 6.7% 7.4% 7.7%
Treatment delivery
Completed therapy 16% 17% 24%
Discontinuation
Disease progression 48% 42% 26%
Adverse events 12% 15% 17%
Effi cacy
Median PFSa 10.3 months 11.2 months (P = NS) 14.1 months (P = .001)
Median OSa 39.3 months 38.7 months (P = NS) 39.7 months (P = NS)
Toxicity
Deaths 1% 1.6% 2.3%
Worse with
bevacizumab 7.2% 16.5% (P < .05) 22.9% (P < .05)
≥ G2 hypertensiona
No difference
GI perforation, fi stula 1.2% 2.8% 2.6%
≥ G3 proteinuria 0.7% 0.7% 1.6%
≥ G2 pain 41.6% 41.5% 47.0%
≥ G4 neutropenia 57.5% 63.3% 63.3%
Venous thrombosis 5.8% 5.3% 6.7%
(continued)
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• Bevacizumab (or placebo) was added in cycle 2 rather than cycle 1 to 
decrease the risk of wound- healing complications. The maintenance 
treatment time of 15 months was selected to exceed the anticipated 
median PFS and to ensure feasibility. The bevacizumab dose of 15 mg/
kg  every 3 weeks was selected based on the approved combination with 
carboplatin and paclitaxel for advanced non– small cell lung cancer.
• Most adverse events  were reported during chemotherapy. All but one 
gastrointestinal (GI) perforation/fi stula occurred during chemotherapy. 
Exceptions included hypertension, proteinuria, and pain, which  were 
more commonly reported during the extended phase in patients receiv-
ing maintenance bevacizumab.
• This cohort had relatively poor prognosis with 40% with suboptimal 
stage III and 26% with stage IV disease.
• The maximum separation in the PFS curves (PC vs PCB + B) occurred 
at 15 months with convergence of the curves 9 months  later. This con-
vergence of PFS curves was also seen in the ICON7 trial (which used 
12 months of maintenance bevacizumab).  There was no convergence 
of PFS curves in the OCEANS trial (for recurrent ovarian cancer) in 
which bevacizumab was used  until disease progression and not discon-
tinued at a predefi ned time. This suggests that the magnitude of ben-
efi t may correlate directly with treatment duration and is consistent with 
preclinical studies that demonstrate regrowth of tumor upon discon-
tinuation of anti- VEGF therapy (Bagri et al. 2010).
• The improvement in PFS was consistent across dif fer ent subgroup anal-
yses (Figure 2C in manuscript).








Arterial thrombosis 0.8% 0.7% 0.7%
Wound disruption 2.8% 3.6% 3.0%
CNS bleeding 0 0 0.3%
Non- CNS bleeding 0.8% 1.3% 2.1%
 PRES 0 0.2% 0.2%
CNS, central ner vous system; GI, gastrointestinal; NS, not signifi cant; PFS, progression- free survival; 
OS, overall survival; PC, paclitaxel + carboplatin; PCB, paclitaxel + carboplatin + bevacizumab; PCB+B, 
paclitaxel + carboplatin + bevacizumab followed by bevacizumab maintenance; PRES, posterior revers-
ible encephalopathy syndrome.
aP values are compared to PC control arm.
(continued)





•  There was no reduction in quality of life with the addition of 
bevacizumab.
•  There was no improvement in OS, but the ability to detect a difference 
may be limited by  later crossover to receiving bevacizumab or other 
anti- VEGF agents.
• Bevacizumab increased the risk of hypertension, which appeared to be 
cumulative, but this tended to be controlled with medical therapy and 
did not lead to many treatment discontinuations.
• The lack of survival difference between control and bevacizumab ini-
tiation suggests that bevacizumab must be continued as a maintenance 
therapy to delay disease progression.
• The change in primary endpoint from OS to PFS is a major limitation 
of this study. The authors note that the GCIG supports the use of PFS 
as a primary endpoint for  trials evaluating front- line therapy  because 
of the infl uences of postprogression therapy on OS (Stuart et al. 2011).
MITO-7 (Pignata, Lancet Oncol 2014)
REFERENCE
• Pignata S, et al. Carboplatin plus paclitaxel once a week versus  every 
3 weeks in patients with advanced ovarian cancer (MITO-7): a ran-
domised, multicentre, open- label, phase 3 trial. Lancet Oncol. 2014;15(4): 
396-405. PMID: 24582486. (Pignata et al. 2014)
TRIAL SPONSORS
• MITO-7 (Multicentre Italian  Trials in Ovarian Cancer)
• ENGOT- OV-10 (Eu ro pean Network of Gynaecological Oncological 
Trial Groups)
• GCIG (Gynecologic Cancer InterGroup) Trial
RATIONALE FOR TRIAL
• Standard paclitaxel- carboplatin chemotherapy  every 3 weeks is toxic 
and  causes alopecia, neurotoxicity, and fatigue.
• Weekly paclitaxel may reduce toxicity by decreasing the peak concen-
trations and increase effi cacy by reducing tumor regrowth and provid-
ing an antiangiogenic effect.
• Weekly paclitaxel in patients with recurrent ovarian cancer resulted in 
fewer hematologic and neurologic side effects.
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• This trial sought to investigate  whether weekly carboplatin and pacli-
taxel is more effective than the  every 3- week regimen.
PATIENT POPULATION
• N = 822.
• Recruited from 67 institutions in Italy and France from November 2008 
to March 2012.
•  Women older than 18 years.
• Stage IC to IV epithelial ovarian, fallopian tube, or peritoneal cancer.
• ECOG per for mance status 0 to 2.
• Life expectancy of at least 3 months.
• Adequate bone marrow, kidney, and liver function.
• Excluded if clinically relevant heart disease or other contraindication 
to treatment.
• Randomization  after initial surgery and staging.
TREATMENT DETAILS
Arm 1: Standard Regimen  Every 21 Days
• Paclitaxel starting dose 175 mg/m2 infused over 3 hours.
• Carboplatin AUC 6 mg/mL per minute, Calvert formula, creatinine 
clearance estimated by Cockcroft- Gault formula.
• Hematologic par ameters to treat  were more restrictive than in the 
weekly treatment with WBC >3000//μL, ANC >1500/μL, platelets 
>100,000/μL.
• Dose reduction of all drugs by 20% if ANC <500/μL or platelets 
<50,000/μL for 7 days or longer.
• Dose reduction by 25% for grade 2 neuropathy.
• Treatment discontinuation for prolonged toxic effects causing treatment 
delay of 2 weeks or longer.
Arm 2: Weekly Regimen
• Paclitaxel 60 mg/m2 infused over 1 hour weekly for 18 weeks.
• Carboplatin AUC 2 mg/mL per minute infused over 30 minutes for 18 
weeks.
• Hematologic par ameters to treat— WBC >3000/μL, ANC >1000/μL, 
platelets >75,000/μL.
• Dose reduction of all drugs by 20% if ANC <500/μL or platelets 
<50,000/μL for 7 days or longer.
• Dose reduction by 25% for grade 2 neuropathy.





• Treatment discontinuation for prolonged toxic effects causing treatment 
delay of 2 weeks or longer.
Surgery
• Interval debulking surgery was allowed  after 3 cycles.
ASSESSMENTS
• Baseline CT or nuclear magnetic resonance (NMR) and CA125.
• Imaging  after 3 and 6 cycles of chemotherapy, response assessed by 
RECIST version 1.0 (French centers did not image  after 3 cycles if clin-
ical suspicion of progression was absent).
• Quality of life assessed by FACT- O version 4.
• FACT- O/TOI (trial outcome index) calculated by adding scores from 
physical, functional, and ovarian cancer- specifi c subscales.
• Neurotoxicity assessed by FACT/GOG- Ntx.
• Adverse events graded according to CTCAE version 3.0.
ENDPOINTS
• Quality of life, mea sured by FACT- O/TOI score (primary endpoint).
• PFS (co- primary endpoint). In 2010, PFS was added as co- primary end-








• Sample size of 350 patients calculated to fi nd a difference between arms 
in FACT- O/TOI changes between baseline and 9 weeks of 0.30 with α 
of 0.05 and power of 80%.
• Sample size adjusted to 810 patients to detect a 0.75 hazard ratio of pro-
gression (median PFS from 18 to 24 months) with α of 0.05 and an 
interim analy sis of effi cacy  after half of events had occurred.
CONCLUSION OF TRIAL
• Weekly carboplatin and paclitaxel.
• Does not improve progression- free survival.





 Table 2.23  Results of MITO-7
Treatment arm
 Every 3 weeks
N = 404
Weekly
N = 406 Statistics
Patient characteristics
Median age (range) 59 (29-83) 60 (23-87)
No residual 41% 41%
≤1 cm residual 12% 12%
>1 cm residual 23% 23%
No surgery 25% 24%
Stage IC 6% 8%
Stage II 8% 8%
Stage III 63% 58%
Stage IV 23% 27%
Serous 72% 67%
Endometrioid 8% 12%
Clear cell 6% 5%
Mucinous 2% 2%
Other 12% 14%
Grade 3 71% 66%
Treatment delivery
Interval debulking 20% 17%
Received all treatment 90% 83%
Stopped for toxicity 4% 8%
At least 1 delay 62% 79%
Dose reduction 36% 19%
Carboplatin dose intensity 82.7% 76.6%
Paclitaxel dose intensity 86.8% 79.1%
Effi cacy
PFS (95% CI) 17.3 months (15.2-20.2) 18.3 months (16.8-20.9) HR 0.96, P = NS
24- month survival 78.9% 77.3% HR 1.20, P = NS
Objective response rate 58.8% 56.2%
Toxicity
FACT- O/TOI QOL scores declined 
 after  every 
chemotherapy cycle
QOL scores declined 
 after week 1, then 
stabilized
Deaths N = 3 N = 5
Worse with q 3 weeks
G3-4 neutropenia 50% 42%
Febrile neutropenia 3% 0.5%
≥ G2 neuropathy 17% 6%
≥ G2 hair loss 59% 29%
Worse with weekly
 ≥ G2 pulmonary 3% 5%
CI, confi dence interval; FACT- O/TOI, Functional Assessment of Cancer Therapy— Ovarian/Trial Outcome 
Index; HR, hazard ratio; NS, not signifi cant; PFS, progression- free survival; QOL, quality of life.





• Better toxicity profi le and better quality of life.
• Less adherence to treatment schedule, challenging regimen.
• Carboplatin and paclitaxel  every 3 weeks.
• More frequent and severe hematologic toxicity, vomiting, neuropa-
thy, hair loss.
COMMENTS
• Differences between NOVEL and MITO-7  every 3- week treatment 
arms.
• Frequency and severity of toxicities  were higher in NOVEL trial.
• G3-4 neutropenia—88% vs 50%.
• Thrombocytopenia—38% vs 7%.
• Anemia—44% vs 8%.
• Suggests pos si ble ge ne tic reasons for drug sensitivity.
• Similar PFS for q 3- week treatment arm across studies, but PFS dif-
fered in the weekly regimens.
• Dose of weekly paclitaxel was 80 mg/m2 in NOVEL compared to 
60 mg/m2 in MITO-7. Dose density may be needed to improve 
outcomes.
• Carboplatin  every 3 weeks may be more effi cacious than carboplatin 
 every week; weekly carboplatin may antagonize the effects of paclitaxel.





Advanced Stage Epithelial 
Ovarian Cancer
Timing of Surgery and Interval Cytoreduction
Two  trials have addressed the utility of a second attempt at surgical cyto-
reduction (following 3 rounds of chemotherapy) when the fi rst attempt 
leaves a residual disease burden of greater than 1 cm (suboptimal cytore-
duction). The EORTC- GCG 55865 trial demonstrated a survival advan-
tage to second cytoreduction while the GOG 152 trial showed no benefi t. 
 Because the residual disease burden was higher among patients in the 
EORTC trial,  these seemingly contradictory results have been reconciled 
with the caveat that patients who had a maximal fi rst cytoreduction 
attempt (ie, GOG 152 patient population) are  those who would not ben-
efi t from a second surgery. The EORTC 55971 and CHORUS  trials sug-
gest that  there is no difference between primary cytoreduction (followed 
by 6 cycles of chemotherapy) and neoadjuvant chemotherapy (3 cycles) 
and interval cytoreduction (followed by 3 cycles of chemotherapy). Both 
of  these  trials  were conducted in patients with a high baseline tumor 
burden.
EORTC- GCG 55865 (van der Burg, NEJM 1995)
REFERENCE
• van der Burg ME, et al. The effect of debulking surgery  after induc-
tion chemotherapy on the prognosis in advanced epithelial ovarian 
cancer. Gynecological Cancer Cooperative Group of the Eu ro pean 
Organ ization for Research and Treatment of Cancer. N Engl J Med. 
1995;332(10):629-634. PMID: 7845426. (van der Burg et al. 1995)
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• Gynecological Cancer Cooperative Group of the Eu ro pean Organ-
ization for Research and Treatment of Cancer (EORTC)
RATIONALE FOR TRIAL
• Reasons for cytoreductive surgery in ovarian cancer.
• Large tumors have poor central blood supply.
• Areas with slow growth rate are relatively insensitive to cytotoxic 
therapy (Skipper 1974).
• Smaller tumors are better perfused and have a higher growth rate and 
chemotherapy more effectively diffuses into the tumors.
• Removal of large tumors also reduces the likelihood of drug- resistant 
clones developing (Goldie and Coldman 1979).
• Smaller tumors require fewer cycles of chemotherapy, which also 
reduces the probability of drug re sis tance developing.
• The value of cytoreductive surgery on survival is controversial.
• Nonrandomized studies demonstrate that patients with optimal 
cytoreduction have better survival than patients left with larger 
residual lesions (Vogl et al. 1983; Omura et al. 1989; Neijt et al. 
1991).  These studies are subject to bias as patients with differ-
ence surgical outcomes also have dif fer ent baseline prognostic 
 factors.
• Other studies have demonstrated that among patients with optimal 
cytoreduction,  those with large masses before cytoreduction still have 
worse survival than patients with small lesions prior to surgery 
(Hacker et al. 1983; Hoskins et al. 1992).
• It is not settled  whether cytoreduction infl uences survival among 
patients with the same- size tumors.
• It is not clear  whether debulking surgery  after induction chemotherapy 
infl uences survival.
• While some studies report similar survival among patients with 
induction chemotherapy and optimal cytoreduction and patients 
with optimal primary cytoreduction (Neijt et al. 1984; Wils et al. 
1986; Jacob et al. 1991; Potter et al. 1991), other studies report infe-
rior survival for  those patients undergoing induction chemotherapy 
(Neijt et al. 1987; Neijt et al. 1991) that is closer to the survival of 
patients undergoing suboptimal cytoreduction.
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• The EORTC initiated a randomized phase 3 trial in 1987 to assess the 
infl uence of debulking surgery  after induction chemotherapy on sur-
vival in ovarian cancer.
PATIENT POPULATION
• N = 425, 391 underwent randomization.
• Patients enrolled from March 1987 to May 1993.
• Biopsy- proven epithelial ovarian cancer, International Federation of 
Gynecol ogy and Obstetrics (FIGO) stage IIB to IV, with residual lesions 
>1 cm  after cytoreductive surgery that occurred no more than 6 weeks 
before treatment began.
• Per for mance status of 0 to 2.
• Age less than 75 years.
• Adequate bone marrow and renal function.
TREATMENT DETAILS
•  After randomization, all patients received 3 cycles of chemotherapy.
• Cyclophosphamide 750 mg/m2.
• Cisplatin 75 mg/m2.
• Treatment  every 3 weeks.
•  After the third cycle, patients underwent clinical assessment.
• Patients with progression or contraindication to surgery  were removed 
from the study.
• Patients with clinical response or stable disease  were randomized to 
undergo interval debulking or no debulking.
Arm 1: No Debulking Surgery
Arm 2: Debulking Surgery
• Surgery scheduled within 28 days of the third cycle of chemotherapy.
• Maximal cytoreduction to include (if not previously done) hysterec-
tomy, bilateral salpingo- oophorectomy, and infracolic omentectomy.
Additional Chemotherapy
• Resumed within 4 weeks of surgery.
• At least 6 total cycles of cyclophosphamide and cisplatin.
• Decision to continue beyond 6 cycles was at the discretion of the 
center.
• Patients with a complete clinical response preferably had a “second- 
look” operation, regardless of randomization arm.
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• Clinical response assessed according to World Health Organ ization 
(WHO) response criteria.
• Complete response was the absence of tumor at surgery.
• Clinical evaluation with physical exam, imaging (computed tomogra-
phy [CT] scan or sonography or both), and cancer antigen 125 (CA125) 
was performed  after the third and sixth cycles of chemotherapy.
•  After therapy, patients  were seen  every 2 months for 2 years, then in def-
initely thereafter per each center’s policy.
ENDPOINTS
• Overall survival (OS) calculated from the day chemotherapy was started 
to death, regardless of cause.
• Progression- free survival (PFS) was calculated from the day chemo-
therapy was started  until the time of progression or death.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Patients  were stratifi ed with a minimization technique to account for 
institution, per for mance status, and clinical response.
Sample Size
• Accrual target of 440 patients to have 80% probability of detecting a 
30% reduction in the risk of death using a 2- tailed log- rank test at an α 
of 0.05 (George and Desu 1974).
• Interim analyses  were performed yearly per EORTC policy (Buyse 
1993).
• A difference in survival was seen in September 1991, October 1992, 
February 1993, and April 1993. At this time, the group deci ded to stop 
enrolling patients.
Statistical Tests
• Kaplan- Meier estimates used to calculate survival and progression- free 
survival.
• Log- rank test used to compare survival across treatment groups.
• Cox regression analyses and stratifi ed analyses  were used to adjust 
treatment comparisons for known prognostic  factors (Cox 1972).












N = 140 Statistics
Patient characteristics
Median age (range) Not stated Not stated 59 (32-74)  whole group
Largest baseline tumor
1-2 cm 4% 6%
2-5 cm 20% 25%
5-10 cm 24% 20%
>10 cm 32% 28%
Unknown, >2 cm 20% 21%
Stage IIB 4% 6%
Stage III 75% 71%




Clear cell 4% 1%
Other 26% 25%
Ovary in situ 31% 29%
Carcinomatosis 43% 46%
Ascites 72% 78%
Response  after 3 cycles
Complete response 17% 18%
Partial response 55% 54%
Stable disease 28% 28%
Treatment delivery
No interval debulking 100%
Interval debulking 93%
No residual 38%
Optimal <1 cm 26%
Suboptimal ≥1 cm 36%
Six cycles of chemotherapy 84% 84%
Stop chemotherapy early for
Progression 3% 5%
Toxicity 2% 3%
Refusal to continue 5% 4%
Unknown 6% 4%
Dose reduction 37% 36%
Dose delay 49% 48%
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• Interval debulking surgery  after induction chemotherapy signifi cantly 
lengthened progression- free and overall survival.
COMMENTS
• The benefi cial effect of surgery on survival was seen throughout the 
follow-up period.
• The survival benefi t was greatest when excluding patients with stage 
IV disease.







N = 140 Statistics
Median time cycle 1 to 6 17.5 weeks 21 weeks
Consolidation chemotherapy 51% 36%
Second- look surgery 51% 52%
Effi cacy
Clinical response 70% 84%
Second look
Complete response 33% 37%
Partial response 37% 28%
Stable disease 6% 2%
Progression 6% 8%
Median OS 20 months 26 months HR 0.69, P = .01




EBL >500 mL 22%
Fever 4%
Ileus 1%
Urinary tract infection 4%
Wound infection 2%
Deep venous thrombosis 1%
Lung embolism 2%
EBL, estimated blood loss; HR, hazard ratio; NS, not signifi cant; PFS, progression- free survival; OS, 
overall survival.
(continued)
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• Survival was comparable between patients with suboptimal interval 
cytoreduction and patients who did not undergo debulking surgery. 
 Either patients with suboptimal cytoreduction did not benefi t from sur-
gery or patients who did not undergo surgery might have benefi ted 
from surgery.
• In multivariate analy sis, all subgroups benefi ted from debulking 
surgery.
•  There  were no severe morbidities or deaths associated with interval 
debulking surgery. Therefore, the 6- month improvement in overall sur-
vival outweighs the risks of surgery in this trial.
GOG 152 (Rose, NEJM 2004)
REFERENCE
• Rose PG, et al. Secondary surgical cytoreduction for advanced ovarian 
carcinoma. N Engl J Med. 2004;351(24):2489-2497. PMID: 15590951. 
(Rose et al. 2004)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• The EORTC trial demonstrated an improvement in progression- free 
survival and overall survival in patients who underwent suboptimal pri-
mary debulking followed by secondary surgery  after 3 cycles of induc-
tion chemotherapy (van der Burg et al. 1995).
• This trial was designed to determine  whether secondary cytoreductive 
surgery infl uences survival among patients with suboptimal primary 
cytoreduction and treatment with cisplatin and paclitaxel.
PATIENT POPULATION
• N = 550 enrolled, 424 randomized.
• Enrollment between June 1994 and January 2001.
Inclusion Criteria
• Stage III or IV ovarian cancer with residual tumor >1 cm  after a maxi-
mum effort.
• In March 1996, patients with stage IV disease (malignant pleural effu-
sion or resected anterior abdominal wall tumor)  were made ineligible 





based on the report from the EORTC trial of greatest benefi t when stage 
IV patients  were excluded (van der Burg et al. 1995).
• GOG per for mance status of 0 to 2.
• Life expectancy of at least 8 weeks.
• Lab requirements.
• Leukocyte count >3000/mm3.
• Platelet count >100,000/mm3.
• Granulocyte count >1500/mm3.
• Serum creatinine <2.0 mg/dL.
• Bilirubin <1.5 times upper limit of normal.
• Serum aspartate aminotransferase (AST), alanine aminotransferase 
(ALT), and alkaline phosphatase <3 times upper limit of normal.
Exclusion Criteria
• Prior cancer, chemotherapy, or radiotherapy.





• History of congestive heart failure, myo car dial infarction, unstable 
angina, or abnormal cardiac conduction within the preceding 6 months.
TREATMENT DETAILS
Chemotherapy
• Chemotherapy with paclitaxel and cisplatin, consistent with prior GOG 
protocols (McGuire et al. 1996; Muggia et al. 2000; Ozols et al. 2003).
• Paclitaxel 130 mg/m2 intravenous (IV) over 24 hours.
• Cisplatin 75 mg/m2 IV.
• Premedications to avoid paclitaxel hypersensitivity reactions and anti-
emetics administered.
• Administered  every 21 days for total of 6 cycles.
• Dose modifi cations.
• Paclitaxel— reduced to 110 mg/m2 for neutropenic fever, grade 4 
thrombocytopenia, or grade 3 to 4 mucositis or diarrhea. In April 1997, 
to be consistent with other GOG protocols, paclitaxel also reduced for 
grade 4 neutropenia, and granulocyte colony- stimulating  factor was to 
be administered for recurrent episodes. Reduced to 90 mg/m2 for per-
sis tent grade 3 to 4 adverse events.
510-66190_ch01_3P.indd   169 11/8/16   7:49 PM




• Cisplatin— reduced to 50 mg/m2 for grade 2 neuropathy, tinnitus, or 
symptomatic hearing loss. Discontinued for grade 3 to 4 neuropathy 
or per sis tent elevation in serum creatinine above 2.0 mg/dL.
• Patients  were removed from study for treatment delay of more than 
2 weeks.
Randomization
•  After 3 cycles of chemotherapy (patients with no progression and no 




• Secondary surgical cytoreduction was performed as soon as pos si ble 
 after hematologic recovery and within 6 weeks of completion of third 
cycle of chemotherapy through laparotomy with maximal effort to 
resect all gross tumor.
• Additional chemotherapy was administered as soon as pos si ble but no 
more than 6 weeks  after secondary surgery.
ASSESSMENTS
• Pretreatment.
• History, physical examination, determination of race and per for-
mance status, electrocardiography, complete blood count, renal and 
liver function tests, urinalysis, imaging (CT scan of the abdomen and 
pelvis, chest radiography), CA125 levels.
• Three weeks  after third cycle of chemotherapy.
• Evaluation for response with physical examination and CT of abdo-
men and pelvis ( unless CT fi ndings  were normal at study entry and 
CA125 had returned to normal). Patients without progression and 
with residual extraperitoneal tumor no more than 1 cm in dia meter 
 were randomized.
• Toxicity graded according to GOG Common Toxicity Criteria and sum-
marized as the maximal reported grade.
Reassessments
• Six to 9 weeks  after completing protocol therapy: history, physical 
exam, evaluation of GOG per for mance status, complete blood count, 
electrolytes, renal and liver function tests, CT of abdomen and pelvis, 
chest radiography, CA125.





•  Every 3 months for 2 years, semiannually for 3 years, yearly thereafter.
ENDPOINTS
• Planned analy sis was log- rank test stratifi ed according to the clinical 
response  after 3 cycles of chemotherapy.
• PFS and OS assessed to compare results to the EORTC study.
• Progression defi ned as clinically evident increase in disease or CA125 
≥100 U/mL, confi rmed by retesting 2 weeks  later (or a doubling of 
the nadir CA125 levels in a patient whose CA125 values did not 
normalize).
• Survival mea sured from date of randomization.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Within each parent institution, patients  were stratifi ed by response 
to fi rst 3 cycles of chemotherapy and by mea sur able disease at study 
entry.
Sample Size
• Enrollment of at least 400 patients. A 29% reduction in death rate with 
secondary cytoreduction was considered clinically signifi cant. This 
is equivalent to an 11% increase in the proportion of patients who sur-
vival more than the expected median of 2.8 years. Assuming propor-
tional hazards, the study would have an 81% chance of detecting this 
treatment effect (hazard ratio [HR], 1.40) with a 1- sided type I error 
of .05.
• An interim analy sis scheduled to be performed  after 60 deaths reported 
in the chemotherapy- alone arm.
• Final analy sis scheduled to occur  after at least 225 deaths reported.
Statistical Tests
• P values reported in publication are 2- sided.
CONCLUSION OF TRIAL
• In this trial, in patients with suboptimal cytoreduction  after a maximal 
effort at primary surgery, chemotherapy plus secondary surgery does 
not improve survival compared to chemotherapy alone. This is in con-
trast to previously reported fi ndings from EORTC, which found sec-
ondary cytoreduction to improve survival.












N = 216 Statistics
Patient characteristics
Median age (range) 57 (27-81) 58 (24-81)
Measurable disease 70% 70%
Residual tumor
1-2 cm 12% 12%
2-5 cm 44% 43%
5-10 cm 38% 33%
>10 cm 6% 12%
Stage III 96% 93%




Clear cell 1% 2%
Other 16% 13%
Grade 1 10% 9%
Grade 2 39% 39%
Grade 3 or clear cell 50% 52%
Treatment delivery
No interval debulking 97%
Interval debulking 93%
Optimal <1 cm 70%
Suboptimal ≥1 cm 30%
Six cycles of chemotherapy 98% 93%
Median time cycle 3 to 4 21 days 45 days P < .001
Consolidation chemotherapy 12% 10%
Effi cacy
Median OS 33.7 months 33.9 months HR 0.99 (95% CI, 0.79-1.24)
Median PFS 10.7 months 10.5 months HR 1.07 (95% CI, 0.87-1.31)
Toxicity
≥ G2 neuropathy 26% 16% P = .01
G3-4 gastrointestinal 4% 7%
G4 pulmonary event N = 0 N = 2
G4 cardiovascular event N = 1 N = 3
CI, confi dence interval; G, grade; HR, hazard ratio; PFS, progression- free survival; OS, overall 
survival.






•  There was no effect of secondary surgery on overall survival in dif fer-
ent subgroups based on maximal residual tumor  after initial cytore-
duction, age, per for mance status, or presence of absence of mea sur able 
disease before chemotherapy.
•  Factors associated with survival.
• Tumor dia meter >1 cm before primary surgery. HR, 1.71 (95% con-
fi dence interval [CI], 1.21-2.42, P = .003).
•  Factors not associated with survival.
• Suboptimal secondary cytoreduction. HR 1.25 (95% CI, 0.79-2.00; 
P = .34).
• Patients undergoing secondary cytoreduction had a longer delay between 
cycles 3 and 4 of chemotherapy as well as a lower rate of grade 2 or 
higher peripheral neuropathy, suggesting the respite may have lessened 
the neurologic adverse effects.
• Differences between GOG and EORTC studies.
• Amount of residual tumor was less in GOG compared to EORTC, 
suggesting a greater effort at primary cytoreduction in the GOG trial. 
Tumor <5 cm was achieved  after primary surgery in about 55% in 
GOG compared to about 28% in EORTC.
• GOG study used the more effi cacious combination of paclitaxel and 
cisplatin, whereas EORTC used cyclophosphamide and cisplatin.
• The frequency and timing of clinical evaluations may have infl uenced 
differences in survival (Eisenhauer et al. 1997).
•  There are hurdles to evaluating surgical interventions (Reynolds 
1999).
• Differences in surgical aggressiveness are diffi cult to quantify.
• Signifi cance of number or tumor deposits and the defi nition of optimal 
residual disease are controversial.
•  There is a high degree of interobserver variability with tumor mea-
sure ments (Prefontaine et al. 1994).
• Patients who undergo initial cytoreduction by a nongynecologic oncol-
ogist (ie, a general surgeon or an obstetrician- gynecologist) might 
benefi t from a secondary cytoreduction.
• The utility of neoadjuvant chemotherapy is being investigated, but the 
value is uncertain as survival among patients who have a complete 
response to chemotherapy is shorter for  those who begin with bulky 
disease (Rubin et al. 1999).
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EORTC 55971 (Vergote, NEJM 2010)
REFERENCE
• Vergote I, et al. Neoadjuvant chemotherapy or primary surgery in stage 
IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-953. PMID: 
20818904. (Vergote et al. 2010)
TRIAL SPONSORS
• EORTC– Gynaecological Cancer Group (EORTC- GCG)
• National Cancer Institute of Canada (NCIC) Clinical  Trials Group
RATIONALE FOR TRIAL
• Primary cytoreduction surgery is considered standard of care for 
advanced ovarian cancer despite a lack of evidence from randomized, 
controlled  trials to support this practice.
• A meta- analy sis of 835 patients suggested that neoadjuvant chemother-
apy was associated with worse outcome than primary cytoreduction 
(Bristow and Chi 2006).
• This was a randomized controlled trial to assess the outcomes of pri-
mary debulking surgery followed by platinum- based chemotherapy 
compared to platinum- based neoadjuvant chemotherapy with interval 
cytoreduction in patients with advanced ovarian cancer.
PATIENT POPULATION
• N = 718 enrolled.
• Patients enrolled between September 1998 and December 2006.
• Biopsy- proven stage IIIC or IV invasive epithelial ovarian cancer, fal-
lopian tube cancer, or primary peritoneal cancer.
• If biopsy was not available, a fi ne- needle aspiration was acceptable 
 under the following conditions: presence of a pelvic mass, presence of 
metastases outside the pelvis of at least 2 cm (noted during surgery or 
on CT scan), regional lymph node metastases or proof of stage IV dis-
ease, and ratio of CA125/carcinoembryonic antigen (CEA) >25.
• If CA125/CEA <25, then results of a barium enema or colonoscopy, 
gastroscopy or radiologic examination of the stomach, and mammo-
gram had to be negative for primary tumor.
• If biopsy was performed during laparoscopy or laparotomy, no further 
procedures could have been performed during surgery.
• WHO per for mance status of 0 to 2.





• Absence of serious disabling diseases that would be contraindications 
to therapy.
• No CT or laparoscopic scoring systems  were used to select patients.
TREATMENT DETAILS
Arm 1
• Primary debulking + at least 6 cycles of platinum- based chemotherapy.
• Interval debulking surgery was permitted if stable disease or response 
documented. However,  after GOG 152 was published (Rose et al. 
2004), interval debulking was not recommended in patients who did 
not have optimal cytoreduction despite a maximal surgical effort at 
the time of primary debulking.
Arm 2
• Three cycles of neoadjuvant platinum- based chemotherapy + interval 
debulking + chemotherapy.
Chemotherapy Details
• Recommended regimen was paclitaxel 175 mg/m2 IV over 3 hours fol-
lowed by carboplatin area  under the curve (AUC) 6 IV over 1 hour.
• Other allowed regimens include cisplatin 75 mg/m2 IV or carboplatin 
AUC 5.
ASSESSMENTS
• Imaging (preferable CT scan) was performed prior to each surgical pro-
cedure, within 1 week prior to cycle 1 of chemotherapy, and in the 
third week of chemotherapy cycles 3 and 6.
• Tumor response evaluated by WHO criteria (Miller et al. 1981).
• EORTC quality- of- life questionnaire (QLQ)– C30 and QLQ- Ov28 ques-
tionnaires at 5 time points.
• Second- look surgery was allowed but not recommended.
ENDPOINTS
• Overall survival (primary endpoint).
• Progression- free survival.
• Quality of life.
• Adverse events  were considered postoperative if they occurred within 
28 days of surgery.
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Stratifi cation  Factors
• Patients stratifi ed by institution, method of biopsy (image- guided lap-
aroscopy, laparotomy, or fi ne- needle aspiration), tumor stage (IIIC or 
IV), and largest preoperative tumor size excluding ovaries (≤5 cm, 
5-10 cm, 10-20 cm, >20 cm).
Sample Size
• Based on a prior EORTC trial evaluating interval debulking surgery, 
patients with suboptimal primary debulking and interval debulking 
surgery had an expected survival of 26 months (van der Burg et al. 
1995). Patients with optimal debulking to residual <1 cm had a median 
survival of 36 months (Vergote et al. 1998). The median survival of 
the  whole group was estimated to be 31 months. In total, 498 events in 
704 patients  were required to show noninferiority with an α of 0.05, 
power of 80%, and accrual time of 4 years and a minimum follow-up 
period of 3 years. A hazard ratio of <1.25 was considered noninferior.
Statistical Tests
• Kaplan- Meier method to estimate OS and PFS.
• Log- rank test to compare survivals with a noninferiority ratio of 0.8.
• Cox proportional hazards model for multivariate time- to- event analy-
sis with univariate screening followed by a stepwise variable- se lection 
procedure.
• Log- rank test for trend used to compare adverse events between treat-
ment groups.
•  Because of an allegation of ethical irregularities at one of the centers, 
all patients from that center  were excluded from the analy sis.
CONCLUSION OF TRIAL
• Survival was similar between upfront debulking followed by adjuvant 
chemotherapy and neoadjuvant chemotherapy with interval debulking 
surgery. No advantages  were seen for  either approach with re spect to 
survival, adverse effects, quality of life, or postoperative morbidity or 
mortality.
COMMENTS
• This was a population with bulky baseline disease with 61.6% with met-
astatic lesions >10 cm and 74.5% with lesions >5 cm, which may par-
tially account for the poor survival outcomes in the trial.












N = 334 Statistics
Patient characteristics
Median age (range) 62 (25-86) 63 (33-81)
Largest baseline tumor
0-2 cm 1.2% 3.0%
2-5 cm 26.8% 25.4%
5-10 cm 26.8% 26.3%
>10 cm 39.0% 41.0%
Stage IIIC 76.5% 75.7%









Image guidance 22.6% 15.9%
Fine- needle aspiration 42.3% 45.8%
Missing data 0.6% 0
Type of chemotherapy
Platinum- taxane 78.4% 87.9%
Platinum only 8.1% 6.2%
Other 6.8% 5.9%
No chemotherapy 6.8% 0
Residual tumor
None 19.4% 51.2%
≤1 cm 22.2% 29.5%
1-2 cm 11.7% 5.8%
>2 cm 41.3% 11.9%
Missing 5.4% 1.7%
Effi cacy
Median OS 29 months 30 months HR 0.98 (95% CI, 0.84-1.13)
Median PFS 12 months 12 months HR 1.01 (95% CI, 0.89-1.15)
Toxicity
Postoperative death 2.5% 0.7%
G3/4 hemorrhage 7.4% 4.1%
Infection 8.1% 1.7%
Venous complications 2.6% 0%
CI, confi dence interval; HR, hazard ratio; PFS, progression- free survival; OS, overall survival.
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• Optimal debulking rates (to <1 cm residual) was 41.6% for patients 
undergoing upfront debulking surgery and 80.6% for patients under-
going neoadjuvant chemotherapy and interval debulking surgery.  These 
rates are similar to other  trials evaluating surgery for stage IIIC and 
IV ovarian cancers (O’Malley et al. 2003; Crawford et al. 2005; Heintz 
et al. 2006; Schrag et al. 2006; Vernooij et al. 2008; du Bois et al. 2009; 
Marth et al. 2009).
•  There was no trend in  favor of primary debulking surgery, even in 
countries with high rates of optimal primary debulking surgery. This 
may be due to the strong correlation between rates of optimal primary 
debulking and rates of optimal interval debulking within each country 
(r = 0.92).
• The most frequent sites of residual tumor  after both types of surgery 
 were the diaphragm, abdominal peritoneum, and pelvis (pouch of 
Douglas, uterus, bladder, rectum, and sigmoid).
• In patients with baseline tumors <5 cm, overall survival was slightly 
better with primary surgery than neoadjuvant chemotherapy (HR, 0.64; 
95% CI, 0.45-0.93).
• In descending order, the strongest predictors for improved overall sur-
vival in Cox regression analyses  were absence of residual tumor  after 
surgery (P < .0001), stage IIIC disease (P = .001), small tumor size at 
baseline (P = .001), and histology (endometrioid, serous, mixed, undif-
ferentiated, mucinous, clear cell) (P = .005).
• Complete resection of all macroscopic disease is the single most impor-
tant prognostic  factor for ovarian cancer survival. This has been shown 
in many prior studies and was confi rmed in this EORTC trial.
• A pos si ble limitation of neoadjuvant chemotherapy may be the result-
ing fi brosis, which may hinder complete resection of macroscopic 
disease.
• This trial only evaluates patients with stage IIIC and IV disease. The 
standard of care for stage IIIB and earlier stage ovarian cancer is still 
primary cytoreductive surgery.
CHORUS (Kehoe, Lancet 2015)
REFERENCE
• Kehoe S, et al. Primary chemotherapy versus primary surgery for newly 
diagnosed advanced ovarian cancer (CHORUS): an open- label, ran-





domised, controlled, non- inferiority trial. Lancet. 2015;386(9990):249-57. 
PMID: 26002111. (Kehoe et al. 2015)
TRIAL SPONSORS
• UK Medical Research Council Clinical  Trials Unit (MRC CTU) Gyn-
aecological Cancer Trial Steering Committee
RATIONALE FOR TRIAL
• Primary cytoreduction followed by platinum- based chemotherapy is the 
international standard of care for advanced ovarian cancer.
• Observational studies consistently report better survival with smaller 
residual tumor  after cytoreduction (Griffi ths 1975; van der Burg et al. 
1995; Bristow et al. 2002; Winter et al. 2007; Winter et al. 2008; du 
Bois et al. 2009; Polterauer et al. 2012), but no randomized  trials exist. 
Even in specialty centers, many  women  will be left with suboptimal 
bulky residual tumor  after surgery.
• An alternative treatment strategy is to use primary chemotherapy fol-
lowed by delayed surgery. Observational studies suggest that this strat-
egy increases rates of optimal cytoreduction and reduces surgical 
complications (Vergote et al. 1998; Hou et al. 2007), but data are con-
fl icting, with 2 meta- analyses demonstrating confl icting results (Bristow 
and Chi 2006; Kang and Nam 2009).
• The CHORUS trial was designed to evaluate primary chemotherapy and 
delayed surgery with the hypothesis that survival outcomes would be 
similar and that surgical morbidity would be reduced compared to a 
primary surgery approach.
PATIENT POPULATION
• N = 552 randomized, 550 included in analy sis.
• Enrollment between March 2004 and August 2010.
•  Women with clinical or imaging evidence of a pelvic mass with metas-
tases consistent with stage III or IV ovarian, fallopian tube, or perito-
neal cancer (Benedet et al. 2000).
• If CA125/CEA ratio was <25, gastrointestinal primary needed to be 
ruled out prior to study entry.
• Histological or cytological diagnosis was not required before 
randomization.
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• Primary debulking surgery followed by 6 cycles of chemotherapy.
•  After randomization, histological or cytological confi rmation of diag-
nosis was required through laparoscopic or imaging- guided biopsy 
or fi ne- needle aspiration of tumor or effusion.
• In  women with more than 1 cm residual disease  after primary sur-
gery, interval debulking surgery was allowed  after 3 cycles of 
chemotherapy.
Arm 2
• Primary chemotherapy × 3 cycles, delayed debulking surgery, 3 cycles 
of chemotherapy.
Chemotherapy Details
• Regimen was deci ded before random assignment and based on patient 
fi tness, choice, and usual local practice.
• Carboplatin AUC 5 or AUC 6 with paclitaxel 175 mg/m2  every 
3 weeks.
• Alternative carboplatin combination regimen.
• Carboplatin AUC 5 or AUC monotherapy.
• Chemotherapy was started within 6 weeks  after surgery in both treat-
ment groups.
Surgery Details
• Done in 64 centers by specialist gynecological oncologists accred-
ited by the Royal College of Obstetricians and Gynaecologists 
(RCOG).
• All surgeons operate on at least 15 patients with ovarian cancer each 
year.
• Intent of surgery was tumor debulking to no macroscopic residual 
disease.
Surgical Procedures
• Recommended procedures included midline incision; cytology; thor-
ough inspection of abdomen, pelvis, upper abdomen, diaphragm, and 
retroperitoneal spaces; hysterectomy; bilateral salpingo- oophorectomy; 
and omentectomy.
• If FIGO stage IIIB or less, then pelvic and para- aortic nodes  were to 
be sampled.





• Ultra- radical procedures included multiple resections of small or large 
bowel, diaphragm stripping, splenectomy, partial cystectomy, and 
complete pelvic or para- aortic lymphadenectomy.  These procedures 
 were recommended if they would assist with the goal of optimal 
debulking.
• The volume of disease was assessed and recorded by the surgeon at the 
start and end of the operation. Disease volume was recorded as the larg-
est dia meter of disease in 13 areas: diaphragm, liver surface, paracolic 
gutters, omentum, intestines, peritoneal surface, pelvis, adnexa, pel-
vic and para- aortic lymph nodes, spleen, and liver.
ASSESSMENTS
At Screening
• Clinical assessment, imaging (CT or magnetic resonance imaging 
[MRI]) of abdomen and pelvis, chest radiograph), CA125 and CEA 
mea sure ments.
During Chemotherapy
• At each cycle, assessments included clinical review and mea sure ment 
of CA125.
 After Protocol Treatment
• Clinical review and CA125  every month for 9 months, then  every 3 
months for 2 years,  every 6 months for 3 years, then annually  until 
death, withdrawal from study, or study completion.
Imaging
• Done  after 3 cycles of chemotherapy and  after completion of therapy.
• During follow-up, imaging was triggered by clinical symptoms or a rise 
in CA125 concentrations.
Disease Progression
• Defi ned according to WHO criteria.
• During follow-up, progression could also be defi ned by a rise in CA125 
concentrations according to GCIG criteria (Vergote et al. 2000).
Quality of Life
• EORTC Quality of Life Questionnaire Core–36 (QLQC-30) and the 
ovarian cancer- specifi c questionnaire (QLQ- Ov28) (Fayers 2001)  were 
completed before randomization,  after 3 and 6 cycles of chemotherapy, 
and at 6 and 12 months  after treatment assignment.
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• Graded according to the National Cancer Instituted Common Termi-
nology Criteria for Adverse Events (CTCAE) version 3.0 at each che-
motherapy cycle and  after.
ENDPOINTS
• Overall survival (primary endpoint).
• OS was defi ned as time from randomization  until death. Data  were 
censored at the time survivors  were last known to be alive.
• PFS.
• PFS was defi ned as time of randomization  until the date of fi rst pro-
gression or death, whichever occurred fi rst. For patients without 
progression or death, data  were censored at the time of last visit.
• Analy sis included only progression events that  were confi rmed radio-
logically or clinically.
• A secondary analy sis was performed that also included progression 
events based on CA125 elevation without clinical or radiologic 
confi rmation.
• Quality of life.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Patients  were stratifi ed according to center, largest radiological tumor 
size, FIGO stage, and prespecifi ed chemotherapy regimen.
Sample Size
• Sample size calculation was based on noninferiority.
• Three- year survival rate was estimated at 50% for primary surgery.
• The noninferiority boundary was selected to exclude a detriment of 
more than 6% with primary chemotherapy with a 10% (1- sided) level 
of signifi cance.
• The upper bound of the 1- sided 90% CI for the hazard ratio had to be 
less than 1.18.
• CHORUS was designed with the intention of combining results with 
the EORTC 55971 trial (Vergote et al. 2010) in a  later meta- analy sis. 
The combined sample size was calculated to give a total of 1250  women 
in the 2  trials with 90% power. CHORUS had 65% power for compari-
son between the 2 treatment groups.





• The predefi ned trigger for analy sis was when the fi nal enrolled patient 
had completed 2 years of follow-up.
Statistical Tests
• Stratifi ed log- rank test used to compare treatment groups, adjust for 
variables used to stratify the random assignments.
• Cox proportional hazards models  were used to calculate hazard ratios 
adjusting for stratifi cation  factors.
• Proportional hazards assumptions  were assessed with the Grambsch- 
Therneau test (Grambsch and Therneau 1994).
• Analy sis of covariance was used to assess global quality of life at 6 
and 12 months with adjustment for baseline scores. Only cases with 
complete information  were included in the analy sis. For comparisons 
of mean scores between treatment groups, a difference of 10 points was 
considered clinically meaningful. For comparisons of mean scores 
between individuals, a difference of 5 points was considered meaning-
ful (Osoba et al. 1998).
CONCLUSION OF TRIAL
• Primary chemotherapy is noninferior to primary surgery in patients with 
advanced stage III and IV ovarian cancer with high tumor burden.
COMMENTS
•  There  were no subgroups that benefi ted more or less from primary 
chemotherapy.
• Debulking to <1 cm residual disease was achieved in 41% with primary 
surgery and 73% with primary chemotherapy (P = .001). Debulking to 
no macroscopic residual was achieved in 17% with primary surgery 
and 39% with primary chemotherapy (P = .001).
• Volume of residual disease was prognostic in both groups (data are in 
appendix of paper).
• Quality of life was slightly higher for patients receiving primary che-
motherapy than patients receiving primary surgery at 6 at 12 months. 
Improvement of global quality of life of at least 5 points was higher in 
patients receiving primary chemotherapy at 6 and 12 months, but the 
differences  were not signifi cant.
• The median survival of 22 to 24 months was lower than expected. Some 
potential explanations:
• Older median age of patients (65 years).












N = 274 Statistics
Patient characteristics
Median age (range) 66 (26-87) 65 (34-88)
Median tumor size
0-2 cm 5% 5%
2-5 cm 21% 22%
5-10 cm 40% 40%
10-20 cm 29% 29%
>20 cm 3% 3%
Unmea sur able 3% 2%
Stage III 75% 75%
Stage IV 25% 25%
Serous, high grade 74% 71%
Serous, low grade 4% 4%
Serous, not specifi ed 10% 12%
Endometrioid 4% 2%
Mucinous 1% 2%
Clear cell 2% 6%
Other 5% 1%
Well differentiated 6% 6%
Moderately differentiated 19% 14%
Poorly differentiated 75% 79%
Type of chemotherapy
Carboplatin- paclitaxel 75% 77%
Other carboplatin combo 1% <1%
Carboplatin only 24% 23%
Residual tumor
None 18% 39%
≤1 cm 24% 34%
>1 cm 58% 27%
Treatment delivery




Received delayed surgery 79%
Median duration of treatment 22 weeks 22 weeks
Median operative time 120 minutes 120 minutes
Received 6 cycles of chemotherapy 82% 79%
Chemotherapy delays 37% 28%
Carboplatin dose modifi cation 38% 39%
Taxol dose modifi cation 26% 28%





• 77% of tumors  were poorly differentiated.
• 19% of patients had per for mance status of 2 or 3.
•  There have been no randomized  trials that compare standard to ultra- 
radical surgery (Ang et al. 2011). It is not known  whether patients in 
this trial would have benefi ted from more aggressive attempts at deb-
ulking surgery.
• Postoperative mortality, delayed discharge  after surgery, and grade 3/4 
surgical morbidities  were all higher in the group undergoing primary 
surgery.
• Based on ICON3 (International Collaborative Ovarian Neoplasm Group 
2002), the addition of paclitaxel is not considered mandatory in upfront 
chemotherapy, and 23% to 24% of patients in this trial received single- 
agent carboplatin.







N = 274 Statistics
Effi cacy
Median OS 22.6 months 24.1 months HR 0.87, NS
Median PFS 10.7 months 12.0 months HR 0.91, NS
Toxicity
Surgical
G3/4 adverse events 24% 14% P = .007
G3/4 hemorrhage 3% 6%
Postoperative deaths 6% <1% P = .001
Hospitalization <14 days 80% 93% P < .001
Chemotherapy
G3/4 toxicity 49% 40% P = .06
G3/4 neutropenia 20% 16%
G, grade; HR, hazard ratio; NS, not signifi cant; PFS, progression- free survival; OS, overall survival.
(continued)




Maintenance therapy is the use of additional chemotherapy, biologic ther-
apy, or other treatment approaches  after a patient has achieved remission 
with the goal of prolonging remission and delaying recurrence. Many dif-
fer ent agents have been studied and have not demonstrated a benefi t. 
This chapter is by no means comprehensive but rather highlights 2 phase 
III  trials conducted by the GOG. The GOG 178/SWOG 9701 study com-
pared 3 vs 12 cycles of maintenance paclitaxel in patients with advanced 
ovarian cancer and found a progression- free survival advantage with 12 
cycles. GOG 175 included patients with early- stage ovarian cancer who 
received 3 cycles of paclitaxel and carboplatin chemotherapy and dem-
onstrated no advantage to the administration of 24 weekly cycles of 
low- dose paclitaxel maintenance therapy compared to observation. In 
both  trials,  there was greater toxicity with the longer administration of 
paclitaxel.
GOG 178/SWOG 9701 (Markman, JCO 2003)
REFERENCE
• Markman M, et al. Phase III randomized trial of 12 vs 3 months of 
maintenance paclitaxel in patients with advanced ovarian cancer  after 
complete response to platinum and paclitaxel- based chemotherapy: a 
Southwest Oncology Group and Gynecologic Oncology Group trial. J 
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• Southwest Oncology Group (SWOG)
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• Initial therapy for ovarian cancer is 5 to 6 courses of platinum/taxane 
(McGuire et al. 1996; Piccart et al. 2000).
•  There are limited randomized trial data to support the use of addi-
tional consolidation chemotherapy in ovarian cancer (Hakes et al. 
1992; Bertelsen et al. 1993; Lambert et al. 1997) or other malignancies 
(Einhorn et al. 1989, Polychemotherapy for early breast cancer . . . 
1998).
• Randomized experience suggests pos si ble utility for prolonged treat-
ment with paclitaxel in ovarian cancer (Einzig et al. 1992; Markman 
et al. 1996; Zanotti et al. 2000).
• This trial hypothesized that more prolonged treatment with paclitaxel 
in patients who responded to front- line therapy that included pacli-
taxel would benefi t from both time to disease progression and overall 
survival.
PATIENT POPULATION
• N = 277 entered trial.
• Accrual from 1997  until September 2001.
• Histologically confi rmed stage III/IV epithelial ovarian cancer, fallo-
pian tube cancer, or primary peritoneal cancer.
• Treatment with 5 to 6 cycles of platinum/paclitaxel with clinical 
complete response, defi ned as no cancer- related symptoms, normal 
physical examination, normal computed tomography (CT) scan of the 
abdomen/pelvis, normal chest x- ray, and cancer antigen 125 (CA125) 
level ≤35 U/mL.
• Optimal or suboptimal residual disease. Suboptimal was defi ned as 
residual disease ≥1 cm in dia meter  after exploratory laparotomy.
• Ineligible.
• Prior treatment on a SWOG or GOG front- line regimen where 
trial endpoint was progression- free survival (PFS) or overall sur-
vival (OS).
• Grade 2 or higher per sis tent neuropathy from prior therapy.
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• Arm 1: paclitaxel 175 mg/m2 over 3 hours  every 28 days for 3 cycles.
• Arm 2: paclitaxel 175 mg/m2 over 3 hours  every 28 days for 12 cycles.
Taxol Dose Reduction
• Dose reduction to 135 mg/m2 for
• Grade 4 neutropenia.
• Grade 3 or 4 thrombocytopenia.




• Prophylactic granulocyte colony- stimulating  factor for recurrent grade 
4 neutropenia in subsequent cycles.
Pa ram e ters to Treat
• Recovery from all toxicities to grade 1 or less.
Treatment Delay
• Maximum delay for toxicity was 2 weeks.
Treatment Discontinuation
• Per sis tent grade 4 neutropenia despite dose reduction and prophylactic 
granulocyte colony- stimulating  factor use.
• Grade 3 or higher neuropathy.
Trial Modifi cation
• In March 2001, more patients  were electing to discontinue treatment 
on the 12- cycle arm (n = 10) compared to the 3- cycle arm (n = 3) due to 
the development of grade 2 and grade 3 peripheral neuropathy.
•  Because the aim was to evaluate total treatment duration rather than 
the total dose administered, the paclitaxel dose was reduced to 135 mg/
m2 for both arms.
• First- level dose reduction for toxicity was to 100 mg/m2.
ASSESSMENTS
• All patients  were followed monthly for 1 year.
• History, physical exam, toxicity evaluation, complete blood cell count 
with differential, and serum CA125  were obtained at each visit.
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•  After 1 year, patients  were followed at regular intervals  until death.
• Disease recurrence was defi ned as appearance of a new lesion or effu-
sion, reappearance of any lesion that had dis appeared, or development 
of tumor- related symptoms.
ENDPOINTS
• PFS (mea sured from date of registration to date of fi rst recurrence or 
death) (primary endpoint).
• OS (mea sured from date of registration  until date of death).
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Prior treatment with paclitaxel for ≥24 hours vs <24 hours.
• Optimal stage III vs suboptimal stage III vs stage IV.
• Age ≤65 years vs age >65 years.
Sample Size
• Sample size estimation was based on PFS. The median PFS  after a clin-
ical complete response to induction therapy for the control arm was 
estimated to be 16 months for stage IV or suboptimal stage III disease 
and 24 months for patients with optimal stage III disease (Alberts et al. 
1996; McGuire et al. 1996; Muggia et al. 2000).
• Assuming equal numbers of patients in the 2 strata, 450 patients needed 
to be entered in the trial over 5 years. With uniform accrual, 2 addi-
tional years’ follow-up, exponential survival distribution, and a 1- sided 
log- rank test at a .05 signifi cance level,  there was approximately 85% 
power to detect a hazard ratio (HR) of 1.33 in PFS.
• With 225 patients per arm, the power to detect an absolute 15% difference 
in the incidence rate of any toxicity is at least 93% using a 1- sided .05 test.
Interim Analy sis
• Interim analy sis was planned to guard against extreme fi ndings of  either 
excessive toxicity or a substantial improvement in effi cacy.  These  were 
planned for when:
• 225 eligible patients  were entered.
• When 50% and 75% of the estimated events had been observed.
Early Termination
• The decision for early termination was to be made by the SWOG Data 
and Safety Monitoring Committee. Evidence for early termination of 
the study included:
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• The null hypothesis of no difference in PFS.
• The alternative hypothesis (that the progression hazard ratio of the 
control arm over the prolonged paclitaxel arm is 1.33 or greater) was 
rejected at the .005 level.
CONCLUSION OF TRIAL
• Twelve additional cycles of paclitaxel maintenance chemotherapy 
(135 mg/m2)  after complete response to platinum/paclitaxel chemother-
apy prolongs the duration of progression- free survival in patients with 
advanced ovarian cancer.
COMMENTS
•  Because of the early closure of this study, all patients in this report ini-
tiated treatment at the 175- mg/m2 dose level, but the protocol dose was 
reduced to 135 mg/m2 for excessive toxicity at the initial dose.







N = 134 Statistics
Patient characteristics
Median age 58.5 years 58 years
Optimal, stage III 66% 66%
Suboptimal stage III 20% 20%
Stage IV 14% 14%
Prior paclitaxel ≥24 hours 14% 13%
Prior paclitaxel <24 hours 86% 87%
Histology Not stated Not stated
Treatment delivery Not stated Not stated
Effi cacy (interim analy sis 
at 50% enrollment)




Grade 4 neutropenia 10% 4%
Grade 2 neuropathy 14% 18%
Grade 3 neuropathy 1% 5%
CI, confi dence interval; HR, hazard ratio; PFS, progression- free survival; OS, overall survival.
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• The only major difference between the 2 arms for toxicity was neu-
ropathy. The trial did not prospectively evaluate the duration of ther-
apy. Information is not available regarding symptom duration  after 
discontinuation of therapy.
• The interim analy sis at 50% enrollment was performed in September 
2001, when 54 PFS had occurred among 222 patients. The SWOG Data 
Safety and Monitoring Committee recommended study closure in Octo-
ber 2001 based on a PFS advantage of 28 months vs 21 months for 12 
cycles vs 3 cycles of paclitaxel maintenance therapy.
• Data from this trial suggest that  there is a higher hazard for disease pro-
gression  after treatment is stopped.
• The hazard ratio for progression posttreatment vs during treatment 
was 5.80 (95% confi dence interval [CI], 2.09-16.10).
• The hazard ratio for progression posttreatment vs during treatment 
when analyzed for the 12- cycle arm only was 9.17 (95% CI, 2.47-34.0).
•  These data  were generated in an exploratory analy sis adding a 
treatment- stop indicator to the Cox model, which also included treat-
ment and stratifi cation  factors. The value of the treatment- stop indi-
cator is time dependent and starts at 0 and changes to 1 at 28 days 
 after treatment is stopped. Patients with disease progression during 
therapy have a value of 0 for this indicator throughout.
• The authors discuss 4 points raised by this trial.
• First, why did the control arm receive 3 cycles of therapy rather than 
no further treatment?
• This control arm was chosen over concern that patients would not 
agree to participate in a trial where one arm received no further ther-
apy. Patients being recruited to the trial would be told:
• Approximately 75% of  women in this clinical situation would recur 
(McGuire et al. 1996; Muggia et al. 2000; Piccart et al. 2000).
• If disease recurs,  there is no evidence that any second- line regimen 
has the potential to provide cure.
• Paclitaxel is a part of the regimen that has led to a complete clinical 
response and was tolerated (other wise, they would not be a candi-
date for the trial).
•  There is evidence that paclitaxel can be given safely for extended 
periods (Markman et al. 1996).
• Extending the duration of paclitaxel administration could expose 
tumor during active cycling (Rowinsky and Donehower 1995) or pro-
vide an antiangiogenic effect with continued intermittent drug expo-
sure (Browder et al. 2000).
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•  There was further concern that a patient might choose not to partici-
pate in the trial and would instead ask her oncologist to administer 
maintenance paclitaxel as the drug was commercially available at the 
time of trial initiation.
• Next, was it appropriate to consider PFS as the primary endpoint rather 
than OS?
• The investigators designing this trial considered prolongation of PFS 
without impairment in overall quality of life would be a highly clini-
cally relevant goal, especially in a disease like ovarian cancer, where 
multiple second- line therapies affect overall survival in de pen dent of 
initial treatment (Gordon et al. 2001). Quality of life was not formally 
assessed in this trial. The authors note that the rate of neurotoxicity 
observed in this trial is within what is generally considered to be 
acceptable in clinical practice (Rowinsky and Donehower 1995; 
McGuire et al. 1996; Neijt et al. 2000). Using a lower dose of pacli-
taxel in  future studies and in clinical practice would make the issue 
of neuropathy an even lesser concern. The authors also speculate that 
the duration rather than the dose of paclitaxel resulted in the benefi -
cial impact of treatment, and reducing the dose of paclitaxel may 
result in further enhancement of the therapeutic ratio (no change in 
effi cacy and reduced toxicity). However, the current trial offers no 
data on  either the effi cacy or toxicity of any regimen starting at a 
lower dose level than 175 mg/m2.
• Next, why did the SWOG Data and Safety Monitoring Committee close 
this study prematurely, considering the negative impact this would have 
on determining an overall survival effect?
• The committee is a federally mandated review panel whose purpose 
is to in de pen dently evaluate the results of ongoing studies and to 
determine  whether a trial should be discontinued for excessive 
toxicity or for extremely favorable or unfavorable results (Smith et al. 
1997). Based on the improvement in PFS with 12 months of pacli-
taxel therapy, the study was closed to allow patients randomized to 
3 months of treatment to consider receiving additional courses of 
therapy.
• Fi nally, what are the implications of the exploratory analy sis that sug-
gests  there is an acceleration of recurrence risk shortly  after complet-
ing maintenance therapy?
• The authors suggest that this effect was not due to the inevitable risk 
of recurrence with the passage of time or from the early discontinu-
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ation of therapy (from toxicity or refusal) in patients with unrecog-
nized symptoms of early disease progression. This leads the authors 
to speculate that even longer maintenance therapy (2 or 3 years) may 
have an even greater impact. The treatment effect could be due to 
the per sis tent chemosensitivity of slowly dividing tumor cells to a 
cycle- specifi c agent or due to an antiangiogenic effect of intermittent 
drug exposure (Rowinsky and Donehower 1995; Browder et al. 2000). 
However, this approach would have to be balanced against the impacts 
of neurotoxicity, continued alopecia, and risk of secondary malig-
nancy (eg, secondary acute leukemia) (Greene et al. 1982).
• Has the standard of care been changed based on  these trial results?
• No. This trial provides no evidence of a favorable impact on overall 
survival. Entry into the trial required a complete clinical response fol-
lowing fi rst- line chemotherapy and no signifi cant preexisting periph-
eral neuropathy, which limits the generalizability of  these trial results 
to the general advanced ovarian cancer population. The decision of 
 whether to use maintenance paclitaxel should balance the favorable 
impact on progression- free survival with the risk of treatment- related 
toxicity.
GOG 175 (Mannel, Gynecol Oncol 2011)
REFERENCE
• Mannel RS, et al. A randomized phase III trial of IV carboplatin and 
paclitaxel × 3 courses followed by observation versus weekly maintenance 
low- dose paclitaxel in patients with early- stage ovarian carcinoma: a 
Gynecologic Oncology Group Study. Gynecol Oncol. 2011;122(1):89-94. 
PMID: 21529904. (Mannel et al. 2011)
TRIAL SPONSOR
• Gynecologic Oncology Group (GOG)
RATIONALE FOR TRIAL
• Consensus on the treatment of low- risk early- stage ovarian cancer.
• Patients with fully staged IA or IB disease with grade 1 or 2 non– 
clear cell histology have greater than 90% survival with surgery alone 
(Young et al. 1990).
• Consensus on treatment of high- risk early- stage ovarian cancer.
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• Patients with stage IA or IB and unfavorable histology including 
grade 3 and clear cell, stage IC, or stage II disease have a recurrence 
risk of 25% to 45% with adjuvant therapy (Young et al. 1990; Ver-
gote et al. 1992; Bolis et al. 1995; Trimbos et al. 2003a, 2003b; Young 
et al. 2003; Bell et al. 2006).
• The 2004 Gynecologic Cancer Intergroup (GCIG) Ovarian Cancer 
Consensus Conference recommended that  these patients receive at 
least 3 cycles of carboplatin chemotherapy (du Bois et al. 2005b).
• The Gynecologic Oncology Group (GOG) chose carboplatin and 
paclitaxel as the standard arm based on data from advanced disease, 
which demonstrates the superiority of cisplatin/paclitaxel over cispla-
tin/cyclophosphamide and the therapeutic equivalence of carboplatin 
to cisplatin (McGuire et al. 1996; Ozols et al. 2003; Bell et al. 2006).
• GOG 157 compared 3 vs 6 cycles of carboplatin area  under the curve 
(AUC) 6 and paclitaxel 175 mg/m2  every 3 weeks in the high- risk 
early- stage ovarian cancer population.  There was no signifi cant dif-
ference in recurrence- free or overall survival, and grade 3 and 4 neu-
rotoxicity increased from 2% to 11% with the increased courses of 
chemotherapy. This led the GOG to recommend 3 cycles of chemo-
therapy as the standard arm.
• In patients with advanced ovarian cancer, GOG 178/SWOG 9701 dem-
onstrated a signifi cant increase in progression- free survival for patients 
receiving 12 cycles of monthly maintenance paclitaxel 175 mg/m2 com-
pared to 3 cycles  after complete remission (Markman et al. 2003a).  There 
was no difference in overall survival, possibly due to crossover effect 
since the control arm received 3 cycles of maintenance therapy.
• Rationale for using a frequent low dose of paclitaxel as a maintenance 
therapy approach.
• Lower dose paclitaxel exerts an antiangiogenic effect in mouse mod-
els (Klauber et al. 1997). Extrapolation from mouse dosing and phase 
I  trials suggests that paclitaxel 40 mg/m2 weekly may have an equiva-
lent effect in  humans.
• Katsumata et al. (2009) reported a survival benefi t to weekly paclitaxel 
dosing in advanced ovarian cancer therapy.
• GOG 175 was designed to evaluate the impact of maintenance pacli-
taxel dosed at 40 mg/m2 weekly for 24 weeks in patients with high- 
risk early- stage ovarian cancer.
• Lower weekly dose could exert an antiangiogenic effect.





• Total monthly dose of 160 mg/m2 is almost 20% higher than the tol-
erable monthly dose of 135 mg/m2 in GOG 178/SWOG 9701.
PATIENT POPULATION
• N = 571 enrolled.
• Enrollment from September 1998 to December 2006.
• Epithelial ovarian cancer.
• Allowable histologies: serous, mucinous, endometrioid, clear cell, 
transitional cell, mixed epithelial, Brenner, and undifferentiated 
carcinoma.
• Completely resected early- stage high- risk ovarian cancer.
• Stage IA or IB grade 3 or clear cell subtype, any stage IC, or any 
stage II.
• Defi nitive surgical staging by GOG guidelines— included total 
abdominal hysterectomy, bilateral salpingo- oophorectomy, resection 
of all gross disease, infracolic omentectomy, selective pelvic and 
para- aortic lymph node dissection, peritoneal biopsies from the pel-
vis and bilateral paracolic gutters, biopsy or cytology from the right 
diaphragm, and aspiration of  free fl uid or abdominal washing for 
cytology.
• Entry into the trial within 6 weeks for staging surgery.
• Adequate bone marrow, renal, and liver function.
• Ineligible.
• Borderline tumors.
• Another invasive malignancy in the past 5 years.
• GOG per for mance status of 4 or more.
TREATMENT DETAILS
• All patients received 3 cycles of paclitaxel 175 mg/m2 intravenous (IV) 
over 3 hours and carboplatin AUC 6 IV  every 21 days, then:
Treatment Arms
• Arm 1: Observation.
• Arm 2: Paclitaxel 40 mg/m2 over 1 hour weekly for 24 weeks.
Carboplatin Dosing
• Calvert formula for AUC calculations.
• Creatinine clearance calculated using the method of Jelliffe.
• Dose of carboplatin was recalculated for each cycle.
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• Maximum body surface area (BSA) or 2.0.
• Standard pretreatment regimen with dexamethasone, diphenhydramine, 
and cimetidine.
• Monthly pretreatment complete blood count (CBC) and physical exam 
prior to each monthly maintenance cycle.
Treatment Modifi cations
• Applied in a sequential manner using delay, dose reduction, and addi-
tion of granulocyte colony stimulating  factor (G- CSF).
• Minimum counts for treatment: absolute neutrophil count (ANC) ≥1500 
cells/mm3 and platelets ≥100,000 cells/mm3.
• No dose modifi cations for uncomplicated nadirs.
• Dose reduction for grade 4 thrombocytopenia, febrile neutropenia, 
delay >2 weeks.
• G- CSF used for recurrent delays or neutropenic precautions  after appro-
priate dose reductions.
ASSESSMENTS
• Weekly blood counts.
• Physical exam prior to each of the initial 3 cycles.
•  After completion of chemotherapy, patients  were evaluated quarterly 
for 2 years, semi- annually for 3 years, then annually thereafter.
• Recurrence defi ned as any clinical or radiographic evidence of new 
tumor.
• CA125 elevation alone was not considered enough evidence for 
recurrence.
ENDPOINTS
• Recurrence rate (primary endpoint).




• Study was designed to provide 85% chance of detecting a true 50% 
decrease in the recurrence rate with a type I error of .05 for a 1- tail test 
(Schoenfeld 1981). The expected effect size is an increase in the 5- year 
recurrence- free proportion from 77% to 88%. The study provided 





guidelines to compensate for pos si ble early withdrawal of patients and 
loss of statistical power.
Interim Analy sis
• An interim analy sis was scheduled when at least 30 recurrences  were 
reported among the control group (3 cycles of carboplatin and pacli-
taxel) to assess for  either extreme differences or futility.
Statistical Tests
• Log- rank test was used to assess the study hypothesis that recurrence 
rates would be equivalent (Mantel 1966).
• Data  were locked in January 2010.
CONCLUSION OF TRIAL
• The addition of 24 weeks of weekly paclitaxel at 40 mg/m2 to 3 cycles 
of carboplatin and paclitaxel does not improve outcomes in patients 
with high- risk early- stage epithelial ovarian cancer but does lead to a 
signifi cant increase in toxicity (neuropathy, infection, dermatologic 
events, and possibly cardiovascular events).
COMMENTS
• Five- year survival by stage.
• Stage I: 88.8%.
• Stage II: 78.9%.
• Attrition was approximately 1% per week during maintenance pacli-
taxel therapy, with 79% of patients completing the entire 24 weeks of 
additional treatment.
• The 5- year recurrence- free survival of this trial falls within the expected 
and previously reported ranges.
• 75% to 80% with adjuvant melphalan, intraperitoneal phospho-
rous-32, cisplatin, carboplatin, and cisplatin plus cyclophosphamide 
(Young et al. 1990; Vergote et al. 1992; Bolis et al. 1995; Trimbos 
et al. 2003a, 2003b; Young et al. 2003).
• 74.6% with 3 cycles of adjuvant carboplatin and paclitaxel in GOG 
157 (Bell et al. 2006).
• 79.9% with 6 cycles of adjuvant carboplatin and paclitaxel in GOG 
157 (Bell et al. 2006).
• 76.8% with 3 cycles of adjuvant CT and observation in this trial.
• 80.0% with 3 cycles of adjuvant CT and 24 weeks of maintenance 
Taxol in this trial.





 Table 4.2  Results of GOG 175
Treatment arm
CT × 3 cycles
N = 268
CT × 3 cycles, 
T × 24 weeks
N = 274 Statistics
Patient characteristics
Median age 56.0 55.1
Stage I 72.8% 70.8%




Clear cell 30.6% 32.1%
Other 13.1% 15.7%
Grade 1 14.2% 10.2%
Grade 2 25.7% 21.9%
Grade 3 29.5% 35.8%
Clear cell (no grade) 30.6% 32.1%
Treatment delivery
Completed 3 cycles CT 97% 96%
Completed 12 weeks T NA 86%
Completed 24 weeks T NA 79%
Reason for discontinuation
Progression 0% 2.2%
Patient refusal 1.5% 9.5%
Toxicity 0.8% 6.9%
Other reason 0.8% 1.8%
Effi cacy
5- year recurrence rate 23.2% 20.4% HR 0.81 
(95% CI, 0.57-1.15)




≥ G2 neuropathy 6.0% 15.5% P < .001
G3/4 peripheral neuropathy 0.7% 4.4% P = .012
≥ G2 infection, fever 8.7% 19.9% P < .001
≥ G2 dermatologic events 52.1% 70.8% P < .001
≥ G2 cardiovascular events 3.8% 8.1% P = .04
 Secondary cancer N = 11 N = 10
CI, confi dence interval; CT, carboplatin + paclitaxel HR, hazard ratio; NA, not applicable T, paclitaxel.





• An exploratory analy sis of GOG 157 suggested that patients with serous 
histology had signifi cantly reduced risk of recurrence with 6 vs 3 cycles 
of adjuvant CT (HR, 0.33; 95% CI, 0.14-0.77) (Chan et al. 2010). Benefi t 
was not seen in the serous subtype in this study comparing maintenance 
weekly paclitaxel to observation (HR, 0.82; 95% CI, 0.44-1.54).
• The lack of benefi t demonstrated in this trial could be attributed to 
histology.
• The patient population in this trial is not representative of a popula-
tion that might be predicted to benefi t from extended paclitaxel treat-
ment. The preponderance of clear cell, mucinous, and low- grade 
tumors in this trial may have affected treatment benefi t as  these 
tumors have shown poor response to standard carboplatin and 
paclitaxel treatment in multiple  trials (Takano et al. 2007; Kurman 
and Shih Ie 2008; Yoshida et al. 2009).




Patients with recurrent epithelial ovarian cancer can be treated with a 
number of dif fer ent treatment options that are generally selected based 
on time since last platinum therapy and other patient and treatment 
regimen characteristics. Patients with platinum- resistant cancer are usu-
ally treated with single- agent chemotherapy with paclitaxel, topotecan, 
pegylated liposomal doxorubicin (PLD) (Topotecan versus Paclitaxel 
study, Doxil Study 30-49, Gemcitabine versus PLD study), or  these 
selected agents in combination with trabectadin or bevacizumab (OVA-
301, AURELIA). Patients with platinum- sensitive cancer are generally 
treated with multiagent regimens, including platinum + paclitaxel (ICON4/
AGO- OVAR2.2), carboplatin + PLD (CALYPSO), or carboplatin + gem-
citabine (AGO- OVAR, NCIG CTG, EORTC GCG trial) with or without 
bevacizumab (OCEANS).
Topotecan Versus Paclitaxel (ten Bokkel, JCO 1997)
REFERENCE
• ten Bokkel Huinick W, et al. Topotecan versus paclitaxel for the 
treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 
1997;15(6):2183-2193. PMID: 9196130. (ten Bokkel Huinink et al. 1997)
TRIAL SPONSOR
• Supported by a grant from SmithKline Beecham Phar ma ceu ti cals, Col-
legeville, PA
CHAPTER 5
Recurrent Epithelial Ovarian Cancer
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• Standard front- line therapy at this time is cyclophosphamide combined 
with a platinum analogue, but the majority of patients relapse and die 
of progressive disease (Neijt et al. 1991; Cannistra 1993; Ozols 1994; 
McGuire et al. 1996).
• In small phase II studies of patients with recurrent disease, second- line 
agents have yielded response rates ranging from 8% to 26%. Treatment 
options include:
• Hexamethylmelamine (Vergote et al. 1992).
• Ifosfamide (Baker et al. 1993).
• Etoposide (Baker et al. 1993; Hoskins and Swenerton 1994).
•  There is an urgent need to develop new treatment strategies with non- 
cross- resistant chemotherapy in recurrent ovarian cancer.
• Paclitaxel has been studied in recurrent ovarian cancer.
• Response rates range from 22% to 37% in small, nonrandomized 
studies (McGuire et al. 1989; Einzig et al. 1992; Thigpen et al. 1994).
• In a large, randomized, international study evaluating 2 dif fer ent 
doses (175 mg/m2 vs 135 mg/m2) and 2 dif fer ent dosing schedules (3 
hours vs 24 hours), responses confi rmed by in de pen dent review 
ranged from 14% to 24% (Eisenhauer et al. 1994). At the approved 
dose of 175 mg/m2 over 3 hours  every 21 days, the response rate was 
15%.
• In the front- line setting, cisplatin and paclitaxel  were found to be 
superior to cisplatin and cyclophosphamide (McGuire et al. 1996; Pic-
cart et al. 2000).
• Topotecan (Hycamtin) has been studied.
•  Water- soluble, semisynthetic analogue of camptothecin, an alkaloid 
antitumor agent isolated from the Camptotheca acuminata tree from 
South China.
• Inhibits topoisomerase I, an enzyme that binds to double- stranded 
DNA and leads to a single- strand break in front of the replication fork 
and relieves DNA torsion caused by replication.
• Topotecan and other camptothecin analogues bind to the topoisom-
erase I– DNA complex and interfere with the pro cess of DNA break-
age and resealing. This blocks the pro gress of the replication fork and 
results in DNA breaks and cell death (Hertzberg et al. 1989; Hsiang 
et al. 1989).
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• Preclinical data suggest that topotecan could be given intermittently 
over multiple days (Houghton et al. 1992).
• Three phase I studies concluded the maximum tolerated dose is 
1.5 mg/m2/d on 5 consecutive days in a 21- day cycle without the use 
of growth  factor support. The dose- limiting toxicity was myelosup-
pression (Rowinsky et al. 1992; Saltz et al. 1993; Verweij et al. 1993).
• Phase II studies demonstrate response rates ranging from 14% to 25% 
in recurrent ovarian cancer (abstract: Armstrong et al. 1995).
• This was a phase III study designed to compare the effi cacy and toxic-
ity of topotecan (1.5 mg/m2 intravenous [IV] over 30 minutes on 5 con-
secutive days  every 21 days) to paclitaxel (175 mg/m2 IV over 3 hours 
 every 21 days) in patients with recurrent ovarian cancer who progressed 
 after 1 platinum- based chemotherapy regimen.
PATIENT POPULATION
• N = 235 enrolled, 226 included in the intent- to- treat analy sis.
• Stage III/IV, histologically confi rmed epithelial ovarian carcinoma.
• Failed fi rst- line therapy with a platinum- based chemotherapy regimen.
• Mea sur able disease—at least 1 bidimensionally mea sur able lesion on 
computed tomography (CT) or magnetic resonance imaging (MRI) 
scan, ultrasound, or physical exam.
• At least 4 weeks from prior surgery, hormonal therapy, radiotherapy 
or chemotherapy, and initiation of study drug.
• Eastern Cooperative Oncology Group (ECOG) per for mance status ≤2.
• Adequate bone marrow function: white blood cells (WBC) ≥3500/μL, 
neutrophil count ≥1000/μL, and platelet count ≥100,000/μL.
• Normal liver function: bilirubin ≤2.0 mg/dL.
• Normal renal function: creatinine level ≤1.5 mg/dL or creatinine clear-
ance >60 mL/min.
• Ineligible:
• More than 1 prior chemotherapy regimen.
• Prior topotecan or paclitaxel.
TREATMENT DETAILS
Arm 1: Topotecan
• Premedications: none initially, but antiemetics could be added as 
indicated.
• Starting dose: 1.5 mg/m2 IV over 30 minutes for 5 consecutive days 
 every 21 days.
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• Dose reduction for toxicity to minimum dose of 1.0 mg/m2/d.
• Due to the limited experience with topotecan in this population, dose 
could also be escalated to 2.0 mg/m2/d.
• Treatment withdrawn for >2- week delay at the minimum dose due to 
medi cation or toxicity.
Arm 2: Paclitaxel
• Premedications: dexamethasone, H1 receptor antagonist, H2 receptor 
antagonist.
• Starting dose: 175 mg/m2 IV over 3 hours  every 21 days.
• Dose reduction for toxicity to minimum dose of 135 mg/m2.
• Treatment withdrawn for >2- week delay at the minimum dose due to 
medi cation or toxicity.
Supportive Mea sures
• To maintain dose- intensity and a 21- day treatment cycle, prophylactic 
granulocyte colony- stimulating  factor (G- CSF) could be added starting 
with second cycle of therapy (on day 6 following topotecan or on day 2 
following paclitaxel) if the patient experienced any of the following:
• Grade 4 neutropenia with fever or infection.
• Grade 4 neutropenia that lasted more than 7 days.
• Grade 3 neutropenia that required a delay in treatment.
Duration of Treatment Depended on Response
• Patients with a complete response (CR) or partial response (PR) could 
continue treatment  until progression or for 6 months past the maximum 
response.
• Patients with progression  were removed from the study.
• Patients with best response of stable disease  after 6 courses could be 
removed from the study or switched to the alternate regimen.
ASSESSMENTS
• Responses  were determined by the World Health Organ ization (WHO) 
criteria.
• All responses required in de pen dent review and confi rmation by a 
radiologist blinded to treatment regimen.
• CR was defi ned as the complete disappearance of all mea sur able and 
assessable disease on 2 separate scans at least 4 weeks apart.
• PR was defi ned as a 50% reduction in the sum of products of the per-
pendicular dia meters of all mea sur able lesions for at least 4 weeks 
and no new lesions or progression of assessable disease.
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• Progressive disease (PD) was defi ned as a 25% increase in a single 
mea sur able lesion, reappearance of mea sur able disease, worsening 
of assessable disease, or the development of a new metastatic lesion.
• Stable disease (SD) was any mea sure ment not fulfi lling the criteria 
for response or progression and lasting at least 8 weeks.
• Nonassessable disease was defi ned as nonmea sur able lesions with an 
elevated cancer antigen (CA125) tumor marker.




• Duration of response mea sured from time of initial documented 
response to fi rst sign of disease progression.
• Time to progression mea sured from time of fi rst study drug adminis-
tration to documented progression or initiation of third- line therapy.
• Time to response mea sured from time of fi rst study drug administra-
tion to initial response.
• Survival mea sured from time of fi rst study drug administration to 
death.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Age: <65 or ≥65 years.
• Ascites: pres ent or absent.
• Response to prior platinum- based therapy: resistant, early, interim, or 
late relapse (van der Burg et al. 1991; Markman et al. 1992).
• Resistant disease defi ned as not having response to initial chemother-
apy or having an initial PR or CR and then progressing while still on 
therapy.
• Early relapse defi ned as CR or PR and relapse within 3 months.
• Interim relapse defi ned as CR or PR and relapse within 3 to 6 months.
• Late relapse defi ned as CR or PR and relapse more than 6 months 
 after chemotherapy. This group is recognized as potentially platinum 
sensitive and responsive to re introduction of platinum therapy.
Statistical Tests
• Kaplan- Meier estimates  were obtained for each effi cacy end point and 
presented in life- table format over 4- week intervals.










N = 114 Statistics
Patient characteristics
Median age (range) 59.2 (29-85) 58.3 (29-79)










<5 cm 48.2% 46.5%






Grade 1 5.0% 7.0%
Grade 2 20.5% 25.4%
Grade 3 50.0% 43.9%
Grade 4 8.9% 10.5%
Unknown grade 15.2% 13.2%
Treatment delivery
Target dose maintained 90% 98%
Median dose intensity 2.3 mg/m2/wk 56.3 mg/m2/wk
Treatment on schedule 77% 92%
Delays beyond 7 days 5% 3%
Effi cacy
Overall response rate 20.5% 13.2% NS
CR 4.5% 2.6%
PR 16.1% 10.5%
Duration of response 32.1 weeks 19.7 weeks RR 0.42, NS
Time to progression 23.1 weeks 14.0 weeks RR 0.58, P = .002
Time to response 9 weeks 6 weeks RR 0.48, P = .041
Median OS 61 weeks 43 weeks RR 1.21, NS
(continued)
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N = 114 Statistics
Toxicity
Greater with topotecan
G4 neutropenia 79% 23% P < .01
G4 thrombocytopenia 25% 2% P < .01
G4 anemia 4% 3% NS
Infection 15% 4%
Sepsis 5% 2%
G- CSF prophylaxis 23% 3%
G- CSF treatment 7% 1%
Platelet transfusions 3% 0%








 Neuropathy 0.9% 15.8%
CR, complete response; G- CSF, granulocyte colony- stimulating  factor; NS, not signifi cant; OS, overall 
survival; PR, partial response; RR, relative risk.
(continued)
• Cox regression was used to compare time- to- event outcomes.
• A model that included treatment and the 3 stratifi cation covariates was 
used to compare treatment effects.
• Hazards ratios (HRs) with 95% confi dence intervals (CIs)  were reported.
CONCLUSION OF TRIAL
• Compared to paclitaxel, topotecan has a higher response rate and longer 
time to progression in patients with recurrent epithelial ovarian cancer.
COMMENTS
• Choice of paclitaxel as the comparison arm was based on prior studies 
suggesting response rates of 22% to 37% with paclitaxel in patients 
who had not responded to fi rst- line platinum (McGuire et al. 1989; 
Einzig et al. 1992; Thigpen et al. 1994). The regimen of 175 mg/m2 
over 3 hours was chosen due to ease of administration, less toxicity, 
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and no other regimen with proven greater efficacy (Eisenhauer 
et al. 1994).
• Topotecan toxicities:
• 79% had grade 4 neutropenia.
• 25% had grade 4 thrombocytopenia.
• Hematologic toxicity was short duration and noncumulative (lack of 
progressively lower hematologic nadirs on subsequent rounds of 
therapy).
• Dose reductions and use of G- CSF resulted in effective prevention 
of signifi cant clinical sequelae from hematologic toxicities.
• Only 5.4% had grade 3 diarrhea and no one had grade 4 diarrhea. 
Incidence of diarrhea is lower with topotecan compared to other 
topoisomerase I inhibitors.
•  There  were no dose- limiting nonhematologic toxicities in this study.
• Topotecan appears to be at least as active as paclitaxel in this paclitaxel- 
naïve population, but paclitaxel is better tolerated.
Doxil Study 30-49 (Gordon, JCO 2001; Gordon, 
Gyn Onc 2004)
REFERENCES
• Gordon AN, et al. Recurrent epithelial ovarian carcinoma: a randomized 
phase III study of pegylated liposomal doxorubicin versus topotecan. 
J Clin Oncol. 2001;19(14):3312-3322. PMID: 11454878. (Gordon et al. 
2001)
• Gordon AN, et al. Long- term survival advantage for  women treated 
with pegylated liposomal doxorubicin compared with topotecan in a 
phase 3 randomized study of recurrent and refractory epithelial ovar-
ian cancer. Gynecol Oncol. 2004;95(1):1-8. PMID: 15385103. (Gordon 
et al. 2004)
TRIAL SPONSOR
• ALZA Corp, Mountain View, CA
RATIONALE FOR TRIAL
• Patients with recurrent ovarian cancer are treated with the goals of 
palliation and optimization of quality of life as the probability of cure 
is remote.
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• Treatment options that lack cross- resistance to front- line therapies of 
platinum and paclitaxel (McGuire et al. 1996) are needed for recurrent 
or refractory disease.
• Options include topotecan, oral etoposide, and gemcitabine (Shapiro 
et al. 1996; Bookman et al. 1998; Rose et al. 1998a).
• At the time of this trial, topotecan is the only approved agent for 
recurrent ovarian cancer. Topotecan has response rates that range 
from 13% to 33% depending on platinum sensitivity (Kudelka et al. 
1996; Swisher et al. 1997; Bookman et al. 1998; McGuire et al. 2000).
• Pegylated liposomal doxorubicin (PLD).
• Received Food and Drug Administration (FDA) approval in June 
1999 for use on patients with disease refractory to paclitaxel and 
platinum- based chemotherapy.
• Encapsulation of doxorubicin in pegylated liposomes decreases the 
toxicities attributed to high peak levels of doxorubicin (nausea, vom-
iting, cardiotoxicity) (Gordon et al. 2000), alters the pharmacokinetic 
profi le of doxorubicin, and enhances the therapeutic benefi t.
• Compared to doxorubicin, PLD has a smaller volume of distribution, 
a larger area  under the curve (AUC), slower clearance, and longer 
elimination half- life of approximately 55 hours (Greene et al. 1983; 
Eksborg et al. 1986).
• Pegylated liposomes are small (approximately 100 nm in dia meter), 
which allows them to pass through endothelial gaps and leaky mem-
branes in tumors (Jain 1987; Dvorak et al. 1988).
• A phase II study using PLD in patients with platinum- resistant and 
refractory ovarian cancers demonstrated overall response rates 
of 16.9% and 18.3% in the overall and refractory populations with 
median times to progression of 19.3 weeks and 17 weeks, respectively. 
Toxicities included stomatitis, palmar- plantar erythrodysesthesia 
(PPE), and skin lesions and  were easily managed with dosing modi-
fi cations (Gordon et al. 2000).
• Given the promising results of PLD in phase I/II studies, this trial was 
performed to compare PLD to topotecan in patients with recurrent epi-
thelial ovarian cancer.
PATIENT POPULATION
• N = 481 randomized, 474 at least partially treated.
• Enrollment from May 1997 to March 1999 from 104 sites in the United 
States and Eu rope.
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• Age ≥18 years.
• Mea sur able or mea sur able and assessable disease.
• Mea sur able defi ned as bidimensionally mea sur able lesion(s) by plain 
x- ray with at least 1 dia meter ≥0.5 cm or by CT, MRI, or other imag-
ing scan with both dia meters ≥2 cm.
• Assessable diseased defi ned as unidimensionally mea sur able lesion(s), 
mass(es) with margins not clearly defi ned, lesion(s) with both dia-
meters ≤0.5 cm, lesion(s) with dia meter smaller than the distance 
between cuts, palpable lesion(s) with  either dia meter ≤2 cm, malignant 
ascites, or pleural effusion with CA125 ≥100 U/mL in the absence of 
cirrhosis.
• Recurrence  after fi rst- line platinum- based chemotherapy.
• Adequate bone marrow function (platelets ≥100,000/mm3, hemoglobin 
≥9 g/dL, absolute neutrophil count ≥1500 cells/mm3).
• Adequate renal function (serum creatinine ≤2.5 mg/dL).
• Adequate liver function (aspartate aminotransferase [AST] ≤2 times the 
upper limit of normal, alkaline phosphatase ≤2 times the upper limit 
of normal, bilirubin equal to or greater than the upper limit of normal).
• Adequate cardiac function (left ventricular ejection fraction [LVEF] 
≥50% or the institutional normal).
• Karnofsky per for mance status ≥60%.
• Disease- free period of >5 years from prior malignancies (excluding 
curatively treated basal cell carcinoma, squamous cell carcinoma of the 
skin, carcinoma in situ of the cervix).
Exclusion Criteria
• Pregnant or breastfeeding.
• Life expectancy of ≤3 months.
• Prior radiation therapy to greater than one- third of hematopoietic sites.
• History of cardiac disease that met the criteria for class 2 or higher by 
the New York State Heart Association Classifi cation system.
• Uncontrolled systemic infection.
• Receipt of investigational agent within 30 days of fi rst dose of study drug.
• Prior PLD or topotecan therapy.
• Receipt of chemotherapy within 29 days of fi rst dose of study drug (or 
within 42 days for nitrosurea or mitomycin).
• Concurrent use of investigational or antineoplastic agents during the study.
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Arm 1: Pegylated Liposomal Doxorubicin (PLD).
• 50 mg/m2 IV over 1 hour  every 28 days.
• Dose modifi cations for PPE, hematologic toxicity, elevated bilirubin, or 
stomatitis (Gordon et al. 2000).
• Dose reduced by 25% for all other grade 3 and 4 events  until resolu-
tion to grade 2 or lower.
• Prophylactic cytokine administration not recommended during fi rst 
cycle of drug but allowed in subsequent cycles for any grade 4 neutro-
penia >7 days or failure of absolute neutrophil count (ANC) to recover 
within 22 days or febrile neutropenia.
• Treatment continued for up to 1 year in the absence of disease progres-
sion or evidence for sustained clinical benefi t.
• Patients who completed 6 months of PLD  were considered to have com-
pleted the protocol.
Arm 2: Topotecan
• 1.5 mg/m2/d IV over 30 minutes daily on days 1 to 5  every 21 days.
• G- CSF could be administered from day 6 at the discretion of the 
treating physician for severe neutropenia. Prophylactic cytokine admin-
istration not recommended during fi rst cycle of drug but allowed in 
subsequent cycles for any grade 4 neutropenia >7 days or failure of ANC 
to recover within 22 days or febrile neutropenia.
• For severe neutropenia during a cycle, dose was reduced by 0.25 mg/
m2 for subsequent courses.
• For moderate renal impairment (creatinine clearance 20-39 mL/min), 
dose reduction to 0.75 mg/m2 recommended. No dose adjustment needed 
for mild renal impairment (creatinine clearance 40-60 mL/min).
• Treatment continued for up to 1 year in the absence of disease progres-
sion or evidence for sustained clinical benefi t.




• Serious or intolerable adverse events precluding further treatment.
• Inability to tolerate study drug despite dose modifi cation.
• LVEF <45% or a 20% decrease from baseline.
• Patient’s decision to withdraw from participation.
• Need for radiation treatment.
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• Radiographic imaging (chest x- ray, CT, or MRI) at baseline and  every 
8 weeks.
• Response based on objective tumor mea sure ments.
• CR defi ned as complete disappearance of all mea sur able and assess-
able disease, no new lesions, and no disease- related symptoms. CR 
confi rmed at least 4 weeks  later by imaging to confi rm the response.
• PR documented in patients with ≥50% decrease in sum of the prod-
ucts of bidimensional perpendicular dia meters of all mea sur able 
lesions; no progression of assessable disease and no new lesions. PR 
confi rmed at least 4 weeks  later by imaging to confi rm the response.
• PD in patients with ≥50% increase in the sum of bidimensionally 
mea sured lesions over the smallest sum obtained at best response; 
reappearance of any lesion that had dis appeared; clear worsening 
of any assessable disease; failure to return for evaluation  because 
of death or deteriorating condition; appearance of any new lesion or 
site.
• SD in any patient that did not meet criteria for CR, PR, or PD.
• LVEF by multiple gated acquisition scan or echocardiogram at base-
line and 4 weeks  after the last dose of study drug for all patients;  after 
 every 2 cycles of PLD  after cumulative dose >300 mg/m2.
• Physical examination, chemistries, and CA125 at baseline and before 
 every cycle.
• Complete blood count performed weekly.
• Toxicity assessed by the National Cancer Institute Common Toxicity 
Criteria (grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, 
life- threatening).
• Quality of life assessed by the Eu ro pean Organ ization for Research and 
Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ- 
C30) (Aaronson et al. 1993) at baseline, during  every cycle, and 4 weeks 
 after the last treatment dose.
• Includes 6 domains (physical functioning, role functioning, cogni-
tive functioning, emotional functional, social functioning, and global 
quality of life) and 8 symptoms scales (fatigue, pain, nausea/vomiting, 
dyspnea, insomnia, appetite loss, constipation, diarrhea).
• Twelve weeks was the fi rst study time point when quality of life 
(QOL) could be assessed at the same time for the 2 groups. Less than 
50% of patients  were completing questionnaires by this time point 
(approximately 100 patients in each arm available for assessment). 
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The main reasons for discontinuation  were disease progression and 
death.
ENDPOINTS
• Time to progression (primary endpoint).
• Overall survival.
• Response rate.
• Time to response.
• Duration of response.
• Safety and toxicity.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Platinum sensitivity.
• Presence or absence of bulky disease (defi ned as tumor mass >5 cm).
Sample Size
• In total, 350 patients allowed 80% probability that the 95% 1- sided con-
fi dence limit of the hazard ratio of topotecan to PLD would not fall 
below 0.757 (80% power to demonstrate statistical equivalence between 
the 2 groups). Based on 2 additional mitigating  factors, the trial was 
designed to enroll 460 patients, depending on the accessibility rate.
• Two interim analyses  were planned, requiring enrollment of approxi-
mately 5% more patients.
• It was anticipated that 20% of patients might not be assessable for effi -
cacy endpoints.
Statistical Tests
• Cochran- Mantel- Haenszel test used to compare baseline differences for 
categorical data, adjusting for platinum sensitivity and bulky disease.
• Three- way analy sis of variance was used to compare continuous vari-
ables with effects for treatment, platinum sensitivity, bulky disease, and 
all 2- way interactions involving the treatment group.
• Kaplan- Meier method used to estimate PFS and OS rates.
• Stratifi ed log- rank test used to compare survival between treatment arms.
• Cochran- Mantel- Haenszel use to compare response rates, stratifi ed by 
platinum sensitivity and bulky disease.
• Quality- adjusted time without symptoms and toxicity used to evaluate 
the impact of treatment on both length and quality of life (Gelber et al. 
1995).










N = 235 Statistics
Patient characteristics
Median age (range) 60 (27-87) 60 (25-85)






Initial stage 5% 6%
Stage I 5% 3%
Stage II 73% 70%
Stage III 17% 20%
Stage IV
Histology Not reported Not reported
Grade Not reported Not reported
Sum of lesions (cm3), median (range) 20 (1-441) 20 (1-296)
Platinum sensitive 46% 47%
Platinum refractory 54% 53%
Bulky disease pres ent 46% 47%
Bulky disease absent 54% 53%
Prior platinum/taxane 74% 72%
Treatment delivery
Total number of dosing cycles 1164 1349
Cumulative dose, mg/m2 200 (47-1301) 36 (3-165)
Mean cycle dose, mg/m2 50 (34-58) 7 (3-10)
Mean cycle length, days 30 (27-56) 24 (20-38)
Effi cacy
2001 publication
CR + PR 19.7% 17.0% NS
SD 32.2% 40.4% NS
Median PFS 16.1 weeks 17.0 weeks NS
Platinum sensitive 28.9 weeks 23.3 weeks P = .037
Platinum resistant 9.1 weeks 13.6 weeks NS
Median OS 60 weeks 56.7 weeks NS
Platinum sensitive 108.0 weeks 71.1 weeks P = .008
Platinum resistant 35.6 weeks 41.3 weeks NS
2004 publication
Median OS 62.7 weeks 59.7 weeks HR 1.21 (95% 
CI, 1.00-1.48)
Platinum sensitive 107.9 weeks 70.1 weeks HR 1.43 (95% 
CI, 1.07-1.92)
(continued)
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• PLD has comparable effi cacy, a favorable safety profi le, and con ve nient 
dosing, which supports its role as a treatment option in patients with 
recurrent ovarian cancer. Long- term follow-up demonstrates a survival 
benefi t to PLD compared to topotecan, which is most pronounced 
among patients with platinum- sensitive recurrent disease.
COMMENTS FROM 2001 STUDY
•  There was no evidence of a relationship between cumulative PLD dose 
and change in LVEF.
• Sixty- one patients received cumulative dose >300 mg/m2 PLD.
• Three of 61 had ≥20% decrease in LVEF.
• Three of 61 had postbaseline LVEF <45% (2 started study with LVEF 
<45%).
• No patients had clinical signs or symptoms of congestive heart failure.
• Fourteen patients received cumulative dose >450 mg/m2 PLD.





N = 235 Statistics




Any grade PPE 49% 1% P < .001
Any grade stomatitis 40% 15% P < .001
Worse with topotecan
G3/4 neutropenia 12% 77% P < .001
G3/4 anemia 5% 28% P < .001
G3/4 thrombocytopenia 1% 34% P < .001
G3/4 leukopenia 10% 50% P < .001
Alopecia 16% 49% P = .007
G- CSF 4.6% 29.1%
Erythropoietin 6.3% 23.1%
Blood transfusions 14.9% 57.8%
Dosing modifi cations 57.3% 78.3%
Sepsis N = 0 N = 9 (3.8%)
Treatment- related deaths N = 0 N = 3
CI, confi dence interval; CR, complete response; G- CSF, granulocyte colony- stimulating  factor; HR, 
hazard ratio; NS, not signifi cant; OS, overall survival; PFS, progression- free survival; PLD, pegylated 
liposomal doxorubicin; PPE, palmar- plantar erythrodysesthesia; PR, partial response; SD, stable disease.
(continued)
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• At 12 weeks,  there  were no differences in quality of life between the 2 
groups.
• Treatment options for recurrent ovarian cancer are limited and response 
rates are modest.
• Intravenous chemotherapy.
• Ifosfamide: 20% (Sutton et al. 1989).
• Hexamethylmelamine: 14% (Vergote et al. 1992).
• Oral etoposide: 26% (Hoskins and Swenerton 1994).
• Gemcitabine: 19% (Lund et al. 1994; Friedlander et al. 1998).
• Vinorelbine: 20% (Bajetta et al. 1996).
• Intraperitoneal chemotherapy.
• Hormonal therapy.
• Secondary cytoreductive surgery.
• Radiotherapy.
• High- dose chemotherapy with stem cell support.
• In the recurrent setting, combination chemotherapy has not proven to 
be more effective but is associated with higher toxicity. Median sur-
vival times are limited, ranging from 6 to 16 months (Bajetta et al. 1996; 
ten Bokkel Huinink et al. 1997; Bookman et al. 1998). Palliation and 
quality of life are impor tant priorities in this setting.
• Overall, PFS and OS  were similar between the 2 groups, but in sub-
group analy sis, PLD was superior to topotecan in PFS and OS among 
platinum- sensitive patients.
• Data on subsequent therapies  were not collected, but topotecan 
was commercially available at the time while PLD was not yet 
approved.
• PLD was associated with less marrow toxicity and may have allowed 
more subsequent doses of marrow- toxic drugs.
• PLD may prevent the development of multidrug re sis tance (Oudard 
et al. 1991; Thierry et al. 1992).
• Topotecan administration was associated with more grade 4 hemato-
logic toxicities, including fatal toxicities. Grade 4 neutropenia has been 
observed in 79% to 94% of patients treated with topotecan in other  trials 
(Swisher et al. 1997; ten Bokkel Huinink et al. 1997; Bookman et al. 
1998).
• PLD was generally well tolerated in this trial.
• The most common treatment- related adverse events  were stomatitis 
and PPE.
• Only 5.3% of dose modifi cations  were due to stomatitis.
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• PPE is a cutaneous reaction typically involving the palms of the hands 
and  soles of the feet.
• PPE typically begins with a 3- to 5- day period of paresthesias fol-
lowed by edema and erythema and possibly with severe pain and 
cracking of the skin.
• Discontinuation of therapy results in desquamation followed by reep-
ithelialization of the affected areas.
• PPE can be prevented and managed by early recognition and dose 
modifi cation (decreasing the dose or lengthening the dosing interval) 
(Uziely et al. 1995; Lopez et al. 1999; Gordon et al. 2000).
• Topical dimethyl sulfoxide or pyridoxine have been used to manage 
PPE (Vail et al. 1998; Lopez et al. 1999), although  there is no defi ni-
tive evidence that pharmacologic therapy is effective.
• PPE typically develops 1 to 3 weeks  after repeated dosing of PLD 
(Gabizon and Muggia 1997).
• The long half- life and small liposomes of PLD are theorized to 
result in accumulation of the drug in the skin (Gabizon and Mug-
gia 1997).
• The primary approach to preventing PPE includes observation for 
early signs.
• The tolerability of PLD makes it a good candidate treatment for long- 
term use.
• The lack of hematologic toxicity makes PLD a candidate for combined 
treatment with other agents.
• PLD is dosed less frequently than other drugs, which makes it more 
con ve nient for administration.
• PLD has a favorable safety profi le and overall comparable effi cacy, 
making it a good candidate treatment for patients who have progressed 
 after front- line platinum- containing chemotherapy.
COMMENTS FROM 2004 STUDY
• Comparison of this study to ICON4 (Parmar et al. 2003).
• In patients with platinum- sensitive disease, median OS was 107.9 
weeks with PLD in this study compared to 116 weeks (29 months) 
with combination platinum/taxane in ICON4.
• In ICON4, approximately 40% of patients received prior taxane ther-
apy. In this study, 73% of patients received prior taxane.
• In ICON4, almost 75% of patients had a platinum- free interval of 
>12 months, compared to 23% of patients in this study. The probability 
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of response increases with increasing treatment- free intervals (Gore 
et al. 1990; Markman et al. 1991).
• Results of this analy sis as well as the con ve nience in administration 
(1- hour infusion  every 28 days) and the safety profi le suggest that PLD 
is the treatment of choice among nonplatinum agents for patients with 
recurrent ovarian cancer, particularly in  those with platinum- sensitive 
disease.
ICON4/AGO- OVAR 2.2 (Parmar, Lancet 2003)
REFERENCE
• Parmar MK, et al. Paclitaxel plus platinum- based chemotherapy ver-
sus conventional platinum- based chemotherapy in  women with relapsed 
ovarian cancer: the ICON4/AGO- OVAR-2.2 trial. Lancet. 2003;361 
(9375):2099-106. PMID: 12826431. (Parmar et al. 2003)
TRIAL SPONSORS
• ICON4 was coordinated by the Instituto Mario Negri, Milan, Italy 
(IRFMN) and the Medical Research Council’s Clinical  Trials Unit, 
London, UK (MRC CTU)
• Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe 
Ovarialkarzinom (AGO- OVAR) 2.2 was coordinated by AGO, Karl-
sruhe, Germany
RATIONALE FOR TRIAL
• At the time of ovarian cancer relapse, the probability of response to 
retreatment is based on the platinum- free interval (Markman et al. 
1991).
• Patients with platinum- sensitive disease (relapse >6 months from last 
platinum therapy) would generally be retreated with another platinum 
agent.
• Patients with platinum- resistant disease (relapse <6 months from last 
platinum therapy) rarely respond to further platinum therapy and 
would be treated with an alternative agent such as paclitaxel.
• It is not known  whether the addition of paclitaxel to platinum therapy 
for platinum- sensitive relapse would improve outcomes. Paclitaxel has 
a dif fer ent mode of action from platinum drugs. In observational stud-
ies, the combination has been reported to have response rates of up to 
90% (Rose et al. 1998b; Dizon et al. 2002).
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• This trial is a randomized controlled trial to evaluate the effi cacy of 
paclitaxel plus platinum versus platinum alone in patients with platinum- 
sensitive relapsed ovarian cancer.
PATIENT POPULATION
• N = 802.
• Enrolled between January 1996 and March 2002 from 119 hospitals in 
5 countries to 1 of 3 protocols, each of which had slightly dif fer ent eli-
gibility criteria.
• One trial coordinated by the MRC CTU for hospitals in the United 
Kingdom, Norway, and Switzerland.
• Allowed to have more than 1 line of prior chemotherapy, which 
included platinum plus or minus paclitaxel.
• Mea sur able disease was not required.
• Diagnosis of relapsed disease could be based on CA125 elevation 
alone.
• One trial coordinated by the IRFMN in Italy.
• Only 1 prior line of chemotherapy, which was platinum plus or minus 
paclitaxel.
• Mea sur able disease was required.
• One trial coordinated by the AGO.
• Only 1 prior line of chemotherapy, which must have been cisplatin 
plus paclitaxel or carboplatin plus paclitaxel.
• Mea sur able disease was not required.
• Epithelial ovarian cancer requiring chemotherapy.
• Previously received platinum- based chemotherapy with relapse more 
than 6 months from last platinum (>12 months for the Italian ICON4 
group).
• No concomitant or prior malignant disease likely to interfere with treat-
ment or outcomes.
TREATMENT DETAILS
Arm 1: Conventional Platinum- Based Chemotherapy
• Carboplatin.
• Dose based on area  under the curve (AUC) method of Calvert (Cal-
vert et al. 1989) with a minimum of 5 (glomerular fi ltration rate 
[GFR] + 25). GFR was determined by a radioisotope method or 24- 
hour urine collection.
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• If GFR was assessed by the Cockcroft formula, the dose was a mini-
mum of 6 (GFR + 25).
• Cisplatin.
• Minimum dose of 75 mg/m2 if given as single agent.
• Minimum dose of 50 mg/m2 if given in combination with other agents.
• Protocol treatments included carboplatin, CAP (cyclophosphamide, 
Adriamycin, cisplatin), carboplatin + cisplatin, cisplatin + doxorubicin, 
cisplatin alone, and carboplatin + nontaxane.
Arm 2: Paclitaxel + Platinum
• ICON4 protocol: paclitaxel 175 mg/m2 IV over 3 hours followed by 
carboplatin or cisplatin as dosed above.
• AGO protocol: paclitaxel 185 mg/m2 IV over 3 hours followed by car-
boplatin or cisplatin as dosed above.
• Protocol treatments included paclitaxel + carboplatin, paclitaxel + cispl-
atin, paclitaxel + carboplatin + cisplatin, and paclitaxel alone.
ASSESSMENTS BASED ON PROTOCOL
• MRC protocol (ICON4)— assigned at least 6 cycles.
• IRFMN protocol (ICON4)— assigned at least 3 cycles, further 3 cycles 
based on results of response assessment.
• AGO protocol— assigned 6 to 8 cycles with response assessments done 
 after second and fourth cycles.
• Quality of life collected for MRC and AGO protocols on slightly dif-
fer ent schedules.
ENDPOINTS
• Overall survival (primary endpoint).
• Progression- free survival.
• Elevated CA125 in the absence of radiologic evidence of disease was 
not considered progression.
• Quality of life.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Stratifi cation for ICON4 protocol included center, age, last chemother-
apy received, time since completion of last chemotherapy, and intended 
platinum treatment. Platinum treatment had to be specifi ed before 
randomization.
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• Stratifi cation for the AGO protocol included time since completion of 
last chemotherapy and  whether the patient underwent secondary deb-
ulking surgery.
Sample Size
• Original was based on the assumption that the 2- year survival would 
be around 5% for the control group and would increase by 5% to 10% 
in the experimental group. Accrual target of 800 patients was set to 
detect this difference with 95% power at the 5% signifi cance level, cor-
responding to a hazard ratio of 0.77.
• In 2001, the data monitoring and ethics committee noted the 2- year sur-
vival in the control group was much higher than originally predicted 
at approximately 50%. In the revised calculation, accrual of 800 patients 
would allow detection of an 11% difference in 2- year survival (from 
50% to 61%) with 90% power at the 5% signifi cance level, correspond-
ing to a hazard ratio of 0.71.
Statistical Tests
• Kaplan- Meier curves for overall and progression- free survival.
• Mantel- Cox log rank test to compare survival.
• χ2 to test for differences in effect size in dif fer ent subgroups.
• Mann- Whitney nonparametric test used to compare quality- of- life mea-
sures: worst score and area  under the curve for the fi rst 6 months.
CONCLUSION OF TRIAL
• Paclitaxel plus platinum chemotherapy improves survival and 
progression- free survival in patients with platinum- sensitive recurrent 
ovarian cancer compared to conventional platinum- based chemother-
apy alone. The benefi t is seen even in the subset of patients who received 
prior front- line treatment with paclitaxel and platinum.
COMMENTS
•  There was no evidence that the effect of combination treatment was 
any dif fer ent in the subgroup of patients that had received prior pacli-
taxel + platinum (about 40% of the population).
• Differences in subsequent treatment at the time of progression: 31% in 
the conventional treatment arm received paclitaxel; 8% in the pacli-
taxel + platinum arm received further taxane- based treatment.
• Myelosuppression was greater in the conventional platinum chemother-
apy arm, supporting prior reports suggesting a myeloprotective effect 
of paclitaxel (van Warmerdam et al. 1997).










N = 392 Statistics
Patient characteristics
Median age 59.2 60.0
Time from prior chemotherapy
6-12 months  27% 23%
≥12 months 73% 77%
No. of prior chemotherapies
1 93% 90%
2 6% 6%






Other platinum 10% 11%




Stage Not stated Not stated
Histology Not stated Not stated
Treatment delivery
Received ≥6 cycles 66% 79%
Received <6 cycles 30% 19%
Effi cacy
2- year OS 50% 57%
Median OS 24 months 29 months HR 0.82 (95% CI, 0.69-0.97)
1- year PFS 40% 50%
Median PFS 9 months 12 months HR 0.76 (95% CI, 0.66, 0.89)




G2-4 nausea/vomiting 40% 35%
Worse with combo





 G2-3 mucositis 6% 7%
CAP, cyclophosphamide + Adriamycin/doxorubicin + cisplatin; CI, confi dence interval; CR, complete 
response; HR, hazard ratio; PFS, progression- free survival; PR, partial response; OS, overall survival.
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AGO- OVAR, NCIC CTG, EORTC GCG Trial 
(Pfi sterer, JCO 2006)
REFERENCE
• Pfi sterer J, et al. Gemcitabine plus carboplatin compared with carbo-
platin in patients with platinum- sensitive recurrent ovarian cancer: an 
intergroup trial of the AGO- OVAR, the NCIC CTG, and the EORTC 
GCG. J Clin Oncol. 2006;24(29):4699-4707. PMID: 16966687. (Pfi s-
terer et al. 2006a)
TRIAL SPONSOR
• Gynecologic Cancer Intergroup
• AGO- OVAR
• National Cancer Institute of Canada Clinical  Trials Group
• Eu ro pean Organisation for Research and Treatment of Cancer 
(EORTC) Gynecologic Cancer Group
RATIONALE FOR TRIAL
• The majority of patients with ovarian cancer relapse and die within 
5 years. Patients with recurrence are classifi ed as having platinum- 
sensitive or platinum- resistant disease based on the time interval from 
last therapy to recurrence (Gore et al. 1990; Markman et al. 1991).
• For patients with platinum- sensitive disease, standard therapy is retreat-
ment with a single- agent platinum compound, and carboplatin is the 
drug of choice due to its favorable therapeutic profi le.
• The ICON4/AGO- OVAR2.2 was a pooled analy sis of 3 randomized 
controlled  trials that demonstrated that retreatment with platinum and 
taxane results in superior PFS and OS compared to treatment with 
platinum alone in patients with platinum- sensitive recurrent ovarian 
cancer (Parmar et al. 2003). Global quality of life did not differ 
between the arms, but 20% of patients treated with platinum/taxane 
experienced grade 2 to 4 neurotoxicity compared to 1% of patients 
receiving platinum alone. This may underestimate the true incidence 
of neurotoxicity as many patients had not received taxane in the fi rst- 
line setting. The OVAR2.2 portion of the study had been discontinued 
early due to concern that retreatment with paclitaxel would lead 
to excessive neuropathy. A large proportion of potentially eligible 
patients could not be entered due to persisting neurotoxicity from fi rst- 
line therapy.
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• In the AGO- OVAR study evaluating fi rst- line cisplatin/paclitaxel vs 
carboplatin/paclitaxel, 83% and 75% of patients developed grade 1 to 
4 neurotoxicity that slowly resolved (du Bois et al. 2003). However, 20% 
of patients continued to have per sis tent neuropathy for 2 or more years.
•  These data underscore the need for an alternative platinum- based com-
bination with less risk of neuropathy.
• Gemcitabine is a nucleoside analogue that has single- agent activity in 
phase II studies of recurrent ovarian cancer, including in patients who 
have received prior platinum and/or taxane (Lund et al. 1994; Lund and 
Neijt 1996; Shapiro et al. 1996).
• The AGO- OVAR group conducted a phase I/II study of carboplatin 
plus gemcitabine in patients with platinum- sensitive recurrent ovarian 
cancer to identify recommended doses. This trial demonstrated a high 
response rate of 62.5% and acceptable toxicity (du Bois et al. 2001).
• This trial is a phase III investigation comparing the effi cacy of carbo-
platin and gemcitabine against carboplatin alone in patients with 
platinum- sensitive recurrent ovarian cancer.
PATIENT POPULATION
• N = 366 enrolled.
• Enrolled between September 1999 and April 2002.
• Recurrent ovarian cancer at least 6 months from completion of fi rst- 
line platinum- based chemotherapy.
• Mea sur able or assessable lesions per Southwest Oncology Group cri-
teria (Green and Weiss 1992).
• ECOG per for mance status of 0, 1, or 2.
• Adequate bone marrow reserve and renal function.
• ANC ≥1500/μL.
• Platelets ≥100,000/μL.
• Estimated glomerular fi ltration rate >50 mL/min.
• No serious concomitant systemic disorders incompatible with the study.
• Estimated life expectancy of 12 weeks or longer.
TREATMENT DETAILS
Arm 1: Standard Chemotherapy
• Carboplatin AUC 5 mg/mL/min IV on day 1.
Arm 2: Experimental Chemotherapy
• Gemcitabine plus carboplatin (du Bois et al. 2001).
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• Gemcitabine 1000 mg/m2 IV on days 1 and 8.
• Carboplatin AUC 4 mg/mL/min IV on day 1.
Dosing Details
• Carboplatin dosed by Calvert formula (Calvert et al. 1989). AUC cal-
culation was based on GFR calculation based on the formula of Jel-
liffe (Jelliffe 1973).
• Patients received treatment  every 21 days for 6 cycles with the option 
to receive a maximum of 10 cycles at the investigator’s discretion. 
Treatment was discontinued for progressive disease or unacceptable 
toxicity.
Dose Modifi cations
• Treatment could be postponed for a maximum of 2 weeks for toxicity, 
including ANC ≤1500/μL and platelets ≤100,000/μL. Longer toxicity- 
related delays resulted in treatment discontinuation.
• For ANC 1000 to 1500/μL or platelets 75,000 to 100,000/μL, gem-
citabine day 8 reduced 50%.
• For ANC ≤1000/μL or platelets ≤75,000/μL, gemcitabine day 8 omitted.
• For G3 nonhematologic toxicities (excluding nausea and vomiting), 
dose modifi cations or study discontinuation  were at the investigator’s 
discretion.
• For toxicity- related treatment delays of >1 week, ANC 500/μL for more 
than 5 days or ANC <100/μL for more than 3 days, febrile neutropenia, 
platelets <25,000/μL, and grade 3 or 4 nonhematologic toxicities (other 
than nausea or vomiting), successive dose reductions by 1 dose level.
• Carboplatin dose reductions.
• Dose level 1: carboplatin AUC 4.
• If additional dose reductions required, patients  were discontinued.
• Gemcitabine plus carboplatin.
• Dose level 1: gemcitabine 800 mg/m2.
• Dose level 2: omission of day 8 gemcitabine.
ASSESSMENTS
• Baseline assessment: medical history, physical examination, blood 
counts, chemistries, and radiologic studies to establish tumor burden.
• Blood counts  were obtained on days 1 and 8 of each cycle.
• Quality of life was assessed by the EORTC QLQ- C30 and QLQ- OV28, 
version 2 (Aaronson et al. 1993; Greimel et al. 2003).
• QOL assessed within 2 weeks before enrollment, before each cycle.
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• Toxicity was assessed before each cycle and 30 days  after last treatment.
• Patient assessment was performed before random assignment, before 
each cycle during treatment, and  every 2 to 3 months  after treatment 
for at least 2 years.
• Progressive disease was based on clinical and/or radiologic evaluation.
• Progressive disease was not based on CA125 elevation alone.
ENDPOINTS
• PFS, defi ned as time from date of randomization to date of disease pro-
gression or death from any cause (primary endpoint).
• Duration of response was mea sured from date of fi rst response to date 
of disease progression or death due to any cause.
• Overall survival was mea sured from the date of random assignment to 
the date of death from any cause.
• Response was mea sured according to Southwest Oncology Group cri-
teria (Green and Weiss 1992).
• Quality of life.
• Toxicity, graded according to the National Cancer Institute Common 
Toxicity Criteria version 2 (Trotti et al. 2000).
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Platinum- free interval (6-12 months vs ≥12 months).
• First- line therapy (platinum/paclitaxel vs other platinum- based therapy).
• Bidimensionally mea sur able disease (yes vs no).
Sample Size
• Target enrollment was 350 patients. Based on historical data, it was 
expected that between 300 and 350 patients with disease progression 
would be observed. Based on the AGO- OVAR phase I/II study (du Bois 
et al. 2001), the expected median PFS for gemcitabine and carboplatin 
was 8.5 months compared to a median PFS for carboplatin alone of 6 
months. The constant HR was 0.71 with a signifi cance level of .05; the 
study had 85% power using the log- rank comparison of PFS.
• The study was not powered to detect differences in OS. To detect a 25% 
improvement of 25% (assuming an HR of 0.8), power would have been 
55% with an α of 0.05 and 352 deaths.











N = 178 Statistics
Patient characteristics
Median age (range) 58 (21-81) 59 (36-78)
Time from prior chemotherapy
<6 months 0% 0.6%
6-12 months 39.9% 39.9%
≥12 months 60.1% 59.6%
Prior platinum/taxane 71.3% 70.2%
Stage IA- IIA 7.9% 9.0%
Stage IIB- IIIB 19.1% 21.4%
Stage IIIC 60.1% 54.5%
Stage IV 12.4% 15.2%
Histology Not specifi ed Not specifi ed
Grade 1 7.3% 8.4%
Grade 2 27.5% 28.7%
Grade 3 49.4% 43.8%
Undifferentiated 3.9% 5.6%
Unknown grade 11.8% 13.5%
Treatment delivery
% planned carboplatin 98.2% 96.2%
% planned gemcitabine day 1 92.8%
% planned gemcitabine day 8 63.4%
D/C for heme toxicity 4.0% 5.1%
Effi cacy
Overall response 30.9% 47.2% P = .0016
Complete response 6.2% 14.6%
Partial response 24.7% 32.6%
Stable disease 38.8% 38.2%
Progressive disease 16.3% 7.9%
Median PFS 5.8 months 8.6 months HR 0.72 
(95% CI, 0.58-0.90)
Median OS 17.3 months 18.0 months HR 0.96, NS
Median DOR 7.3 months 8.4 months P = NS
Toxicity
Worse in carboplatin/gemcitabine
G3/4 anemia 8.0% 27.4% P < .001
G3/4 neutropenia 12.0% 70.3% P < .001
G3/4 thrombocytopenia 11.4% 34.9% P < .001
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• Kaplan- Meier estimations  were used for time- to- event par ameters.
• Log rank χ2 tests used to compare the distribution between groups.
• Univariate Cox models  were fi tted for each covariate and PFS.
• Covariates included age (≤60 vs >60 years), per for mance status (0 
vs 1-2), prior platinum therapy (platinum plus nonpaclitaxel vs plati-
num plus paclitaxel), disease status (bidimensionally mea sur able vs 
assessable), and duration of platinum- free interval (6-12 months vs 
>12 months).
• Unadjusted normal approximation for the difference of 2 binomial pro-
portions used to compare response rates.
• Paired t test and analy sis of variance (ANOVA)  were used to analyze 
changes in QLQ- C30 and QLQ- OV38 baseline scores within and 
between arms.
CONCLUSION OF TRIAL
• Gemcitabine and carboplatin signifi cantly improve PFS and response 
rate without worsening quality of life in patients with platinum- sensitive 
ovarian cancer.
COMMENTS
• In the Cox proportional hazards model, the improved PFS was main-
tained in patients who had received prior platinum- taxane as fi rst- line 
therapy and in patients with a short platinum- free interval of less than 
12 months.
• Quality of life did not differ between treatment arms.






N = 178 Statistics
No difference
Febrile neutropenia 0% 1.1% NS
G1-4 neuropathy, motor 4.0% 6.3% NS
G1-4 neuropathy, sensory 26.9% 29.7% NS
 G1/2 alopecia 17.8% 49.2%
CI, confi dence interval; D/C, discontinue; DOR, duration of response; HR, hazard ratio; NS, not signifi -
cant; PFS, progression- free survival.
(continued)
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• Postprogression therapy: no major differences between carboplatin or 
carboplatin/gemcitabine.
• Platinum: 23% vs 29%.
• Topotecan: 21% vs 29%.
• Anthracyclines: 18% vs 15%.
• Etoposide: 4% vs 12%.
• Alkylating agents: 20% vs 12%.
• Taxanes: 7% vs 1%.
• Gemcitabine: 6% vs 0%.
•  Because epithelial ovarian cancer often behaves like a chronic illness, 
 there is an urgent need to identify active platinum- based combinations 
that do not have the same cumulative neurotoxicity of platinum and 
taxane.
• Carboplatin and gemcitabine are feasible and increase progression- free 
survival and response rates in patients with platinum- sensitive ovar-
ian cancer, irrespective of  factors such as prior taxane exposure and 
platinum- free interval.
• This study did not show a benefi t to OS, but it was not designed or pow-
ered to do so.  Because the OS outcome refl ects all treatments admin-
istered and not just the treatment received during a trial, PFS has been 
considered an impor tant endpoint in ovarian cancer patients.
• Carboplatin and gemcitabine  were associated with greater hematologic 
toxicity, but it was tolerable and associated with infrequent sequelae 
such as febrile neutropenia and no detrimental effect to quality of life.
• Compared to treatment with taxanes, carboplatin and gemcitabine  were 
associated with a better toxicity profi le with less neuropathy and alo-
pecia. This treatment combination represents a treatment option for 
patients with platinum- sensitive ovarian cancer recurrence.
Gemcitabine Versus PLD (Mutch, JCO 2007)
REFERENCE
• Mutch DG, et al. Randomized phase III trial of gemcitabine compared 
with pegylated liposomal doxorubicin in patients with platinum- 
resistant ovarian cancer. J Clin Oncol. 2007;25(19):2811-2818. PMID: 
17602086. (Mutch et al. 2007)
TRIAL SPONSOR
• Eli Lilly & Co.
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•  There are limited treatment options for patients with platinum- resistant 
ovarian cancer that has progressed within 6 months of prior platinum 
treatment.
•  These patients are typically treated sequentially with single- agent 
regimens, including topotecan, gemcitabine, and pegylated liposo-
mal doxorubicin (PLD).
• Treatment choice depends on possibility of effi cacy, cumulative 
adverse effects, and optimal sequencing of agents.
• PLD is approved by the US Food and Drug Administration (FDA) for 
use in patients with progressive or recurrent ovarian cancer  after 
platinum- based chemotherapy. Single- agent PLD has equivalent effi -
cacy and safety to topotecan (Gordon et al. 2001) and is commonly used 
in patients with platinum- resistant ovarian cancer.
• Gemcitabine has been extensively studied in phase II studies as a single 
agent (Lund and Neijt 1996; Friedlander et al. 1998; D’Agostino et al. 
2003; Markman et al. 2003b) and in combination regimens (Greggi 
et al. 2001; Goff et al. 2003; Rose et al. 2003; Raspagliesi et al. 2004; 
Tewari et al. 2004; Ferrandina et al. 2005; Rose 2005) and is active and 
generally well tolerated.
• This phase III trial was designed to compare the effi cacy and safety of 
gemcitabine to PLD in patients with platinum- resistant recurrent ovar-
ian cancer.
PATIENT POPULATION
• N = 195 randomized.
• Patients enrolled between July 2002 and May 2004 from 44 in de pen-
dent sites in the United States.
Inclusion Criteria
• Age ≥18 years.
• Documented pathologic diagnosis of epithelial ovarian, fallopian tube, 
or primary peritoneal carcinoma.
• Prior platinum- based chemotherapy.
• No more than 2 prior regimens.
• Platinum re sis tance was based on the most recent exposure to a 
platinum- containing regimen and was defi ned as progressive disease 
within 6 months of completing therapy.
• Mea sur able disease (Therasse et al. 2000) or CA125 ≥100 U/mL.
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• Zubrod per for mance status of 0 to 2.
• Adequate bone marrow reserve and hepatic and neurologic function.
Exclusion Criteria
• Prior radiation to the breast, head, or neck within the past 3 years.
• Any prior abdominal or pelvic radiation therapy.
• Tumors of low malignant potential.
• Prior PLD or gemcitabine treatment.
• Tamoxifen use (concurrent low- dose corticosteroid or hormone replace-
ment therapy was allowed).
TREATMENT DETAILS
Arm 1
• PLD 50 mg/m2 IV over 60 minutes on day 1  every 28 days.
• Treatment continued  until progressive disease or unacceptable toxicity.
Arm 2
• Gemcitabine 1000 mg/m2 IV over 30 to 60 minutes on days 1 and 8 
 every 21 days.
• Treatment continued  until progressive disease or unacceptable toxicity.
Crossover to Other Therapy Allowed
• At progressive disease.
• At toxicity requiring withdrawal  after reversal to grade 1 or less.
• At a cumulative PLD dose of 500 mg/m2 .
Dose Modifi cations
• Dose/cycle delay or reduction.
• Cytokines  were allowed for neutropenia >7 days or febrile neutropenia.
• Dose adjustments  were based on ANC counts, platelets, and nonhema-
tologic toxicities.
• Therapy could be resumed  after toxicities resolved to grade 2 or less.
ASSESSMENTS
• Patients allowed with mea sur able and/or assessable disease.
• CT scan evaluated by Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria (Therasse et al. 2000).
• Baseline within 28 days of enrollment.
• Gemcitabine: CT before  every fourth 21- day cycle.
• PLD: CT before  every third 28- day cycle.
• CA125 assessable disease.
• Progression defi ned by Rustin criteria (Rustin et al. 2001).
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• Quality of life assessed by Functional Assessment of Cancer Therapy– 
Ovarian (FACT- O) (Basen- Engquist et al. 2001).
• Safety evaluated using the National Cancer Institute Common Toxic-
ity Criteria, version 2.0.
ENDPOINTS
• PFS, defi ned as time from random assignment to PD or death (primary 
endpoint).
• OS.
• Disease control rate (DCR), defi ned as percentage of patients with con-
fi rmed complete response, partial response, or stable disease.
STATISTICAL CONSIDERATIONS
Sample Size
• Calculation was based on Freedman’s method (Freedman 1982). Assum-
ing a constant hazard ratio of 0.625, 148 events (progressions or death) 
 were needed to have 80% power to detect a difference between the 
treatment arms with a 2- sided α of .05.
Statistical Tests
• Log- rank test to compared PFS between the 2 arms.
• Kaplan- Meier method (Kaplan and Meier 1958) to estimate survival 
curves.
• Multiple Cox regression model to explore the impact of prognostic 
 factors on survival.
• Descriptive statistics for quality- of- life data.
• Two- sided Fisher’s exact test to compare incidences of toxicities.
CONCLUSION OF TRIAL
• Although this was not designed as an equivalency trial, gemcitabine 
seemed to have a comparable therapeutic index to pegylated liposomal 
doxorubicin in patients with platinum- resistant ovarian cancer, and 
single- agent gemcitabine could be considered an acceptable treatment 
alternative.
COMMENTS
• Impact of prognostic  factors on survival.
• Stepwise Cox regression model (P = .20 for entry, P = .10 to stay), 
including age, number of prior chemotherapies, number of prior 
platinum regimens, response to prior platinum therapy, disease 










N = 96 Statistics
Patient characteristics
Median age (range) 59 (38-85) 62 (28-83)
Time from prior chemotherapy 3.5 months 4.3 months




Response: CR + PR 46.5% 45.8%
Nonresponse: SD + PD 53.5% 54.2%
Mea sur able disease 65.7% 62.5%
CA125 only 34.3% 37.5%
Stage Not reported Not reported
Histology Not reported Not reported
Grade Not reported Not reported
Treatment delivery
Median No. of cycles (range) 4 (1-21) 3 (1-13)
Median No. of doses 8 3
Mean dose intensity 90.8% 92.4%
% cycles with reduction 14.5% 9.0%
Crossover N = 64 (PLD) N = 66 (gemcitabine)
Effi cacy
Median PFS 3.6 months 3.1 months NS
Median OS 12.7 months 13.5 months NS
Median time to failure 2.7 months 2.5 months NS
ORR, initial treatment 6.1% 8.3% NS
SD, initial treatment 54.5% 38.5%
DCR, initial treatment 60.6% 46.9% P = .63
ORR, crossover 7.6% 4.7% NS
DCR, crossover 63.6% 45.3% P = .52
Toxicity— initial treatment Gemcitabine (N = 99) PLD (N = 96)
Higher with gemcitabine
Grade 2-4 constipation 25 9 P = .004
Grade 2-4 nausea/vomiting 28 12 P = .008
Grade 2-4 fatigue 36 23 P = .043
Grade 3-4 neutropenia 38 18 P = .003
Higher with PLD
Grade 2-3 PPE 0 19 P < .0001
Grade 2-3 mucositis 3 15 P = .003
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measurability at baseline, and baseline CA125 and baseline Zubrod 
per for mance status.
• PFS: only baseline CA125 was a signifi cant predictor. Patients with 
a higher than median CA125 level had a higher risk of progression 
and death.
• OS: both baseline CA125 and per for mance status  were signifi cant 
prognostic  factors.
• Quality- of- life analy sis.
• Study was not able to examine changes in QOL from baseline to 
study end.
• Post hoc analy sis of baseline QOL and treatment outcome demon-
strated that higher baseline FACT- O scores  were associated with 
lower hazard for death (HR, 0.54; P = .003).
• Identifi cation of agents active against platinum- resistant ovarian can-
cer is a priority.
• Second- line agents should lack cross- resistance.
• Second- line agents should have a favorable toxicity profi le due to the 
palliative nature of therapy.
• Limited number of randomized studies evaluating single agents in 
platinum- resistant ovarian cancer (ten Bokkel Huinink et al. 1997; 
Piccart et al. 2000; Bolis et al. 2001; Gordon et al. 2001; du Bois et al. 





N = 96 Statistics
No difference
Grade 2-4 dyspnea 20 10 NS
Grade 2-4 neuropathy 3 8 NS
Grade 2-4 rash 5 5 NS
Grade 3-4 thrombocytopenia 6 5 NS
Grade 3-4 anemia 3 2 NS
Febrile neutropenia 4 4 NS
Toxicity— crossover treatment PLD (N = 64) Gemcitabine (N = 66)
Grade 2-4 fatigue 22 38 P = .009
Grade 2-3 PPE 11 13 NS
Grade 3-4 neutropenia 12 27 P = .007
 Febrile neutropenia 7 3 NS
CA125, cancer antigen 125; CR, complete response; DCR, disease control rate; NS, not signifi cant; 
ORR, overall response rate; OS, overall survival; PFS, progression- free survival; PLD, pegylated lipo-
somal doxorubicin; PPE, palmar- plantar erythrodysesthesia; PR, partial response; SD, stable disease.
(continued)
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2002; Gore et al. 2002; Rosenberg et al. 2002; Buda et al. 2004; ten 
Bokkel Huinink et al. 2004) have shown no statistically signifi cant 
differences in therapeutic index with the exception of treatments con-
sidered nonstandard, including treosulfan and luteinizing hormone- 
releasing hormone analogues (du Bois et al. 2002).
• ten Bokkel phase III study suggested that topotecan and paclitaxel 
are equivalent, but this was in patients who did not receive prior 
taxane therapy (ten Bokkel Huinink et al. 2004).
• Largest randomized phase III trial in this patient population com-
pared topotecan and PLD (Gordon et al. 2001).  There was no sur-
vival benefi t to  either agent. Only 74% of patients treated with PLD 
received prior taxane therapy. Patients receiving topotecan had sig-
nifi cantly more grade 3 and 4 hematologic toxicity.
• This study demonstrates comparable effi cacy between gemcitabine and 
PLD with response rates in line with prior studies evaluating PLD (Gor-
don et al. 2000; Gordon et al. 2001) and gemcitabine (Lund and Neijt 
1996; Friedlander et al. 1998; D’Agostino et al. 2003; Markman et al. 
2003b; Rose et al. 2003; Rose 2005).
• Gemcitabine trends  toward a higher rate of stable disease, an impor-
tant effi cacy mea sure in platinum- resistant patients.
•  There  were no differences in PFS or OS in this study. OS should be 
interpreted with caution due to the crossover study design. Further-
more, this trial was not designed as an equivalency trial, and so cau-
tion must be exercised in interpreting the results.
• Toxicity.
• Twenty  percent of patients who crossed over from PLD to gemcitabine 
experienced PPE during gemcitabine administration. Based on the 
timing of this toxicity, much of this is attributed to latent or delayed 
toxicity from initial PLD administration.
• A phase II study reported lower rates of grade 2 PPE (12%) when dos-
ing PLD at 40 mg/m2  every 28 days (Markman et al. 2000). No grade 
3 or 4 events  were observed. However, the median number of cycles 
was 2 (range, 1-12 cycles), and 12% of patients had dose adjustments.
• This is the second largest population of platinum- resistant ovarian can-
cer patients studied in a phase III randomized trial. This trial includes 
almost exclusively patients previously treated with platinum and tax-
ane and therefore refl ects current clinical practice patterns.
• Gemcitabine is an option to consider for taxane- pretreated platinum- 
resistant ovarian cancer patients.





OVA-301 (Monk, JCO 2010)
REFERENCE
• Monk BJ, et al. Trabectedin plus pegylated liposomal doxorubicin in 
recurrent ovarian cancer. J Clin Oncol. 2010;28(19):3107-3114. PMID: 
20516432. (Monk et al. 2010)
TRIAL SPONSORS
• Johnson & Johnson Phar ma ceu ti cal Research & Development, Rari-
tan, NJ
• PharmaMar, Madrid, Spain
RATIONALE FOR TRIAL
• Recurrent ovarian cancer is a clinical challenge with limited numbers 
of compounds with clinical activity. The only approved drugs by the 
US FDA are carboplatin, cisplatin, paclitaxel, altretamine, topotecan, 
PLD, and gemcitabine (in combination with carboplatin).
• Clinical  trials to identify new agents for recurrent ovarian cancer have 
been hampered by several  factors, including
• Slow accrual.
• Nonstandardized endpoint reporting (CA125, tumor response, 
progression- free survival, overall survival).
• The FDA partnered with the American Society of Clinical Oncol-
ogy (ASCO) and the American Association for Cancer Research 
(AACR) in 2006 to evaluate surrogate endpoints for ovarian can-
cer and concluded that PFS might be an acceptable endpoint 
(Bast et al. 2007). The panel posed the question as to what degree 
of PFS improvement would be clinically meaningful and recom-
mended that studies should also be designed to evaluate the OS 
outcome.
• Trabectedin is a synthetically produced antineoplastic agent that was 
originally isolated from the marine tunicate Ecteinascidia turbinata.
• Trabectedin exerts its antineoplastic effect by binding to the minor 
groove of DNA, bending DNA  toward the major groove, disrupting 
transcription, and leading to G2- M cycle arrest and apoptosis (Car-
ter and Keam 2007).
• Trabectedin is more effective in cells that have a functioning 
transcription- coupled nucleotide excision repair system.
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• This compound has encouraging single- agent activity in recurrent 
ovarian cancer and is tolerable (Sessa et al. 2005; Krasner et al. 2007; 
von Mehren et al. 2008).
• In vitro studied demonstrate synergy between trabectedin and 
pegylated liposomal doxorubicin (Takahashi et al. 2001; Meco 
et al. 2003).
• This phase III randomized multicenter trial was performed to assess 
the effi cacy of PLD vs PLD plus trabectedin in patients with relapsed 
ovarian cancer.
PATIENT POPULATION
• N = 672 enrolled.
• Enrolled between April 2005 and May 2007 from 124 centers in 21 
countries.
Inclusion Criteria
• Age ≥18 years.
• Histologically confi rmed epithelial ovarian, fallopian tube, or primary 
peritoneal carcinoma.
• One prior platinum- based chemotherapy regimen only followed by per-
sis tence, recurrence, or progression.
• Platinum resistant: platinum- free interval (PFI) <6 months.
• Platinum sensitive: PFI ≥6 months.
• Mea sur able disease by RECIST.
• ECOG per for mance status ≤2.
• Adequate bone marrow function: hemoglobin ≥9 g/dL, ANC ≥1500/
μL, platelets ≥100,000/μL.
• Adequate renal function: serum creatinine ≤1.5 mg/dL or creatinine 
clearance ≥60 mL/min.
• Creatine phosphokinase less than or equal to upper limit of normal 
(ULN).
• Adequate liver function: total bilirubin ≤1.5× ULN, direct bilirubin less 
than or equal to ULN, total alkaline phosphatase (ALP) ≤1.5× ULN, 
AST and alanine aminotransferase (ALT) ≤2.5× ULN.
• Adequate cardiac function: LVEF within institutional limits.
• Interval between prior treatment and study initiation.
• ≥4 weeks for radiation or experimental therapy.
• ≥2 weeks for hormonal therapy.
• ≥3 weeks for chemotherapy or biologic therapy.






• Platinum refractory— disease progression during front- line therapy.
•  Women of childbearing potential and not using adequate contraception.
TREATMENT DETAILS
Stratifi cation  Factors
• ECOG per for mance status (0 to 1 vs 2).
• Platinum sensitivity (sensitive vs resistant).
Arm 1: PLD
• Treatment on day 1 of a 4- week cycle.
• PLD 50 mg/m2 IV over 90 minutes.
• Maximum of 2 dose reductions allowed.
• PLD could be reduced to 37.5 mg/m2, then to 28 mg/m2.
Arm 2: PLD + Trabectedin
• Treatment on day 1 of a 3- week cycle.
• IV dexamethasone 20 mg (or equivalent) (Donald et al. 2003) 30 min-
utes prior to treatment.
• PLD 30 mg/m2 IV over 90 minutes.
• Trabectedin 1.1 mg/m2 IV over 3 hours through a central venous 
catheter.
• Maximum of 2 dose reductions for each drug allowed.
• Trabectedin could be reduced to 0.9 mg/m2, then to 0.75 mg/m2.
• PLD could be reduced to 25 mg/m2, then to 20 mg/m2 .
Additional Treatment Details
• Treatment continued  until disease progression or confi rmation of com-
plete response and could be continued for 2 or more cycles beyond 
confi rmed CR.
• Colony- stimulating  factors  were permitted  after cycle 1 per ASCO 
guidelines (Smith et al. 2006).
• Additional antiemetics could be added per the investigator’s discretion.
Dose Reductions
• One level for neutrophils <500/μL with temperature ≥38.5°C or 
infection.
• One level for neutrophils <500/μL lasting >5 days.
• One level for platelets ≤25,000/μL.
• One level for grade ≥3 nausea/vomiting (despite adequate treatment).
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• PLD reduction for stomatitis.
• PLD reduction for fi rst occurrence of hand- foot syndrome (HFS) and 
day 15 transaminase elevation.
• Trabectedin reduction for fi rst occurrence of grade ≥2 ALP elevation.
• PLD reduction for grade ≥1 HFS  after fi rst occurrence of grade 3 to 4 
HFS.
• Trabectedin reduction of conjugated bilirubin more than ULN.
• Trabectedin reduction for second occurrence of grade ≥1 ALP elevation.
• One level reduction of both drugs if grade ≥3 transaminase elevations 
on day 15 recovered to grade 1 or less by day 1 of the next cycle or 
within 3 weeks  after that date.
• Both drugs terminated if grade ≥3 transaminase elevations on day 15 
and no recovery to grade 1 or less by day 1 of the next cycle or within 
3 weeks.
ASSESSMENTS
• Disease assessments at screening and  every 8 weeks thereafter.
• In de pen dent radiology review by RECIST criteria (Therasse et al. 
2000).
• Secondary analyses of PFS based on in de pen dent oncologist and 
investigator’s assessments.
• Both in de pen dent radiologists and oncologists  were blinded to treat-
ment assignment.
• Evaluation of LVEF.
•  Every 2 cycles for patients with cardiac history or total cumulative 
anthracycline dose more than 360 mg/m2.
• At treatment discontinuation for all patients.
• Complete blood count (CBC) and chemistries  every week.
• Safety evaluated by National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE), version 3.0.
• Quality- of- life questionnaires at screening, day 1 of each cycle, and at 
treatment end.
• EORTC QLQ- C30 (Aaronson et al. 1993).
• EORTC QLQ- OV28 (ovarian cancer module) (Greimel et al. 2003).
ENDPOINTS
• PFS (primary endpoint).
• OS.





• Overall response rate (ORR; response maintained ≥4 weeks by 
RECIST).
• Duration of response (date from fi rst documentation of response to date 





• In total, 650 patients  were to be enrolled over 2 years and 415 PFS events 
 were required to test a statistical difference assuming a median PFS of 
16 weeks for PLD and 22 weeks for trabectedin/PLD with 90% power 
and 2- sided α of .05.
• OS analy sis was to be performed when 520 deaths  were observed to 
allow for testing of a statistical difference assuming a median OS of 
63 weeks for PLD and 83 weeks for PLD/trabectedin with 90% power 
and a 2- sided α of .05.
• In December 2006,  after the FDA/ASCO/AACR public workshop eval-
uating endpoints for ovarian cancer clinical  trials (Bast et al. 2007), 
the endpoints  were changed to a single primary endpoint of PFS. OS 
was made a secondary endpoint. Sample size remained unchanged. 
This occurred when 440 subjects had been enrolled and before central 
radiology review.
Statistical Tests
• Kaplan- Meier method was used to estimate survival.
• The log- rank test was used to compare survival.
• The stratifi ed log- rank test was used to compare PFS between treat-
ment arms while adjusting for ECOG PS and platinum sensitivity 
(Kaplan and Meier 1958).
• A Cox proportional hazards model was used to compare treatment arms 
while adjusting by prognostic  factors as a secondary analy sis (Cox 
1972).
CONCLUSION OF TRIAL
• Trabectedin combined with PLD improves PFS compared to PLD alone 
with acceptable toxicity in patients with recurrent ovarian cancer.











N = 337 Statistics
Patient characteristics
Median age (range) 58 (27-87) 56 (26-82)
Time from prior chemotherapy
<6 months 35% 35%
6-12 months 28% 37%
≥12 months 37% 29%







Clear cell 5% 4%
Other 21% 21%
Grade 1 3% 5%
Grade 2 18% 17%
Grade 3 52% 52%




NA 5.6 mg/m2 
(1-23)







Median PFS 5.8 months 7.3 months HR 0.79 (95% CI, 0.64-0.96)
Platinum sensitive 7.5 months 9.2 months HR 0.73 (95% CI, 0.56-0.95)
Platinum resistant 3.7 months 4.0 months NS
Overall survival Immature Immature
Toxicity
More common with PLD/T
Grade 3/4 neutropenia 22.4% 62.7%
Grade 3/4 ALT elevations 0.3% 30.9%
Colony- stimulating  factors 17% 42%
Congestive heart failure N = 1 N = 6
More common with PLD
Hand- foot syndrome 19.7% 3.9%
Mucosal infl ammation 5.8% 2.1%
Stomatitis 5.1% 0.9%






• Incidence of dose reductions was similar between arms.
• Cycle delays  were more common with PLD/trabectedin.
• Drug- related adverse events  were the most common reason for cycle 
delay in both arms.
• HFS was most common reason for treatment termination or dose 
adjustment for PLD alone.
• Neutropenia was most common reason for treatment termination or 
dose adjustment for PLD/trabectedin.
• Treatment effect with PLD/trabectedin was seen across dif fer ent 
subgroups.
• OS data are immature at the time of publication.
• ORR was higher with trabectedin/PLD (Appendix  Table A2 in manu-
script), P = .008.
• Response duration did not differ between arms.
• Duration of disease stabilization was improved with the combination, 
P = .0106.
• Proportion of patients receiving subsequent ovarian cancer therapy was 
similar in both groups.
•  There  were no differences in quality of life using mixed- effects models to 
predict baseline and follow-up scores as a function of treatment, days 
 after baseline and interaction between treatment and days  after baseline.
• Toxicities.
• The criteria for Hy’s law (concurrent increase in both transaminases 
and bilirubin) ( Temple 2006), which predicts severe liver toxicity, 
 were met for 3 patients (0.9%) receiving PLD/trabectedin. Liver tox-
icity resolved in all 3 cases and was never severe.






N = 337 Statistics
Death during treatment N = 8 N = 11
Progressive disease N = 6 N = 6
Adverse event N = 1 N = 5
Unknown cause N = 1 N = 0
ALT, alanine aminotransferase; CI, confi dence interval; HR, hazard ratio; NA, not applicable; NS, not 
signifi cant; PFS, progression- free survival; OS, overall survival; PLD, pegylated liposomal doxorubicin; 
PLD- T, pegylated liposomal doxorubicin + trabectedin.
(continued)
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• Preferred treatment for patients with platinum- resistant disease.
• Also considered in patients with platinum- sensitive disease as a poten-
tial means of increasing the benefi t of subsequent platinum- based 
treatment.
• Prior to this trial, 4 positive randomized phase III  trials in second- line 
treatment of recurrent ovarian cancer have led to regulatory approval 
of a drug or a change in treatment paradigm.
• Topotecan vs paclitaxel trial demonstrated effi cacy of topotecan (ten 
Bokkel Huinink et al. 1997).
• Topotecan vs PLD trial demonstrated improved effi cacy, conventional 
dosing, and a favorable safety profi le for PLD, supporting regulatory 
approval for PLD for both platinum- resistant and platinum- sensitive 
ovarian cancer (Gordon et al. 2001; Gordon et al. 2004).
• ICON4/AGO- OVA 2.2 trial comparing single- agent platinum to 
platinum + paclitaxel demonstrated prolonged PFS and OS for com-
bination therapy (Parmar et al. 2003).
• AGO- OVAR, NCIC CTG, and EORTC GCG  trials comparing car-
boplatin to carboplatin + gemcitabine showed improvement in PFS 
with the combination treatment (Pfi sterer et al. 2006a).
• This current trial differs from  these prior  trials in that it combines 
nonplatinum agents and demonstrates superiority in PFS with the com-
bination regimen.
•  Because most  women with recurrent ovarian cancer die of their dis-
ease, mea sures such as quality of life, con ve nience, and safety are as 
impor tant as effi cacy in evaluating a regimen.
• Findings of this trial and  others demonstrate that doublets are more 
toxic than monotherapies, and this must be weighed in the benefi t- 
risk ratio when choosing a therapy.
CALYPSO (Pujade- Lauraine, JCO 2010) 
Caelyx in Platinum Sensitive Ovarian Patients
REFERENCE
• Pujade- Lauraine E, et al. Pegylated liposomal doxorubicin and car-
boplatin compared with paclitaxel and carboplatin for patients with 
platinum- sensitive ovarian cancer in late relapse. J Clin Oncol. 
2010;28(20):3323-3329. PMID: 20498395. (Pujade- Lauraine et al. 
2010)






• Gynecologic Cancer Intergroup Trial of Groupe d’Investigateurs Nation-
aux pour l’Etude des Cancers Ovariens (GINECO)
• Arbeitsgemeinschaft Gynakologische Onkologie Studiengruppe 
Ovarialkarzinom (AGO- OVAR)
• Nordic Society Gynecologic Oncology (NSGO)
• Australia New Zealand Gynaecological Oncology Group (ANZGOG)
• National Cancer Institute of Canada Clinical  Trials Group 
(NCIC-CTG)
• Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Austria
• Eu ro pean Organisation for Research and Treatment of Cancer 
(EORTC)
• Multicenter Italian  Trials in Ovarian Cancer (MITO)
• Mario Negri Gynecologic Oncology (MaNGO)
RATIONALE FOR TRIAL
• A pooled analy sis of 3 randomized controlled  trials from AGO- OVAR 
and ICON showed improved PFS and OS in patients with platinum- 
sensitive recurrent ovarian cancer treated with paclitaxel and carbo-
platin compared to platinum alone (Parmar et al. 2003). A GEICO phase 
II study demonstrated a signifi cant improvement in time to tumor pro-
gression in patients treated with paclitaxel and carboplatin compared 
to carboplatin alone (Gonzalez- Martin et al. 2005).
• Retreatment with paclitaxel and carboplatin is limited by the risk of 
cumulative peripheral neuropathy. In addition, grade 2 alopecia (total 
hair loss) occurs in 80% of patients.
• Carboplatin and gemcitabine improve PFS and response rates in 
platinum- sensitive recurrent ovarian cancer, but OS is not improved 
compared to carboplatin alone in a phase III trial (Pfi sterer et al. 2006a). 
Hematologic toxicities are greater.  There remains a need for other active 
carboplatin combinations.
• PLD is an active drug against ovarian cancer in the second- line set-
ting (Gordon et al. 2001; Gordon et al. 2004; Ferrandina et al. 2008). 
PLD has equivalent to superior activity in this setting compared to other 
agents such as paclitaxel or gemcitabine (ten Bokkel Huinink et al. 
1997; Ferrandina et al. 2008).
• A phase II study showed the combination of PLD 30 mg/m2 followed 
by carboplatin AUC 5  every 4 weeks is safe and effi cacious with a high 
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response rate of 63% and median PFS and OS of 9.4 months and 32.0 
months, respectively (Ferrero et al. 2007).
• This phase III trial was designed to compare the effi cacy of PLD/
carboplatin  every 4 weeks vs standard paclitaxel and carboplatin  every 
3 weeks.
PATIENT POPULATION
• N = 976 enrolled.
• Enrollment from April 2005 to September 2007.
• Cancer of ovary, fallopian tube, or extra- ovarian papillary serous tumor 
with disease progression >6 months  after receiving fi rst- or second- line 
platinum- based chemotherapy.
• Prior taxane therapy was required.
• Mea sur able disease according to RECIST or CA125 assessable disease 
according to Gynecologic Cancer InterGroup criteria or histologic 
proven relapse (Therasse et al. 2000; Vergote et al. 2000).
• ECOG per for mance status of 0, 1, or 2.
• Life expectancy of at least 12 weeks.
• Adequate bone marrow, renal, and hepatic function.
• Exclusion: preexisting more than grade 1 neuropathy.
TREATMENT DETAILS
Arm 1: Paclitaxel and Carboplatin
• Paclitaxel 175 mg/m2 IV on day 1.
• Carboplatin AUC 5 IV on day 1 based on Calvert formula using glo-
merular fi ltration rate calculated from serum creatinine values by Cock-
croft and Gault method (Cockroft and Gault 1976).
• Treatment administered  every 3 weeks for 6 courses in the absence of 
unacceptable toxicity or disease progression.
• In the event of partial response or stable disease, patients  were allowed 
to stay on treatment  until disease progression.
Arm 2: Pegylated Liposomal Doxorubicin and Carboplatin
• PLD 30 mg/m2 IV on day 1.
• Carboplatin AUC 5 IV.
• Treatment administered  every 4 weeks for 6 courses in the absence of 
unacceptable toxicity or disease progression.
• In the event of partial response or stable disease, patients  were allowed 
to stay on treatment  until disease progression.





Treatment Plan and Dose Modifi cation
• All patients received antiemetics, including a serotonin antagonist and 
a corticosteroid. Patients receiving paclitaxel received premedications 
to prevent hypersensitivity reactions.
• Guidelines for dose delay and reduction are in the appendix of the man-
uscript (Smith et al. 2006).
ASSESSMENTS
• Baseline:
• History and physical examination, including a gynecologic exami-
nation, laboratory studies including CA125, radiographic imaging 
(CT scan, ultrasound, MRI, or site- specifi c radiography) within 4 
weeks of study entry.
• Baseline electrocardiogram (ECG) for patients receiving paclitaxel.
• Baseline left ventricular ejection fraction by ECG or multigated angi-
ography for patients receiving PLD.
• Before each cycle:
• Clinical, hematologic, and biochemical assessments, including eval-
uation for toxic events as assessed by the NCI CTCAE.
• For patients receiving PLD, a left ventricular ejection fraction 
mea sure ment was performed before each course of therapy if cumu-
lative anthracycline dose was >450 mg/m2.
• At 3 month intervals during treatment:
• CA125.
• Quality- of- life evaluations by EORTC QLQ C30 version 3.0 and 
OV-28 version 1 (Aaronson et al. 1993; Greimel et al. 2003).
• Follow-up  after treatment discontinuation:
• Clinical examination, including gynecologic examination, CA125, 
and adverse event evaluation  every 3 months for 2 years and  every 6 
months thereafter for 5 years.
• Quality- of- life evaluation  every 3 months for 1 year from the date of 
enrollment.
• Defi nition of disease progression was based on RECIST and GCIG 
modifi cations and included clinical or imaging signs of any new lesions, 
increase in mea sur able and/or nonmea sur able tumor defi ned by 
RECIST, CA-125 elevation defi ned by GCIG criteria, health status dete-
rioration attributable to disease, and death of any cause before pro-
gression was diagnosed (Therasse et al. 2000; Vergote et al. 2000).
510-66190_ch01_3P.indd   245 11/8/16   7:49 PM





• PFS (primary endpoint).
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Patients stratifi ed by therapy- free interval (6-12 vs >12 months), mea-
sur able disease (yes vs no), center.
• Based on method of random assignment, a slight imbalance in treat-
ment allocation was observed but treatment arms  were well balanced 
for baseline characteristics and stratifi cation  factors.
Sample Size
• Designed as a 2- arm parallel noninferiority trial. Calculations  were 
based on the results of ICON4/AGO- OAR 2-2, which showed a 23% 
relative benefi t for PFS and OS favoring paclitaxel and carboplatin (Par-
mar et al. 2003). A sample size of 898 evaluable patients with 745 pro-
gressions was estimated for a noninferiority margin with an HR of 1.23 
at 15 months or a 7.9% absolute difference at 12 months with 90% power 
and a 1- sided confi dence interval of 95%.
Statistical Tests
• Cox proportional hazards  were used to calculate hazard ratios for 
survival.
• Kaplan- Meier curves and the log- rank test  were used to compare sur-
vival curves.
• χ2 and Wilcoxon rank- sum tests  were used as appropriate for toxicity 
comparisons.
CONCLUSION OF TRIAL
• Pegylated liposomal doxorubicin and carboplatin  were associated with 
a statistically signifi cant improvement in PFS and lower toxicity com-
pared to paclitaxel and carboplatin in patients with platinum- sensitive 
ovarian cancer.
COMMENTS
• This is one of the largest  trials to be conducted in relapsed/recurrent 
ovarian cancer to date.
• In addition to demonstrating an improvement in PFS, CD (carboplatin 
and PLD) produced less severe toxicities, including less carboplatin 
hypersensitivity reactions and less peripheral neuropathy and less alo-
pecia compared to CP (carboplatin and paclitaxel).












N = 466 Statistics
Patient characteristics
Median age (range) 61 (27-82) 60.5 (24-82)
Time from prior chemotherapy
<6 months 0% 0%
6-12 months 36.1% 35%
≥12 months 63.9% 65%





Stage I/II 13.0% 12.3%




Clear cell 2.6% 3.0%
Other 16.7% 15.2%
Grade 1 4.5% 6.2%
Grade 2 25.2% 21.5%
Grade 3 53.3% 55.1%
Unknown grade 17.0% 17.2%
Mea sur able disease 63.3% 60.3%
Tumor size >5 cm 17.7% 19.1%
Surgery for this relapse 19.6% 18.7%
Treatment delivery
Completed 6 cycles 77% 85% P < .001
Completed 9 cycles 7% 8%
Median duration of treatment 16 weeks 21 weeks
Delay >7 days 5% 7%
D/C for toxicity 15% 6% P < .001
Effi cacy
Median PFS 9.4 months 11.3 months HR 0.82 (95% CI, 
0.72-0.94)
Progression by RECIST 80% 79%
Progression by CA125 20% 21%
(continued)
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• Toxicities of CD included a greater degree of mucositis, nausea, 
vomiting, and PPE.  These side effects  were generally short term and 
manageable.
• The addition of PLD to carboplatin appears to reduce the risk of 
hypersensitivity reactions (HSR) to carboplatin. The rate of HSR with 
carboplatin retreatment alone is 23% (Alberts et al. 2008a). The 
mechanism for this reduced effect is unknown.
• This trial was designed to be a noninferiority trial but actually demon-
strated superiority of CD over CP. Testing for superiority in the setting 
on noninferiority is considered acceptable.
• PFS is considered a valid endpoint for recurrent platinum- sensitive 
ovarian cancer (du Bois et al. 2005b; Bast et al. 2007). PFS refl ects tumor 
shrinkage and disease stabilization effects and is not confounded by the 
impact of subsequent treatment as the OS endpoint can be.
• Aside from treatment arm, other covariates that predicted improved 
PFS included therapy- free interval >12 months (HR, 0.56; 95% CI, 
0.48-0.65), lack of mea sur able disease, and CA125 <100.







N = 466 Statistics
Toxicity
Deaths during protocol N = 1 N = 5
Worse with CP
G3/4 nonheme toxicity 36.8% 28.4% P < .001
≥ G2 neurosensory 26.9% 4.9% P < .001
≥ G2 arthralgia/myalgia 19.2% 4.0% P < .001
Allergic/hypersensitivity 18.8% 5.6% P < .001
Alopecia 83.6% 7% P < .001
G3/4 neutropenia 45.7% 35.2% P < .01
Worse with CD
Hand- foot syndrome, PPE 2.2% 12% P < .001
G3/4 thrombocytopenia 6.2% 15.9% P < .001
≥ G2 mucositis 7.0% 13.9% P < .001
≥ G2 nausea 24.2% 35.2% P < .001
 ≥ G2 vomiting 15.6% 22.5% P < .001
CA125, cancer antigen 125; CI, confi dence interval; D/C, discontinue; G, grade; HR, hazard ratio; PFS, 
progression- free survival; PLD, pegylated liposomal doxorubicin; PPE, palmar- plantar erythrodysesthe-
sia; RECIST, Response Evaluation Criteria in Solid Tumors.
(continued)





• Pos si ble explanations for improved PFS with carboplatin and PLD:
• Carboplatin appears to enhance the activity of PLD. CD has supe-
rior OS to carboplatin alone in platinum- sensitive ovarian cancer in 
a small randomized controlled trial (26 vs 18 months, P = .02) (Alberts 
et al. 2008a).
• Duration of therapy was longer with CD (21 vs 16 weeks)  because 
the interval between cycles was longer (4 vs 3 weeks) and  because of 
lower toxicity- related treatment discontinuations. The time from end 
of treatment to progression was almost similar between arms (6.7 
months for CD, 5.9 months for CP).
OCEANS (Aghajanian, JCO 2012)
REFERENCE
• Aghajanian C, et al. OCEANS: a randomized, double- blind, placebo- 
controlled phase III trial of chemotherapy with or without bevacizumab 
in patients with platinum- sensitive recurrent epithelial ovarian, primary 
peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-
2045. PMID: 22529265. (Aghajanian et al. 2012)
TRIAL SPONSOR
• Genentech, South San Francisco, CA
RATIONALE FOR TRIAL
• Patients with platinum- sensitive recurrent ovarian cancer (relapse ≥6 
months from initial platinum- based therapy) are usually retreated with 
platinum- based chemotherapy (Parmar et al. 2003; Pfi sterer et al. 2006a; 
Pujade- Lauraine et al. 2010).
• The combination of gemcitabine and carboplatin (GC) was approved 
for use in platinum- sensitive ovarian cancer in 2004 in Eu rope and in 
2006 in the United States based on an intergroup (AGO- OVAR/NCIC- 
CTG/EORTC) phase III study (Pfi sterer et al. 2006a). Compared to 
carboplatin alone, the combination of gemcitabine with carboplatin 
improved progression- free survival from 5.8 months to 8.6 months (HR, 
0.72; 95% CI, 0.58-0.90; P = .0031) (Pfi sterer et al. 2006a).
• Bevacizumab is a monoclonal antibody targeting vascular endothelial 
growth  factor (VEGF- A) and has demonstrated activity in phase II 
studies in recurrent ovarian cancer.
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• GOG 170D treated 62 patients who had received 1 to 2 prior regi-
mens (platinum sensitive or platinum resistant) with single- agent bev-
acizumab at 15 mg/kg  every 3 weeks and showed an objective response 
rate of 21% and a median duration of response of 10.3 months. Forty 
 percent of patients  were progression  free at 6 months (Burger et al. 
2007).
• In a single- arm study evaluating bevacizumab with metronomic 
cyclophosphamide, 70 patients who had received 1 to 3 prior regimens 
(platinum sensitive or platinum resistant) demonstrated a 24% objec-
tive response rate and 56% of patients  were progression  free at 6 
months (Garcia et al. 2008). Four patients (5.7%) had a gastrointestinal 
(GI) perforation or fi stula.
• Forty- four patients with platinum- refractory or platinum- resistant 
ovarian cancer, recurrence  after 2 to 3 prior regimens, and progression 
during or within 3 months of topotecan or pegylated liposomal doxoru-
bicin showed a response rate of 15.9%, and 27.8% of patients  were 
progression  free at 6 months (Cannistra et al. 2007). While single- 
agent bevacizumab was active in this heavi ly pretreated population, 
 there  were 5 GI perforations (11%), leading to early closure of this study.
• Based on data demonstrating effi cacy of bevacizumab in recurrent 
ovarian cancer, OCEANS (Ovarian Cancer Study Comparing Effi cacy 
and Safety of Chemotherapy and Anti- Angiogenic Therapy in Platinum- 
Sensitive Recurrent Disease) was designed as a randomized, double- 
blind, phase III trial to compare GC to GC + bevacizumab in patients 
with platinum- sensitive ovarian cancer.
PATIENT POPULATION
• N = 484 randomized.
• Enrollment from April 2007 to January 2010.
Inclusion Criteria
• Recurrent ovarian cancer with disease progression ≥6 months  after 
completion of front- line platinum- based chemotherapy.
• Mea sur able disease according to RECIST version 1.0 (Therasse et al. 
2000).
• ECOG status of 0 or 1 (Oken et al. 1982).
• Life expectancy of at least 12 weeks.
• Adequate bone marrow, coagulation, renal, and hepatic function.






• Prior chemotherapy for recurrent ovarian cancer.
• Prior treatment with bevacizumab or other VEGF pathway- targeted 
therapy.
• Other malignancies within 5 years ( unless low risk of recurrence).
• History of abdominal fi stula, GI perforation, or intra- abdominal 
abscess.
• Clinical signs or symptoms of GI obstruction.
• Requirement for parenteral hydration or nutrition.
• Nonhealing wound, ulcer, or bone fracture.
• Bleeding diatheses or signifi cant coagulopathy.
• Known central ner vous system (CNS) disease (except for treated brain 
metastases).
• Clinically signifi cant cardiovascular disease.
• Major surgical procedure within 28 days of enrollment or anticipated 
surgery during course of study.
TREATMENT DETAILS
• Dosing matched to AGO- OVAR- NCIC CTG- EORTC trial (Pfi sterer 
et al. 2006).
Arm 1: Gemcitabine + Carboplatin + Placebo (GC + PL).
• Gemcitabine 1000 mg/m2 on days 1 and 8.
• Carboplatin area  under the curve 4 mg/mL/min on day 1 based on the 
Calvert formula.
• Placebo on day 1 or each cycle, administered before GC.
• Cycles repeated  every 21 days.
Arm 2: Gemcitabine + Carboplatin + Bevacizumab (GC + BV).
• Gemcitabine 1000 mg/m2 on days 1 and 8.
• Carboplatin area  under the curve 4 mg/mL/min on day 1 based on the 
Calvert formula.
• Bevacizumab 15 mg/kg IV on day 1 or each cycle, administered 
before GC.
• Cycles repeated  every 21 days.
Additional Treatment Details
• Patients received 6 cycles but  were allowed to receive up to 10 cycles 
if continued response was seen.
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•  After completion of GC, placebo or bevacizumab was continued  until 
progressive disease or unacceptable toxicity.
Treatment Modifi cations
• Day 1 treatment held if ANC <1500, hemoglobin <8.5, or platelets 
<100,000 within 24 hours of scheduled treatment.
• Cycles could be delayed for a maximum of 3 weeks  until minimum val-
ues achieved.
• Day 8 gemcitabine dose modifi cations  were made per the package insert.
• Bevacizumab or placebo could be held for toxicity for a maximum of 
6 weeks. Beyond 6 weeks, bevacizumab was discontinued.
• If a component of therapy was discontinued for toxicity, the other com-
ponents could still be administered per protocol.
ASSESSMENTS
• CT scan  every 9 weeks from day 1 of cycle 1, regardless of treatment 
delay or discontinuation. Radiologic evaluation was done according to 
RECIST 1.0.
• Progression could be determined clinically but not by CA125 elevation 
alone.
• Toxicity was graded according to the CTCAE version 3.0.
• Patients  were observed for adverse events for 30 days  after treatment 
discontinuation and survival  every 3 months  until death.
ENDPOINTS
• PFS, as determined by investigators (primary endpoint).
• Overall response rate.
• Overall survival.
• Duration of response.
STATISTICAL CONSIDERATIONS
Stratifi cation  Factors
• Time from last platinum treatment to recurrence (6-12 months, >12 
months).
• Cytoreductive surgery for recurrence (yes, no).
Sample Size
• Approximately 317 progression events  were required to detect a PFS 
HR of 0.73 in  favor of the bevacizumab arm with a 2- sided α of .05 
and 80% power.






• Kaplan- Meier test (Kaplan and Meier 1958) was used to estimate the 
median PFS and duration of response (DOR) for each treatment group.
• The Brookmeyer- Crowley method (Brookmeyer and Crowley 1982) 
was used to construct 95% confi dence intervals for median values.
• The Cox regression model was used to estimate the stratifi ed HR.
• A 2- sided stratifi ed log- rank test was used to compare between groups..
• The Cochran- Mantel- Haenszel test was used to compare response rates.
• Effi cacy analyses  were performed on the intent- to- treat population.
• Safety analyses  were performed on all patients who received at least 1 
partial dose of any part of protocol treatment.
• Study was blinded, but patients could be unblinded at time of progres-
sion at the request of the investigator.
Additional Statistical Considerations
• Trial was initiated as a phase II study with extensive safety reviews 
focused on GI toxicity.
•  After approximately 20 patients  were accrued to each arm and no per-
forations  were reported  after >10 weeks of follow-up, the trial was con-
verted to a phase III trial.
CONCLUSION OF TRIAL
• Gemcitabine, carboplatin (GC) + bevacizumab administered  until pro-
gression extends progression- free survival compared to GC in patients 
with platinum- sensitive recurrent ovarian cancer.
COMMENTS
• This is the fi rst randomized phase III study to demonstrate a positive 
outcome for the addition of a biologic therapy to standard chemother-
apy in platinum- sensitive recurrent ovarian cancer.
• Improvement in PFS.
• Improvement in ORR.
• Improvement in DOR.
• No difference in OS, but data are immature at the time of publication.
• No new safety concerns, no reports of GI perforation during 
treatment.
• Subgroup analyses all supported the primary analy sis. PFS was supe-
rior with bevacizumab for subcategories of age, ECOG per for mance 
status, platinum- free interval, and cytoreductive surgery status.










N = 242 Statistics
Patient characteristics
Median age (range) 61 (28-86) 60 (38-87)
Time from prior chemotherapy
6-12 months 42% 41%










Median No. of chemotherapies (range) 6 (1-10) 6 (1-10)
Median No. of PL or BV (range) 10 (1-36) 12 (1-43)
Treatment D/C, progression 66.1% 43.0%
Treatment D/C, HTN 0% 3.6%
Treatment D/C, proteinuria 0% 2.4%
Subsequent cancer therapy 88% 84%
Subsequent bevacizumab 31% 15%
Effi cacy
Median PFS 8.4 months 12.4 months HR 0.48 (95% CI, 
0.38-0.61)
Overall RR 57.4% 78.5% P < .0001
Duration of response 7.4 months 10.4 months HR 0.53 (95% CI, 
0.41-0.70)
Median OS (immature data) 35.2 months 33.3 months
Toxicity
Serious adverse events 24.9% 34.8%
G3-5 toxicity 82.4% 89.5%
≥G3 hypertension 0.4% 17.4%
≥G3 proteinuria 0.9% 8.5%
RPLS 0% 1.2%
BV, bevacizumab; CI, confi dence interval; D/C, discontinue; GC+BV, gemcitabine and carbo-
platin + bevacizumab; GC+PL, gemcitabine and carboplatin + placebo; HR, hazard ratio; HTN, hyperten-
sion; OS, overall survival; PFS, progression- free survival; PL, placebo; RPLS, reversible posterior leuko-
encephalopathy syndrome; RR, response rate.





• The overall response rate was 21% higher in the BV arm. The majority 
of responses  were partial responses.
•  There was no difference in overall survival, but the data are immature 
at the time of publication.  There was a high degree of data censoring 
beyond 18 months, and the median OS was longer than expected in both 
arms.
• Toxicity comments.
• Proteinuria tended to develop  after more extended bevacizumab 
treatment and was monitored using urine protein- to- creatinine ratio 
mea sure ments. The median time to development of grade 3 or higher 
proteinuria was 26.5 months.
• Three cases of reversible posterior leukoencephalopathy syndrome 
 were reported in the bevacizumab arm: 2 cases  were confi rmed by 
magnetic resonance imaging.
• No GI perforations occurred during study treatment or within the 
30- day safety period. Two GI perforations occurred in the bevaci-
zumab arm  after the safety period, both at 69 days  after study drug 
discontinuation. Patient 1 received 34 cycles of bevacizumab and 
developed small bowel obstruction and gastric ulcer perforation at 
69 days. Patient 2 received 39 cycles of bevacizumab and devel-
oped intestinal perforation at 69 days  after study drug discontinua-
tion and  after receipt of 1 dose of pegylated liposomal doxorubicin 
off study.
• The rates of neutropenia and febrile neutropenia  were similar in both 
arms.
• As ovarian cancer becomes a chronic illness, treatments that prolong 
PFS and time without cytotoxic chemotherapy are clinically relevant.
• Limitations of OCEANS:
• Lack of quality- of- life data.
• Lack of specimen collection for biomarker analy sis.
• Strengths of OCEANS:
• Robustness of primary endpoint with strict adherence to RECIST- 
defi ned progression and its supportive in de pen dent review commit-
tee (IRC) analy sis and the schedule of assessments.
• The 4- month improved PFS is well above the frequency of radiologic 
assessments ( every 9 weeks) (Panageas et al. 2007; Dancey et al. 
2009).
• Platinum- based doublets are accepted as the best treatment option for 
platinum- sensitive recurrent ovarian cancer (ROC) based on ICON4, 
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AGO- OVAR- NCIC CTG- EORTC, and CALYPSO (Caelyx in Plati-
num Sensitive Ovarian Patients)  trials (Parmar et al. 2003; Pfi sterer 
et al. 2006a; Pujade- Lauraine et al. 2010). Data from OCEANS sug-
gest that the addition of bevacizumab to the GC doublet improves 
outcomes.
• ICON4 and CALYPSO differ from OCEANS based on inclusion of 
nonmea sur able and CA125- evaluable disease, allowed length of cyto-
toxic chemotherapy, assessment modalities, assessment intervals and 
method to determine progression.  These  factors infl uence survival.
AURELIA (Pujade- Lauraine, JCO 2014)
REFERENCE
• Pujade- Lauraine E, et al. Bevacizumab combined with chemotherapy 
for platinum- resistant recurrent ovarian cancer: The AURELIA open- 
label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308. 
PMID: 24637997. (Pujade- Lauraine et al. 2014)
TRIAL SPONSOR
• Written on behalf of the Eu ro pean Network of Gynaecological Onco-
logical Trial Groups (ENGOT)– Gynecologic Cancer Intergroup (GCIG) 
investigators
• Sponsored by F. Hoffmann- La Roche (Basel, Switzerland), which also 
provided third- party writing assistance
RATIONALE FOR TRIAL
• Approximately 25% of patients with advanced ovarian cancer have 
fi rst relapse within 6 months of primary platinum- based chemother-
apy and are classifi ed as having platinum- resistant disease. Almost all 
patients with recurrent ovarian cancer eventually develop platinum 
re sis tance.
• The most active single agents for platinum- resistant disease are PLD, 
paclitaxel, and topotecan (Gordon et al. 2001; Buda et al. 2004; Mutch 
et al. 2007; Vergote et al. 2009).
• Median overall survival is approximately 12 months for platinum- 
resistant ovarian cancer (Naumann and Coleman 2011).
• Combined chemotherapy appears to increase toxicity without improving 
effi cacy (Buda et al. 2004; Sehouli et al. 2008; Lortholary et al. 2012).





• An alternative treatment strategy is to combine single- agent chemo-
therapy with a biologic therapy.
• Bevacizumab.
• Is a monoclonal antibody that targets all isoforms of VEGF- A.
• Has activity in platinum- resistant ovarian cancer as a monotherapy 
(Burger et al. 2007; Cannistra et al. 2007) and combined with che-
motherapy (Garcia et al. 2008; McGonigle et al. 2011).
• AURELIA (Avastin Use in Platinum- Resistant Epithelial Ovarian Can-
cer) is a randomized trial evaluating the combination of bevacizumab 
and chemotherapy in platinum- resistant ovarian cancer.
PATIENT POPULATION
• N = 361 enrolled.
• Enrolled between October 2009 and April 2011.
• Histologically confi rmed epithelial ovarian, fallopian tube, or primary 
peritoneal cancer.
• Mea sur able disease by RECIST version 1.0 or assessable by GCIG 
CA-125 response criteria.
• Progression within 6 months of completing ≥4 cycles of platinum- based 
therapy.
Inclusion Criteria
• Age ≥18 years.
• ECOG per for mance status ≤2.
• Adequate liver, renal, and bone marrow function.
Exclusion Criteria.
• Strict exclusion criteria  were defi ned to reduce the risk of GI perfora-
tion, which was a concern in patients with heavi ly pretreated ovarian 
cancer (Cannistra et al. 2007).
• More than 2 prior anticancer regimens.
• Refractory disease (progression during previous platinum- containing 
therapy).
• Risk  factors for bowel complications.
• History of bowel obstruction (including subocclusive disease) related 
to disease.
• History of abdominal fi stula.
• History of GI perforation.
• History of intra- abdominal abscess.
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• Evidence of rectosigmoid involvement by pelvic examination.
• Bowel involvement seen on computed tomography.
• Clinical symptoms of bowel obstruction.
• Prior radiotherapy to the pelvis or abdomen.
• Surgery (including open biopsy) within 4 weeks of study therapy 
(within 24 hours if a minor surgical procedure).
• Anticipated need for major surgery during study treatment.
• Current or recent treatment with another investigational drug within 
30 days of fi rst study dose.
• Untreated CNS symptoms or symptomatic CNS metastasis.
• History or evidence of thrombotic or hemorrhagic disorders within 6 
months before fi rst study treatment.
• Uncontrolled hypertension.
• Active clinically signifi cant cardiovascular disease.
• Nonhealing wound, ulcer, or bone fracture.
TREATMENT DETAILS
Standard Chemotherapy Se lection
• Investigator choice of single- agent chemotherapy with appropriate 
premedications.
• Paclitaxel 80 mg/m2 IV on days 1, 8, 15, and 22  every 4 weeks.
• PLD 40 mg/m2 IV on day 1  every 4 weeks.
• Topotecan 4 mg/m2 IV on days 1, 8, and 15  every 4 weeks.
• Topotecan 1.25 mg/m2 IV on days 1 to 5  every 3 weeks.
•  After chemotherapy regimen was selected, patients  were randomized 
to chemotherapy vs chemotherapy plus bevacizumab.
• Chemotherapy and bevacizumab  were continued  until disease progres-
sion, unacceptable toxicity, or withdrawal of consent.
• Investigator se lection of chemotherapy was evenly distributed due to 
capping of the cohorts.
• PLD, n = 126, complete accrual in October 2010.
• Paclitaxel, n = 115, complete accrual in April 2011.
• Topotecan, n = 120, complete accrual in April 2011.
Arm 1: Chemotherapy Alone (CT)
Arm 2: Chemotherapy Plus Bevacizumab (BEV- CT)
• Bevacizumab 10 mg/kg  every 2 weeks or
• Bevacizumab 15 mg/kg  every 3 weeks for patients receiving topote-
can  every 3 weeks.






• For patients receiving BEV- CT, if 1 agent was discontinued for toxic-
ity, the other could be continued as a single agent.
• Bevacizumab was discontinued for any grade GI perforation.
Dose Reductions.
• Bevacizumab dose reductions  were not allowed.
• Chemotherapy dose modifi cation guidelines  were according to standard 
clinical practice.
Crossovers
• Patients assigned to CT could cross over to single- agent bevacizumab 
15 mg/kg  every 3 weeks on clear evidence for progression  after a careful 
risk- benefi t assessment.
• Patients assigned to BEV- CT received standard- of- care treatment with-
out bevacizumab at progression.
ASSESSMENTS
• Imaging studies.
• At baseline and  every 8 weeks (or  every 9 weeks for patients receiv-
ing topotecan  every 3 weeks), using the same technique. Computed 
tomography and magnetic resonance imaging (in case of contrast 
allergy)  were the preferred imaging modalities.
• Reponses  were confi rmed by computed tomography scan at least 4 
weeks  after the fi rst response.
• Follow- up: patients  were observed for survival for ≥12 months.
• Safety: assessed before each cycle and within 30 days of completing 
treatment.
• Adverse events: graded according to the NCI CTCAE (version 3.0).
ENDPOINTS
• Investigator- assessed PFS by RECIST— defi ned as the interval between 
randomization and fi rst radiologically documented disease progression 
or death (primary endpoint).





• Quality of life.
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Stratifi cation  Factors
• Selected chemotherapy (PLD vs paclitaxel vs topotecan).
• Prior antiangiogenic therapy (yes vs no).
• Platinum- free interval (<3 months vs 3-6 months).
Sample Size
• Initially, a sample size of 300 patients was planned so that 228 progres-
sion events would provide 80% power with a 1- sided log- rank test at 
an α of .05, assuming a hazard ratio of 0.72 corresponding to a median 
PFS of 4.0 months with CT vs 5.56 months with BEV- CT.
• The sample size was increased to 332 patients to provide 80% power 
to detect a PFS HR of 0.70 with a 2- sided log- rank test with an α of 
0.05  after 247 events, assuming a median PFS of 4.0 months with CT 
and 5.7 months with BEV- CT.
• The in de pen dent data monitoring committee (IDMC) recommended 
the sample size be increased to ≥360 patients with a primary analy sis 
planned  after 290 PFS events based on an HR of 0.72 and 80% power.
Statistical Tests
• Unstratifi ed 2- sided log- rank test used to compare PFS between the 2 
treatment arms.
• Stratifi ed 2- sided log- rank test was used for the post hoc analy sis.
• Exploratory analyses of safety and effi cacy  were prespecifi ed for the 
subgroup of patients with ascites at baseline.
• Post hoc analyses  were performed to determine the proportion of 
patients undergoing paracentesis during study therapy.
CONCLUSION OF TRIAL
• In patients with platinum- resistant ovarian cancer, the addition of bev-
acizumab to chemotherapy signifi cantly improves PFS and ORR. OS 
is not improved, and no new safety signals for bevacizumab have been 
observed. This should be considered a standard treatment option for 
platinum- resistant ovarian cancer.
COMMENTS
• This is the fi rst randomized phase III trial to demonstrate a PFS advan-
tage with combined therapy compared to single- agent therapy.
• The benefi t to PFS was seen across all subgroup analyses.













N = 179 Statistics
Patient characteristics
Median age (range) 61 (25-84) 62 (25-80)
<3 months, prior chemotherapy 25% 28%
Two prior chemotherapies 43% 40%
Prior antiangiogenic 8% 7%
Serous/adenocarcinoma 84% 87%
Endometrioid 5% 5%
Clear cell 7% 2%
Grade 1 5% 6%
Grade 2 26% 30%
Grade 3 58% 53%
Unknown grade 11% 12%
Mea sur able disease 79% 80%
Ascites 30% 33%
Treatment delivery
Median duration 3 cycles (range 
1-17)
6 cycles (range 
1-24)
Effi cacy
Median PFS 3.4 months 6.7 months HR 0.48 (95% CI, 
0.38-0.60)
ORR 12.6% 30.9% P < .001
ORR, RECIST alone 11.8% 27.3% P = .001
ORR, GCIG CA125 alone 11.6% 31.8% P < .001
Median OS 13.3 months 16.6 months HR 0.85 (95% CI, 
0.66, 1.08)
Required paracentesis 17% 2%
Toxicity
AE, special interest 40.3% 57.0%
≥ G2 hypertension 7% 20%
≥ G2 proteinuria 0% 2%
≥ G2 GI perforation 0% 2%
≥ G2 fi stula, abscess 0% 2%
Arterial thrombosis 0% 2%
 Venous thrombosis 4% 3%
AE, adverse event; CA125, cancer antigen 125; CI, confi dence interval; GCIG, Gynecologic Cancer 
InterGroup; HR, hazard ratio; ORR, overall response rate; OS, overall survival; PFS, progression- free 
survival; RECIST, Response Evaluation Criteria in Solid Tumors.
510-66190_ch01_3P.indd   261 11/8/16   7:49 PM




• Chemotherapy exposure was greater in the BEV- CT arm, refl ecting 
the longer PFS.
• The trial was not powered to detect a difference in OS, and crossover 
to bevacizumab was allowed.
• At the time of data cutoff for OS analy sis, 40% of patients in the CT 
arm had crossed over to receive bevacizumab  after progression on 
CT alone.
• The addition of bevacizumab appears to improve the control of ascites.
• The 2.2% rate of GI perforation is lower than previously reported (Can-
nistra et al. 2007; Simpkins et al. 2007).
• Strict exclusion criteria  were used to ensure high- risk patients  were 
not enrolled.
• Safety of bevacizumab.
• Higher rates of grade ≥2 hypertension and proteinuria.
• No new safety signals.
• The higher cumulative incidence of peripheral neuropathy and HFS 
in the bevacizumab- containing arm likely refl ects the longer chemo-
therapy exposure and longer PFS.
• The AURELIA results add to the lit er a ture demonstrating improved 
PFS with the addition of bevacizumab to chemotherapy.
• GOG 218 (Burger et al. 2011).
• ICON7 (Perren et al. 2011).
• OCEANS (Aghajanian et al. 2012).
• The utility of bevacizumab use  after relapse and front- line bevacizumab 
containing therapy is unknown.
• In AURELIA, only 7% of patients received prior antiangiogenic ther-
apy, so no conclusions can be drawn from this study.
• In colorectal cancer, survival is improved with second- line bevaci-
zumab use (Bennouna et al. 2013).
• Criticisms of trial.
• Potential for bias as PFS was determined by investigators.
• No third arm with bevacizumab alone.
• Patient- reported outcomes are described in an accompanying article 
(Stockler et al. 2014).






AACR American Association for Cancer Research
ACTION Adjuvant ChemoTherapy in Ovarian Neoplasm Trial
AGO Arbeitsgemeinschaft Gynakologische Onkologie




ANC Absolute neutrophil count
ANZGOG Australia New Zealand Gynaecological Oncology Group
ASCO American Society of Clinical Oncology
AST Aspartate aminotransferase
AUC Area  under the curve
AURELIA Avastin Use in Platinum- Resistant Epithelial Ovarian Cancer
BEV Bevacizumab
BSA Bovine serum albumin
BUN Blood urea nitrogen
CA125 Cancer Antigen 125
CALYPSO Caelyx in Platinum Sensitive Ovarian Patients
CAP Cyclophosphamide (C), doxorubicin/Adriamycin (A), cisplatin (P)
CBC Complete blood count
CD Carboplatin and pegylated liposomal doxorubicin
CEA Carcinoembryonic antigen
CI Confi dence interval
CNS Central ner vous system
CP Cyclophosphamide (C), cisplatin (P)






CTCAE Common Toxicity Criteria for Adverse Events
CT scan Computed tomography scan
DCR Disease control rate
D5W 5% dextrose in  water
DOR Duration of response
ECG Electrocardiogram
ECHO Echocardiogram
ECOG Eastern Cooperative Oncology Group
EDTA Ethylenediaminetetraacetic acid
ENGOT Eu ro pean Network of Gynaecological Oncological Trial Groups
EORTC Eu ro pean Organ ization for Research and Treatment of Cancer
FACT- O Functional Assessment of Cancer Therapy—Ovarian
FDA Food and Drug Administration
FIGO International Federation of Gynecol ogy and Obstetrics
FLIC Functional Living Index– Cancer
GC Gemcitabine and carboplatin
GCIG Gynecologic Cancer InterGroup
G- CSF Granulocyte colony- stimulating  factor
GEICO Grupo Espanol de Investigacion en Cancer de Ovario
GFR Glomerular fi ltration rate
GI Gastrointestinal
GICOG Gruppo Interregionale Collaborativo in Oncologico Ginecologia
GINECO Groupe d’Investigateurs Nationaux pour l’Etude des Cancers 
Ovariens
GM- CSF Granulocyte macrophage colony- stimulating  factor
GOG Gynecologic Oncology Group
HFS Hand- foot syndrome
HR Hazard ratio
HSR Hypersensitivity reaction
ICON International Collaborative Ovarian Neoplasm
IDMC In de pen dent Data Monitoring Committee
IL-6 Interleukin 6
IP Intraperitoneal
IRC In de pen dent review committee
IRFMN Instituto Mario Negri, Milan, Italy
ITG Integrated Therapeutics Group






JGOG Japa nese Gynecologic Oncology Group
LMP Low malignant potential
LVEF Left ventricular ejection fraction
MaNGO Mario Negri Gynecologic Oncology
MITO Multicentre Italian  Trials in Ovarian Cancer
MRC CTU Clinical  Trials Unit of the Medical Research Council
MRI Magnetic resonance imaging
MTD Maximum tolerated dose
NCCTG North Central Cancer Treatment Group
NCI National Cancer Institute
NCIC National Cancer Institute of Canada
NCI- C- CTG National Cancer Institute of Canada Clinical  Trials Group
NMR Nuclear magnetic resonance
NOCOVA Nordic Gynecological Cancer Study Group
NS Not signifi cant
NSGO Nordic Society for Gynecologic Oncology
OCEANS Ovarian Cancer Study Comparing Effi cacy and Safety of 
Chemotherapy and Anti- Angiogenic Therapy in Platinum- 
Sensitive Recurrent Disease
ORR Overall response rate
OS Overall survival
pCR Pathologic complete response
PD Progressive disease
PFS Progression- free survival
PLD Pegylated liposomal doxorubicin
PPE Palmar- plantar erythrodysesthesia
PR Partial response
PS Papillary serous
PT Paclitaxel plus cisplatin
QLQ Quality- of- life questionnaires
QOL Quality of life
RCOG Royal College of Obstetricians and Gynaecologists
RECIST Response Evaluation Criteria in Solid Tumors
RFS Recurrence- free survival
ROC Recurrent ovarian cancer
RR Response rate





SAAK Swiss Group for Clinical Cancer Research
SD Stable disease
SWOG Southwest Oncology Group
TC Paclitaxel plus carboplatin
ULN Upper limit of normal
VEGF Vascular endothelial growth  factor
WHO World Health Organ ization
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wound healing, 146, 153, 251
bilirubin. See toxicity, bilirubin
biologic progression- free interval, ICON7, 
147
biomarkers, ICON7, 151
bleeding. See toxicity, bleeding
Blyth- Still- Casella method, AGO- OVAR9, 
135
bone marrow function: AGO- OVAR-3, 101; 
AGO- OVAR9, 133; AGO- OVAR/NCIC/
EORTC trial, 223; Danish Netherlands 
Trial, 75; Doxil Study 30–49, 209; GOG 
97, 54; GOG 111, 58; GOG 114, 87; GOG 
132, 71; GOG 152, 169; GOG 158, 96; 
GOG 175, 196; GOG 182/ICON5, 115; 
JGOG 3016, 120; MITO-7, 158; OV-10, 
81; OV16, 138; OVA-301, 236; topotecan 
versus paclitaxel study, 202
borderline ovarian tumors: inclusion in 
trial, 5, 9; indolent course, 5
bowel obstruction. See toxicity bowel 
obstruction
bowel perforation. See gastrointestinal 
perforation
bowel resection, CHORUS, 181
bradyarrhythmias, 60
Breslow tests for signifi cance, Danish 
Netherlands Trial, 77
Bristol- Meyers Squibb, 75
Brookmeyer- Crowley method, OCEANS, 
253
CA. See cyclophosphamide + doxorubicin/
Adriamycin
CA125: assessable disease, 230, 244; 
AURELIA, 257, 259; CALYPSO, 244, 
245; criteria for disease progression, 122, 
141, 171; CHORUS, 181, 182; Danish 
Netherlands Trial, 77, 79; Doxil Study 
30–49, 209; EORTC- GCG 55865, 165; 
GCIG criteria, 153, 244, 245, 257, 259; 
gemcitabine versus PLD trial, 229, 230; 
GICOG, 12; GOG 97, 55; GOG 104, 63; 
GOG 132, 72; GOG 152, 170; GOG 172, 
111; GOG 175, 196; GOG 178/SWOG 
9701, 187; GOG 182/ICON5, 117; GOG 
218, 153; ICON4/AGO- OVAR 2.2, 218, 
219; ICON7, 148; JGOG 3016, 122; 
MITO-7, 159; normalization as endpoint, 
144; OCEANS, 252; OV-10, 83; OV16, 
140; OV16, 141; prognostic  factor, 233, 
248; Rustin method, 107, 153–154, 230; 
SCOTROC, 107–109; sign of progressive 
disease, 79; surrogate for outcome, 83, 
144
CA125 normalization in advanced- stage 
ovarian cancer. See advanced- stage 
ovarian cancer, CA125 normalization
CA125 progression in recurrent ovarian 
cancer. See recurrent ovarian cancer, 
progression by CA125
CA125 response in recurrent ovarian 
cancer. See recurrent ovarian cancer, 
response by CA125 criteria
CA125 to CEA ratio: CHORUS, 179; 
EORTC 55971, 174; JGOG 3016, 120; 
OV16, 138
Calvert formula: AGO- OVAR-3, 101; 
AGO- OVAR9, 133; CALYPSO, 244; 
Danish Netherlands Trial, 76; GOG 114, 
87; GOG 158, 96; GOG 175, 195; ICON1, 
33; ICON2, 68; ICON3, 91; ICON4/
AGO- OVAR 2.2, 218; JGOG 3016, 
120, 121; MITO-2, 128; MITO-7, 158; 
SCOTROC, 107
CALYPSO (Pujade- Lauraine 2010), 200, 
242–249, 249, 255–256
cancer- specifi c survival, defi nition, 29
cancer- specifi c survival in high- risk 
early- stage ovarian cancer. See early- 
stage ovarian cancer, high- risk, 
cancer- specifi c survival
CAP. See cyclophosphamide + doxorubicin/
Adriamycin + platinum (CAP)
carboplatin: ACTION, 21, 27; AGO- OVAR/
NCIC/EORTC trial, 223; AUC 2, 158; 





AUC 4, 224; AUC 5, 33, 68, 76, 107, 128, 
115, 128, 133, 139, 146, 223, 244, 251; 
AUC 6, 99, 101, 116, 120, 121, 152, 158, 
195; AUC 7, 107; AUC 7.5, 39, 96, 99; 
AUC 9, 86, 90; Calvert formula, 76, 91, 
96, 101, 107, 120, 121, 128, 134, 158, 
195, 218, 224, 244, 251; Cockcroft- Gault 
formula, 68, 128, 139, 158, 219, 244; 
combination regimens, 33; dose, 99; dose 
reduction, 224; dose reduction for GFR 
method, 68; early- stage ovarian cancer, 
20, 25, 33; equivalence to CAP, 68; 
equivalence to cisplatin, 66, 91, 95, 103; 
FDA approval, 235; fi rst- line treatment, 
95; hypersensitivity reaction, 246, 248; 
ICON1, 21; ICON2, 68, 91; ICON3, 91, 
100; ICON4/AGO- OVAR 2.2, 218; 
inferior to cisplatin, 75; Jelliffe method, 
87, 96, 101, 121, 134, 195, 224; less 
toxicity than cisplatin, 67, 75, 99, 100, 
103, 105; maximum tolerated dose, 101; 
neurotoxicity, 99; platinum- sensitive 
ovarian cancer, 222, 243; preferred agent 
in early- stage ovarian cancer, 24, 37; 
progression- free survival, 225; recom-
mendation against upfront use, 96; 
SCOTROC, 107; substitution for 
cisplatin, 82; toxicity, 95; use in United 
Kingdom, 67; weekly administration, 161
carboplatin + docetaxel. See 
docetaxel + carboplatin
carboplatin + gemcitabine: AGO- OVAR/
NCIC/EORTC trial, 222–228, 242, 243; 
approval in Eu rope, 249; approval in 
United States, 249; combined with 
bevacizumab, 251; dose reduction, 224; 
OCEANS, 251; platinum- sensitive 
ovarian cancer, 227; progression- free 
survival, 225, 249; response rate, 223
carboplatin + paclitaxel. See paclitaxel + 
carboplatin (TC)
carboplatin + pegylated liposomal doxorubi-
cin (PLD): alternative front- line therapy, 
131; CALYPSO, 244, 249; duration of 
therapy, 249; MITO-2, 126–132; overall 
survival, 244, 249; platinum- sensitive 
ovarian cancer, 249; progression- free 
survival, 244; response rate, 243–244; 
superior to carboplatin alone, 249; 
toxicity profi le, 131
cardiac function: Doxil Study 30–49, 209; 
OVA-301, 236, 238
cardiac ischemia. See toxicity, cardiac 
ischemia
cardiac toxicity. See toxicity, cardiac
central ner vous system bleeding. 
See toxicity, central ner vous system 
bleeding
chemical tumor debulking, 86
chemore sis tance: early- stage ovarian 
cancer, 42; infl uence on survival, 137; 
time to treatment failure, 137
chemotherapy, superiority of combination 
regimens, 66
chest radiography: Doxil Study 30–49, 211; 
GICOG  trials, 11, 12; GOG 152, 170; 
GOG 178/SWOG 9701, 187; GOG 7601, 3; 
GOG 7602, 6
Chi- square test: ACTION, 29; CALYPSO, 
246; ICON1/ACTION, 21, 23; ICON3, 
92; ICON4/AGO- OVAR 2.2, 220; JGOG 
3016, 123; MITO-2, 131; OV10, 83; test 
for interaction, 92; test for trend, 92
chlorambucil, GOG 97, 55
chlorpheniramine, 106
CHORUS (Kehoe 2015), 162, 178–185
chromic phosphate (32P). See intraperitoneal 
32P
cimetidine, 39, 76, 88, 96, 102, 106, 196
cisplatin: ACTION, 21, 26; dose adjust-
ment, 71; dosing, 11, 33, 71; effi cacy, 
47; equivalence to carboplatin, 66, 91; 
equivalence to PC (paclitaxel +cisplatin), 
74; FDA approval, 235; GICOG  trials, 11; 
GOG 132, 70; higher dose in GOG 132, 
71; ICON4/AGO- OVAR 2.2, 219; 
immediate versus delayed treatment, 
13–14; intraperitoneal, 63, 86, 88; renal 
monitoring, 48, 51; superiority of, 12, 
20, 48; toxicity, 99
cisplatin + cyclophosphamide. See 
cyclophosphamide + cisplatin (CP)
cisplatin + cyclophosphamide + doxorubicin/
Adriamycin. See cyclophosphamide + 
doxorubicin/Adriamycin + platinum 
(CAP)
cisplatin + doxorubicin/Adriamycin + 
cyclophosphamide. See cyclophospha-
mide + doxorubicin/Adriamycin + 
platinum (CAP)





cisplatin + paclitaxel. See paclitaxel + 
cisplatin (TP)
clear cell histology: no benefi t with 
dose- dense paclitaxel administration, 
123; poor response to chemotherapy, 199; 
prognostic  factor, 2, 17; response rate to 
chemotherapy, 44–45; worse outcomes, 
5, 9, 52
clemastine, 102
clinical response rate, GOG 97, 57
clinical  trials limitations, 235
coagulopathy: bevacizumab, 153; GOG 
218, 153
Cochran- Mantel- Haenszel: Doxil Study 
30–49, 212; OCEANS, 253; OV16, 142
Cockcroft- Gault formula: CALYPSO, 244; 
ICON2, 68; ICON4/AGO- OVAR 2.2, 
219; MITO-2, 128; MITO-7, 158; 
OV16, 139
Colonoscopy: EORTC 55971, 174; OV16, 
138
combination chemotherapy, recurrent 
ovarian cancer, 215
Common Terminology Criteria for Adverse 
Events (CTCAE): AGO- OVAR9, 134; 
AGO- OVAR/NCIC/EORTC trial, 225; 
AURELIA, 259; CALYPSO, 245; 
CHORUS, 182; Doxil Study 30–49, 211; 
gemcitabine versus PLD trial, 230; GOG 
152, 170; GOG 182/ICON5, 115; GOG 
218, 153; MITO-2, 129; MITO-7, 159; 
OCEANS, 252; OVA-301, 238; SCO-
TROC, 107; topotecan versus paclitaxel 
trial, 204
competing risks: GOG 157, 40; GOG 95, 17
complete pathologic response in advanced- 
stage ovarian cancer. See advanced- stage 
ovarian cancer, pathologic complete 
response
complete response (CR): Doxil Study 
30–49, 211; GOG 47, 48; EORTC- GCG 
55865, 165; topotecan versus paclitaxel 
trial, 203
computed tomography (CT) scan: AGO- 
OVAR-3, 103; AURELIA, 259; 
CALYPSO, 245; CHORUS, 181; Danish 
Netherlands Trial, 77; Doxil Study 
30–49, 209, 211; EORTC 55971, 175; 
EORTC- GCG 55865, 165; gemcitabine 
versus PLD trial, 230; GICOG  trials, 11, 
12; GOG 132, 72; GOG 152, 170; GOG 
178/SWOG 9701, 187; GOG 218, 153; 
GOG 7601, 3; GOG 7602, 6; ICON7, 147; 
JGOG 3016, 122; MITO-2, 129; MITO-7, 
159; OCEANS, 252; OV-10, 83; OV16, 
140; SCOTROC, 107–109; topotecan 
versus paclitaxel study, 202
confi dence limits, Simon method, 5, 7
congestive heart failure. See toxicity, 
congestive heart failure
constipation. See toxicity, constipation
cost effectiveness: bevacizumab, 151; 
endpoint, 83; ICON7, 151
covariance matrix, GOG 172, 112
covariance par ameters, GOG 172, 112
Cox proportional hazards regression: 
ACTION, 27; AGO- OVAR9, 135; 
AGO- OVAR/NCIC/EORTC trial, 227; 
CALYPSO, 246; CHORUS, 183; Danish 
Netherlands Trial, 77; EORTC 55971, 
176; EORTC- GCG 55865, 165; gem-
citabine versus PLD trial, 231; GICOG 
 trials, 12; GOG 52, 52; GOG 104, 64; 
GOG 114, 88; GOG 158, 97; GOG 172, 
112; GOG 178/SWOG 9701, 191; GOG 
218, 154; GOG 7601, 4; GOG 7602, 7; 
ICON2, 68; ICON7, 148; MITO-2, 131; 
OCEANS, 253; OV-10, 83; OVA-301, 
239; topotecan versus paclitaxel trial, 
206
C- reactive protein, 79
creatine phosphokinase, OVA-301, 236
creatinine: par ameters to discontinue 
chemotherapy, 11; par ameters to hold 
chemotherapy, 11
creatinine clearance: Danish Netherlands 
Trial, 76; ICON2, 68; MITO-2, 128; 
par ameters to discontinue chemo-
therapy, 11; par ameters to hold chemo-
therapy, 11
Cremophor EL, 76
crossover: AURELIA, 259, 262; gem-
citabine versus PLD trial, 230; GOG 111, 
62, 85; GOG 132, 74; GOG 178/SWOG 
9701, 194; GOG 218, 157; ICON1, 37; 
ICON3, 95; OV-10, 85
CTCAE. See Common Terminology 
Criteria for Adverse Events
CT scan. See computed tomography scan
cumulative incidence, 12





cutaneous toxicity. See toxicity, skin
cyclophosphamide: alkylating agent, 48; 
dose modifi cations, 59; hemorrhagic 
cystitis, 55; maintenance therapy in 
GOG 47, 47, 48; metronomic, 250
cyclophosphamide + cisplatin (CP): disease 
control rate with, 57, 58; dose modifi ca-
tions, 82; EORTC- GCG 55865, 164; 
equivalence to cyclophosphamide + 
doxorubicin/Adriamycin + platinum 
(CAP), 100; GOG 52, 51, 100; GOG 95, 
9, 15, 16; GOG 97, 53; GOG 104, 63; 
GOG 111, 58, 80, 100; GOG 114 arm 
discontinued, 87; inferiority compared 
to paclitaxel + cisplatin (TP) regimen, 
60, 74, 83, 90; inferiority compared to 
single- agent platinum, 95; intensive 
intravenous dosing, 54; intraperitoneal 
dosing, 63; OV-10, 80, 81, 100; pos si ble 
antagonistic effect, 74; standard 
intravenous dosing, 54; standard of 
care, 57, 201; superiority of, 17; toxicity 
of, 56
cyclophosphamide + doxorubicin/Adriamy-
cin (CA): GOG 47, 47; subsequent 
treatment with cisplatin, 49–50
cyclophosphamide + doxorubicin/Adriamy-
cin + platinum (CAP): fi rst line treatment, 
95; GOG 47, 47, 48, 100; GOG 52, 51; 
ICON1, 21, 33; ICON2, 36, 67, 91; 
ICON3, 92, 100; lower cyclophospha-
mide dose than in CA regimen, 52; 
superiority over cyclophosphamide + 
doxorubicin, 48, 50, 100; superiority 
over cyclophosphamide + cisplatin, 
66–67; toxicity, 70; use in Italy, 67
cystectomy (bladder), CHORUS, 181
cytoreductive surgery: drug- resistant clones, 
163; EORTC- GCG 55865, 162–168; 
rationale, 163; tumor growth rate, 163
Danish Netherlands trial (Neijt 2000), 46, 
75–79, 91, 99, 105
death due to treatment. See toxicity, death 
due to treatment
delay in treatment: AGO- OVAR-3, 102; 
AGO- OVAR/NCIC/EORTC trial, 224; 
CALYPSO, 245; gemcitabine versus PLD 
trial, 230; GOG 104, 63; GOG 111, 59; 
GOG 132, 72; GOG 157, 39; GOG 158, 
96–97; GOG 172, 111; GOG 175, 196; 
GOG 178/SWOG 9701, 188; GOG 182/
ICON5, 117; JGOG, 121; MITO-2, 128; 
OCEANS, 252; OV16, 139; OVA-301, 
241; SCOTROC, 107
dermatologic toxicity. See toxicity, skin
dexamethasone, 11, 39, 59, 76, 81, 88, 96, 
102, 106, 196, 203, 237
diaphragm stripping, CHORUS, 181
diarrhea. See toxicity, diarrhea
diphenhydramine, 39, 59, 76, 81, 88, 96, 
106, 196
disease control rate in recurrent ovarian 
cancer. See recurrent ovarian cancer, 
disease- control rate
disease- free survival in high- risk early- 
stage ovarian cancer. See early- stage 
ovarian cancer, high- risk, disease- free 
survival
disease- free survival in low- risk early- stage 
ovarian cancer. See early- stage ovarian 
cancer, low- risk, disease- free survival
disease- free survival in stage I ovarian 
cancer. See stage I ovarian cancer, 
disease- free survival
docetaxel: activity in ovarian cancer, 105; 
combination with carboplatin, 105, 106, 
109; dexamethasone treatment, 106; 
dose, 106; dose discontinuation, 107; 
dose reduction, 106, 107; hypersensitivity 
reaction, 107; substitution for paclitaxel, 
152
docetaxel + carboplatin, 105–109
dose- dense paclitaxel: antiangiogenic 
effect, 123; hematologic toxicity, 
123; improved survival, 123; rationale, 
123
dose escalation: GOG 47, 48; GOG 52, 51; 
topotecan versus paclitaxel trial, 203
dose intensity: GOG 97, 54; GOG 114, 88; 
GOG 157, 39; no impact on outcome, 57, 
126; topotecan versus paclitaxel trial, 
203
dose reduction: AGO- OVAR-3, 102; 
AGO- OVAR9, 133, 134; AGO- OVAR/
NCIC/EORTC trial, 224; AURELIA, 
259; CALYPSO, 245; Danish Nether-
lands Trial, 76; Doxil Study 30–49, 210, 
214t; gemcitabine versus PLD trial, 230; 
GOG 47, 47–48; GOG 52, 51; GOG 97, 






 54; GOG 157, 39; GOG 158, 96; GOG 
172, 111; GOG 175, 196; GOG 178/
SWOG 9701, 188; GOG 182/ICON5, 117; 
JGOG 3016, 121; MITO-2, 128; MITO-7, 
158; OV16, 139, 140; OVA-301, 237; 
pegylated liposomal doxorubicin, 210; 
SCOTROC, 106–107; topotecan, 210; 
topotecan versus paclitaxel trial, 203, 
207
Doxil study 30–49 (Gordon 2001, Gordon 
2004), 115, 200, 207–217, 234, 242, 243, 
256
doxorubicin (Adriamycin): alopecia, 127; 
cardiac toxicity, 127; congestive heart 
failure, 48, 51; cumulative dose, 48, 51; 
dose- limiting toxicity, 127; fi rst- line 
treatment, 126; gastrointestinal toxicity, 
127; improved survival, 126, 132; lack of 
treatment benefi t, 50, 52; myelosuppres-
sion, 127; toxicity, 48, 208
doxorubicin + cyclophosphamide. See 
cyclophosphamide + doxorubicin/
Adriamycin (CA)
doxorubicin + cyclophosphamide + platinum. 
See cyclophosphamide + doxorubicin/
Adriamycin + platinum (CAP)
duration of chemotherapy, 38
duration of response in recurrent ovarian 
cancer. See recurrent ovarian cancer, 
duration of response
dyspnea. See toxicity, dyspnea
early- stage ovarian cancer: GOG 7601, 1–5; 
prevalence, 37; recurrence risk, 17, 25, 
32, 37, 38, 42, 43, 194
early- stage ovarian cancer, high- risk: GCIG 
consensus recommendations, 194; 
GICOG  trials, 9–15; GOG 7602, 5–9; 
recurrence risk, 7, 17, 36; survival, 7, 36
early- stage ovarian cancer, high- risk, 
cancer- specifi c survival: ACTION, 29t, 
31t; grade 3 tumors, 31t; no further 
therapy, 29t, 31t; non- optimally staged, 
29t, 31t; optimally staged, 29t, 31t; 
platinum- based chemo therapy, 29t, 31t
early- stage ovarian cancer, high- risk, 
disease- free survival: cisplatin, 14t; 
GICOG trial 2, 14t; GOG 157, 42; 
intraperitoneal 32P, 14t
early- stage ovarian cancer, high- risk, 
overall survival: ACTION, 28t; by 
histology, 45t; carboplatin + paclitaxel, 
41t; cisplatin, 14t; cyclophospha-
mide + cisplatin (CP), 18t; GICOG trial 2, 
14t; GOG 95, 18t; GOG 157, 41t; GOG 
175, 198t; GOG 7602, 8t; ICON1, 35t; 
ICON1/ACTION, 22t; intraperitoneal 32P, 
8t, 14t, 18t; maintenance chemotherapy, 
198t; melphalan, 8t; no further therapy, 
22t, 28t, 35t; non- optimally staged, 28t; 
non- serous histology, 45t; optimally 
staged, 28t; paclitaxel + carboplatin (TC), 
41t; platinum- based chemotherapy, 22t, 
28t, 35t; serous histology, 45t
early- stage ovarian cancer, high- risk, 
recurrence- free survival: ACTION, 28t, 
29t, 31t; by ascites, 45t; by cytology, 45t; 
by grade, 45t; by histology, 45t; by 
per for mance status, 45t; by stage, 45t; by 
tumor rupture, 45t; GOG 157, 45t; grade 
3 tumors, 31t; ICON1, 35t; ICON1/
ACTION, 22t; no further therapy, 22t, 28t, 
29t, 31t, 35t; non- optimally staged, 28t, 
29t, 31t; non- serous histology, 45t; 
optimally staged, 28t, 29t, 31t; platinum- 
based chemotherapy, 22t, 28t, 29t, 31t, 35t; 
serous histology, 45t
early- stage ovarian cancer, high- risk, 
recurrence rate: ACTION, 28t, 29t; 
carboplatin + paclitaxel, 41t; complete 
staging, 41t; cyclophosphamide + cispla-
tin (CP), 18t; GOG 95, 18t; GOG 157, 41t; 
GOG 158, 100; GOG 175, 198t; 
intraperitoneal 32P, 18t; maintenance 
chemotherapy, 198t; no further therapy, 
28t, 29t; paclitaxel + carboplatin (TC), 
41t; platinum- based chemotherapy, 28t, 
29t; stage I, 42; stage II, 42; stage III, 100
early- stage ovarian cancer, low- risk: 
cisplatin in, 15; defi nition, 5, 10; GICOG 
 trials, 9–15; GOG 7601, 1–5, 25; no 
further treatment, 5, 10, 25
early- stage ovarian cancer, low- risk, 
disease- free survival: cisplatin, 13t; 
GICOG trial 1, 13t; GOG 7601, 4t; 
melphalan, 4t; no further treatment, 4t, 13t
early- stage ovarian cancer, low- risk, overall 
survival: cisplatin, 13t; GICOG trial 1, 
13t; no further treatment, 13t





early termination of trial: federal mandate, 
192; GOG 178/SWOG 9701, 189–190, 
191, 192
Eastern Cooperative Oncology Group 
(ECOG), 86
echocardiogram, 211
ECOG. See Eastern Cooperative Oncology 
Group
Ecteinascidia turbinata, 235
electrocardiography: CALYPSO, 245; 
GOG 152, 170
Eli Lilly & Co, 228
endpoints: adverse events, 122, 141, 175; 
biologic progression- free interval, 147; 
CA125 as surrogate for outcome, 83, 
144, 182; CA125 normalization at three 
cycles, 144; clinical response rate, 83, 171; 
complications, 117; cost- effectiveness, 
83; cumulative dose delivery, 117; disease 
control rate, 231; dose intensity, 117; 
duration of response, 204, 212, 225, 239, 
252; endorsed by AACR, 235; endorsed 
by ASCO, 235; endorsed by FDA, 235; 
endorsed by GCIG, 157; FACT- O/TOI 
score, 159; fi ve- year survival, 68; health 
economics, 147; laboratory results, 
147; negative second look, 53; non- 
standardized, 235; objective response 
rate, 159; overall response rate, 239, 252, 
259; overall survival, 12, 21, 27, 34, 55, 
60, 68, 72, 83, 88, 92, 97, 103, 109, 112, 
117, 122, 129, 134, 141, 147, 159, 165, 171, 
175, 182, 189, 196, 212, 219, 225, 228, 
231, 238, 252, 259; pathologic response 
rate, 63, 90; per for mance status, 147; 
progression- free interval, 53, 55, 68, 153; 
progression- free survival, 60, 72, 77, 83, 
88, 92, 97, 103, 109, 112, 117, 122, 129, 
135, 141, 147, 153, 159, 165, 171, 175, 182, 
189, 219, 225, 231, 238, 246, 252, 259; 
proportion without progression, 103; 
quality of life, 83, 103, 109, 112, 129, 
135, 147, 175, 182, 219, 225, 239, 259; 
recurrence- free survival, 21, 27, 34; 
recurrence rate, 40, 196; relapse- free 
survival, 12; response rate, 48, 55, 72, 
122, 137, 204, 212; response to treatment, 
103, 135, 147, 225; safety, 212, 239, 259; 
surrogate, 235; survival, 2, 7, 53, 63, 68, 
137, 204; time at risk of recurrence, 40; 
time to progression, 212; time to 
recurrence, 196, 204; time to response, 
204, 212; time to treatment failure, 137; 
tolerability, 259; toxicity, 103, 117, 129, 
135, 147, 159, 212, 225; translational 
research, 147; treatment activity, 129
ENGOT. See Eu ro pean Network of 
Gynaecological Oncological Trial Group
EORTC. See Eu ro pean Organ ization of 
Research and Treatment in Cancer
EORTC 55971 (Vergote 2010), 162, 
174–178, 182
EORTC- GCG 55865 (van der Burg 1995), 
162, 162–168, 168, 171, 173
epogen, 136t
erythropoietin, 145t, 214t
ethylenediaminetetraacetic acid (EDTA) 
clearance, Danish Netherlands Trial, 76
etoposide: lack of cross- resistance to 
platinum and taxanes, 208; response 
rates, 215; second- line therapy, 201
Eu ro pean Network of Gynaecological 
Oncological Trial Group (ENGOT), 
157, 256
Eu ro pean Organ ization of Research and 
Treatment in Cancer (EORTC), 19, 24, 
80, 138, 163, 174, 222, 243
exact linear rank test, MITO-2, 131
fatigue. See toxicity, fatigue
febrile neutropenia. See toxicity, febrile 
neutropenia
fever. See toxicity, fever
F. Hoffmann- La Roche, 256
fi lgrastim, GOG 157, 39
fi ne needle aspiration, EORTC 55971, 174
Fisher’s exact test: gemcitabine versus PLD 
trial, 231; GOG 104, 64; GOG 218, 154; 
JGOG 3016, 123; MITO-2, 131; OV-10, 
83; OV16, 142
fi stula. See toxicity, fi stula
fl exible parametric survival models, 
ICON7, 148
Food and Drug Administration, approval of 
pegylated liposomal doxorubicin, 208
Freedman’s method for sample size calculation, 
gemcitabine versus PLD trial, 231
Functional Assessment of Cancer 
Therapy— Gynecologic Oncology 
Group— Ntx, MITO-7, 159





Functional Assessment of Cancer 
Therapy— Ovarian (FACT- O) question-
naire: GOG 172, 111; GOG 218, 153, 154; 
MITO-7, 159, 160t; primary endpoint, 
159
Functional Living Index— Cancer (FLIC), 
GOG 97, 55
gastrointestinal perforation. See toxicity, 
gastrointestinal perforation
gastrointestinal toxicity. See toxicity, 
gastrointestinal
gastroscopy: EORTC 55971, 174; OV16, 138
GCIG. See Gynecologic Cancer Intergroup
GCIG criteria for CA125 response, 153, 
244, 245, 257, 259
GEICO. See Grupo de Investigacion de 
Cancer De Ovario
gemcitabine: combination regimens, 
223–224, 229, 251; combined with 
paclitaxel and carboplatin, 116–117, 
132–137; dose modifi cations, 252; dose 
reduction, 224; dosing, 230; FDA 
approval, 235; front- line chemotherapy, 
116–117, 132–137; gemcitabine versus 
PLD trial, 228–234; fatigue, 137; 
hematologic toxicity, 137; lack of 
cross- resistance to platinum and taxanes, 
208; nucleoside analogue, 223; phase II 
studies, 229; platinum- resistant ovarian 
cancer, 229; recurrent ovarian cancer, 
115, 132, 133, 223, 243; response rates, 
215
gemcitabine + carboplatin. See 
carboplatin + gemcitabine
Gemcitabine versus PLD trial (Mutch 
2007), 132, 200, 228–234, 256
Gemzar. See gemcitabine
Genentech, 249
genitourinary toxicity. See toxicity, 
genitourinary
GICOG  trials (Bolis 1995), 1, 9–15, 19, 20, 
24, 25, 32, 36, 38, 193, 197
GINECO. See Group d’Investigateurs 
Nationaux pour l’Etude des Cancers 
Ovariens
global deterioration of health, GOG 218, 
154
global test of heterogeneity, GICOG  trials, 
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cancer, pathologic complete response
pathologic response rate: GOG 97, 55, 57; 
GOG 104, 63, 64; with intraperitoneal 
cisplatin, 64
patient- reported outcomes, 262
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prognostic  factor, 233; World Health 
Organ ization (WHO), 76, 81, 174; 
Zubrod, 230
peripheral edema. See toxicity, peripheral 
edema
PharmaMar, 235
platelet count, prognostic impact, 79
platelet toxicity. See toxicity, platelet
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AGO- OVAR/NCIC/EORTC trial, 223, 
249; CALYPSO, 24, 2464; choice of 
chemotherapy agents, 217, 222, 242, 249, 
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free survival, 127, 249; response rate, 
127; topotecan activity, 127
PLD. See pegylated liposomal doxorubicin
posterior reversible encephalopathy 
syndrome (PRES). See toxicity, posterior 
reversible encephalopathy syndrome
postoperative mortality, CHORUS, 185
power analy sis. See sample size
primary cytoreduction: CHORUS, 180; 
EORTC 55971, 175; standard of care, 
174, 179
proctosigmoidoscopy, 3, 6, 11
progression: AGO- OVAR/NCIC/EORTC 
trial, 225; GOG 152, 171; GOG 178/
SWOG 9701, 191; greater hazard for 





progression  after maintenance paclitaxel, 
191; OCEANS, 252
progression- free interval in advanced- stage 
ovarian cancer. See advanced- stage 
ovarian cancer, progression- free interval
progression- free survival, 225
progression- free survival as primary 
endpoint: AGO- OVAR/NCIC/EORTC 
trial, 225; AURELIA, 259; CALYPSO, 
246; Danish Netherlands Trial, 77; 
determined by investigators, 252, 259; 
endorsed by AACR ASCO and FDA, 
235, 239; endorsed by GCIG, 157; 
gemcitabine versus PLD trial, 231; 
GOG 52, 52; GOG 111, 60; GOG 132, 72; 
GOG 178/SWOG 9701, 189, 192; GOG 
218, 153; ICON7, 147; JGOG 3016, 122; 
median, 144; MITO-2, 129; MITO-7, 
159; OCEANS, 252; OV-10, 83; OV16, 
141; OVA-301, 238; rationale, 192, 228, 
248; SCOTROC, 109
progression- free survival in advanced- stage 
ovarian cancer. See advanced- stage 
ovarian cancer, progression- free survival
progression- free survival in recurrent 
ovarian cancer. See recurrent ovarian 
cancer, progression- free survival
progressive disease: Doxil Study 30–49, 
211; MITO-2, 129; OV16, 141; topotecan 
versus paclitaxel trial, 204
proportional hazards model: CHORUS, 183; 
Grambsch- Therneau test, 183; GOG 95, 
17; GOG 97, 55; GOG 111, 60; GOG 152, 
171; GOG 157, 40
proportion without progression as primary 
endpoint, AGO- OVAR-3, 103
proteinuria. See toxicity, proteinuria
pulmonary toxicity. See toxicity, 
pulmonary
QLQ- C30 questionnaire: AGO- OVAR-3, 
102; AGO- OVAR9, 134; AGO- OVAR/
NCIC/EORTC trial, 224, 227; 
CALYPSO, 245; CHORUS, 181; 
domains, 140, 211; Doxil Study 30–49, 
211; EORTC 55971, 175; ICON7, 147; 
OV16, 140; OVA-301, 238; SCOTROC, 
107; symptom scales, 211
QLQ- OV28 questionnaire: AGO- OVAR9, 
134; AGO- OVAR/NCIC/EORTC trial, 
224, 227; CALYPSO, 245; CHORUS, 
181; EORTC 55971, 175; ICON7, 147; 
OV16, 140; OVA-301, 238; questions 
related to ovarian cancer symptoms and 
treatments, 141; SCOTROC, 107
quality of life: AGO- OVAR9, 134; 
AGO- OVAR/NCIC/EORTC trial, 224, 
227; CALYPSO, 245; CHORUS, 181, 
183; Doxil Study 30–49, 211; endpoint, 
83, 100, 102; EORTC 55971, 175; 
Functional Assessment of Cancer 
Therapy— Ovarian (FACT- O) question-
naire, 111, 153, 159, 231; gemcitabine 
versus PLD trial, 231, 233; goal in 
recurrent ovarian cancer, 215, 242; GOG 
172, 111, 114; GOG 218, 153, 157; ICON4/
AGO- OVAR 2.2, 219, 222; ICON7, 147; 
MITO-2, 129; MITO-7, 159; OV16, 140; 
OVA-301, 238, 241; prognostic  factor, 
233; QLQ- C30 questionnaire, 102, 107, 
129, 134, 140–141, 147, 175, 181, 211, 224, 
238, 245; QLQ- OV28 questionnaire, 107, 
134, 140, 147, 175, 181, 224, 238, 245; 
SCOTROC, 107; treatment toxicities, 126
radiotherapy: treatment option for 
early- stage ovarian cancer, 10; treatment 
option for recurrent ovarian cancer, 215
ranitidine, 81, 88, 106
RECIST (Response Evaluation Criteria in 
Solid Tumors): AGO- OVAR9, 134; 
AURELIA, 257; CALYPSO, 244, 245; 
gemcitabine versus PLD trial, 230; GOG 
218, 153; ICON7, 147; MITO-2, 129; 
MITO-7, 159; OCEANS, 250, 252; OV16, 
141; OVA-301, 236; SCOTROC, 107
RECIST response in advanced- stage 
ovarian cancer. See advanced- stage 
ovarian cancer, RECIST response
RECIST response in recurrent ovarian 
cancer. See recurrent ovarian cancer, 
RECIST response
recurrence defi nition, GOG 178/SWOG 
9701, 189
recurrence- free survival: defi nition, 29, 34; 
suboptimal staging, 43
recurrence- free survival in high- risk 
early- stage ovarian cancer. See early- 
stage ovarian cancer, high- risk, 
recurrence- free survival





recurrence patterns: ACTION, 28t; GICOG 
 trials, 13t, 14t; GOG 7602, 9
recurrence rate as primary endpoint: GOG 
157, 40; GOG 175, 196
recurrence rate in high- risk early- stage 
ovarian cancer. See early- stage ovarian 
cancer, high- risk, recurrence rate
recurrent ovarian cancer, disease- control 
rate: gemcitabine, 231t; gemcitabine 
versus PLD trial, 231, 231t; pegylated 
liposomal doxorubicin, 231t
recurrent ovarian cancer, duration of 
response: AGO- OVAR/NCIC/EORTC 
trial, 225, 226t; carboplatin, 226t; 
carboplatin + gemcitabine, 226t, 254t; 
carboplatin + gemcitabine + bevacizumab, 
254t; OCEANS, 254t; OVA-301, 239; 
paclitaxel, 205t; topotecan, 205t; 
topotecan versus paclitaxel trial, 205–206t
recurrent ovarian cancer, overall survival: 
AGO- OVAR/NCIC/EORTC trial, 226t; 
AURELIA, 261t; carboplatin, 226t; 
carboplatin + gemcitabine, 226t, 254t; 
carboplatin + gemcitabine + bevacizumab, 
254t; chemotherapy alone, 261t; 
chemotherapy + bevacizumab, 261t; 
Doxil study 30–49, 213t; gemcitabine, 
231t; gemcitabine versus PLD trial, 231t; 
ICON4/AGO- OVAR 2.2, 221t; OCEANS, 
254t; paclitaxel, 205t; pegylated 
liposomal doxorubicin, 213t, 231t; 
platinum chemotherapy, 221t; plati-
num + paclitaxel, 221t; platinum- resistant, 
213t, 214t; platinum- sensitive, 213t; 
topotecan, 205t, 213t; topotecan versus 
paclitaxel trial, 205–206t
recurrent ovarian cancer, progression by 
CA125: CALYPSO, 247t; carbopla-
tin + pegylated liposomal doxorubicin 
(C- PLD), 247t; paclitaxel + carboplatin 
(TC), 247t
recurrent ovarian cancer, progression- free 
survival: AGO- OVAR/NCIC/EORTC 
trial, 226t; AURELIA, 261t; CALYPSO, 
247t; carboplatin, 226t; carboplatin + 
gemcitabine, 226t, 254t; carboplatin + 
gemcitabine + bevacizumab, 254t; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 247t; chemotherapy 
alone, 261t; chemotherapy + bevacizumab, 
261t; Doxil study 30–49, 213t; gem-
citabine, 231t; gemcitabine versus PLD 
trial, 231t; ICON4/AGO- OVAR 2.2, 221t; 
OCEANS, 254t; OVA-301, 240t; 
paclitaxel + carboplatin (TC), 247t; 
pegylated liposomal doxorubicin, 213t, 
231t, 240t; pegylated liposomal doxorubi-
cin + trabectedin, 240t; platinum chemo-
therapy, 221t; platinum + paclitaxel, 221t; 
platinum- resistant, 213t, 240t; platinum- 
sensitive, 213t, 240t; topotecan, 213t
recurrent ovarian cancer, RECIST 
response: AGO- OVAR/NCIC/EORTC 
trial, 226t; AURLEIA, 261t; CALYPSO, 
247t; carboplatin, 226t; carboplatin + 
gemcitabine, 226t; carboplatin + 
pegylated liposomal doxorubicin 
(C- PLD), 247t; chemotherapy alone, 
261t; chemotherapy + bevacizumab, 261t; 
Doxil study 30–49, 213t; gemcitabine, 
231t; gemcitabine versus PLD trial, 231t; 
ICON4/AGO- OVAR 2.2, 221t; paclitaxel, 
205–206t; paclitaxel + carboplatin (TC), 
247t; pegylated liposomal doxorubicin, 
213t, 231t; platinum chemotherapy, 221t; 
platinum + paclitaxel, 221t; topotecan, 
205–206t, 213t; topotecan versus 
paclitaxel trial, 205–206t
recurrent ovarian cancer, response by 
CA125 criteria: AURELIA, 261t; 
chemotherapy alone, 261t; chemotherapy + 
bevacizumab, 261t
recurrent ovarian cancer, response rate: 
AGO- OVAR/NCIC/EORTC trial, 226t; 
AURELIA, 261t; carboplatin, 226t; 
carboplatin + gemcitabine, 226t, 254t; 
carboplatin + gemcitabine + bevacizumab, 
254t; chemotherapy alone, 261t; 
chemotherapy + bevacizumab, 261t; 
gemcitabine, 231t; gemcitabine versus 
PLD trial, 231t; OCEANS, 254t; 
pegylated liposomal doxorubicin, 231t
recurrent ovarian cancer, time to failure: 
gemcitabine, 231t; gemcitabine versus 
PLD trial, 231t; pegylated liposomal 
doxorubicin, 231t
recurrent ovarian cancer, time to progres-
sion: paclitaxel, 205–206t; topotecan, 
205–206t; topotecan versus paclitaxel 
trial, 205–206t





recurrent ovarian cancer, time to response: 
paclitaxel, 205–206t; topotecan, 205–206t; 
topotecan versus paclitaxel trial, 205–206t
relapse: early relapse, 204; interim relapse, 
204; late relapse, 204; resistant disease, 204
relapse- free survival, 12
renal function: AGO- OVAR-3, 101; 
AGO- OVAR9, 133; AGO- OVAR/NCIC/
EORTC trial, 223; Danish Netherlands 
Trial, 75–76; Doxil Study 30–49, 209; 
GOG 97, 54; GOG 104, 62; GOG 111, 58; 
GOG 114, 87; GOG 132, 71; GOG 152, 
169; GOG 158, 96; GOG 182/ICON5, 
115; JGOG 3016, 120; OV16, 138; 
OVA-301, 236; topotecan versus 
paclitaxel study, 202
renal toxicity. See toxicity, renal
residual disease status, prognostic impact, 
52, 64, 79, 119, 131, 178, 179, 183
response duration, GOG 97, 57
response duration in advanced- stage 
ovarian cancer. See advanced- stage 
ovarian cancer, response duration
Response Evaluation Criteria in Solid 
Tumors (RECIST). See RECIST
response rate: Cochran- Mantel Haenszel 
test, 253; lack of correlation with 
survival, 137; phase II endpoint, 137
response rate as primary endpoint, GOG 
47, 48
response rate in advanced- stage ovarian 
cancer. See advanced- stage ovarian 
cancer, response rate
response rate in recurrent ovarian cancer. 
See recurrent ovarian cancer, response 
rate
restricted maximum likelihood, GOG 172, 
112
restricted mean difference, ICON7, 148
reversible posterior leukoencephalopathy 
syndrome. See toxicity, reversible 
posterior leukoencephalopathy syndrome 
(RPLS)
RPLS. See toxicity, reversible posterior 
leukoencephalopathy syndrome
SAAK. See Swiss Group for Clinical 
Cancer Research
salvage therapy: better treatments needed, 
52; early- stage ovarian cancer, 25, 30; 
intraperitoneal, 62; paclitaxel activity, 
58; timing of initiation, 74
sample size: ACTION, 27; AGO- OVAR-3, 
103; AGO- OVAR9, 135; AGO- OVAR/
NCIC/EORTC trial, 225; AURELIA, 
260; CHORUS, 182; Danish Netherlands 
Trial, 77; Doxil Study 30–49, 211; 
EORTC 55971, 176; EORTC- GCG 55865, 
165; Freedman’s method, 231; gem-
citabine versus PLD trial, 231; GOG 47, 
48; GOG 52, 52; GOG 95, 17; GOG 104, 
64; GOG 132, 72; GOG 152, 171; GOG 
157, 40; GOG 158, 97; GOG 172, 112; 
GOG 175, 196; GOG 178/SWOG 9701, 
189; GOG 182/ICON5, 117; GOG 218, 
154; GOG 7601, 3; GOG 7602, 7; ICON1, 
34; ICON2, 68; ICON3, 92; ICON4/
AGO- OVAR 2.2, 220; ICON7, 147; 
JGOG 3016, 123; MITO-2, 129; MITO-7, 
159; OCEANS, 252; OV-10, 83; OV16, 
141; OVA-301, 239; SCOTROC, 109
Schering- Plough Italy, 126
Schoenfeld residuals, OV16, 142
SCOTROC (Vasey 2004), 46, 105–109
Scottish Group, 80
Scottish Gynacological Cancer  Trials 
Group, 105
secondary debulking surgery: diffi culty in 
assessing effi cacy, 173; EORTC- GCG 
55865, 162–168; GOG 152, 168–173, 
JGOG 3016, 122; timing  after chemo-
therapy, 170
secondary malignancy. See toxicity, 
secondary malignancy
second- line chemotherapy: impact on 
overall survival, 192; non- curative, 191
second- look surgery: AGO- OVAR-3, 103; 
does not infl uence survival, 52; EORTC 
55971, 175; EORTC- GCG 55865, 164; 
GOG 47, 47; GOG 52, 51; GOG 97, 55; 
GOG 104, 63, 64; GOG 111, 60; GOG 
114, 88, 90; GOG 158, 97; GOG 172, 111; 
JGOG 3016, 122; no clinical benefi t, 117; 
OV-10, 82
sepsis. See toxicity, sepsis
serous histology: number of chemotherapy 
cycles, 44–45; response to chemotherapy, 
44–45
SIAK. See Swiss Institute for Cancer 
Research





skin toxicity. See toxicity, skin
small bowel perforation. See gastrointestinal 
perforation
SmithKline Beecham Phar ma ceu ti cals, 200
Southwest Oncology Group (SWOG), 15, 
86, 115, 187
splenectomy, CHORUS, 181
stable disease: Doxil Study 30–49, 211; 
topotecan versus paclitaxel trial, 204
stage, prognostic impact, 79, 131, 178
stage I ovarian cancer, disease- free 
survival: cisplatin, 13t; GICOG  trials, 
13t; GOG 7601, 4t; melphalan, 4t; no 
further treatment, 4t, 13t
stage I ovarian cancer, overall survival: 
GOG 7601, 4t; melphalan, 4t; no further 
treatment, 4t
stem cell support, treatment option for 
recurrent ovarian cancer, 215
stomatitis. See toxicity, stomatitis
stratifi cation  factors: age, 141, 189, 204; 
ascites, 204; bulky disease, 212; cell 
type, 3, 7; center, 129, 141, 182, 219, 
246; chemotherapy regimen, 182, 260; 
clinical response, 165; differentiation, 
34; fi rst- line therapy, 225; GCIG group, 
147; grade, 27; histologic grade, 3, 7; 
institution, 27, 34, 165, 176; intended 
platinum treatment, 219; interval 
between surgery and chemotherapy, 147; 
largest preoperative tumor size, 176; last 
chemotherapy received, 219; mea sur able 
disease, 171, 225, 246; method of biopsy, 
176; minimization technique, 165; 
optimal versus suboptimal, 189; 
per for mance status, 129, 154, 165, 237; 
platinum- free interval, 225, 252, 260; 
platinum sensitivity, 212, 237; prior 
antiangiogenic therapy, 260; prior 
treatment with paclitaxel, 189; radiologic 
tumor size, 182; residual disease, 112, 
129, 141, 154; residual tumor size, 103, 
135, 147; response to chemotherapy, 171, 
204; secondary debulking surgery, 220; 
second- look surgery, 112; stage, 7, 27, 34, 
103, 129, 135, 147, 154, 176, 182; surgery 
for recurrence, 252; therapy- free interval, 
246; time since completion of last 
chemotherapy, 219, 220
subgroup analy sis, 21
suboptimal debulking: EORTC- GCG 
55865, 164, 168; GOG 47, 47; GOG 97, 
54; GOG 111, 58; GOG 132, 71; GOG 
152, 168–169; GOG 178/SWOG 9701, 
187; GOG 182/ICON5, 115; GOG 218, 
152; ICON7, 146; JGOG 3016, 124; 
OV-10, 80; overall survival, 43
surgical morbidities, CHORUS, 185
surgical re- exploration: GOG 7601, 3; 
GOG 7602, 7
surgical staging: description, 2, 6, 11, 
16, 20, 26, 39, 195; improved survival, 
30; incomplete documentation, 42; 
prognostic  factor, 2, 30;  trials including 
comprehensive staging, 2, 16, 20, 39, 195; 
 trials lacking comprehensive staging, 24, 
26, 33
survival as endpoint: ACTION, 21, 27; 
GOG 104, 63; GOG 7601, 3; GOG 7602, 
7; GICOG  trials, 12; ICON1, 21, 34; 
ICON2, 68
survival in advanced- stage ovarian cancer: 
bulky disease with complete response to 
chemotherapy, 173; gross optimal, 119; 
microscopic residual, 119; not other wise 
specifi ed, 100, 115; optimal, 176; 
platinum- sensitive, 216, 220; suboptimal, 
119; suboptimal primary debulking and 
interval debulking, 176
survival in early- stage ovarian cancer, 2, 
10, 15, 19, 20, 36, 193, 197
survival in high- risk early- stage ovarian 
cancer: GOG 7602, 9, 38; GOG 95, 17, 
19; ICON1, 36
survival in low- risk early- stage ovarian 
cancer: GOG 7601, 5, 15, 37; stage I, 197; 
stage Ia1 (GOG 7601), 5; stage Ib1 ovarian 
cancer (GOG 7601), 5; stage II, 197
survival in stage III ovarian cancer: GOG 
158, 99; GOG 172, 114
Swiss Group for Clinical Cancer Research 
(SAAK), 32, 90
Swiss Institute for Cancer Research 
(SIAK), 66
SWOG. See Southwest Oncology Group
Taxol. See paclitaxel
TC. See paclitaxel + carboplatin
Tenckhoff catheter, 88
therapeutic ratio, 192





therapy- free interval, prognostic  factor, 248
thrombocytopenia. See toxicity, platelet
thromboembolism. See toxicity, 
thromboembolism
time to failure in recurrent ovarian cancer. 
See recurrent ovarian cancer, time to 
failure
time to progression as primary endpoint, 
Doxil Study 30–49, 212
time to progression in recurrent ovarian 
cancer. See recurrent ovarian cancer, 
time to progression
time to response in recurrent ovarian 
cancer. See recurrent ovarian cancer, 
time to response
timing of chemotherapy initiation, no 
prognostic impact, 52
tinnitus. See toxicity, tinnitus
topoisomerase inhibitor, topotecan, 201
topotecan (Hycamtin): 3- day dosing, 142; 
5- day dosing, 144, 202–203, 210, 258; 
approved agent, 208, 235; AURELIA, 
258; camptothecin analogue, 138, 201; 
combined with bevacizumab, 258; 
combined with paclitaxel and carbopla-
tin, 116, 137, 137–144; dose escalation, 
203; dose- limiting toxicity, 202, 207; 
dose reduction, 203; Doxil study, 
207–217, 242; equivalent to pegylated 
liposomal doxorubicin, 200–207, 234; 
FDA approval, 235; GOG182/ICON5, 
142; intermittent daily dosing, 202; lack 
of cross- resistance to platinum and 
taxanes, 208; maximum tolerated dose, 
202; platinum- resistant ovarian cancer, 
229, 256; recurrent ovarian cancer, 115; 
refractory ovarian cancer, 144; response 
rates, 208; sequential doublets, 138, 139; 
topoisomerase inhibitor, 201; topotecan 
versus paclitaxel study, 200–207, 234, 
242; treatment discontinuation, 203; 
toxicities, 210, 215; weekly dosing, 258
Topotecan versus paclitaxel (ten Bokkel 
1997), 115, 200, 200–207, 229, 234, 242, 
243
toxicity, abdominal pain: cyclophospha-
mide + cisplatin (CP), 65t; GOG 104, 66, 
65t; GOG 172, 111; GOG 7602, 8t; 
intraperitoneal 32P, 8t; intraperitoneal 
cisplatin- based chemotherapy, 65t; 
paclitaxel + carboplatin (TC), 108t; 
SCOTROC, 108t
toxicity, allergic reaction: CALYPSO, 
248t; carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 248t; 
cyclophosphamide + cisplatin (CP), 
61t; Danish Netherlands Trial, 79; 
docetaxel + carboplatin, 108t; GOG 111, 
59, 61t; OV16, 145t; paclitaxel + 
carboplatin (TC), 145t, 248t; paclitaxel + 
cisplatin (TP), 61t; SCOTROC, 108t
toxicity, alopecia: AGO- OVAR/NCIC/
EORTC trial, 227t, 228; CALYPSO, 
246, 248t; carboplatin, 69t, 94t, 227t; 
carboplatin + gemcitabine, 227t, 228; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 130t, 248t; 
cyclophosphamide + cisplatin (CP), 61t, 
85t; cyclophosphamide + doxorubi-
cin + cisplatin (CAP), 69t, 94t; Danish 
Netherlands Trial, 79; Doxil study 
30–49, 214t; GOG 111, 61t; GOG 132, 72; 
GOG 178/SWOG 9701, 193; ICON2, 69t, 
70, ICON3, 94t, 95; ICON4/AGO- OVAR 
2.2, 221t; MITO-2, 130t, 131, 161; 
MITO-7, 160t, 161; OV-10, 85t; pacli-
taxel, 206t; paclitaxel + carboplatin (TC), 
94t, 95, 108t, 130t, 157, 160t, 161, 243, 
248t; paclitaxel + cisplatin (TP), 61t, 85t; 
pegylated liposomal doxorubicin (PLD), 
127, 214t; platinum chemotherapy, 221t; 
platinum + paclitaxel, 221t; SCOTROC, 
108t; topotecan, 206t, 214t; topotecan 
versus paclitaxel trial, 206t; weekly 
paclitaxel + carboplatin, 160t
toxicity, anaphylaxis, OV16, 140
toxicity, anemia: AGO- OVAR/NCIC/
EORTC trial, 226t; AGO/OVAR-3, 104t; 
AGO- OVAR9, 136t; carboplatin, 226t; 
carboplatin + gemcitabine, 226t; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 130t; cisplatin, 73t; 
cyclophosphamide + cisplatin (CP), 56t, 
61t, 65t; Danish Netherlands Trial, 78t; 
docetaxel + carboplatin, 108t; dose- dense 
paclitaxel + carboplatin, 125t; Doxil 
study 30–49, 214t; gemcitabine, 233t; 
gemcitabine versus PLD trial, 233t; 
GOG 97, 56t; GOG 104, 65t; GOG 111, 
61t; GOG 132, 73t, 74; GOG 157, 41t; 






 GOG 182/ICON5, 118t; intraperitoneal 
cisplatin- based chemotherapy, 65t; JGOG 
3016, 125t, 161; MITO-2, 130t; MITO-7, 
161; OCEANS, 252; paclitaxel, 73t, 206t; 
paclitaxel + carboplatin (TC), 41t, 104t, 
108t, 118t, 136t, 161; paclitaxel + 
carboplatin (TC), 78t, 104t, 125t, 130t; 
paclitaxel + cisplatin (TP), 61t, 73t, 78t; 
pegylated liposomal doxorubicin (PLD), 
214t, 233t; SCOTROC, 108t; topotecan, 
206t, 214t; topotecan versus paclitaxel 
trial, 206t
toxicity, anorexia, MITO-2, 131
toxicity, arterial thrombosis: AURELIA, 
261t; bevacizumab, 153; chemotherapy 
alone, 261t; chemotherapy + bevaci-
zumab, 261t; GOG 218, 153, 156t; 
paclitaxel + carboplatin (PC), 156t; 
paclitaxel + carboplatin + bevacizumab 
(PCB), 156t
toxicity, arthralgia: CALYPSO, 248t; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 248t; cyclophos-
phamide + cisplatin (CP), 85t; Danish 
Netherlands Trial, 79; OV-10, 85t; OV16, 
140; paclitaxel, 206t; paclitaxel + 
carboplatin (TC), 108t, 248t; paclitaxel + 
cisplatin (TP), 85t; SCOTROC, 108t; 
topotecan, 206t; topotecan versus 
paclitaxel trial, 206t
toxicity, bilirubin, Doxil Study 30–49, 210
toxicity, bleeding: carboplatin + pegylated 
liposomal doxorubicin (C- PLD), 131t; 
GOG 218, 156t; ICON7, 150t; MITO-2, 
131t; paclitaxel + carboplatin (TC), 131t, 
150t, 156t; paclitaxel + carboplatin + 
bevacizumab (PCB), 150t, 156t
toxicity, cardiac: Danish Netherlands Trial, 
79; doxorubicin, 208; GOG 111, 59–60; 
GOG 114, 89t; GOG 172, 113t; GOG 175, 
197, 198t; intraperitoneal cisplatin- based 
chemotherapy, 89t, 113t; maintenance 
chemotherapy, 198t; maintenance 
paclitaxel, 197; OV-10, 82; paclitaxel + 
cisplatin (TP), 89t, 113t; pegylated 
liposomal doxorubicin (PLD), 127
toxicity, cardiac ischemia, GOG 111, 60
toxicity, central ner vous system bleeding: 
GOG 218, 156t; paclitaxel + carboplatin 
(TC), 156t; paclitaxel + carboplatin + 
bevacizumab (PCB), 156t
toxicity, congestive heart failure: OVA-301, 
240t; pegylated liposomal doxorubicin 
(PLD), 240t; pegylated liposomal 
doxorubicin + trabectedin, 240t
toxicity, constipation: Danish Netherlands 
Trial, 79; gemcitabine, 231t; gemcitabine 
versus PLD trial, 231t; pegylated 
liposomal doxorubicin, 231t
toxicity, cutaneous. See toxicity, skin
toxicity, death due to treatment: CALYPSO, 
248t; carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 130t, 248t; 
cyclophosphamide + cisplatin (CP), 61t, 
65t; docetaxel + carboplatin, 108t; GOG 
104, 65t; GOG 111, 61t; Doxil study 
30–49, 214t; GOG 114, 89t; GOG 172, 
113t; GOG 218, 155t; ICON7, 150t; 
intraperitoneal cisplatin- based chemo-
therapy, 65t, 89t, 113t; MITO-2, 130t; 
MITO-7, 160t; OV16, 143t; OVA-301, 
241t; paclitaxel + carboplatin (TC), 108t, 
130t, 143t, 150t, 155t, 160t, 248t; 
paclitaxel + carboplatin + bevacizumab 
(PCB), 150t, 155t; paclitaxel + cisplatin 
(TP), 61t, 89t, 113t; pegylated liposomal 
doxorubicin (PLD), 214t, 241t; pegylated 
liposomal doxorubicin + trabectedin, 
241t; SCOTROC, 108t; topotecan, 214t, 
215; weekly paclitaxel + carboplatin, 160t
toxicity, dermatologic. See toxicity, skin
toxicity, diarrhea: carboplatin + pegylated 
liposomal doxorubicin (C- PLD), 130t; 
Danish Netherlands Trial, 79; MITO-2, 
130t, 131; paclitaxel + carboplatin (TC), 
130t; paclitaxel + cisplatin (TP), 169; 
topotecan versus paclitaxel trial, 207
toxicity, dyspnea: gemcitabine, 233t; 
gemcitabine versus PLD trial, 233t; GOG 
104, 66; pegylated liposomal doxorubicin 
(PLD), 233t
toxicity, fatigue: AGO- OVAR9, 137; GOG 
172, 112, 113t; gemcitabine, 231t, 233t; 
gemcitabine versus PLD trial, 231t, 233t; 
intraperitoneal cisplatin- based chemo-
therapy, 113t; paclitaxel + carboplatin 
(TC), 157; paclitaxel + cisplatin (TP), 
113t; pegylated liposomal doxorubicin 
(PLD), 231t, 233t





toxicity, febrile neutropenia: AGO- OVAR/
NCIC/EORTC trial, 227t; AGO/OVAR-3, 
104t; AGO- OVAR9, 136t; AGO- OVAR/
NCIC/EORTC trial, 224; carboplatin, 
227t; carboplatin + gemcitabine, 227t; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 131t; cyclophos-
phamide + cisplatin (CP), 56t, 84t; 
docetaxel + carboplatin, 108t; Doxil 
Study 30–49, 210; gemcitabine, 233t; 
gemcitabine versus PLD trial, 230, 233t; 
GOG 97, 56t; GOG 175, 196; GOG 218, 
152; JGOG 3016, 121; MITO-2, 131t; 
MITO-7, 160t; OCEANS, 255; OV-10, 
82, 84t; OV16, 139, 143t; OVA-301, 237; 
paclitaxel + carboplatin, 104t, 108t, 131t, 
136t, 143t, 160t; paclitaxel + cisplatin 
(TP), 84t, 104t; pegylated liposomal 
doxorubicin, 233t; SCOTROC, 108t; 
weekly paclitaxel + carboplatin, 160t
toxicity, fever: carboplatin, 94t; 
cyclophosphamide + cisplatin (CP), 61t; 
cyclophosphamide + doxorubicin + 
cisplatin (CAP), 94t; Danish Netherlands 
Trial, 78t, 79; GOG 111, 61t; GOG 132, 
72; GOG 172, 113t; GOG 182/ICON5, 
118t; ICON3, 94t, 95; intraperitoneal 
cisplatin- based chemotherapy, 113t; 
paclitaxel, 206t; paclitaxel + carboplatin 
(TC), 78t, 94t, 95, 118t; paclitaxel + 
cisplatin (TP), 61t, 78t, 113t; pegylated 
liposomal doxorubicin (PLD) + carboplatin, 
127; topotecan, 206t; topotecan versus 
paclitaxel trial, 203. 206t
toxicity, fi stula: AURELIA, 261t; bevaci-
zumab, 250; chemotherapy alone, 261t; 
chemotherapy + bevacizumab, 261t; GOG 
218, 155t; paclitaxel + carboplatin (TC), 
155t; paclitaxel + carboplatin + 
bevacizumab (PCB), 155t
toxicity, gastrointestinal: AGO- OVAR-3, 
105; cisplatin, 73t; cyclophosphamide + 
cisplatin (CP), 56t, 61t; cyclophospha-
mide + doxorubicin (CA), 49t; 
cyclophosphamide + doxorubicin + 
cisplatin (CAP), 49t; cyclophosphamide + 
cisplatin (CP), 18t; docetaxel + carboplatin, 
108t; GOG 47, 49t; GOG 95, 18t; GOG 
97, 55, 56t; GOG 111, 59, 61t; GOG 114, 
89t; GOG 132, 73t, 74; GOG 158, 97, 98t, 
99; GOG 172, 112, 113t; GOG 182/
ICON5, 118t; GOG 7602, 8t; intraperito-
neal 32P, 18t; intraperitoneal cisplatin- 
based chemotherapy, 89t, 113t; melphalan, 
8t; paclitaxel, 73t; paclitaxel + carboplatin 
(TC), 98t, 118t; paclitaxel + cisplatin (TP), 
61t, 73t, 89t, 98t, 113t; SCOTROC, 108t
toxicity, gastrointestinal perforation: 
AURELIA, 257, 259, 261t, 262; 
bevacizumab, 153, 250; chemotherapy 
alone, 261t; chemotherapy + bevacizumab, 
261t; GOG 95, 18; GOG 218, 153, 155t, 
156; ICON7, 150t; intraperitoneal 32P, 18; 
OCEANS, 255; paclitaxel + carboplatin 
(TC), 150t, 155t; paclitaxel + carboplatin + 
bevacizumab (PCB), 150t, 155t; 
risk- factors, 257–258
toxicity, genitourinary: GOG 158, 98t; 
paclitaxel + carboplatin (TC), 98t; 
paclitaxel + cisplatin (TP), 98t
toxicity, granulocyte: cisplatin, 73t; 
cyclophosphamide + cisplatin (CP), 18t, 
65t; Danish Netherlands Trial, 78t; GOG 
47, 47–48; GOG 52, 51; GOG 95, 18t; 
GOG 104, 65t; GOG 132, 73t; GOG 157, 
41t; GOG 158, 98t; intraperitoneal 32P, 
18t; intraperitoneal cisplatin- based 
chemotherapy, 65t; OV16, 143t; 
paclitaxel, 73t; paclitaxel + carboplatin 
(TC), 41t, 78t, 98t, 143t; paclitaxel + cis-
platin (TP), 73t, 78t, 98t
toxicity, hearing loss. See toxicity, ototoxicity
toxicity, heart block: GOG 111, 60; 
paclitaxel, 60
toxicity, hematologic: AGO- OVAR9, 137; 
AGO- OVAR/NCIC/EORTC trial, 228; 
carboplatin, 94t; carboplatin + 
gemcitabine, 228, 243; cyclophospha-
mide + doxorubicin + cisplatin (CAP), 94t; 
GOG 114, 89t; GOG 172, 112; ICON3, 
94t; ICON4/AGO- OVAR 2.2, 221t; 
intraperitoneal cisplatin- based chemo-
therapy, 89t; JGOG 3016, 121, 123; 
MITO-2, 131–132; MITO-7, 161; 
paclitaxel + carboplatin (TC), 94t, 157, 
161; paclitaxel + cisplatin (TP), 89t; 
pegylated liposomal doxorubicin, 116, 
210; platinum chemotherapy, 221t; 
platinum + paclitaxel, 221t; topotecan, 
215, 234





toxicity, hemorrhagic cystitis, GOG 97, 55
toxicity, hepatic: GOG 172, 113t; GOG 182/
ICON5, 118t; intraperitoneal cisplatin- 
based chemotherapy, 113t; Hy’s law, 241; 
OVA-301, 238, 240t, 241; paclitaxel + 
carboplatin (TC), 118t; paclitaxel + 
cisplatin (TP), 113t; pegylated liposomal 
doxorubicin (PLD), 240t; pegylated 
liposomal doxorubicin + trabectedin, 
240t, 241; SCOTROC, 106
toxicity, hospitalization: OV16, 145t; 
paclitaxel + carboplatin (TC), 145t
toxicity, hypersensitivity: bevacizumab, 
153; CALYPSO, 246, 248, 248t; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 248t; 
cyclophosphamide + cisplatin (CP), 85t; 
dose- dense paclitaxel + carboplatin, 125t; 
GOG 218, 152, 153; JGOG 3016, 125t; 
OV-10, 82, 85t; paclitaxel, 106, 152; 
paclitaxel + carboplatin (TC), 125t, 248t; 
paclitaxel + cisplatin (TP), 85t; SCOTROC, 
106
toxicity, hypertension: AURELIA, 257, 
261t, 262; bevacizumab, 153, 157; 
carboplatin + gemcitabine, 254t; 
carboplatin + gemcitabine + bevacizumab, 
254t; chemotherapy alone, 261t; 
chemotherapy + bevacizumab, 261t; GOG 
218, 153, 155t, 156, 157; ICON7, 150t; 
OCEANS, 254t; paclitaxel + carboplatin 
(TC), 150t, 155t; paclitaxel + carboplatin + 
bevacizumab (PCB), 150t, 155t
toxicity, infection: AGO/OVAR-3, 104t; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 131t; cyclophos-
phamide + cisplatin (CP), 56t; GOG 97, 
56t; GOG 114, 89t; GOG 172, 113t; GOG 
175, 197, 198t; ICON4/AGO- OVAR 2.2, 
221t; intraperitoneal cisplatin- based 
chemotherapy, 89t, 113t; maintenance 
chemotherapy, 198t; maintenance 
paclitaxel, 197; MITO-2, 131t; OV16, 
139; OVA-301, 237; paclitaxel, 206t; 
paclitaxel + carboplatin (TC), 104t, 131t; 
paclitaxel + cisplatin (TP), 89t, 104t, 113t; 
platinum chemotherapy, 221t; plati-
num + paclitaxel, 221t; topotecan, 206t; 
topotecan versus paclitaxel trial, 203, 
206t
toxicity, leukopenia: AGO/OVAR-3, 104t; 
AGO- OVAR9, 136t; carboplatin, 69t; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 131t; cyclophos-
phamide + cisplatin (CP), 18t, 52t, 56t, 
65t; cyclophosphamide + doxorubicin + 
cisplatin (CAP), 52t, 69t; Doxil study 
30–49, 214t; GOG 95, 18t; GOG 97, 56t; 
GOG 104, 65t; GOG 114, 89t; GOG 158, 
98t; GOG 172, 113t; ICON2, 69t, 70; 
intraperitoneal 32P, 18t; intraperitoneal 
cisplatin- based chemotherapy, 65t, 89t, 
113t; MITO-2, 131t; paclitaxel + 
carboplatin (TC), 98t, 104t, 131t, 136t; 
paclitaxel + cisplatin (TP), 89t, 98t, 104t, 
113t; pegylated liposomal doxorubicin 
(PLD), 214t; topotecan, 214t
toxicity, metabolic: GOG 114, 89t; GOG 
158, 98t, 99; GOG 172, 112, 113t; 
intraperitoneal cisplatin- based chemo-
therapy, 89t, 113t; paclitaxel + carboplatin 
(TC), 98t; paclitaxel + cisplatin (TP), 89t, 
98t, 113t
toxicity, mucositis: CALYPSO, 248, 248t; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 248t; Danish 
Netherlands Trial, 79; gemcitabine, 
231t; gemcitabine versus PLD trial, 231t; 
ICON4/AGO- OVAR 2.2, 221t; MITO-2, 
131; OV16, 140; OVA-301, 240t; 
paclitaxel + carboplatin (TC), 248t; 
paclitaxel + cisplatin (TP), 169; pegylated 
liposomal doxorubicin (PLD), 116, 
127, 231t, 240t; pegylated liposomal 
doxorubicin + trabectedin, 240t; platinum 
chemotherapy, 221t; platinum + paclitaxel, 
221t; SCOTROC, 107
toxicity, myalgia: CALYPSO, 248t; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 248t; 
cyclophosphamide + cisplatin (CP), 85t; 
Danish Netherlands Trial, 79; OV-10, 
85t; OV16, 140; paclitaxel, 206t; 
paclitaxel + carboplatin (TC), 108t, 
248t; paclitaxel + cisplatin (TP), 85t; 
SCOTROC, 108t; topotecan, 206t; 
topotecan versus paclitaxel trial, 206t
toxicity, myelotoxicity: AGO- OVAR-3, 
105; carboplatin, 75; cyclophosphamide + 
doxorubicin (CA), 49t; cyclophospha-





mide + doxorubicin + cisplatin (CAP), 49t; 
GOG 47, 49t; GOG 7601, 4t; GOG 7602, 
8t; ICON4/AGO- OVAR 2.2, 220; limits 
intravenous chemotherapy intensity, 111; 
melphalan, 4t, 8t; OV-10, 82; pegylated 
liposomal doxorubicin (PLD), 127; 
SCOTROC, 109; topotecan, 202; 
topotecan combination therapy, 138
toxicity, nail changes: docetaxel + 
carboplatin, 108t; SCOTROC, 108t
toxicity, nausea: AGO/OVAR-3, 104t; 
CALYPSO, 248, 248t; carboplatin, 69t, 
94t; carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 248t; cisplatin, 13t, 
14t; cyclophosphamide + cisplatin (CP), 
52t, 85t; cyclophosphamide + doxorubicin + 
cisplatin (CAP), 52t, 69t, 94t; Danish 
Netherlands Trial, 78t; doxorubicin, 208; 
gemcitabine, 231t; gemcitabine versus 
PLD trial, 231t; GICOG  trials, 13t, 14t; 
ICON2, 69t, 70; ICON3, 94t; ICON4/
AGO- OVAR 2.2, 221t; OV-10, 85t; OV16, 
143t; OVA-301, 237; paclitaxel, 206t; 
paclitaxel + carboplatin (TC), 78t, 94t, 
104t, 143t, 248t; paclitaxel + cisplatin 
(TP), 78t, 85t, 104t; pegylated liposomal 
doxorubicin (PLD), 127, 231t; platinum 
chemotherapy, 221t; platinum + paclitaxel, 
221t; topotecan, 206t; topotecan versus 
paclitaxel trial, 206t
toxicity, neuropathy. See toxicity, 
neurotoxicity
toxicity, neurotoxicity: AGO- OVAR/NCIC/
EORTC trial, 227t; AGO/OVAR-3, 104t, 
105, 223; AGO- OVAR/NCIC/EORTC 
trial, 228; AURELIA, 262; CALYPSO, 
244, 246, 248t; carboplatin, 94t, 227t; 
carboplatin + gemcitabine, 117t, 228; 
carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 130t, 248t; 
cisplatin, 73t, 75; cyclophosphamide + 
cisplatin (CP), 61t, 65t, 85t; cyclophos-
phamide + doxorubicin + cisplatin (CAP), 
94t; cumulative, 243; Danish Netherlands 
Trial, 78t, 79; docetaxel + carboplatin, 
108t; dose- dense paclitaxel + carboplatin, 
125t; gemcitabine, 233t; gemcitabine 
versus PLD trial, 233t; GOG 97, 55; 
GOG 104, 63, 65t; GOG 111, 59, 61t, 85; 
GOG 114, 88, 89t; GOG 132, 71, 73t; 
GOG 152, 173; GOG 158, 97, 98t, 99; 
GOG 157, 41t, 194; GOG 172, 111, 112, 
113t; GOG 175, 197, 198t; GOG 178/
SWOG 9701, 188, 190t, 191, 192, 193; 
GOG 182/ICON5, 118t; GOG 218, 152; 
ICON3, 94t, 95; ICON4/AGO- OVAR 2.2, 
221t, 222; intraperitoneal cisplatin- based 
chemotherapy, 65t, 89t, 113t; JGOG 3016, 
121, 125t, 125; maintenance chemother-
apy, 198t; maintenance paclitaxel, 190t, 
191, 197; MITO-2, 128, 130t, 131; 
MITO-7, 158, 159, 160t, 161; OV-10, 82, 
85, 85t; OV16, 140, 145t; paclitaxel, 73t, 
206t; paclitaxel + carboplatin (TC), 41t, 
78t, 79, 93, 94t, 98t, 104t, 108t, 118t, 125t, 
130t, 145t, 57, 160t, 161, 243, 248t; 
paclitaxel + cisplatin (TP), 61t, 73t, 78t, 
79, 85t, 85, 89t, 98t, 104t, 113t, 170; 
pegylated liposomal doxorubicin (PLD), 
233t; pegylated liposomal doxorubicin 
(PLD) + carboplatin, 127; platinum 
chemotherapy, 221t; platinum + pacli-
taxel, 221t; SCOTROC, 106, 108t, 109; 
topotecan, 206t; topotecan versus 
paclitaxel trial, 206t; weekly pacli-
taxel + carboplatin, 160t
toxicity, neutropenia: AGO- OVAR/NCIC/
EORTC trial, 226t; AGO/OVAR-3, 104t; 
AGO- OVAR9, 136t; AGO- OVAR/NCIC/
EORTC trial, 224; CALYPSO, 248t; 
carboplatin, 226t; carboplatin + 
gemcitabine, 224, 226t; carboplatin + 
pegylated liposomal doxorubicin 
(C- PLD), 131t, 248t; CHORUS, 185t; 
cyclophosphamide + cisplatin (CP), 61t, 
84t; docetaxel + carboplatin, 108t; 
dose- dense paclitaxel + carboplatin, 125t; 
Doxil Study 30–49, 210, 214t; gem-
citabine, 231t, 233t; gemcitabine versus 
PLD trial, 230, 231t, 233t; GOG 104, 66; 
GOG 111, 61t; GOG 132, 71, 72; GOG 
178/SWOG 9701, 188, 190t; GOG 182/
ICON5, 118t; GOG 218, 152, 155t; JGOG 
3016, 121, 125t, 161; maintenance 
paclitaxel, 190t; MITO-2, 131t; MITO-7, 
158, 160t, 161; neoadjuvant chemother-
apy, 185t; OCEANS, 252, 255; OV-10, 
82, 84t; OV16, 139; OVA-301, 237, 240t, 
241; paclitaxel, 206t; paclitaxel + 
carboplatin (TC), 104t, 108t, 118t, 125t, 






 131t, 136t, 155t, 160t, 161, 248t; 
paclitaxel + carboplatin + bevacizumab 
(PCB), 155t; paclitaxel + cisplatin (TP), 
61t, 84t, 104t, 169; pegylated liposomal 
doxorubicin (PLD), 214t, 231t, 233t, 240t; 
pegylated liposomal doxorubicin 
(PLD) + carboplatin, 127; pegylated 
liposomal doxorubicin (PLD) + trabect-
edin, 240t, 241; primary debulking 
surgery, 185t; SCOTROC, 106, 107, 108t; 
topotecan, 206t, 210, 214t, 215; topotecan 
versus paclitaxel trial, 203, 206t, 207; 
weekly paclitaxel + carboplatin, 160t
toxicity, ototoxicity: AGO/OVAR-3, 104t; 
cisplatin, 75; cyclophosphamide + 
cisplatin (CP), 65t, 85t; GOG 97, 55; 
GOG 104, 65t, 66; GOG 111, 59; GOG 
132, 74; intraperitoneal cisplatin- based 
chemotherapy, 65t; OV-10, 82, 85t; 
paclitaxel + carboplatin (TC), 104t; 
paclitaxel + cisplatin (TP), 85t, 104t, 
170
toxicity, pain: GOG 158, 98t; GOG 172, 
112, 113t; GOG 218, 155t, 156; intraperi-
toneal cisplatin- based chemotherapy, 
113t; paclitaxel + carboplatin (TC), 98t, 
155t; paclitaxel + carboplatin + bevaci-
zumab (PCB), 155t; paclitaxel + cisplatin 
(TP), 98t, 113t
toxicity, palmar- plantar erythrodysesthesia 
(PPE): AURELIA, 262; CALYPSO, 248, 
248t; carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 127, 248t; 
description, 216; dimethyl sulfoxide, 216; 
Doxil study 30–49, 214t; dose modifi ca-
tions, 216; gemcitabine, 231t, 233t; 
gemcitabine versus PLD trial, 231t, 233t, 
234; OVA-301, 238, 241; OVA-301, 240t; 
paclitaxel + carboplatin (TC), 248t; 
pegylated liposomal doxorubicin (PLD), 
127, 208, 210, 214t, 215, 216, 231t, 233t, 
234, 240t, 241; pegylated liposomal 
doxorubicin + trabectedin, 240t; 
pyridoxine, 216; treatment, 216; 
topotecan, 214t
toxicity, peripheral edema: docetaxel + 
carboplatin, 108t; SCOTROC, 108t
toxicity, platelet: AGO- OVAR/NCIC/
EORTC trial, 226t; AGO/OVAR-3, 104t; 
AGO- OVAR9, 136t; AGO- OVAR/NCIC/
EORTC trial, 224; CALYPSO, 248t; 
carboplatin, 69t, 226t; carboplatin + 
gemcitabine, 224, 226t; carboplatin + 
pegylated liposomal doxorubicin 
(C- PLD), 130t, 248t; cyclophosphamide + 
cisplatin (CP), 56t, 61t, 65t; cyclophos-
phamide + doxorubicin (CA), 49t; 
cyclophosphamide + doxorubicin + 
cisplatin (CAP), 49t, 52t, 69t; 
cyclophosphamide + cisplatin (CP), 18t, 
52t, 85t; Danish Netherlands Trial, 78t; 
docetaxel + carboplatin, 108t; dose- dense 
paclitaxel + carboplatin, 125t; Doxil study 
30–49, 214t; gemcitabine, 233t; 
gemcitabine versus PLD trial, 230, 233t; 
GOG 47, 47–48, 49t; GOG 52, 51; GOG 
95, 18t; GOG 97, 56t; GOG 104, 65t; 
GOG 111, 61t; GOG 114, 89t; GOG 132, 
71, 74; GOG 158, 98t; GOG 172, 113t; 
GOG 175, 196; GOG 178/SWOG 9701, 
188; GOG 182/ICON5, 118t; ICON2, 69t; 
intraperitoneal 32P, 18t; intraperitoneal 
cisplatin- based chemotherapy, 65t, 89t, 
113t; JGOG 3016, 121, 125t, 161; ICON2, 
70; MITO-2, 130t; MITO-7, 158, 161; 
OCEANS, 252; OV-10, 82, 85t; OV16, 
139, 143t; OVA-301, 237; paclitaxel, 206t; 
paclitaxel + carboplatin (TC), 78t, 89t, 
104t, 108t, 118t, 125t, 130t, 136t, 143t, 
161, 248t; paclitaxel + cisplatin (TP), 61t, 
78t, 85t, 89t, 98t, 104t, 113t, 169; 
pegylated liposomal doxorubicin (PLD), 
214t, 233t; SCOTROC, 107, 108t; 
topotecan, 206t, 214t; topotecan versus 
paclitaxel trial, 206t, 207
toxicity, posterior reversible encephalopa-
thy syndrome (PRES): GOG 218, 156t; 
paclitaxel + carboplatin (TC), 156t; 
paclitaxel + carboplatin + bevacizumab 
(PCB), 156t
toxicity, proteinuria: AURELIA, 261t, 262; 
bevacizumab, 153; chemotherapy alone, 
261t; chemotherapy + bevacizumab, 261t; 
GOG 218, 153, 155t, 156; carboplatin + 
gemcitabine, 254t; carboplatin + gem-
citabine + bevacizumab, 254t; OCEANS, 
254t, 255; paclitaxel + carboplatin (TC), 
155t; paclitaxel + carboplatin + bevaci-
zumab (PCB), 155t





toxicity, pulmonary: cyclophosphamide + 
cisplatin (CP), 65t; Danish Netherlands 
Trial, 79; GOG 104, 65t; GOG 182/
ICON5, 118t; intraperitoneal cisplatin- 
based chemotherapy, 65t; MITO-7, 160t; 
paclitaxel + carboplatin (TC), 118t, 160t; 
weekly paclitaxel + carboplatin, 160t
toxicity, renal: AGO/OVAR-3, 104t; 
cisplatin, 73t, 75; cyclophosphamide + 
cisplatin (CP), 18t, 56t, 61t; Danish 
Netherlands Trial, 79; GOG 95, 18t; 
GOG 97, 55, 56t; GOG 104, 63; GOG 
111, 59, 61t; GOG 132, 71, 73t, 74; GOG 
158, 97; GOG 172, 111, 113t; ICON4/
AGO- OVAR 2.2, 221t; intraperitoneal 
32P, 18t; intraperitoneal cisplatin- based 
chemotherapy, 113t; MITO-2, 128; 
OV-10, 82; OV16, 140; paclitaxel, 73t; 
paclitaxel + carboplatin, 104t; pacli-
taxel + cisplatin (TP), 61t, 73t, 104t, 113t, 
170; platinum chemotherapy, 221t; 
platinum + paclitaxel, 221t; topotecan, 
210
toxicity, reversible posterior leukoencepha-
lopathy syndrome (RPLS): bevacizumab, 
153; carboplatin + gemcitabine, 254t; 
carboplatin + gemcitabine + bevacizumab, 
254t; GOG 218, 153; OCEANS, 254t, 255
toxicity, RPLS. See toxicity, reversible 
posterior leukoencephalopathy syndrome
toxicity, secondary malignancy: GOG 175, 
198t; maintenance chemotherapy, 198t
toxicity, sepsis: Doxil study 30–49, 214t; 
paclitaxel, 206t; pegylated liposomal 
doxorubicin (PLD), 214t; topotecan, 206t, 
214t; topotecan versus paclitaxel trial, 
206t
toxicity, skin: carboplatin + pegylated 
liposomal doxorubicin (C- PLD), 130t; 
Danish Netherlands Trial, 79; gem-
citabine, 233t; gemcitabine versus PLD 
trial, 233t; GOG 175, 197, 198t; mainte-
nance chemotherapy, 198t; MITO-2, 128, 
130t, 131; paclitaxel + carboplatin (TC), 
130t; pegylated liposomal doxorubicin 
(PLD), 116, 127, 208, 233t; SCOTROC, 
107
toxicity, stomatitis: carboplatin + pegylated 
liposomal doxorubicin (C- PLD), 130t; 
cyclophosphamide + cisplatin (CP), 85t; 
Doxil study 30–49, 214t; MITO-2, 
130t; OV-10, 85t; OVA-301, 238, 240t; 
paclitaxel + carboplatin (TC), 130t; 
paclitaxel + cisplatin (TP), 85t; pegylated 
liposomal doxorubicin (PLD), 127, 208, 
210, 214t, 215, 240t; pegylated liposomal 
doxorubicin + trabectedin, 240t; 
topotecan, 214t
toxicity, thrombocytopenia. See toxicity, 
platelet
toxicity, thromboembolism: AURELIA, 
261t; bevacizumab, 153; chemotherapy 
alone, 261t; chemotherapy + bevacizumab, 
261t; GOG 218, 153, 155t; ICON7, 150t; 
OV16, 143t; paclitaxel + carboplatin (TC), 
143t, 150t, 155t; paclitaxel + carbopla-
tin + bevacizumab (PCB), 150t, 155t
toxicity, tinnitus: cyclophosphamide + 
cisplatin (CP), 65t; GOG 104, 65t, 66; 
GOG 132, 71; intraperitoneal cisplatin- 
based chemotherapy, 65t; paclitaxel + 
cisplatin (TP), 170
toxicity, venous thrombosis. See toxicity, 
thromboembolism
toxicity, vomiting: AGO/OVAR-3, 104t; 
CALYPSO, 248, 248t; carboplatin, 69t, 
94t; carboplatin + pegylated liposomal 
doxorubicin (C- PLD), 248t; cisplatin, 13t, 
14t; cyclophosphamide + cisplatin (CP), 
52t, 56t, 85t; cyclophosphamide + doxoru-
bicin + cisplatin (CAP), 52t, 69t, 94t; 
doxorubicin, 208; gemcitabine, 231t; 
gemcitabine versus PLD trial, 231t; 
GICOG  trials, 13t, 14t; GOG 97, 56t; 
ICON2, 69t, 70; ICON3, 94t; ICON4/
AGO- OVAR 2.2, 221t; MITO-7, 161; 
OV-10, 85t; OV16, 145t; OVA-301, 237; 
paclitaxel, 206t; paclitaxel + carboplatin 
(TC), 94t, 104t, 145t, 161, 248t; 
paclitaxel + cisplatin (TP), 85t, 104t; 
pegylated liposomal doxorubicin (PLD), 
127, 231t; platinum chemotherapy, 221t; 
platinum + paclitaxel, 221t; topotecan, 
206t; topotecan versus paclitaxel trial, 
206t
toxicity, wound disruption: bevacizumab, 
153, 156; GOG 218, 153, 156, 156t; 
paclitaxel + carboplatin (TC), 156t; 
paclitaxel + carboplatin + bevacizumab 
(PCB), 156t





toxicity assessments: GICOG  trials, 12; 
GOG 111, 59; GOG 157, 39; SCOTROC, 
107
toxicity bowel obstruction: GOG 7602, 
8t; intraperitoneal 32P, 8t
TP. See paclitaxel + cisplatin
trabectedin: activity in ovarian cancer, 
236; dosing, 237; Ecteinascidia turbinata, 
235; mechanism of antineoplastic effect, 
235; OVA-310, 235–242; synergy with 
pegylated liposomal doxorubicin, 236; 
transcription- coupled nucleotide excision 
repair, 235
transcription- coupled nucleotide excision 
repair, 235
transfusion, blood: Doxil study 30–49, 
214t; topotecan versus paclitaxel trial, 
206t
transfusion, platelets, topotecan versus 
paclitaxel trial, 206t
treatment discontinuation: AGO- OVAR-3, 
102; AGO- OVAR9, 134; AURELIA, 259; 
Doxil Study 30–49, 210; GOG 97, 55; 
GOG 104, 63; GOG 111, 59; GOG 152, 
170; GOG 158, 97; GOG 178/SWOG 
9701, 188; GOG 218, 152; MITO-2, 128; 
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